-DOCSTART- -X- O O
In	O
this	O
paper	O
,	O
we	O
determined	O
the	O
agonist	O
-	O
activated	O
structure	O
of	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
coupled	O
to	O
this	O
paper	O
canonical	O
transducer	O
Gαq	O
,	O
compared	O
this	O
paper	O
with	O
inactive	O
state	O
structures	O
stabilized	O
by	O
both	O
the	O
partial	O
agonist	O
LSD	B-DRUG
and	O
the	O
inverse	O
agonist	O
methiothepin	B-DRUG
,	O
and	O
identified	O
key	O
determinants	O
essential	O
for	O
agonist	B-NEURAL MECHANISM/CORRELATE
actions	I-NEURAL MECHANISM/CORRELATE
and	O
receptor	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
coupling	I-NEURAL MECHANISM/CORRELATE
.	O
Because	O
the	O
5	O
-	O
HT2A	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
is	O
essential	O
for	O
the	O
actions	B-OUTCOME
of	I-OUTCOME
classical	I-OUTCOME
psychedelics	I-OUTCOME
including	O
LSD	B-DRUG
,	O
psilocin	B-DRUG
,	O
mescaline	B-DRUG
,	O
and	O
various	O
N	O
-	O
BOH	O
analogs	O
,	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
is	O
essential	O
for	O
the	O
actions	O
of	O
classical	O
psychedelics	B-DRUG
including	O
LSD	B-DRUG
,	O
psilocin	B-DRUG
,	O
mescaline	B-DRUG
,	O
and	O
various	O
N	O
-	O
BOH	O
analogs	O
provide	O
structural	O
insights	O
into	O
the	O
actions	O
of	O
psychedelics	B-DRUG
at	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
is	O
essential	O
for	O
the	O
actions	O
of	O
classical	O
psychedelics	B-DRUG
including	O
LSD	B-DRUG
,	O
psilocin	B-DRUG
,	O
mescaline	B-DRUG
,	O
and	O
various	O
N	O
-	O
BOH	O
analogs	O
molecular	O
target	O
.	O
Importantly	O
,	O
we	O
also	O
discovered	O
that	O
the	O
specific	O
interactions	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
achieves	O
with	O
Gq	O
residues	O
are	O
essential	O
for	O
the	O
apparently	O
selective	O
engagement	O
of	O
this	O
receptor	O
with	O
Gq	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
family	I-NEURAL MECHANISM/CORRELATE
proteins	I-NEURAL MECHANISM/CORRELATE
in	O
vitro	O
Some	O
of	O
these	O
findings	O
contrast	O
with	O
predictions	O
from	O
a	O
recent	O
study	O
utilizing	O
chimeric	O
Gα	B-NEURAL MECHANISM/CORRELATE
subunits	I-NEURAL MECHANISM/CORRELATE
that	O
indicated	O
that	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
interact	O
efficiently	O
with	O
all	O
of	O
the	O
11	O
tested	O
Gα	B-NEURAL MECHANISM/CORRELATE
subunits	I-NEURAL MECHANISM/CORRELATE
,	O
albeit	O
with	O
low	O
efficacy	O
at	O
Gαs	B-NEURAL MECHANISM/CORRELATE
(	O
Inoue	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
However	O
,	O
the	O
Gα	B-NEURAL MECHANISM/CORRELATE
subtypes	I-NEURAL MECHANISM/CORRELATE
in	O
that	O
study	O
(	O
Inoue	O
et	O
al	O
.	O
,	O
2019	O
)	O
were	O
created	O
by	O
replacing	O
the	O
terminal	O
seven	O
amino	O
acids	O
of	O
Gq	B-NEURAL MECHANISM/CORRELATE
with	O
the	O
corresponding	O
sequences	O
from	O
several	O
other	O
Gα	B-NEURAL MECHANISM/CORRELATE
subunits	I-NEURAL MECHANISM/CORRELATE
using	O
the	O
motif	O
LXXXLX	O
(	O
where	O
X	O
=	O
subtype	O
selective	O
sequences	O
)	O
(	O
Inoue	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Pertinent	O
to	O
this	O
,	O
we	O
note	O
that	O
immediately	O
prior	O
to	O
L353	B-NEURAL MECHANISM/CORRELATE
is	O
Q352	B-NEURAL MECHANISM/CORRELATE
that	O
is	O
conserved	O
among	O
all	O
of	O
the	O
chimeric	O
G	B-NEURAL MECHANISM/CORRELATE
proteins	I-NEURAL MECHANISM/CORRELATE
employed	O
in	O
the	O
study	O
by	O
Inoue	O
et	O
al	O
.	O
(	O
2019	O
)	O
.	O
Here	O
,	O
we	O
discovered	O
that	O
the	O
Q352	B-NEURAL MECHANISM/CORRELATE
cognate	O
residue	O
directly	O
interacts	O
with	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
TM6	I-NEURAL MECHANISM/CORRELATE
residue	O
N3176.29	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
mutation	O
of	O
this	O
residue	O
abolishes	O
the	O
ability	O
of	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
to	O
activate	O
Gq	O
.	O
We	O
also	O
point	O
out	O
that	O
in	O
the	O
only	O
other	O
Gq	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
GPCR	I-NEURAL MECHANISM/CORRELATE
structure	O
available	O
,	O
the	O
same	O
Q352	B-NEURAL MECHANISM/CORRELATE
interacts	O
directly	O
with	O
the	O
TM5	B-NEURAL MECHANISM/CORRELATE
residue	O
R5.46	B-NEURAL MECHANISM/CORRELATE
(	O
Maeda	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Importantly	O
,	O
using	O
assays	O
in	O
which	O
full	O
-	O
length	O
heterotrimeric	O
G	B-NEURAL MECHANISM/CORRELATE
proteins	I-NEURAL MECHANISM/CORRELATE
were	O
used	O
,	O
we	O
find	O
that	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
productively	O
couples	O
weakly	O
with	O
only	O
one	O
Gi	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
family	I-NEURAL MECHANISM/CORRELATE
member	I-NEURAL MECHANISM/CORRELATE
,	O
Gαz	O
Relevant	O
to	O
these	O
findings	O
,	O
we	O
also	O
found	O
important	O
interactions	O
outside	O
the	O
α5	B-NEURAL MECHANISM/CORRELATE
helix	I-NEURAL MECHANISM/CORRELATE
that	O
are	O
essential	O
for	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
interactions	I-NEURAL MECHANISM/CORRELATE
.	O
Thus	O
,	O
R132ICL2	B-NEURAL MECHANISM/CORRELATE
interacts	O
via	O
an	O
extended	O
backbone	O
interaction	O
with	O
N32	B-NEURAL MECHANISM/CORRELATE
of	O
the	O
α	O
-	O
helical	B-NEURAL MECHANISM/CORRELATE
domain	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
we	O
further	O
demonstrated	O
via	O
mutagenesis	O
and	O
functional	O
assays	O
that	O
this	O
interaction	O
is	O
essential	O
for	O
agonist	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
induced	I-NEURAL MECHANISM/CORRELATE
activation	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
.	O
This	O
GPCR	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
interaction	O
is	O
not	O
seen	O
in	O
the	O
M1	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
G11	I-NEURAL MECHANISM/CORRELATE
structure	O
,	O
although	O
R134ICL2	B-NEURAL MECHANISM/CORRELATE
in	O
M1	B-NEURAL MECHANISM/CORRELATE
could	O
weakly	O
interact	O
with	O
the	O
backbone	O
carbonyl	O
of	O
R32	B-NEURAL MECHANISM/CORRELATE
in	O
Gq	O
based	O
on	O
an	O
examination	O
of	O
that	O
prior	O
structure	O
.	O
These	O
results	O
underscore	O
suggestions	O
made	O
decades	O
ago	O
that	O
the	O
selectivity	O
determinants	O
for	O
Gα	B-NEURAL MECHANISM/CORRELATE
subunits	I-NEURAL MECHANISM/CORRELATE
may	O
not	O
be	O
entirely	O
specified	O
by	O
reside	O
in	O
Gα	B-NEURAL MECHANISM/CORRELATE
subunits	I-NEURAL MECHANISM/CORRELATE
terminal	O
5–7	O
amino	O
acids	O
(	O
Wess	O
,	O
1997	O
)	O
We	O
also	O
discovered	O
that	O
a	O
key	O
hydrophobic	O
residue	O
essential	O
for	O
G	B-NEURAL MECHANISM/CORRELATE
protein	I-NEURAL MECHANISM/CORRELATE
coupling	I-NEURAL MECHANISM/CORRELATE
among	O
various	O
GPCRs	B-NEURAL MECHANISM/CORRELATE
—	I-NEURAL MECHANISM/CORRELATE
I181ICL2	I-NEURAL MECHANISM/CORRELATE
—	O
when	O
mutated	O
,	O
abolishes	O
Gαq	B-NEURAL MECHANISM/CORRELATE
coupling	I-NEURAL MECHANISM/CORRELATE
while	O
potentiating	O
arrestin	O
binding	O
at	O
HTR2A.	B-NEURAL MECHANISM/CORRELATE
This	O
result	O
was	O
unexpected	O
because	O
there	O
was	O
no	O
prior	O
data	O
with	O
sufficiently	O
high	O
resolution	O
of	O
GPCR	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
arrestin	I-NEURAL MECHANISM/CORRELATE
complexes	I-NEURAL MECHANISM/CORRELATE
that	O
could	O
illuminate	O
how	O
the	O
mutation	O
of	O
a	O
single	O
amino	O
acid	O
at	O
the	O
GPCR	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gα	I-NEURAL MECHANISM/CORRELATE
interface	I-NEURAL MECHANISM/CORRELATE
would	O
switch	O
the	O
coupling	O
of	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
from	O
an	O
unbiased	O
to	O
an	O
arrestin	O
-	O
exclusive	O
state	O
.	O
While	O
this	O
paper	O
was	O
in	O
revision	O
,	O
however	O
,	O
a	O
3.3	O
Å	O
resolution	O
structure	O
of	O
the	O
turkey	O
β1	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
adrenergic	I-NEURAL MECHANISM/CORRELATE
receptor	O
complexed	O
with	O
human	O
β	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
arrestin1	I-NEURAL MECHANISM/CORRELATE
was	O
reported	O
(	O
Lee	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
A	O
comparison	O
of	O
this	O
structure	O
with	O
the	O
Gs	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
coupled	I-NEURAL MECHANISM/CORRELATE
β2	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
adrenergic	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
(	O
Rasmussen	O
et	O
al	O
.	O
,	O
2011	O
)	O
and	O
our	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
structure	I-NEURAL MECHANISM/CORRELATE
reveals	O
that	O
the	O
cognate	O
hydrophobic	O
residue	O
F139ICL2	B-NEURAL MECHANISM/CORRELATE
in	O
β2	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
AR	I-NEURAL MECHANISM/CORRELATE
interacts	O
with	O
the	O
Gs	B-NEURAL MECHANISM/CORRELATE
α5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
helix	I-NEURAL MECHANISM/CORRELATE
in	O
a	O
manner	O
similar	O
to	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
.	O
In	O
the	O
β1	B-NEURAL MECHANISM/CORRELATE
adrenergic	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Arrestin	I-NEURAL MECHANISM/CORRELATE
structure	I-NEURAL MECHANISM/CORRELATE
,	O
by	O
contrast	O
,	O
F147ICL2	B-NEURAL MECHANISM/CORRELATE
is	O
displaced	O
upward	O
where	O
F147ICL2	B-NEURAL MECHANISM/CORRELATE
would	O
potentially	O
clash	O
with	O
residues	O
in	O
the	O
α5	B-NEURAL MECHANISM/CORRELATE
helix	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
Gs	I-NEURAL MECHANISM/CORRELATE
(	O
Figure	O
7I	O
)	O
and	O
where	O
F147ICL2	B-NEURAL MECHANISM/CORRELATE
is	O
engaged	O
in	O
no	O
productive	O
interactions	O
.	O
A	O
similar	O
relative	O
lack	O
of	O
extensive	O
engagement	O
of	O
this	O
cognate	O
residue	O
with	O
arrestins	O
can	O
be	O
seen	O
in	O
the	O
lower	O
resolution	O
muscarinic-	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
neurotensin	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
arrestin	I-NEURAL MECHANISM/CORRELATE
complexes	I-NEURAL MECHANISM/CORRELATE
(	O
Huang	O
et	O
al	O
.	O
,	O
2020	O
;	O
Staus	O
et	O
al	O
.	O
,	O
2020	O
)	O
(	O
Figure	O
7J	O
)	O
This	O
analysis	O
provides	O
a	O
potential	O
structural	O
explanation	O
for	O
how	O
loss	O
of	O
this	O
hydrophobic	O
interaction	O
impairs	O
Gq	B-NEURAL MECHANISM/CORRELATE
subunit	I-NEURAL MECHANISM/CORRELATE
coupling	I-NEURAL MECHANISM/CORRELATE
while	O
preserving	O
arrestin	O
interaction	O
—	O
at	O
least	O
for	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
In	O
addition	O
to	O
these	O
fundamental	O
insights	O
into	O
GPCR	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Gq	I-NEURAL MECHANISM/CORRELATE
interactions	O
,	O
our	O
findings	O
have	O
relevance	O
for	O
neuropsychiatric	O
drug	O
discovery	O
.	O
Psilocybin	B-DRUG
and	O
LSD	B-DRUG
have	O
emerged	O
as	O
potential	O
therapeutics	O
for	O
a	O
number	O
of	O
neuropsychiatric	O
conditions	O
including	O
depression	B-HEALTH CONDITION
,	O
anxiety	B-HEALTH CONDITION
,	O
substance	B-HEALTH CONDITION
abuse	I-HEALTH CONDITION
,	O
and	O
cluster	B-HEALTH CONDITION
headaches	I-HEALTH CONDITION
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
;	O
Bogenschutz	O
,	O
2013	O
;	O
Gasser	O
et	O
al	O
.	O
,	O
2015	O
;	O
Sewell	O
et	O
al	O
.	O
,	O
2006	O
;	O
Nutt	O
et	O
al	O
.	O
,	O
2020	O
)	O
.	O
Because	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	O
is	O
essential	O
for	O
the	O
actions	O
of	O
psilocybin	B-DRUG
in	O
humans	O
(	O
Kometer	O
et	O
al	O
.	O
,	O
2013	O
;	O
Nutt	O
et	O
al	O
.	O
,	O
2020	O
)	O
,	O
insights	O
into	O
the	O
molecular	O
details	O
of	O
both	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
ligand	I-NEURAL MECHANISM/CORRELATE
recognition	I-NEURAL MECHANISM/CORRELATE
and	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
effector	I-NEURAL MECHANISM/CORRELATE
coupling	I-NEURAL MECHANISM/CORRELATE
are	O
key	O
to	O
arriving	O
at	O
a	O
molecular	O
understanding	O
of	O
hallucinogen	O
actions	O
.	O
Additionally	O
,	O
these	O
studies	O
will	O
provide	O
a	O
framework	O
for	O
a	O
structure	O
-	O
guided	O
search	O
to	O
identify	O
more	O
selective	O
and	O
efficacious	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
as	O
potential	O
innovative	O
neuropsychiatric	O
therapeutics	O
as	O
recently	O
exemplified	O
by	O
us	O
for	O
other	O
GPCRs	B-NEURAL MECHANISM/CORRELATE
(	O
Lyu	O
et	O
al	O
.	O
,	O
2019	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2017	O
;	O
Stein	O
et	O
al	O
.	O
,	O
2020	O
)	O
-DOCSTART- -X- O O
In	O
this	O
6	O
-	O
week	O
randomized	O
trial	O
comparing	O
psilocybin	B-DRUG
with	O
escitalopram	B-ANTIDEPRESSANT_DRUG
in	O
patients	O
with	O
long	O
-	O
standing	O
,	O
mild	O
-	O
to	O
-	O
severe	O
depression	B-HEALTH CONDITION
,	O
the	O
change	O
in	O
depression	B-HEALTH CONDITION
scores	O
on	O
the	O
QIDS	O
-	O
SR-16	O
at	O
week	O
6	O
(	O
the	O
primary	O
outcome	O
)	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
trial	O
groups	O
.	O
Secondary	O
outcomes	O
generally	O
favored	O
psilocybin	B-DRUG
over	O
escitalopram	B-ANTIDEPRESSANT_DRUG
;	O
however	O
,	O
the	O
confidence	O
intervals	O
for	O
the	O
between	O
-	O
group	O
differences	O
were	O
not	O
adjusted	O
for	O
multiple	O
comparisons	O
,	O
and	O
no	O
conclusions	O
can	O
be	O
drawn	O
from	O
these	O
data	O
.	O
In	O
both	O
trial	O
groups	O
,	O
the	O
scores	O
on	O
the	O
depression	B-HEALTH CONDITION
scales	O
at	O
week	O
6	O
were	O
numerically	O
lower	O
than	O
the	O
baseline	O
scores	O
,	O
but	O
the	O
absence	O
of	O
a	O
placebo	O
group	O
in	O
the	O
trial	O
limits	O
conclusions	O
about	O
the	O
effect	O
of	O
either	O
agent	O
alone	O
.	O
The	O
incidence	O
of	O
adverse	B-OUTCOME
events	I-OUTCOME
was	O
similar	O
in	O
the	O
trial	O
groups	O
,	O
and	O
no	B-OUTCOME
serious	I-OUTCOME
adverse	I-OUTCOME
events	I-OUTCOME
occurred	I-OUTCOME
.	O
The	O
percentages	O
of	O
patients	O
who	O
had	O
anxiety	B-HEALTH CONDITION
,	O
dry	B-OUTCOME
mouth	I-OUTCOME
,	O
sexual	B-OUTCOME
dysfunction	I-OUTCOME
,	O
or	O
reduced	B-OUTCOME
emotional	I-OUTCOME
responsiveness	I-OUTCOME
were	O
higher	O
in	O
the	O
escitalopram	B-ANTIDEPRESSANT_DRUG
group	O
than	O
in	O
the	O
psilocybin	B-DRUG
group.19	O
Four	O
patients	O
in	O
the	O
escitalopram	B-ANTIDEPRESSANT_DRUG
group	O
stopped	O
taking	O
Four	O
patients	O
in	O
the	O
escitalopram	B-ANTIDEPRESSANT_DRUG
group	O
daily	O
capsules	O
entirely	O
,	O
and	O
1	O
patient	O
halved	O
the	O
dose	O
because	O
of	O
perceived	B-OUTCOME
adverse	I-OUTCOME
events	I-OUTCOME
.	O
No	O
patient	O
in	O
the	O
psilocybin	B-DRUG
group	O
requested	O
to	O
cancel	O
the	O
second	O
psilocybin	B-DRUG
dose	O
.	O
Three	O
patients	O
were	O
unable	O
to	O
attend	O
sessions	O
to	O
receive	O
the	O
second	O
psilocybin	B-DRUG
dose	O
owing	O
to	O
the	O
Covid-19	O
lockdown	O
(	O
2	O
patients	O
in	O
the	O
psilocybin	B-DRUG
group	O
and	O
1	O
in	O
the	O
escitalopram	O
group	O
)	O
.	O
The	O
most	O
common	O
adverse	B-OUTCOME
event	I-OUTCOME
in	O
the	O
psilocybin	B-DRUG
group	O
was	O
transient	B-OUTCOME
headache	I-OUTCOME
reported	O
within	O
24	O
hours	O
after	O
the	O
day	O
of	O
psilocybin	B-DRUG
dosing	O
.	O
The	O
incidence	O
of	O
headache	B-OUTCOME
was	O
similar	O
to	O
those	O
reported	O
in	O
previous	O
studies	O
of	O
psilocybin	B-DRUG
Acute	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
psilocybin	B-DRUG
relating	O
to	O
the	O
psychedelic	O
experience	O
were	O
not	O
included	O
as	O
adverse	B-OUTCOME
events	I-OUTCOME
in	O
our	O
trial	O
,	O
because	O
previous	O
studies	O
have	O
suggested	O
that	O
those	O
reported	O
in	O
previous	O
studies	O
of	O
psilocybin	B-DRUG
Acute	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
psilocybin	B-DRUG
relating	O
to	O
the	O
psychedelic	O
experience	O
may	O
have	O
a	O
mediating	B-OUTCOME
influence	I-OUTCOME
on	I-OUTCOME
positive	I-OUTCOME
outcomes.21	I-OUTCOME
The	O
altered	B-SUBJECTIVE EXPERIENCE
quality	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
conscious	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
typically	O
induced	O
by	O
a	O
25	O
-	O
mg	O
dose	O
of	O
psilocybin	B-DRUG
adds	O
complexity	O
to	O
this	O
treatment	O
model	O
,	O
because	O
this	O
treatment	O
model	O
requires	O
that	O
psychological	O
support	O
be	O
provided	O
to	O
patients	O
during	O
and	O
after	O
treatment	O
sessions.15	O
This	O
requirement	O
informed	O
this	O
trial	O
’s	O
screening	O
criteria	O
that	O
excluded	O
patients	O
with	O
preexisting	O
psychiatric	B-HEALTH CONDITION
conditions	I-HEALTH CONDITION
believed	O
to	O
be	O
incompatible	O
with	O
the	O
limited	O
psychological	O
support	O
that	O
could	O
be	O
made	O
available	O
within	O
the	O
trial	O
.	O
This	O
exclusion	O
criterion	O
may	O
have	O
biased	O
the	O
trial	O
sample	O
toward	O
patients	O
who	O
could	O
receive	O
psilocybin	B-DRUG
without	O
unacceptable	B-OUTCOME
side	I-OUTCOME
effects	I-OUTCOME
.	O
However	O
,	O
psychological	O
support	O
was	O
provided	O
for	O
both	O
groups	O
in	O
this	O
trial	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
adjunctive	O
psychological	B-OUTCOME
support	I-OUTCOME
improved	B-OUTCOME
outcomes	I-OUTCOME
among	O
those	O
in	O
the	O
escitalopram	B-ANTIDEPRESSANT_DRUG
group	O
A	O
limitation	O
of	O
the	O
trial	O
is	O
the	O
brief	O
duration	O
of	O
escitalopram	B-ANTIDEPRESSANT_DRUG
treatment	O
,	O
because	O
this	O
drug	O
has	O
a	O
delayed	B-OUTCOME
therapeutic	I-OUTCOME
action	I-OUTCOME
on	I-OUTCOME
depression.22	I-OUTCOME
Had	O
the	O
course	O
of	O
escitalopram	B-ANTIDEPRESSANT_DRUG
been	O
extended	O
,	O
it	O
is	O
possible	O
that	O
better	B-OUTCOME
efficacy	I-OUTCOME
would	O
have	O
been	O
observed	O
among	O
the	O
patients	O
in	O
the	O
escitalopram	B-ANTIDEPRESSANT_DRUG
group	O
.	O
Patients	O
who	O
received	O
the	O
25	O
-	O
mg	O
dose	O
of	O
psilocybin	B-DRUG
rated	O
the	O
intensity	O
of	O
acute	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
higher	O
than	O
patients	O
who	O
received	O
the	O
1	O
-	O
mg	O
dose	O
(	O
Fig	O
.	O
S7	O
)	O
.	O
We	O
did	O
not	O
assess	O
the	O
effectiveness	O
of	O
blinding	O
within	O
each	O
treatment	O
group	O
.	O
It	O
was	O
assumed	O
that	O
the	O
active	O
comparator	O
design	O
would	O
mitigate	O
expectancy	O
bias	O
,	O
but	O
we	O
can	O
not	O
be	O
confident	O
that	O
guessing	O
of	O
the	O
trial	O
-	O
group	O
assignment	O
or	O
biased	B-OUTCOME
expectations	I-OUTCOME
in	O
favor	O
of	O
psilocybin	B-DRUG
did	O
not	O
influence	O
the	O
results	O
.	O
Although	O
efforts	O
were	O
made	O
to	O
recruit	O
patients	O
by	O
external	O
referrals	O
,	O
most	O
of	O
the	O
recruited	O
volunteers	O
referred	O
the	O
recruited	O
volunteers	O
,	O
and	O
many	O
expressed	O
a	O
preference	O
for	O
psilocybin	B-DRUG
over	O
escitalopram	B-ANTIDEPRESSANT_DRUG
.	O
This	O
created	O
a	O
selected	O
trial	O
population	O
and	O
limits	O
generalization	O
of	O
the	O
results	O
The	O
patients	O
in	O
the	O
trial	O
were	O
not	O
from	O
diverse	O
ethnic	O
or	O
socioeconomic	O
backgrounds	O
.	O
Strategies	O
to	O
improve	O
recruitment	O
of	O
more	O
diverse	O
study	O
populations	O
are	O
needed	O
in	O
studies	O
of	O
psilocybin	B-DRUG
for	O
depression	B-HEALTH CONDITION
.	O
Also	O
,	O
average	O
symptom	O
severity	O
scores	O
at	O
baseline	O
were	O
in	O
the	O
range	O
for	O
moderate	O
depression	B-HEALTH CONDITION
,	O
thus	O
limiting	O
extrapolations	O
to	O
patients	O
with	O
severe	B-HEALTH CONDITION
depressive	I-HEALTH CONDITION
symptoms	I-HEALTH CONDITION
or	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
Psychedelic	B-DRUG
agents	I-DRUG
have	O
been	O
shown	O
to	O
enhance	B-OUTCOME
suggestibility,23	I-OUTCOME
and	O
treatment	B-OUTCOME
-	I-OUTCOME
resistant	I-OUTCOME
depression	I-OUTCOME
Psychedelic	B-DRUG
agents	I-DRUG
psychological	B-OUTCOME
effects	I-OUTCOME
are	O
assumed	O
to	O
be	O
context	O
-	O
dependent.24,25	O
In	O
other	O
words	O
,	O
the	O
content	O
and	O
subjective	B-SUBJECTIVE EXPERIENCE
quality	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
the	I-SUBJECTIVE EXPERIENCE
psychedelic	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
is	O
influenced	O
by	O
a	O
person	O
’s	O
memories	B-SUBJECTIVE EXPERIENCE
,	O
perceptions	B-SUBJECTIVE EXPERIENCE
,	O
and	O
degree	B-SUBJECTIVE EXPERIENCE
to	I-SUBJECTIVE EXPERIENCE
which	I-SUBJECTIVE EXPERIENCE
the	I-SUBJECTIVE EXPERIENCE
environment	I-SUBJECTIVE EXPERIENCE
is	I-SUBJECTIVE EXPERIENCE
supportive	I-SUBJECTIVE EXPERIENCE
at	O
the	O
time	O
of	O
administration	O
of	O
the	O
agent	O
.	O
In	O
a	O
study	O
in	O
which	O
various	O
psychedelic	B-DRUG
compounds	I-DRUG
were	O
administered	O
to	O
rats	O
,	O
the	O
compounds	B-DRUG
were	O
shown	O
to	O
increase	B-OUTCOME
dendritic	I-OUTCOME
arbor	I-OUTCOME
complexity	I-OUTCOME
,	O
promote	B-OUTCOME
dendritic	I-OUTCOME
spine	I-OUTCOME
growth	I-OUTCOME
,	O
and	O
stimulate	B-OUTCOME
synapse	I-OUTCOME
formation	I-OUTCOME
in	O
the	O
rat	O
cortex	O
,	O
mediated	O
by	O
serotonin	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonism,26	O
all	O
of	O
which	O
are	O
forms	O
of	O
neuronal	B-OUTCOME
plasticity	I-OUTCOME
that	O
may	O
be	O
related	O
to	O
the	O
principle	O
that	O
responses	O
to	O
psychedelics	B-DRUG
are	O
especially	O
dependent	O
on	O
contextual	O
conditions	O
This	O
trial	O
comparing	O
psilocybin	B-DRUG
with	O
escitalopram	B-ANTIDEPRESSANT_DRUG
in	O
a	O
selected	O
group	O
of	O
patients	O
showed	O
that	O
the	O
change	O
in	O
scores	O
for	O
depression	B-HEALTH CONDITION
at	O
6	O
weeks	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
trial	O
groups	O
.	O
Secondary	O
outcomes	O
mostly	O
favored	O
psilocybin	B-DRUG
over	O
escitalopram	B-ANTIDEPRESSANT_DRUG
,	O
but	O
the	O
confidence	O
intervals	O
for	O
the	O
between	O
-	O
group	O
differences	O
were	O
not	O
adjusted	O
for	O
multiple	O
comparisons	O
.	O
Larger	O
and	O
longer	O
trials	O
are	O
needed	O
to	O
compare	O
psilocybin	B-DRUG
with	O
established	O
treatments	O
for	O
depression	B-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
Increased	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	O
emotional	O
faces	O
were	O
observed	O
one	O
day	O
after	O
treatment	O
with	O
psilocybin	B-DRUG
for	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
.	O
Post	O
-	O
treatment	O
increases	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	O
fearful	O
versus	O
neutral	O
faces	O
were	O
related	O
to	O
a	O
successful	B-OUTCOME
clinical	I-OUTCOME
outcome	I-OUTCOME
one	O
week	O
later	O
Importantly	O
,	O
the	O
present	O
findings	O
are	O
in	O
contrast	O
to	O
observations	O
of	O
decreased	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
after	O
treatment	O
with	O
conventional	O
antidepressants	B-ANTIDEPRESSANT_DRUG
and	O
particularly	O
with	O
SSRIs	B-ANTIDEPRESSANT_DRUG
(	O
Ma	O
,	O
2015	O
)	O
.	O
It	O
has	O
been	O
proposed	O
that	O
decreased	B-OUTCOME
amygdala	I-OUTCOME
responsiveness	I-OUTCOME
to	O
negative	O
emotional	O
stimuli	O
under	O
SSRIs	B-ANTIDEPRESSANT_DRUG
is	O
a	O
key	O
component	O
of	O
SSRIs	B-ANTIDEPRESSANT_DRUG
therapeutic	B-OUTCOME
action	I-OUTCOME
(	O
Harmer	O
et	O
al	O
.	O
,	O
2017	O
)	O
,	O
but	O
the	O
present	O
study	O
's	O
findings	O
suggest	O
that	O
this	O
model	O
does	O
not	O
extend	O
to	O
the	O
therapeutic	B-OUTCOME
action	I-OUTCOME
of	O
psilocybin	B-DRUG
for	O
TRD	B-HEALTH CONDITION
(	O
Carhart	O
-	O
Harris	O
and	O
Nutt	O
,	O
2017	O
)	O
Observations	O
of	O
reduced	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	O
negative	O
emotional	O
stimuli	O
(	O
Ma	O
,	O
2015	O
)	O
and	O
reduced	B-OUTCOME
behavioural	I-OUTCOME
response	I-OUTCOME
biases	I-OUTCOME
to	I-OUTCOME
negative	I-OUTCOME
stimuli	I-OUTCOME
with	O
conventional	B-ANTIDEPRESSANT_DRUG
antidepressants	I-ANTIDEPRESSANT_DRUG
(	O
Harmer	O
et	O
al	O
.	O
,	O
2009	O
)	O
have	O
been	O
interpreted	O
as	O
evidence	O
of	O
a	O
functional	B-OUTCOME
remediation	I-OUTCOME
,	O
linked	O
to	O
the	O
correcting	B-OUTCOME
of	I-OUTCOME
negative	I-OUTCOME
cognitive	I-OUTCOME
biases	I-OUTCOME
in	O
depression	B-HEALTH CONDITION
.	O
However	O
,	O
it	O
is	O
suggested	O
that	O
chronically	B-ANTIDEPRESSANT_DRUG
-	I-ANTIDEPRESSANT_DRUG
used	I-ANTIDEPRESSANT_DRUG
antidepressants	I-ANTIDEPRESSANT_DRUG
have	O
a	O
more	O
generalised	B-OUTCOME
effect	I-OUTCOME
on	I-OUTCOME
emotional	I-OUTCOME
processing	I-OUTCOME
,	O
moderating	B-OUTCOME
not	I-OUTCOME
just	I-OUTCOME
responsiveness	I-OUTCOME
to	I-OUTCOME
negative	I-OUTCOME
emotional	I-OUTCOME
stimuli	I-OUTCOME
,	I-OUTCOME
but	I-OUTCOME
emotional	I-OUTCOME
stimuli	I-OUTCOME
more	I-OUTCOME
broadly	I-OUTCOME
(	O
Price	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Focusing	O
specifically	O
on	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
,	O
this	O
structure	O
is	O
known	O
to	O
be	O
generally	O
sensitive	O
to	O
emotional	O
salience	O
,	O
regardless	O
of	O
the	O
emotional	O
valence	O
of	O
the	O
stimuli	O
(	O
Adolphs	O
,	O
2010	O
,	O
Santos	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
It	O
is	O
possible	O
that	O
the	O
notion	O
that	O
SSRIs	B-ANTIDEPRESSANT_DRUG
have	O
a	O
selective	O
action	O
on	O
amygdala	B-NEURAL MECHANISM/CORRELATE
responses	O
to	O
negative	O
stimuli	O
is	O
fallible	O
,	O
and	O
rather	O
,	O
SSRIs	B-ANTIDEPRESSANT_DRUG
and	O
related	O
antidepressants	B-ANTIDEPRESSANT_DRUG
have	O
a	O
more	O
generalised	O
muting	B-OUTCOME
influence	I-OUTCOME
on	I-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
emotionally	I-OUTCOME
salient	I-OUTCOME
stimuli	I-OUTCOME
.	O
Relatedly	O
,	O
negative	O
stimuli	O
may	O
be	O
processed	O
as	O
especially	O
salient	O
,	O
and	O
thus	O
be	O
associated	O
with	O
greater	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
–	O
which	O
are	O
subsequently	O
hyper	B-OUTCOME
-	I-OUTCOME
sensitive	I-OUTCOME
to	I-OUTCOME
intervention	I-OUTCOME
-	I-OUTCOME
led	I-OUTCOME
change	I-OUTCOME
Reduced	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
emotional	I-OUTCOME
stimuli	I-OUTCOME
after	O
chronic	B-ANTIDEPRESSANT_DRUG
antidepressant	I-ANTIDEPRESSANT_DRUG
medication	I-ANTIDEPRESSANT_DRUG
has	O
been	O
linked	O
with	O
activation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
post	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
synaptic	I-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
1A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1ARs	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
,	O
which	O
have	O
an	O
inhibitory	O
action	O
on	O
pyramidal	O
cell	O
firing	O
(	O
Andrade	O
,	O
2011	O
)	O
and	O
are	O
densely	O
expressed	O
in	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
.	O
While	O
this	O
mechanism	O
has	O
a	O
solid	O
empirical	O
basis	O
(	O
Cowen	O
and	O
Browning	O
,	O
2015	O
,	O
Deakin	O
and	O
Graeff	O
,	O
1991	O
)	O
,	O
there	O
is	O
no	O
known	O
mechanism	O
to	O
explain	O
how	B-OUTCOME
5	I-OUTCOME
-	I-OUTCOME
HT1AR	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
attenuation	I-OUTCOME
of	I-OUTCOME
amygdala	I-OUTCOME
responsiveness	I-OUTCOME
can	O
selectively	O
apply	O
to	O
negative	O
stimuli	O
,	O
without	O
simultaneously	O
affecting	O
the	O
processing	B-OUTCOME
of	I-OUTCOME
positive	I-OUTCOME
stimuli	I-OUTCOME
of	O
an	O
equivalent	O
salience	O
.	O
Indeed	O
,	O
there	O
is	O
evidence	O
of	O
blunting	B-OUTCOME
of	I-OUTCOME
positive	I-OUTCOME
mood	I-OUTCOME
with	O
SSRIs	B-ANTIDEPRESSANT_DRUG
(	O
Price	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Moreover	O
the	O
relative	O
ineffectiveness	O
of	O
conventional	O
serotonergic	B-ANTIDEPRESSANT_DRUG
antidepressant	I-ANTIDEPRESSANT_DRUG
medications	I-ANTIDEPRESSANT_DRUG
to	O
alleviate	O
anhedonia	B-HEALTH CONDITION
may	O
be	O
explained	O
by	O
a	O
generalised	O
moderation	B-OUTCOME
of	I-OUTCOME
emotional	I-OUTCOME
responsiveness	I-OUTCOME
with	I-OUTCOME
these	I-OUTCOME
drugs	I-OUTCOME
(	O
McCabe	O
et	O
al	O
.	O
,	O
2010	O
)	O
We	O
recently	O
carried	O
out	O
a	O
qualitative	O
analysis	O
of	O
patient	O
experiences	O
from	O
this	O
clinical	O
trial	O
,	O
asking	O
patients	O
whether	O
psilocybin	B-DRUG
with	O
psychological	O
support	O
has	O
been	O
effective	O
for	O
patients	O
,	O
and	O
if	O
so	O
,	O
how	O
?	O
Since	O
the	O
majority	O
of	O
patients	O
reported	B-OUTCOME
improvements	I-OUTCOME
with	I-OUTCOME
the	I-OUTCOME
treatment	I-OUTCOME
,	O
most	O
answered	O
in	O
the	O
affirmative	O
and	O
described	O
a	O
greater	B-OUTCOME
willingness	I-OUTCOME
to	I-OUTCOME
accept	I-OUTCOME
all	I-OUTCOME
emotions	I-OUTCOME
post	I-OUTCOME
-	I-OUTCOME
treatment	I-OUTCOME
(	O
including	O
negative	O
ones	O
)	O
.	O
These	O
effects	O
were	O
often	O
contrasted	O
with	O
those	O
of	O
These	O
effects	O
previous	B-ANTIDEPRESSANT_DRUG
depression	I-ANTIDEPRESSANT_DRUG
treatments	I-ANTIDEPRESSANT_DRUG
which	O
These	O
effects	O
described	O
as	O
working	O
to	O
reinforce	O
emotional	B-OUTCOME
avoidance	I-OUTCOME
and	I-OUTCOME
disconnection	I-OUTCOME
(	O
Watts	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Conversely	O
,	O
psilocybin	B-DRUG
was	O
said	O
to	O
make	B-OUTCOME
emotional	I-OUTCOME
‘	I-OUTCOME
confrontation	I-OUTCOME
’	I-OUTCOME
more	I-OUTCOME
likely	I-OUTCOME
,	O
and	O
the	O
accompanying	O
psychological	O
support	O
helped	O
patients	O
achieve	O
an	O
emotional	B-OUTCOME
breakthrough	I-OUTCOME
(	O
catharsis	O
)	O
and	O
resolution	B-OUTCOME
(	O
Eisner	O
and	O
Cohen	O
,	O
1958	O
,	O
Gasser	O
et	O
al	O
.	O
,	O
2014b	O
)	O
.	O
Consistently	O
,	O
recent	O
work	O
has	O
suggested	O
that	O
overcoming	B-OUTCOME
challenging	I-OUTCOME
emotional	I-OUTCOME
phenomena	I-OUTCOME
under	O
a	O
psychedelic	B-DRUG
is	O
predictive	O
of	O
better	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
mental	I-OUTCOME
health	I-OUTCOME
outcomes	I-OUTCOME
(	O
Carbonaro	O
et	O
al	O
.	O
,	O
2016	O
)	O
It	O
is	O
important	O
to	O
highlight	O
an	O
important	O
discrepancy	O
between	O
the	O
present	O
results	O
,	O
observed	O
post	O
acutely	O
in	O
patients	O
treated	O
with	O
psilocybin	B-DRUG
for	O
major	B-HEALTH CONDITION
depression	I-HEALTH CONDITION
viewing	O
emotional	O
faces	O
and	O
those	O
from	O
a	O
previous	O
study	O
in	O
which	O
amygdala	B-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
emotional	I-OUTCOME
stimuli	I-OUTCOME
(	O
not	O
faces	O
)	O
were	O
assessed	O
during	O
the	O
acute	O
psilocybin	B-DRUG
‘	O
high	O
’	O
in	O
healthy	O
individuals	O
(	O
Kraehenmann	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
This	O
latter	O
study	O
reported	O
unspecific	O
decreases	B-OUTCOME
in	I-OUTCOME
right	I-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	O
negative	O
and	O
neutral	O
stimuli	O
under	O
psilocybin	B-DRUG
,	O
which	O
,	O
based	O
on	O
the	O
aforementioned	O
similarities	O
with	O
the	O
action	O
of	O
conventional	B-ANTIDEPRESSANT_DRUG
antidepressants	I-ANTIDEPRESSANT_DRUG
,	O
the	O
authors	O
interpreted	O
as	O
supporting	O
an	O
antidepressant	B-OUTCOME
action	I-OUTCOME
for	O
psilocybin	B-DRUG
.	O
We	O
advise	O
caution	O
with	O
this	O
interpretation	O
however	O
,	O
not	O
least	O
because	O
We	O
pre	O
versus	O
post	O
resting	O
-	O
state	O
fMRI	O
findings	O
suggest	O
that	O
post	O
-	O
acute	O
changes	B-OUTCOME
in	I-OUTCOME
spontaneous	I-OUTCOME
brain	I-OUTCOME
function	I-OUTCOME
are	O
very	O
different	O
if	O
not	O
antithetical	O
to	O
psilocybin	B-DRUG
's	O
acute	B-OUTCOME
brain	I-OUTCOME
effects	I-OUTCOME
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Moreover	O
,	O
findings	O
of	O
‘	O
attenuated	B-OUTCOME
responses	I-OUTCOME
’	O
with	O
potent	O
interventions	O
may	O
be	O
explained	O
by	O
compromised	O
task	O
engagement	O
.	O
A	O
consistent	O
explanation	O
has	O
been	O
used	O
to	O
account	O
for	O
apparent	O
functional	B-OUTCOME
impairments	I-OUTCOME
in	O
imaging	O
studies	O
of	O
pathological	O
states	O
such	O
as	O
schizophrenia	B-HEALTH CONDITION
,	O
i.e.	O
impoverished	O
responses	O
are	O
observed	O
because	O
patients	O
do	O
not	O
properly	O
engage	O
with	O
the	O
task	O
and	O
its	O
stimuli	O
(	O
Corbetta	O
et	O
al	O
.	O
,	O
1990	O
,	O
Rees	O
et	O
al	O
.	O
,	O
1997	O
)	O
It	O
is	O
important	O
to	O
acknowledge	O
the	O
limitations	O
of	O
the	O
present	O
study	O
.	O
It	O
would	O
be	O
interesting	O
to	O
collect	O
longer	O
-	O
term	O
imaging	O
data	O
than	O
the	O
1	O
-	O
day	O
post	O
treatment	O
scanning	O
point	O
chosen	O
here	O
(	O
e.g.	O
one	O
week	O
and	O
one	O
month	O
after	O
treatment	O
with	O
psilocybin	B-DRUG
)	O
.	O
If	O
feasible	O
,	O
it	O
would	O
also	O
be	O
interesting	O
to	O
collect	O
imaging	O
data	O
during	O
the	O
acute	O
experience	O
to	O
see	O
how	O
this	O
relates	O
to	O
post	B-OUTCOME
treatment	I-OUTCOME
brain	I-OUTCOME
changes	I-OUTCOME
.	O
Future	O
work	O
may	O
look	O
to	O
combine	O
PET	O
and	O
fMRI	O
to	O
systematically	O
address	O
potential	O
relationships	O
between	O
receptor	B-NEURAL MECHANISM/CORRELATE
densities	I-NEURAL MECHANISM/CORRELATE
and	O
functional	B-OUTCOME
brain	I-OUTCOME
measures	I-OUTCOME
before	O
and	O
after	O
treatment	O
with	O
psilocybin	B-DRUG
.	O
The	O
recruitment	O
of	O
a	O
healthy	O
control	O
group	O
,	O
receiving	O
the	O
same	O
interventions	O
would	O
also	O
add	O
value	O
,	O
as	O
would	O
the	O
inclusion	O
of	O
a	O
meaningful	O
comparator	O
condition	O
such	O
as	O
psilocybin	B-DRUG
alone	O
versus	O
psilocybin	B-DRUG
in	O
combination	O
with	O
psychological	O
support	O
,	O
plus	O
the	O
same	O
for	O
placebo	O
and	O
perhaps	O
an	O
active	O
pharmacological	O
control	O
,	O
such	O
as	O
an	O
SSRI	B-ANTIDEPRESSANT_DRUG
and/or	O
methylphenidate	B-DRUG
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
As	O
this	O
study	O
was	O
not	O
placebo	O
controlled	O
,	O
the	O
contribution	O
of	O
psilocybin	B-DRUG
with	O
psychological	O
support	O
can	O
not	O
be	O
differentiated	O
from	O
psychological	O
support	O
and	O
other	O
aspects	O
of	O
the	O
therapy	O
.	O
It	O
would	O
also	O
be	O
worthwhile	O
to	O
see	O
if	O
the	O
present	O
results	O
extend	O
to	O
a	O
less	O
severe	O
population	O
of	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
,	O
including	O
those	O
with	O
less	O
extensive	O
histories	O
of	O
exposure	O
to	O
psychiatric	O
medication	O
Psilocybin	B-DRUG
represents	O
a	O
novel	B-OUTCOME
intervention	I-OUTCOME
for	I-OUTCOME
major	I-OUTCOME
depression	I-OUTCOME
that	O
appears	O
to	O
be	O
safe	B-OUTCOME
,	I-OUTCOME
rapid	I-OUTCOME
and	I-OUTCOME
potentially	I-OUTCOME
enduring	I-OUTCOME
in	I-OUTCOME
its	I-OUTCOME
antidepressant	I-OUTCOME
action	I-OUTCOME
.	O
Furthermore	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
psilocybin	B-DRUG
's	O
abuse	B-OUTCOME
potential	I-OUTCOME
is	I-OUTCOME
low	I-OUTCOME
(	O
Johnson	O
and	O
Griffiths	O
,	O
2017	O
)	O
.	O
The	O
original	O
rationale	O
for	O
using	O
psychedelic	B-DRUG
(	O
‘	O
mind	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
revealing	I-SUBJECTIVE EXPERIENCE
’	O
)	O
drugs	O
as	O
aides	O
to	O
psychotherapy	O
was	O
that	O
they	O
serve	O
to	O
dismantle	B-OUTCOME
psychological	I-OUTCOME
defences	I-OUTCOME
,	O
allowing	O
suppressed	B-OUTCOME
emotional	I-OUTCOME
material	I-OUTCOME
to	I-OUTCOME
surface	I-OUTCOME
,	O
sometimes	O
with	O
cathartic	B-OUTCOME
effect	I-OUTCOME
(	O
Eisner	O
and	O
Cohen	O
,	O
1958	O
,	O
Gasser	O
et	O
al	O
.	O
,	O
2014b	O
,	O
Grof	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
The	O
present	O
findings	O
of	O
increased	B-OUTCOME
amygdala	I-OUTCOME
responsiveness	I-OUTCOME
post	O
psilocybin	B-DRUG
resonate	O
with	O
patients	O
'	O
descriptions	O
of	O
feeling	B-OUTCOME
emotionally	I-OUTCOME
re	I-OUTCOME
-	I-OUTCOME
connected	I-OUTCOME
and	I-OUTCOME
accepting	I-OUTCOME
after	O
the	O
treatment	O
(	O
Watts	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
The	O
finding	O
of	O
a	O
relationship	O
between	O
increased	B-OUTCOME
right	I-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
fearful	I-OUTCOME
>	I-OUTCOME
neutral	I-OUTCOME
faces	I-OUTCOME
post	O
treatment	O
and	O
subsequent	O
clinical	O
improvements	O
adds	O
further	O
endorsement	O
to	O
this	O
interpretation	O
.	O
Future	O
work	O
is	O
required	O
to	O
test	O
the	O
replicability	O
of	O
these	O
findings	O
and	O
test	O
whether	O
enhanced	B-OUTCOME
amygdala	I-OUTCOME
responsiveness	I-OUTCOME
is	O
related	O
to	O
the	O
potentially	O
enduring	B-OUTCOME
positive	I-OUTCOME
mood	I-OUTCOME
effects	I-OUTCOME
of	I-OUTCOME
psychedelics	I-OUTCOME
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
,	O
Schmid	O
and	O
Liechti	O
,	O
2017	O
)	O
.	O
If	O
confirmed	O
,	O
this	O
would	O
suggest	O
an	O
alternative	O
neurobiological	B-NEURAL MECHANISM/CORRELATE
basis	I-NEURAL MECHANISM/CORRELATE
to	O
the	O
alleviation	B-OUTCOME
of	I-OUTCOME
depressive	I-OUTCOME
symptoms	I-OUTCOME
distinct	O
from	O
that	O
of	O
the	O
SSRI	B-ANTIDEPRESSANT_DRUG
antidepressants	I-ANTIDEPRESSANT_DRUG
(	O
Carhart	O
-	O
Harris	O
and	O
Nutt	O
,	O
2017	O
)	O
“	O
“	O
I	O
felt	O
so	O
much	O
lighter	O
,	O
like	O
something	O
had	O
been	O
released	O
,	O
it	O
was	O
an	O
emotional	O
purging	O
,	O
the	O
weight	O
and	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
had	O
been	O
lifted	O
.	O
”	O
“	O
“	O
I	O
have	O
felt	O
a	B-OUTCOME
sense	I-OUTCOME
of	I-OUTCOME
acceptance	I-OUTCOME
;	O
more	B-OUTCOME
acceptance	I-OUTCOME
of	I-OUTCOME
agony	I-OUTCOME
,	I-OUTCOME
boredom	I-OUTCOME
,	I-OUTCOME
loneliness	I-OUTCOME
.	O
[	O
A	O
]	O
willingness	B-OUTCOME
to	I-OUTCOME
try	I-OUTCOME
to	I-OUTCOME
accept	I-OUTCOME
the	I-OUTCOME
negative	I-OUTCOME
times	I-OUTCOME
-	I-OUTCOME
but	I-OUTCOME
also	I-OUTCOME
an	I-OUTCOME
appreciation	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
wonderful	I-OUTCOME
times	I-OUTCOME
.	O
”	O
-DOCSTART- -X- O O
Scientific	O
interest	O
in	O
the	O
effects	O
of	O
psychedelics	B-DRUG
has	O
risen	O
sharply	O
in	O
the	O
past	O
decade	O
.	O
Preclinical	O
and	O
clinical	O
studies	O
leveraging	O
modern	O
neuroscientific	O
methods	O
have	O
produced	O
various	O
novel	O
results	O
with	O
significant	O
implications	O
for	O
understanding	O
the	O
neuropharmacology	O
of	O
human	O
cognition	B-SUBJECTIVE EXPERIENCE
,	O
emotion	B-SUBJECTIVE EXPERIENCE
and	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
regulation	I-SUBJECTIVE EXPERIENCE
,	O
discovering	O
potential	O
trans	B-OUTCOME
-	I-OUTCOME
diagnostic	I-OUTCOME
treatment	I-OUTCOME
mechanisms	I-OUTCOME
in	I-OUTCOME
psychiatry	I-OUTCOME
and	O
the	O
development	B-OUTCOME
of	I-OUTCOME
novel	I-OUTCOME
rapid	I-OUTCOME
-	I-OUTCOME
acting	I-OUTCOME
and	I-OUTCOME
long	I-OUTCOME
-	I-OUTCOME
lasting	I-OUTCOME
treatment	I-OUTCOME
approaches	I-OUTCOME
Pharmacological	O
challenge	O
studies	O
investigating	O
the	O
acute	O
effects	O
of	O
single	O
doses	O
of	O
psychedelics	B-DRUG
in	O
healthy	O
human	O
participants	O
have	O
revealed	O
important	O
insights	O
into	O
the	O
role	O
of	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
in	O
human	B-SUBJECTIVE EXPERIENCE
cognition	I-SUBJECTIVE EXPERIENCE
,	O
emotion	B-SUBJECTIVE EXPERIENCE
and	O
self	O
-	O
regulation	B-SUBJECTIVE EXPERIENCE
.	O
These	O
studies	O
have	O
shown	O
that	O
this	O
specific	O
receptor	O
system	O
is	O
implicated	O
in	O
modulating	O
social	O
functioning	O
,	O
mood	O
regulation	O
and	O
coherent	O
self	O
-	O
representations	O
.	O
Importantly	O
,	O
these	O
studies	O
have	O
also	O
revealed	O
the	O
importance	O
of	O
targeting	O
and	O
studying	O
specific	O
sub	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
systems	I-NEURAL MECHANISM/CORRELATE
to	O
be	O
able	O
to	O
conclusively	O
understand	O
human	O
psychopharmacology	O
and	O
eventually	O
be	O
able	O
to	O
inform	O
the	O
development	O
of	O
new	O
pharmacological	O
therapeutics	O
Recent	O
neuroimaging	O
studies	O
have	O
furthermore	O
started	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
ways	O
in	O
which	O
psychedelics	B-DRUG
temporarily	O
change	O
the	B-OUTCOME
functional	I-OUTCOME
architecture	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
brain	I-OUTCOME
.	O
Although	O
different	O
analytical	O
approaches	O
often	O
limit	O
the	O
comparability	O
between	O
studies	O
(	O
see	O
Box	O
2	O
)	O
,	O
some	O
congruent	O
patterns	O
have	O
started	O
to	O
emerge	O
.	O
Changes	O
in	O
functional	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
directed	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
between	O
the	O
thalamus	B-NEURAL MECHANISM/CORRELATE
and	O
cortical	B-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
have	O
been	O
reported	O
across	O
different	O
analysis	O
techniques31,70,71	O
.	O
In	O
addition	O
,	O
increased	B-NEURAL MECHANISM/CORRELATE
synchrony	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
sensory	I-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
and	O
decreased	B-NEURAL MECHANISM/CORRELATE
integrity	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
associative	I-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
(	O
including	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
frontoparietal	B-NEURAL MECHANISM/CORRELATE
control	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
)	O
have	O
been	O
reported	O
after	O
the	O
administration	O
of	O
LSD	B-DRUG
,	O
psilocybin	B-DRUG
and	O
DMT31,78,79,83,86,87,89,96,153	O
.	O
However	O
,	O
it	O
has	O
to	O
be	O
noted	O
that	O
some	O
of	O
these	O
effects	O
are	O
sensitive	O
to	O
GSR	O
as	O
outlined	O
in	O
Box	O
2	O
.	O
Increases	O
in	O
various	O
measures	O
of	O
entropy	B-OUTCOME
and	O
signal	B-OUTCOME
complexity	I-OUTCOME
have	O
also	O
been	O
reported	O
after	O
the	O
administration	O
of	O
LSD	B-DRUG
,	O
psilocybin	B-DRUG
and	O
DMT101,102,104,105,106	O
.	O
Other	O
analytical	O
approaches	O
,	O
such	O
as	O
the	O
investigation	O
of	O
between	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
during	O
the	O
resting	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
,	O
have	O
so	O
far	O
revealed	O
inconsistent	O
results	O
or	O
still	O
need	O
replication	O
.	O
These	O
results	O
support	O
hypotheses	O
that	O
are	O
not	O
mutually	O
exclusive	O
but	O
,	O
rather	O
,	O
reflect	O
different	O
aspects	O
of	O
changes	O
in	O
neuronal	B-NEURAL MECHANISM/CORRELATE
dynamics	I-NEURAL MECHANISM/CORRELATE
.	O
It	O
is	O
conceivable	O
that	O
future	O
studies	O
will	O
reveal	O
a	O
more	O
detailed	O
(	O
in	O
terms	O
of	O
both	O
spatial	O
and	O
temporal	O
resolution	O
)	O
pattern	O
of	O
psychedelic	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
brain	I-OUTCOME
connectivity	I-OUTCOME
that	O
will	O
allow	O
one	O
to	O
better	O
associate	O
these	O
neuronal	O
effects	O
with	O
specific	O
psychedelic	O
-	O
induced	O
subjective	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
Studies	O
of	O
the	O
effects	O
of	O
psychedelics	B-DRUG
in	O
healthy	O
participants	O
have	O
shown	O
that	O
these	O
substances	O
modulate	B-OUTCOME
a	I-OUTCOME
person	I-OUTCOME
’s	I-OUTCOME
self	I-OUTCOME
-	I-OUTCOME
focus	I-OUTCOME
,	O
reduce	B-OUTCOME
negative	I-OUTCOME
emotional	I-OUTCOME
processing	I-OUTCOME
and	O
strengthen	B-OUTCOME
social	I-OUTCOME
functioning12,120,138	O
.	O
Patients	O
across	O
different	O
disorders	O
who	O
underwent	O
treatment	O
with	O
psychedelics	B-DRUG
identified	O
these	O
effects	O
as	O
contributing	O
to	O
treatment	O
success149,150	O
.	O
These	O
experiences	O
may	O
therefore	O
represent	O
trans	B-OUTCOME
-	I-OUTCOME
diagnostic	I-OUTCOME
mechanisms	I-OUTCOME
for	O
the	O
treatment	O
of	O
psychiatric	B-HEALTH CONDITION
illnesses	I-HEALTH CONDITION
within	O
and	O
beyond	O
the	O
framework	O
of	O
psychedelic	O
-	O
assisted	O
therapy	O
.	O
Additionally	O
,	O
preclinical	O
results	O
point	O
to	O
the	O
potential	O
of	O
induced	B-OUTCOME
neuroplasticity	I-OUTCOME
as	O
a	O
promising	O
neuronal	O
mechanism	O
that	O
could	O
be	O
leveraged	O
in	O
psychotherapy	O
Lastly	O
,	O
studies	O
in	O
patient	O
populations	O
show	O
that	O
psychedelics	B-DRUG
may	O
constitute	O
promising	O
therapeutic	B-OUTCOME
agents	I-OUTCOME
that	O
represent	O
a	O
novel	O
treatment	O
model	O
in	O
psychiatry	O
:	O
psychedelics	B-DRUG
may	O
constitute	O
promising	O
therapeutic	B-OUTCOME
agents	I-OUTCOME
that	O
represent	O
a	O
novel	O
treatment	O
model	O
in	O
psychiatry	O
have	O
been	O
shown	O
to	O
act	B-OUTCOME
rapidly	I-OUTCOME
and	O
to	O
have	O
long	B-OUTCOME
-	I-OUTCOME
lasting	I-OUTCOME
effects	I-OUTCOME
after	O
only	O
a	O
few	O
doses	O
.	O
This	O
is	O
in	O
stark	O
contrast	O
to	O
the	O
current	O
treatment	O
approaches	O
in	O
psychiatry	O
,	O
which	O
usually	O
consist	O
of	O
a	O
regular	O
intake	O
of	O
psychotropic	B-ANTIDEPRESSANT_DRUG
medication	I-ANTIDEPRESSANT_DRUG
.	O
However	O
,	O
many	O
open	O
questions	O
remain	O
.	O
The	O
exact	O
mechanisms	B-NEURAL MECHANISM/CORRELATE
underlying	O
the	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
are	O
still	O
not	O
well	O
understood	O
and	O
beneficial	O
clinical	O
results	O
need	O
to	O
be	O
replicated	O
in	O
larger	O
trials	O
.	O
It	O
is	O
unclear	O
whether	O
the	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
of	O
these	O
substances	O
are	O
due	O
to	O
these	O
substances	O
direct	O
effects	O
on	O
brain	B-NEURAL MECHANISM/CORRELATE
activity	I-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
or	O
due	O
to	O
the	O
cognitive	B-SUBJECTIVE EXPERIENCE
and	I-SUBJECTIVE EXPERIENCE
psychological	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
of	O
an	O
altered	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
.	O
In	O
other	O
words	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
conscious	O
experience	O
of	O
the	O
psychedelic	B-DRUG
-	O
induced	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
is	O
necessary	O
for	O
therapeutic	B-OUTCOME
efficacy	I-OUTCOME
.	O
Furthermore	O
,	O
the	O
field	O
still	O
needs	O
to	O
uncover	O
individual	O
predictors	O
or	O
biomarkers	O
of	O
treatment	B-OUTCOME
efficacy	I-OUTCOME
.	O
The	O
impact	O
of	O
different	O
approaches	O
to	O
accompanying	O
psychotherapy	O
will	O
also	O
require	O
empirical	O
investigation	O
.	O
Accompanying	O
psychotherapy	O
may	O
turn	O
out	O
to	O
be	O
of	O
critical	O
importance	O
,	O
if	O
the	O
proposed	O
neuroplastic	B-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
indeed	O
contribute	O
to	O
Accompanying	O
psychotherapy	O
clinical	B-OUTCOME
efficacy	I-OUTCOME
.	O
Using	O
psychedelics	B-DRUG
in	O
a	O
clinical	O
setting	O
can	O
therefore	O
be	O
understood	O
as	O
pharmacologically	O
assisted	O
psychotherapy	O
that	O
leverages	O
the	O
molecular	B-OUTCOME
,	I-OUTCOME
systems	I-OUTCOME
-	I-OUTCOME
level	I-OUTCOME
and	I-OUTCOME
functional	I-OUTCOME
alterations	I-OUTCOME
induced	O
by	O
psychedelic	B-DRUG
substances	I-DRUG
.	O
-DOCSTART- -X- O O
Several	O
clinical	O
studies	O
have	O
demonstrated	O
that	O
acute	O
,	O
hallucinogenic	O
doses	O
of	O
psychedelic	B-DRUG
compounds	I-DRUG
can	O
produce	O
rapid	B-OUTCOME
,	I-OUTCOME
long	I-OUTCOME
-	I-OUTCOME
lasting	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
behavior	I-OUTCOME
in	O
humans	O
.	O
(	O
43−45	O
)	O
Recent	O
data	O
also	O
suggests	O
that	O
a	O
single	O
hallucinogenic	O
dose	O
of	O
DMT	B-DRUG
can	O
change	B-OUTCOME
rodent	I-OUTCOME
brain	I-OUTCOME
structure	I-OUTCOME
and	I-OUTCOME
behavior	I-OUTCOME
long	O
after	O
the	O
drug	O
has	O
been	O
cleared	O
from	O
the	O
body	O
.	O
(	O
16,24	O
)	O
Furthermore	O
,	O
we	O
previously	O
demonstrated	O
that	O
a	O
nonhallucinogenic	O
1	O
mg	O
/	O
kg	O
dose	O
of	O
DMT	B-DRUG
leads	O
to	O
increased	B-OUTCOME
frequency	I-OUTCOME
and	I-OUTCOME
amplitude	I-OUTCOME
of	I-OUTCOME
spontaneous	I-OUTCOME
excitatory	I-OUTCOME
postsynaptic	I-OUTCOME
currents	I-OUTCOME
(	O
sEPSCs	O
)	O
in	O
layer	B-NEURAL MECHANISM/CORRELATE
V	I-NEURAL MECHANISM/CORRELATE
pyramidal	I-NEURAL MECHANISM/CORRELATE
neurons	I-NEURAL MECHANISM/CORRELATE
of	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
24	O
h	O
after	O
administration	O
.	O
(	O
16	O
)	O
Therefore	O
,	O
we	O
hypothesized	O
that	O
administering	O
DMT	B-DRUG
on	O
a	O
chronic	O
,	O
intermittent	O
,	O
low	O
dose	O
regimen	O
—	O
similar	O
to	O
psychedelic	B-DRUG
microdosing	I-DRUG
—	O
might	B-OUTCOME
alter	I-OUTCOME
behavior	I-OUTCOME
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
has	O
only	O
been	O
one	O
peer	O
-	O
reviewed	O
scientific	O
report	O
on	O
the	O
effects	O
of	O
psychedelic	B-DRUG
microdosing	I-DRUG
in	O
rodents	O
.	O
This	O
study	O
employed	O
three	O
doses	O
of	O
psilocin	B-DRUG
spaced	O
over	O
6	O
days	O
,	O
with	O
behavioral	O
testing	O
occurring	O
48	O
h	O
after	O
the	O
final	O
dose	O
.	O
(	O
46	O
)	O
In	O
agreement	O
with	O
our	O
findings	O
,	O
the	O
authors	O
report	O
no	O
statistically	O
significant	O
changes	B-OUTCOME
in	I-OUTCOME
EPM	I-OUTCOME
behavior	I-OUTCOME
when	O
two	O
-	O
tailed	O
statistical	O
tests	O
were	O
employed	O
.	O
The	O
distinct	O
lack	B-OUTCOME
of	I-OUTCOME
robust	I-OUTCOME
anxiogenic	I-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effects	I-OUTCOME
following	O
chronic	O
,	O
intermittent	O
,	O
low	O
doses	O
of	O
psychedelics	B-DRUG
is	O
striking	O
when	O
compared	O
to	O
the	O
effects	O
of	O
acute	O
high	O
doses	O
.	O
A	O
hallucinogenic	O
dose	O
of	O
DMT	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
)	O
decreases	O
exploratory	B-OUTCOME
behavior	I-OUTCOME
in	O
the	O
NIL	O
paradigm	O
(	O
i.e.	O
,	O
both	O
locomotion	O
and	O
rearing	O
)	O
,	O
decreases	B-OUTCOME
the	I-OUTCOME
number	I-OUTCOME
of	I-OUTCOME
open	I-OUTCOME
arm	I-OUTCOME
entries	I-OUTCOME
in	O
the	O
EPM	O
,	O
and	O
increases	B-OUTCOME
freezing	I-OUTCOME
behavior	I-OUTCOME
immediately	O
following	O
the	O
administration	O
of	O
foot	O
shocks	O
.	O
(	O
24	O
)	O
None	O
of	O
these	O
effects	O
are	O
observed	O
when	O
a	O
subhallucinogenic	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
DMT	B-DRUG
is	O
administered	O
on	O
a	O
chronic	O
intermittent	O
schedule	O
(	O
Figures	O
2	O
and	O
3c	O
)	O
Unlike	O
the	O
anxiogenic	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effects	I-OUTCOME
produced	O
by	O
an	O
acute	O
hallucinogenic	O
dose	O
of	O
DMT	B-DRUG
,	O
the	O
beneficial	B-OUTCOME
effects	I-OUTCOME
on	I-OUTCOME
fear	I-OUTCOME
extinction	I-OUTCOME
learning	I-OUTCOME
and	O
forced	O
swim	O
behavior	O
(	O
24	O
)	O
are	O
reproduced	O
by	O
the	O
chronic	O
,	O
intermittent	O
low	O
dose	O
regimen	O
(	O
Figures	O
3f	O
and	O
4	O
)	O
.	O
These	O
antidepressant	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effects	I-OUTCOME
are	O
consistent	O
with	O
the	O
anecdotal	O
human	O
reports	O
regarding	O
psychedelic	B-DRUG
microdosing	I-DRUG
providing	O
strong	O
supporting	O
evidence	O
that	O
psychedelic	B-DRUG
microdosing	I-DRUG
might	O
actually	O
have	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
.	O
Compounds	O
capable	O
of	O
enhancing	O
fear	B-OUTCOME
extinction	I-OUTCOME
learning	O
in	O
rodents	O
,	O
such	O
as	O
3,4	O
-	O
methylenedioxymethamphetamine	O
(	O
MDMA	B-DRUG
)	O
,	O
(	O
47,48	O
)	O
are	O
excellent	O
candidates	O
for	O
treating	O
PTSD	B-HEALTH CONDITION
symptoms	O
in	O
humans	O
We	O
hypothesize	O
that	O
chronic	O
,	O
intermittent	O
low	O
doses	O
of	O
DMT	B-DRUG
increase	B-OUTCOME
the	I-OUTCOME
excitability	I-OUTCOME
of	I-OUTCOME
pyramidal	I-OUTCOME
neurons	I-OUTCOME
in	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
that	O
project	O
to	O
the	O
basolateral	O
amygdala	B-NEURAL MECHANISM/CORRELATE
and	O
dorsal	B-NEURAL MECHANISM/CORRELATE
raphe	I-NEURAL MECHANISM/CORRELATE
nucleus	I-NEURAL MECHANISM/CORRELATE
to	O
decrease	O
the	O
expression	B-OUTCOME
of	I-OUTCOME
conditioned	I-OUTCOME
fear	I-OUTCOME
responses	I-OUTCOME
and	O
increase	B-OUTCOME
swimming	I-OUTCOME
behavior	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
forced	I-OUTCOME
swim	I-OUTCOME
test	I-OUTCOME
,	O
respectively	O
.	O
DMT	B-DRUG
and	O
other	O
psychedelics	B-DRUG
are	O
potent	O
psychoplastogens	O
—	O
compounds	O
capable	O
of	O
promoting	B-OUTCOME
the	I-OUTCOME
rapid	I-OUTCOME
growth	I-OUTCOME
of	I-OUTCOME
dendritic	I-OUTCOME
branches	I-OUTCOME
,	I-OUTCOME
spines	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
synapses	I-OUTCOME
—	O
due	O
to	O
DMT	B-DRUG
and	O
other	O
psychedelics	B-DRUG
ability	O
to	O
stimulate	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
mTOR	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
through	O
activation	O
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
.	O
(	O
16	O
)	O
These	O
receptors	O
are	O
enriched	O
in	O
the	O
prefrontal	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
an	O
area	O
of	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
that	O
is	O
known	O
to	O
exert	O
top	O
-	O
down	O
control	O
over	O
mood	O
and	O
anxiety	B-HEALTH CONDITION
.	O
It	O
is	O
likely	O
that	O
the	O
behavioral	B-OUTCOME
changes	I-OUTCOME
induced	O
by	O
chronic	O
,	O
intermittent	O
low	O
doses	O
of	O
DMT	B-DRUG
are	O
the	O
result	O
of	O
positive	B-NEURAL MECHANISM/CORRELATE
neuroadaptations	I-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
circuits	I-NEURAL MECHANISM/CORRELATE
involving	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
that	O
are	O
relevant	O
to	O
fear	B-OUTCOME
extinction	I-OUTCOME
(	O
22	O
)	O
and	O
effortful	B-OUTCOME
response	I-OUTCOME
to	I-OUTCOME
behavioral	I-OUTCOME
challenge	I-OUTCOME
(	O
i.e.	O
,	O
FST	O
)	O
(	O
21	O
)	O
as	O
DMT	B-DRUG
has	O
an	O
extremely	O
short	O
half	O
-	O
life	O
in	O
rats	O
(	O
ca	O
.	O
15	O
min	O
)	O
(	O
49	O
)	O
and	O
the	O
behaviors	O
were	O
performed	O
on	O
days	O
when	O
DMT	B-DRUG
was	O
NOT	O
administered	O
.	O
In	O
fact	O
,	O
we	O
have	O
previously	O
shown	O
that	O
a	O
1	O
mg	O
/	O
kg	O
dose	O
of	O
DMT	B-DRUG
increases	O
the	O
frequency	O
and	O
amplitude	O
of	O
spontaneous	B-NEURAL MECHANISM/CORRELATE
EPSCs	I-NEURAL MECHANISM/CORRELATE
in	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
long	O
after	O
DMT	B-DRUG
had	O
been	O
cleared	O
from	O
the	O
body	O
.	O
Despite	O
producing	O
similar	O
anxiolytic	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
and	I-OUTCOME
antidepressant	I-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
,	O
an	O
acute	O
hallucinogenic	O
dose	O
and	O
chronic	O
,	O
intermittent	O
,	O
low	O
doses	O
of	O
DMT	B-DRUG
produce	O
very	B-OUTCOME
different	I-OUTCOME
biochemical	I-OUTCOME
and	I-OUTCOME
structural	I-OUTCOME
phenotypes	I-OUTCOME
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
single	O
hallucinogenic	O
dose	O
of	O
DMT	B-DRUG
(	O
10	O
mg	O
/	O
kg	O
)	O
increases	B-OUTCOME
dendritic	I-OUTCOME
spine	I-OUTCOME
density	I-OUTCOME
on	I-OUTCOME
pyramidal	I-OUTCOME
neurons	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
PFC	I-OUTCOME
,	O
(	O
16	O
)	O
but	O
a	O
similar	O
effect	O
was	O
not	O
observed	O
following	O
administration	O
of	O
chronic	O
,	O
intermittent	O
low	O
doses	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
DMT	B-DRUG
(	O
Figure	O
5	O
)	O
.	O
We	O
hypothesize	O
that	O
chronic	O
,	O
intermittent	O
low	O
doses	O
of	O
DMT	B-DRUG
promote	B-OUTCOME
sufficient	I-OUTCOME
plasticity	I-OUTCOME
to	I-OUTCOME
strengthen	I-OUTCOME
key	I-OUTCOME
circuits	I-OUTCOME
involved	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
regulation	I-OUTCOME
of	I-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
fear	I-OUTCOME
,	O
thus	O
impacting	O
behavior	O
,	O
but	O
that	O
homeostatic	B-NEURAL MECHANISM/CORRELATE
plasticity	I-NEURAL MECHANISM/CORRELATE
tightly	O
controls	O
the	O
overall	O
synaptic	O
input	O
to	O
these	O
neurons	O
leading	O
to	O
similar	B-OUTCOME
spine	I-OUTCOME
densities	I-OUTCOME
between	I-OUTCOME
treatment	I-OUTCOME
groups	I-OUTCOME
over	I-OUTCOME
time	I-OUTCOME
While	O
there	O
were	O
no	O
major	O
behavioral	B-OUTCOME
differences	I-OUTCOME
between	I-OUTCOME
male	I-OUTCOME
and	I-OUTCOME
female	I-OUTCOME
rats	O
following	O
DMT	B-DRUG
treatment	O
,	O
there	O
were	O
distinct	B-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
neuronal	I-OUTCOME
structure	I-OUTCOME
.	O
Dendritic	B-NEURAL MECHANISM/CORRELATE
spine	I-NEURAL MECHANISM/CORRELATE
density	I-NEURAL MECHANISM/CORRELATE
on	O
pyramidal	O
neurons	O
of	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
was	O
unchanged	O
in	O
male	O
rats	O
administered	O
chronic	O
,	O
intermittent	O
,	O
low	O
doses	O
of	O
DMT	B-DRUG
;	O
however	O
,	O
female	O
rats	O
exhibited	O
a	O
reduction	B-OUTCOME
in	I-OUTCOME
spine	I-OUTCOME
density	I-OUTCOME
(	O
Figure	O
5	O
)	O
.	O
As	O
psychedelics	B-DRUG
are	O
known	O
to	O
increase	B-OUTCOME
glutamate	I-OUTCOME
release	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
cortex	I-OUTCOME
,	O
(	O
50	O
)	O
the	O
reduced	O
spine	O
density	O
observed	O
in	O
females	O
could	O
reflect	O
greater	O
sensitivity	O
to	O
glutamatergic	O
excitotoxicity	O
.	O
This	O
highlights	O
the	O
fact	O
that	O
the	O
overall	O
psychedelic	B-DRUG
microdosing	I-DRUG
load	O
,	O
which	O
includes	O
the	O
amount	O
of	O
drug	O
in	O
each	O
dose	O
,	O
the	O
frequency	O
of	O
administration	O
,	O
and	O
the	O
length	O
of	O
treatment	O
,	O
is	O
likely	O
to	O
be	O
critical	O
for	O
achieving	O
the	O
beneficial	B-OUTCOME
effects	I-OUTCOME
of	O
psychedelic	B-DRUG
microdosing	I-DRUG
without	O
negative	O
repercussions	O
.	O
Long	O
-	O
term	O
intermittent	O
use	O
of	O
ayahuasca	B-DRUG
is	O
correlated	O
with	O
thinning	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
posterior	I-OUTCOME
cingulate	I-OUTCOME
cortex	I-OUTCOME
(	O
PCC	O
)	O
in	O
humans	O
,	O
(	O
51	O
)	O
but	O
not	O
increased	O
risk	B-OUTCOME
for	I-OUTCOME
mental	I-OUTCOME
illness	I-OUTCOME
.	O
(	O
52	O
)	O
However	O
,	O
Nichols	O
and	O
co	O
-	O
workers	O
have	O
shown	O
that	O
chronic	O
(	O
>	O
3	O
months	O
)	O
,	O
intermittent	O
,	O
high	O
doses	O
of	O
LSD	B-DRUG
administered	O
to	O
rats	O
produce	O
neuroadaptations	B-NEURAL MECHANISM/CORRELATE
leading	O
to	O
a	O
persistent	O
behavioral	O
state	O
consisting	O
of	O
hyperactivity	B-OUTCOME
,	O
anhedonia	B-OUTCOME
,	O
and	O
social	B-OUTCOME
deficits	I-OUTCOME
.	O
(	O
53	O
)	O
These	O
behavioral	O
changes	O
are	O
accompanied	O
by	O
significant	B-OUTCOME
gene	I-OUTCOME
expression	I-OUTCOME
changes	I-OUTCOME
in	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
related	O
to	O
neural	B-NEURAL MECHANISM/CORRELATE
plasticity	I-NEURAL MECHANISM/CORRELATE
.	O
(	O
35	O
)	O
As	O
a	O
similar	O
dose	O
of	O
LSD	B-DRUG
given	O
over	O
11	O
days	O
resulted	O
in	O
antidepressant	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effects	I-OUTCOME
,	O
(	O
54	O
)	O
it	O
appears	O
that	O
the	O
total	O
length	O
of	O
treatment	O
is	O
critical	O
for	O
determining	O
behavioral	B-OUTCOME
outcomes	I-OUTCOME
A	O
single	O
hallucinogenic	O
dose	O
of	O
several	O
psychedelic	B-DRUG
compounds	I-DRUG
has	O
been	O
shown	O
to	O
increase	O
gene	B-OUTCOME
expression	I-OUTCOME
of	I-OUTCOME
several	I-OUTCOME
genes	I-OUTCOME
related	I-OUTCOME
to	I-OUTCOME
neural	I-OUTCOME
plasticity	I-OUTCOME
.	O
(	O
55,56	O
)	O
However	O
,	O
we	O
did	O
not	O
observe	O
similar	O
changes	O
following	O
the	O
administration	O
of	O
chronic	O
,	O
intermittent	O
low	O
doses	O
of	O
DMT	B-DRUG
(	O
Figure	O
6	O
)	O
.	O
Duman	O
and	O
co	O
-	O
workers	O
also	O
observed	O
that	O
repeated	O
dosing	O
of	O
2,5	O
-	O
dimethoxy-4	O
-	O
iodoamphetamine	O
(	O
DOI	O
)	O
,	O
an	O
amphetamine	B-DRUG
-	I-DRUG
based	I-DRUG
psychedelic	I-DRUG
,	O
caused	O
minimal	B-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
BDNF	I-OUTCOME
expression	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
cortex	I-OUTCOME
when	O
compared	O
to	O
a	O
single	O
acute	O
dose	O
.	O
Duman	O
and	O
co	O
-	O
workers	O
hypothesized	O
that	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2	I-NEURAL MECHANISM/CORRELATE
downregulation	I-NEURAL MECHANISM/CORRELATE
might	O
explain	O
the	O
differences	O
observed	O
between	O
the	O
two	O
dosing	O
regimens	O
.	O
However	O
,	O
in	O
the	O
case	O
of	O
chronic	O
,	O
intermittent	O
administration	O
of	O
low	O
dose	O
DMT	B-DRUG
,	O
we	O
do	O
not	O
observe	O
any	O
changes	O
in	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
expression	I-NEURAL MECHANISM/CORRELATE
(	O
Figure	O
6	O
)	O
,	O
and	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
has	O
been	O
previously	O
shown	O
that	O
DMT	B-DRUG
does	O
not	O
induce	O
receptor	B-OUTCOME
downregulation	I-OUTCOME
in	O
cellular	O
studies	O
,	O
(	O
57	O
)	O
nor	O
does	O
HTR2A	B-NEURAL MECHANISM/CORRELATE
cause	O
tolerance	B-OUTCOME
in	I-OUTCOME
humans	I-OUTCOME
.	O
(	O
58	O
)	O
This	O
distinct	O
lack	O
of	O
increased	B-OUTCOME
BDNF	I-OUTCOME
expression	I-OUTCOME
following	O
chronic	O
,	O
intermittent	O
,	O
low	O
doses	O
of	O
DMT	B-DRUG
highlights	O
an	O
important	O
mechanistic	O
difference	O
between	O
psychedelic	B-DRUG
microdosing	I-DRUG
and	O
chronic	O
treatment	O
with	O
selective	B-ANTIDEPRESSANT_DRUG
serotonin	I-ANTIDEPRESSANT_DRUG
reuptake	I-ANTIDEPRESSANT_DRUG
inhibitors	I-ANTIDEPRESSANT_DRUG
and	O
other	O
slow	O
-	O
acting	O
antidepressants	O
.	O
In	O
the	O
latter	O
case	O
,	O
increased	O
BDNF	O
expression	O
is	O
believed	O
to	O
facilitate	O
the	O
repair	B-OUTCOME
of	I-OUTCOME
damaged	I-OUTCOME
circuits	I-OUTCOME
relevant	I-OUTCOME
to	I-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
anxiety	I-OUTCOME
.	O
(	O
59	O
)	O
Chronic	O
,	O
intermittent	O
low	O
doses	O
of	O
DMT	B-DRUG
appear	O
to	O
accomplish	O
this	O
without	O
any	O
obvious	O
changes	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
expression	I-OUTCOME
of	I-OUTCOME
BDNF	I-OUTCOME
or	O
other	O
genes	O
known	O
to	O
be	O
differentially	O
regulated	O
following	O
administration	O
of	O
a	O
single	O
high	O
dose	O
of	O
a	O
psychedelic	O
-DOCSTART- -X- O O
In	O
this	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
a	O
very	O
low	O
“	O
microdose	B-DRUG
”	O
of	O
LSD	B-DRUG
(	O
13	O
μg	O
)	O
on	O
resting	B-NEURAL MECHANISM/CORRELATE
state	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
in	O
healthy	O
human	O
volunteers	O
.	O
we	O
found	O
that	O
LSD	B-DRUG
increased	B-OUTCOME
amygdala	I-OUTCOME
seed	I-OUTCOME
-	I-OUTCOME
based	I-OUTCOME
connectivity	I-OUTCOME
with	O
the	O
right	B-NEURAL MECHANISM/CORRELATE
angular	I-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
,	O
right	B-NEURAL MECHANISM/CORRELATE
middle	I-NEURAL MECHANISM/CORRELATE
frontal	I-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
the	O
cerebellum	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
decreased	B-OUTCOME
amygdala	I-OUTCOME
connectivity	I-OUTCOME
with	O
the	O
left	O
and	O
right	B-NEURAL MECHANISM/CORRELATE
postcentral	I-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
and	O
the	O
superior	B-NEURAL MECHANISM/CORRELATE
temporal	I-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
.	O
Although	O
the	O
drug	B-OUTCOME
’s	I-OUTCOME
effects	I-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
were	I-OUTCOME
small	I-OUTCOME
and	I-OUTCOME
variable	I-OUTCOME
,	O
the	O
increase	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
–	I-OUTCOME
middle	I-OUTCOME
frontal	I-OUTCOME
gyrus	I-OUTCOME
connectivity	I-OUTCOME
strength	O
was	O
positively	O
correlated	O
with	O
positive	B-OUTCOME
mood	I-OUTCOME
after	O
the	O
drug	O
.	O
No	O
changes	O
in	O
CBF	O
were	O
recorded	O
.	O
Despite	O
the	O
growing	O
popularity	O
of	O
the	O
practice	O
of	O
microdosing	B-DRUG
in	O
the	O
community	O
and	O
handful	O
of	O
studies	O
investigating	O
the	O
subjective	B-OUTCOME
and	I-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
of	I-OUTCOME
microdoses	I-OUTCOME
of	O
LSD	B-DRUG
,	O
to	O
we	O
knowledge	O
this	O
the	O
first	O
study	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
very	O
low	O
dose	O
of	O
the	O
drug	B-DRUG
on	O
resting	B-NEURAL MECHANISM/CORRELATE
state	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
and	O
CBF	O
Our	O
results	O
are	O
in	O
line	O
with	O
previous	O
studies	O
investigating	O
changes	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
under	O
the	O
influence	O
of	O
higher	O
doses	O
of	O
LSD	B-DRUG
and	O
other	O
psychedelics	B-DRUG
,	O
including	O
psilocybin	B-DRUG
.	O
The	O
amygdala	B-NEURAL MECHANISM/CORRELATE
receives	O
inputs	O
from	O
all	O
manner	O
of	O
sensory	O
information	O
-	O
focused	O
areas	O
and	O
prefrontal	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
the	O
latter	O
is	O
also	O
a	O
target	O
of	O
amygdala	B-NEURAL MECHANISM/CORRELATE
afferents	O
,	O
making	O
the	O
interpretation	O
of	O
results	O
involving	O
amygdala	B-NEURAL MECHANISM/CORRELATE
connectivity	B-NEURAL MECHANISM/CORRELATE
a	I-NEURAL MECHANISM/CORRELATE
complex	O
process	O
.	O
Nonetheless	O
,	O
our	O
study	O
is	O
consistent	O
with	O
prior	O
work	O
showing	O
reduced	B-OUTCOME
amygdala	I-OUTCOME
system	I-OUTCOME
modulation	I-OUTCOME
.	O
Using	O
a	O
much	O
higher	O
dose	O
of	O
LSD	B-DRUG
(	O
100	O
μg	O
compared	O
to	O
13	O
μg	O
)	O
Mueller	O
(	O
15	O
)	O
reported	O
dampened	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
fearful	I-OUTCOME
facial	I-OUTCOME
expressions	I-OUTCOME
and	O
Kraehenmann	O
(	O
13	O
)	O
found	O
similar	O
results	O
with	O
the	O
serotonergic	O
drug	O
psilocybin	B-DRUG
.	O
Grimm	O
(	O
18	O
)	O
found	O
that	O
psilocybin	B-DRUG
not	O
only	O
modulated	B-OUTCOME
amygdala	I-OUTCOME
activation	I-OUTCOME
,	O
but	O
also	O
decreased	B-OUTCOME
amygdala	I-OUTCOME
connectivity	I-OUTCOME
to	O
the	O
frontal	B-NEURAL MECHANISM/CORRELATE
pole	I-NEURAL MECHANISM/CORRELATE
during	O
the	O
viewing	O
of	O
happy	O
faces	O
,	O
and	O
decreased	B-OUTCOME
amygdala	I-OUTCOME
connectivity	I-OUTCOME
with	O
the	O
striatum	O
during	O
the	O
viewing	O
of	O
angry	O
faces	O
.	O
Though	O
Grimm	O
(	O
18	O
)	O
investigated	O
task	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
based	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
and	O
our	O
study	O
investigated	O
resting	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
state	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
,	O
our	O
result	O
that	O
LSD	B-DRUG
decreases	B-OUTCOME
connectivity	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
amygdala	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
superior	I-OUTCOME
temporal	I-OUTCOME
gyrus	I-OUTCOME
,	O
a	O
region	O
shown	O
to	O
be	O
involved	O
in	O
the	O
perception	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
emotions	I-SUBJECTIVE EXPERIENCE
in	O
facial	O
stimuli	O
(	O
30	O
)	O
,	O
is	O
of	O
interest	O
in	O
light	O
of	O
these	O
previous	O
findings	O
.	O
Notably	O
,	O
however	O
,	O
the	O
previous	O
studies	O
used	O
substantially	O
higher	O
doses	O
of	O
the	O
drugs	B-DRUG
,	O
and	O
the	O
previous	O
studies	O
is	O
of	O
particular	O
interest	O
that	O
we	O
detected	O
these	O
changes	B-OUTCOME
in	I-OUTCOME
neural	I-OUTCOME
function	I-OUTCOME
at	O
doses	O
of	O
LSD	B-DRUG
that	O
produce	O
minimal	O
direct	O
subjective	B-OUTCOME
or	I-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
and	O
do	O
not	O
alter	O
CBF	O
Amygdala	B-NEURAL MECHANISM/CORRELATE
hyperreactivity	I-NEURAL MECHANISM/CORRELATE
has	O
been	O
associated	O
with	O
a	O
host	O
of	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
involving	O
negative	B-SUBJECTIVE EXPERIENCE
processing	I-SUBJECTIVE EXPERIENCE
bias	I-SUBJECTIVE EXPERIENCE
,	O
including	O
major	B-HEALTH CONDITION
depressive	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
disorders	O
(	O
31	O
,	O
32	O
)	O
.	O
Further	O
,	O
standard	O
antidepressant	B-ANTIDEPRESSANT_DRUG
medications	I-ANTIDEPRESSANT_DRUG
,	O
such	O
as	O
selective	B-ANTIDEPRESSANT_DRUG
serotonin	I-ANTIDEPRESSANT_DRUG
reuptake	I-ANTIDEPRESSANT_DRUG
inhibitors	I-ANTIDEPRESSANT_DRUG
(	I-ANTIDEPRESSANT_DRUG
SSRIs	I-ANTIDEPRESSANT_DRUG
)	I-ANTIDEPRESSANT_DRUG
act	O
acutely	O
to	O
dampen	B-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
thereby	I-OUTCOME
normalize	I-OUTCOME
,	I-OUTCOME
disrupted	I-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
,	O
which	O
may	O
be	O
a	O
mechanism	O
underlying	O
standard	O
antidepressant	B-ANTIDEPRESSANT_DRUG
medications	I-ANTIDEPRESSANT_DRUG
,	O
such	O
as	O
selective	B-ANTIDEPRESSANT_DRUG
serotonin	I-ANTIDEPRESSANT_DRUG
reuptake	I-ANTIDEPRESSANT_DRUG
inhibitors	I-ANTIDEPRESSANT_DRUG
(	I-ANTIDEPRESSANT_DRUG
SSRIs	I-ANTIDEPRESSANT_DRUG
)	I-ANTIDEPRESSANT_DRUG
efficacy	O
(	O
33	O
,	O
34	O
)	O
.	O
The	O
extent	O
to	O
which	O
microdoses	O
of	O
LSD	B-DRUG
or	O
other	O
serotonin	O
agonists	O
dampen	B-OUTCOME
amygdala	I-OUTCOME
activity	I-OUTCOME
and	I-OUTCOME
connectivity	I-OUTCOME
,	O
after	O
either	O
acute	O
or	O
repeated	O
dosing	O
,	O
and	O
how	O
these	O
are	O
related	O
to	O
mood	B-OUTCOME
symptoms	I-OUTCOME
remain	O
an	O
important	O
direction	O
for	O
future	O
research	O
Interestingly	O
,	O
we	O
also	O
observed	O
increased	B-OUTCOME
connectivity	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
amygdala	I-OUTCOME
and	I-OUTCOME
middle	I-OUTCOME
frontal	I-OUTCOME
gyrus	I-OUTCOME
,	I-OUTCOME
right	I-OUTCOME
angular	I-OUTCOME
gyrus	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
cerebellum	I-OUTCOME
.	O
Beyond	O
dampening	B-OUTCOME
amygdala	I-OUTCOME
responses	I-OUTCOME
to	I-OUTCOME
negative	I-OUTCOME
stimuli	I-OUTCOME
,	O
negative	O
stimuli	O
has	O
been	O
suggested	O
that	O
SSRIs	B-ANTIDEPRESSANT_DRUG
may	O
act	O
by	O
enhancing	B-OUTCOME
cortico	I-OUTCOME
-	I-OUTCOME
limbic	I-OUTCOME
connectivity	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
brain	I-OUTCOME
,	O
thereby	O
facilitating	O
appropriate	O
emotion	B-OUTCOME
regulation	I-OUTCOME
(	O
35	O
)	O
.	O
In	O
line	O
with	O
these	O
findings	O
,	O
in	O
our	O
study	O
,	O
changes	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
-	I-OUTCOME
middle	I-OUTCOME
frontal	I-OUTCOME
gyrus	I-OUTCOME
connectivity	I-OUTCOME
were	O
significantly	O
correlated	O
with	O
changes	B-OUTCOME
in	I-OUTCOME
positive	I-OUTCOME
mood	I-OUTCOME
.	O
Furthermore	O
,	O
reduced	B-OUTCOME
connectivity	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
right	I-OUTCOME
amygdala	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
cerebellum	I-OUTCOME
has	O
been	O
reported	O
in	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
(	O
36	O
)	O
.	O
These	O
alterations	B-OUTCOME
in	I-OUTCOME
connectivity	I-OUTCOME
have	O
been	O
suggested	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathophysiology	O
of	O
depression	B-HEALTH CONDITION
given	O
that	O
dysfunctions	B-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
cerebellar	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
limbic	I-NEURAL MECHANISM/CORRELATE
circuits	I-NEURAL MECHANISM/CORRELATE
have	O
been	O
shown	O
to	O
disrupt	O
emotional	B-OUTCOME
processing	I-OUTCOME
(	O
36	O
,	O
37	O
)	O
.	O
In	O
a	O
future	O
study	O
it	O
will	O
be	O
important	O
to	O
determine	O
whether	O
small	O
doses	O
of	O
LSD	B-DRUG
normalize	O
decreased	B-OUTCOME
amygdala	I-OUTCOME
-	I-OUTCOME
cerebellar	I-OUTCOME
connectivity	I-OUTCOME
in	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
In	O
contrast	O
to	O
LSD	B-DRUG
-	O
induced	O
changes	O
in	O
amygdala	B-NEURAL MECHANISM/CORRELATE
connectivity	B-NEURAL MECHANISM/CORRELATE
,	I-NEURAL MECHANISM/CORRELATE
we	O
did	O
not	O
find	O
alterations	O
in	O
thalamo	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
cortical	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
.	O
This	O
is	O
not	O
surprising	O
given	O
that	O
altered	B-OUTCOME
information	I-OUTCOME
processing	I-OUTCOME
in	O
thalamo	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
cortical	I-NEURAL MECHANISM/CORRELATE
loops	I-NEURAL MECHANISM/CORRELATE
has	O
been	O
suggested	O
to	O
underlie	O
the	O
psychedelic	O
-	O
induced	O
altered	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
(	O
9	O
)	O
.	O
The	O
“	O
microdose	B-DRUG
”	O
used	O
in	O
this	O
study	O
did	O
not	O
induce	O
psychedelic	B-OUTCOME
symptoms	I-OUTCOME
or	O
an	O
altered	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
and	O
may	O
therefore	O
not	O
influence	O
these	O
pathways	O
,	O
but	O
rather	O
change	B-OUTCOME
information	I-OUTCOME
processing	I-OUTCOME
in	I-OUTCOME
emotional	I-OUTCOME
networks	I-OUTCOME
Our	O
study	O
design	O
had	O
several	O
limitations	O
.	O
First	O
,	O
Our	O
study	O
included	O
only	O
healthy	O
volunteers	O
,	O
and	O
the	O
effects	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
drug	I-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
or	O
brain	O
function	O
may	O
be	O
different	O
in	O
individuals	O
with	O
symptoms	O
of	O
depression	B-HEALTH CONDITION
or	O
anxiety	B-HEALTH CONDITION
.	O
Second	O
,	O
Our	O
investigated	O
effects	O
of	O
only	O
a	O
single	O
administration	O
of	O
LSD	B-DRUG
,	O
whereas	O
individuals	O
who	O
“	O
microdose	B-DRUG
”	O
the	O
drug	O
in	O
real	O
-	O
world	O
settings	O
report	O
using	O
the	O
drug	O
repeatedly	O
,	O
every	O
3	O
or	O
4	O
days	O
.	O
Whether	O
drug	O
produces	O
different	B-OUTCOME
effects	I-OUTCOME
on	I-OUTCOME
brain	I-OUTCOME
activity	I-OUTCOME
or	I-OUTCOME
mood	I-OUTCOME
after	O
repeated	O
doses	O
remains	O
to	O
be	O
determined	O
.	O
Another	O
limitation	O
is	O
that	O
we	O
did	O
not	O
examine	O
subjects	O
’	O
responses	B-OUTCOME
to	I-OUTCOME
behavioral	I-OUTCOME
tasks	I-OUTCOME
implicated	I-OUTCOME
in	I-OUTCOME
mood	I-OUTCOME
-	I-OUTCOME
enhancing	I-OUTCOME
effects	I-OUTCOME
of	I-OUTCOME
drugs	I-OUTCOME
such	I-OUTCOME
as	I-OUTCOME
tasks	I-OUTCOME
assessing	I-OUTCOME
cognitive	I-OUTCOME
and	I-OUTCOME
emotion	I-OUTCOME
processing	I-OUTCOME
.	O
Finally	O
,	O
perhaps	O
because	O
of	O
the	O
low	O
dose	O
,	O
the	O
effects	O
of	O
the	O
drug	B-DRUG
were	O
subtle	O
.	O
For	O
example	O
,	O
we	O
detected	O
correlations	B-OUTCOME
between	I-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
connectivity	I-OUTCOME
in	O
both	O
the	O
placebo	O
and	O
drug	O
conditions	O
.	O
The	O
specificity	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
effect	I-OUTCOME
to	O
the	O
drug	B-DRUG
condition	O
will	O
await	O
further	O
study	O
with	O
additional	O
subjects	O
and	O
repeated	O
dosing	O
In	O
summary	O
,	O
here	O
we	O
report	O
the	O
results	O
of	O
the	O
first	O
study	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
very	O
low	O
,	O
“	O
microdose	B-DRUG
”	O
of	O
LSD	B-DRUG
on	O
resting	B-NEURAL MECHANISM/CORRELATE
state	I-NEURAL MECHANISM/CORRELATE
functional	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
in	O
a	O
sample	O
of	O
healthy	O
human	O
volunteers	O
.	O
We	O
describe	O
changes	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
connectivity	I-OUTCOME
in	O
brain	O
regions	O
that	O
are	O
implicated	O
in	O
depression	B-HEALTH CONDITION
.	O
It	O
remains	O
to	O
be	O
determined	O
with	O
repeated	O
doses	O
of	O
this	O
low	O
-	O
dose	O
drug	B-DRUG
result	O
in	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
.	O
These	O
promising	O
findings	O
provide	O
a	O
good	O
basis	O
for	O
pursuing	O
the	O
efficacy	B-OUTCOME
of	O
low	O
doses	O
of	O
serotonin	B-DRUG
agonists	I-DRUG
in	O
psychiatric	O
treatment	O
-DOCSTART- -X- O O
The	O
initial	O
goals	O
of	O
this	O
research	O
project	O
were	O
to	O
establish	O
feasibility	O
and	O
safety	O
for	O
a	O
hallucinogen	B-DRUG
treatment	O
model	O
in	O
patients	O
with	O
advanced	B-HEALTH CONDITION
-	I-HEALTH CONDITION
stage	I-HEALTH CONDITION
cancer	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
.	O
Following	O
discussion	O
with	O
federal	O
and	O
state	O
regulatory	O
agencies	O
as	O
well	O
as	O
hospital	O
institutional	O
review	O
board	O
and	O
research	O
committees	O
,	O
a	O
modest	O
0.2	O
-	O
mg	O
/	O
kg	O
psilocybin	B-DRUG
dose	O
was	O
chosen	O
.	O
Although	O
not	O
comparable	O
to	O
higher	O
doses	O
of	O
hallucinogens	B-DRUG
administered	O
in	O
the	O
past	O
to	O
severely	O
ill	O
patients	O
,	O
the	O
dose	O
used	O
here	O
was	O
still	O
believed	O
capable	O
of	O
inducing	B-OUTCOME
an	I-OUTCOME
alteration	I-OUTCOME
of	I-OUTCOME
consciousness	I-OUTCOME
with	I-OUTCOME
potential	I-OUTCOME
therapeutic	I-OUTCOME
benefit	I-OUTCOME
while	O
optimizing	B-OUTCOME
patient	I-OUTCOME
safety	I-OUTCOME
.	O
Determining	O
safe	O
parameters	O
with	O
this	O
novel	O
treatment	O
paradigm	O
is	O
critical	O
to	O
establishing	O
a	O
strong	O
foundation	O
for	O
this	O
field	O
of	O
study	O
that	O
would	O
allow	O
for	O
future	O
investigations	O
.	O
Consistent	O
with	O
previous	O
research	O
,	O
we	O
found	O
no	B-OUTCOME
untoward	I-OUTCOME
cardiovascular	I-OUTCOME
sequelae	I-OUTCOME
in	O
we	O
subject	O
population.19	O
Minor	B-OUTCOME
HR	I-OUTCOME
and	I-OUTCOME
BP	I-OUTCOME
elevations	I-OUTCOME
after	O
psilocybin	B-DRUG
administration	O
were	O
evidence	O
only	O
of	O
a	O
mild	B-OUTCOME
sympathomimetic	I-OUTCOME
effect	I-OUTCOME
.	O
Holter	O
monitoring	O
did	O
not	O
identify	O
increased	B-OUTCOME
cardiac	I-OUTCOME
arrhythmias	I-OUTCOME
in	O
comparison	O
with	O
niacin	O
placebo	O
,	O
even	O
in	O
subjects	O
who	O
presented	O
with	O
some	O
baseline	O
cardiac	B-HEALTH CONDITION
arrhythmia	I-HEALTH CONDITION
.	O
Niacin	O
may	O
acutely	O
lower	O
BP	O
through	O
vasodilation35	O
but	O
had	O
minimal	B-OUTCOME
effects	I-OUTCOME
on	O
BP	O
and	O
HR	O
in	O
our	O
subjects	O
,	O
except	O
for	O
a	O
reduction	B-OUTCOME
in	I-OUTCOME
diastolic	I-OUTCOME
BP	I-OUTCOME
that	O
was	O
noted	O
1	O
hour	O
after	O
administration	O
of	O
niacin	O
.	O
This	O
transient	B-OUTCOME
effect	I-OUTCOME
may	O
have	O
contributed	O
to	O
our	O
detection	O
of	O
a	O
significant	B-OUTCOME
psilocybin	I-OUTCOME
effect	I-OUTCOME
at	O
that	O
time	O
but	O
can	O
not	O
explain	O
the	O
significant	B-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
over	O
the	O
subsequent	O
intervals	O
because	O
the	O
initial	O
niacin	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
reduction	I-OUTCOME
of	I-OUTCOME
diastolic	I-OUTCOME
BP	I-OUTCOME
did	I-OUTCOME
not	I-OUTCOME
persist	I-OUTCOME
.	O
We	O
also	O
observed	O
no	O
adverse	B-OUTCOME
psychological	I-OUTCOME
effects	I-OUTCOME
from	O
the	O
treatment	O
.	O
All	O
subjects	O
tolerated	B-OUTCOME
the	I-OUTCOME
treatment	I-OUTCOME
sessions	I-OUTCOME
well	I-OUTCOME
,	O
with	O
no	O
indication	O
of	O
severe	O
anxiety	B-HEALTH CONDITION
or	O
a	O
“	O
bad	B-OUTCOME
trip	I-OUTCOME
.	O
”	O
The	O
fact	O
that	O
psilocybin	B-DRUG
produced	O
only	O
modest	B-OUTCOME
effects	I-OUTCOME
on	O
the	O
anxious	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
scale	O
of	O
the	O
5D	O
-	O
ASC	O
confirmed	O
this	O
conclusion	O
.	O
When	O
hallucinogens	B-DRUG
were	O
administered	O
to	O
patients	O
with	O
terminal	B-HEALTH CONDITION
cancer	I-HEALTH CONDITION
in	O
the	O
1960s	O
and	O
early	O
1970s	O
,	O
the	O
occurrence	O
of	O
a	O
profound	B-OUTCOME
psychospiritual	I-OUTCOME
experience	I-OUTCOME
was	O
correlated	O
with	O
therapeutic	B-OUTCOME
outcome.10,12	I-OUTCOME
Such	O
transcendent	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
are	O
usually	O
associated	O
with	O
higher	O
doses	O
of	O
hallucinogens	B-DRUG
,	O
so	O
our	O
expectation	O
of	O
demonstrating	O
efficacy	B-OUTCOME
was	O
limited.21	O
Common	O
themes	O
reported	O
by	O
subjects	O
included	O
examining	B-OUTCOME
how	I-OUTCOME
Common	I-OUTCOME
illness	I-OUTCOME
had	I-OUTCOME
impacted	I-OUTCOME
Common	I-OUTCOME
lives	I-OUTCOME
,	O
relationships	B-OUTCOME
with	I-OUTCOME
family	I-OUTCOME
and	I-OUTCOME
close	I-OUTCOME
friends	I-OUTCOME
,	O
and	O
sense	B-OUTCOME
of	I-OUTCOME
ontological	I-OUTCOME
security	I-OUTCOME
.	O
In	O
addition	O
,	O
subjects	O
reported	O
powerful	B-OUTCOME
empathic	I-OUTCOME
cathexis	I-OUTCOME
to	I-OUTCOME
close	I-OUTCOME
friends	I-OUTCOME
and	I-OUTCOME
family	I-OUTCOME
members	I-OUTCOME
and	O
examined	O
how	B-OUTCOME
subjects	I-OUTCOME
wished	I-OUTCOME
to	I-OUTCOME
address	I-OUTCOME
subjects	I-OUTCOME
limited	I-OUTCOME
life	I-OUTCOME
expectancy	I-OUTCOME
.	O
In	O
monthly	O
follow	O
-	O
up	O
discussions	O
,	O
subjects	O
reflected	O
on	O
insights	O
and	O
new	B-OUTCOME
perspectives	I-OUTCOME
gained	I-OUTCOME
during	O
subjects	O
psilocybin	B-DRUG
treatment	O
.	O
However	O
,	O
the	O
frequency	O
of	O
these	O
reports	O
was	O
not	O
quantified	O
.	O
Although	O
past	O
researchers	O
reported	O
more	O
pronounced	B-OUTCOME
therapeutic	I-OUTCOME
effects	I-OUTCOME
with	O
a	O
higher	O
-	O
dose	O
model	O
,	O
even	O
the	O
lower	O
dose	O
of	O
psilocybin	B-DRUG
used	O
in	O
the	O
current	O
study	O
gave	O
some	O
indication	O
of	O
therapeutic	B-OUTCOME
benefit	I-OUTCOME
in	O
quantitative	O
psychological	O
evaluations	O
.	O
In	O
particular	O
,	O
we	O
found	O
that	O
the	O
STAI	O
trait	O
anxiety	B-HEALTH CONDITION
subscale	O
demonstrated	O
a	O
sustained	O
reduction	O
in	O
anxiety	B-HEALTH CONDITION
that	O
reached	O
significance	O
at	O
the	O
1-	O
and	O
3	O
-	O
month	O
points	O
after	O
treatment	O
.	O
This	O
reduction	O
might	O
reflect	O
a	O
reduced	O
level	O
of	O
stress	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
over	O
time	O
.	O
Although	O
the	O
state	O
anxiety	B-HEALTH CONDITION
on	O
the	O
STAI	O
showed	O
a	O
modest	O
elevation	O
at	O
6	O
months	O
,	O
the	O
change	O
was	O
not	O
statistically	O
significant	O
and	O
might	O
have	O
resulted	O
from	O
the	O
deteriorating	O
medical	O
status	O
of	O
most	O
subjects	O
over	O
time	O
.	O
Mood	B-OUTCOME
also	O
improved	O
for	O
2	O
weeks	O
after	O
treatment	O
with	O
psilocybin	B-DRUG
,	O
with	O
sustained	O
improvement	O
on	O
the	O
BDI	O
reaching	O
significance	O
at	O
the	O
6	O
-	O
month	O
follow	O
-	O
up	O
point	O
.	O
The	O
POMS	O
scores	O
also	O
reflected	O
improved	O
mood	B-OUTCOME
2	O
weeks	O
after	O
receiving	O
psilocybin	B-DRUG
.	O
Although	O
not	O
statistically	O
significant	O
,	O
there	O
was	O
a	O
trend	O
toward	O
positive	B-OUTCOME
outcome	I-OUTCOME
.	O
With	O
a	O
larger	O
cohort	O
of	O
subjects	O
and	O
use	O
of	O
a	O
higher	O
dose	O
of	O
psilocybin	B-DRUG
,	O
it	O
seems	O
possible	O
that	O
significant	O
results	O
would	O
be	O
obtained	O
on	O
these	O
measures	O
.	O
Compared	O
with	O
placebo	O
sessions	O
,	O
POMS	O
scores	O
were	O
elevated	O
in	O
subjects	O
immediately	O
prior	O
to	O
psilocybin	B-DRUG
administration	O
.	O
The	O
reasons	O
for	O
this	O
difference	O
in	O
POMS	O
scores	O
1	O
day	O
before	O
administration	O
are	O
not	O
entirely	O
clear	O
.	O
Subject	O
expectations	O
were	O
unlikely	O
to	O
have	O
played	O
a	O
role	O
in	O
the	O
elevation	O
of	O
the	O
POMS	O
scores	O
on	O
the	O
day	O
before	O
treatment	O
because	O
the	O
elevation	O
occurred	O
regardless	O
of	O
treatment	O
order	O
.	O
The	O
most	O
likely	O
explanation	O
for	O
the	O
elevation	O
of	O
POMS	O
scores	O
prior	O
to	O
treatment	O
with	O
psilocybin	B-DRUG
may	O
be	O
that	O
subject	O
randomization	O
was	O
not	O
complete	O
with	O
regard	O
to	O
this	O
instrument	O
.	O
Nonetheless	O
,	O
POMS	O
scores	O
declined	O
after	O
administration	O
of	O
psilocybin	B-DRUG
in	O
11	O
of	O
12	O
subjects	O
,	O
suggesting	O
that	O
psilocybin	B-DRUG
produces	O
mood	B-OUTCOME
-	I-OUTCOME
elevating	I-OUTCOME
effects	I-OUTCOME
that	O
persist	O
after	O
the	O
acute	O
effects	O
of	O
the	O
drug	O
.	O
Another	O
focus	O
of	O
the	O
study	O
was	O
the	O
effect	O
of	O
a	O
0.2	O
-	O
mg	O
/	O
kg	O
psilocybin	B-DRUG
dose	O
on	O
somatic	O
symptoms	O
,	O
particularly	O
pain	O
perception	O
.	O
In	O
contrast	O
to	O
previous	O
investigations	O
,	O
we	O
did	O
not	O
find	O
robust	B-OUTCOME
reductions	I-OUTCOME
in	I-OUTCOME
pain	I-OUTCOME
perception	I-OUTCOME
or	O
lessened	B-OUTCOME
need	I-OUTCOME
for	I-OUTCOME
narcotic	I-OUTCOME
pain	I-OUTCOME
medication	I-OUTCOME
.	O
In	O
the	O
2	O
weeks	O
following	O
experimental	O
treatment	O
sessions	O
,	O
several	O
subjects	O
reported	O
lessened	B-OUTCOME
pain	I-OUTCOME
,	O
whereas	O
others	O
did	O
not	O
.	O
There	O
was	O
no	O
apparent	O
difference	O
between	O
subjects	O
treated	O
with	O
psilocybin	B-DRUG
and	O
those	O
treated	O
with	O
placebo	O
(	O
data	O
not	O
shown	O
)	O
.	O
Although	O
this	O
modest	O
dose	O
of	O
psilocybin	B-DRUG
was	O
not	O
observed	O
to	O
impact	O
pain	B-OUTCOME
,	O
given	O
the	O
impressive	O
reports	O
of	O
earlier	O
researchers,6	O
this	O
measure	O
would	O
certainly	O
be	O
indicated	O
for	O
study	O
with	O
higher	O
doses	O
.	O
Although	O
we	O
used	O
a	O
within	O
-	O
subject	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
design	O
,	O
the	O
drug	O
order	O
was	O
almost	O
always	O
apparent	O
to	O
subjects	O
and	O
investigators	O
whether	O
the	O
treatment	O
was	O
psilocybin	B-DRUG
or	O
placebo	O
.	O
In	O
fact	O
,	O
one	O
consistent	O
subject	O
critique	O
of	O
the	O
study	O
was	O
that	O
the	O
placebo	B-OUTCOME
sessions	I-OUTCOME
were	I-OUTCOME
perceived	I-OUTCOME
as	I-OUTCOME
far	I-OUTCOME
less	I-OUTCOME
worthwhile	I-OUTCOME
than	I-OUTCOME
those	I-OUTCOME
with	I-OUTCOME
psilocybin	I-OUTCOME
.	O
Many	O
of	O
the	O
subjects	O
suggested	O
that	O
future	O
protocols	O
provide	O
the	O
opportunity	O
for	O
a	O
second	O
psilocybin	B-DRUG
session	O
several	O
weeks	O
after	O
the	O
first	O
.	O
The	O
general	O
consensus	O
among	O
subjects	O
was	O
that	O
a	O
follow	O
-	O
up	O
experience	O
with	O
psilocybin	B-DRUG
would	O
reinforce	O
and	O
extend	O
the	O
perceived	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
of	O
the	O
initial	O
session	O
.	O
Future	O
studies	O
also	O
will	O
need	O
to	O
address	O
the	O
issue	O
of	O
controlling	O
for	O
a	O
placebo	O
effect	O
that	O
might	O
otherwise	O
be	O
attributed	O
to	O
the	O
active	O
treatment	O
.	O
Given	O
the	O
subjects	O
'	O
grave	O
prognosis	O
and	O
limited	O
life	O
expectancy	O
,	O
we	O
decided	O
to	O
provide	O
all	O
subjects	O
with	O
an	O
opportunity	O
to	O
experience	O
the	O
experimental	O
medicine	O
and	O
to	O
serve	O
as	O
all	O
subjects	O
own	O
control	O
.	O
Although	O
we	O
believed	O
that	O
to	O
be	O
the	O
ethical	O
course	O
to	O
take	O
,	O
given	O
the	O
life	O
circumstances	O
subjects	O
were	O
encountering	O
,	O
the	O
protocol	O
design	O
contains	O
some	O
inherent	O
limitations	O
.	O
A	O
better	O
experimental	O
design	O
might	O
incorporate	O
an	O
independent	O
control	O
group	O
,	O
receiving	O
only	O
either	O
placebo	O
treatment	O
or	O
a	O
conventional	O
psychopharmacological	O
intervention	O
.	O
Although	O
there	O
is	O
no	O
question	O
that	O
the	O
extensive	O
attention	O
paid	O
to	O
the	O
subjects	O
influenced	O
outcomes	O
,	O
the	O
unique	O
qualities	O
of	O
the	O
psilocybin	B-DRUG
experience	O
in	O
facilitating	O
strong	B-OUTCOME
therapeutic	I-OUTCOME
bonds	I-OUTCOME
and	O
ameliorating	B-OUTCOME
underlying	I-OUTCOME
psychological	I-OUTCOME
demoralization	I-OUTCOME
are	O
important	O
factors	O
worthy	O
of	O
further	O
exploration	O
.	O
Another	O
limitation	O
of	O
this	O
study	O
was	O
variability	O
in	O
the	O
extent	O
of	O
contact	O
with	O
subjects	O
after	O
treatment	O
.	O
A	O
minimum	O
contact	O
of	O
1	O
hour	O
monthly	O
was	O
established	O
,	O
but	O
variability	O
in	O
additional	O
ad	O
hoc	O
communication	O
depended	O
on	O
the	O
needs	O
and	O
wishes	O
of	O
the	O
subjects	O
,	O
some	O
of	O
whom	O
were	O
near	O
death	O
compared	O
with	O
others	O
who	O
were	O
more	O
functional	O
.	O
Despite	O
the	O
limitations	O
,	O
this	O
study	O
demonstrates	O
that	O
the	O
careful	O
and	O
controlled	O
use	O
of	O
psilocybin	B-DRUG
may	O
provide	O
an	O
alternative	B-OUTCOME
model	I-OUTCOME
for	I-OUTCOME
the	I-OUTCOME
treatment	I-OUTCOME
of	I-OUTCOME
conditions	I-OUTCOME
that	I-OUTCOME
are	I-OUTCOME
often	I-OUTCOME
minimally	I-OUTCOME
responsive	I-OUTCOME
to	O
conventional	O
therapies	O
,	O
including	O
the	O
profound	O
existential	B-HEALTH CONDITION
anxiety	I-HEALTH CONDITION
and	O
despair	B-HEALTH CONDITION
that	O
often	O
accompany	O
advanced	B-HEALTH CONDITION
-	I-HEALTH CONDITION
stage	I-HEALTH CONDITION
cancers	I-HEALTH CONDITION
.	O
A	O
recent	O
review	O
from	O
the	O
psilocybin	B-DRUG
research	O
group	O
at	O
Johns	O
Hopkins	O
University	O
describes	O
the	O
critical	O
components	O
necessary	O
for	O
ensuring	O
subject	O
safety	O
in	O
hallucinogen	B-DRUG
research.36	O
Taking	O
into	O
account	O
these	O
essential	O
provisions	O
for	O
optimizing	O
safety	O
as	O
well	O
as	O
adhering	O
to	O
strict	O
ethical	O
standards	O
of	O
conduct	O
for	O
treatment	O
facilitators	O
,	O
the	O
results	O
provided	O
herein	O
indicate	O
the	O
safety	B-OUTCOME
and	I-OUTCOME
promise	I-OUTCOME
of	O
continued	O
investigations	O
into	O
the	O
range	O
of	O
medical	O
effects	O
of	O
hallucinogenic	B-DRUG
compounds	I-DRUG
such	O
as	O
psilocybin	B-DRUG
.	O
-DOCSTART- -X- O O
The	O
fMRI	O
studies	O
reported	O
here	O
revealed	O
significant	B-OUTCOME
and	I-OUTCOME
consistent	I-OUTCOME
outcomes	I-OUTCOME
.	O
Psilocybin	B-DRUG
significantly	O
decreased	B-OUTCOME
brain	I-OUTCOME
blood	I-OUTCOME
flow	I-OUTCOME
and	I-OUTCOME
venous	I-OUTCOME
oxygenation	I-OUTCOME
in	O
a	O
manner	O
that	O
correlated	O
with	O
venous	B-OUTCOME
oxygenation	I-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
,	O
and	O
significantly	O
decreased	B-OUTCOME
the	I-OUTCOME
positive	I-OUTCOME
coupling	I-OUTCOME
of	I-OUTCOME
two	I-OUTCOME
key	I-OUTCOME
structural	I-OUTCOME
hubs	I-OUTCOME
(	I-OUTCOME
the	I-OUTCOME
mPFC	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
PCC	I-OUTCOME
)	I-OUTCOME
.	O
Our	O
use	O
of	O
fMRI	O
to	O
measure	O
resting	O
-	O
state	O
brain	B-NEURAL MECHANISM/CORRELATE
activity	O
after	O
a	O
psychedelic	B-DRUG
is	O
unique	O
,	O
and	O
because	O
the	O
results	O
are	O
unexpected	O
,	O
the	O
results	O
require	O
some	O
explanation	O
.	O
The	O
effect	O
of	O
psilocybin	B-DRUG
on	O
resting	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
state	I-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
activity	I-NEURAL MECHANISM/CORRELATE
has	O
been	O
measured	O
before	O
with	O
PET	O
and	O
glucose	O
metabolism	O
(	O
8)	O
.	O
The	O
fMRI	O
studies	O
reported	O
here	O
found	O
a	O
global	B-OUTCOME
increase	I-OUTCOME
in	I-OUTCOME
glucose	I-OUTCOME
metabolism	I-OUTCOME
after	O
oral	O
psilocybin	B-DRUG
,	O
which	O
is	O
inconsistent	O
with	O
our	O
fMRI	O
results	O
.	O
One	O
possible	O
explanation	O
for	O
this	O
discrepancy	O
relates	O
to	O
the	O
fact	O
that	O
the	O
radiotracer	O
used	O
to	O
measure	O
glucose	B-NEURAL MECHANISM/CORRELATE
metabolism	I-NEURAL MECHANISM/CORRELATE
(	O
18F	O
-	O
fluorodeoxyglucose	O
)	O
has	O
a	O
long	O
half	O
-	O
life	O
(	O
110	O
min	O
)	O
.	O
Thus	O
,	O
the	O
effects	O
of	O
psilocybin	B-DRUG
,	O
as	O
measured	O
by	O
PET	O
,	O
are	O
over	O
much	O
greater	O
timescales	O
than	O
indexed	O
by	O
our	O
fMRI	O
measures	O
.	O
It	O
is	O
therefore	O
possible	O
that	O
phasic	B-OUTCOME
or	I-OUTCOME
short	I-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
show	O
some	O
rebound	O
that	O
is	O
detected	O
by	O
longer	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
glucose	I-OUTCOME
metabolism	I-OUTCOME
.	O
More	O
direct	O
measures	O
of	O
neural	O
activity	O
will	O
help	O
inform	O
this	O
hypothesis	O
,	O
but	O
in	O
support	O
of	O
the	O
inference	O
that	O
psilocybin	B-DRUG
does	O
decrease	B-OUTCOME
neural	I-OUTCOME
activity	I-OUTCOME
,	O
direct	O
recordings	O
of	O
cortical	O
local	O
field	O
potentials	O
(	O
LFPs	O
)	O
in	O
rats	O
found	O
broadband	O
decreases	B-OUTCOME
in	I-OUTCOME
resting	I-OUTCOME
state	I-OUTCOME
LFP	I-OUTCOME
power	I-OUTCOME
after	O
psilocybin	B-DRUG
infusion	O
—	O
including	O
γ	O
-	O
power	O
(	O
9)—changes	O
in	O
which	O
are	O
known	O
to	O
correlate	O
with	O
changes	O
in	O
the	O
BOLD	O
signal	O
(	O
10	O
)	O
.	O
It	O
has	O
been	O
commonly	O
assumed	O
that	O
psychedelics	B-DRUG
work	O
by	O
increasing	B-OUTCOME
neural	I-OUTCOME
activity	I-OUTCOME
;	O
however	O
,	O
our	O
results	O
put	O
this	O
into	O
question	O
.	O
Psilocin	B-DRUG
is	O
a	O
mixed	O
serotonin	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonist	I-NEURAL MECHANISM/CORRELATE
,	O
but	O
there	O
is	O
a	O
general	O
consensus	O
that	O
the	O
characteristic	O
subjective	B-OUTCOME
and	I-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
are	O
initiated	O
via	O
stimulation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
Hydroxytryptamine	I-NEURAL MECHANISM/CORRELATE
,	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
(	O
11	O
)	O
.	O
It	O
is	O
possible	O
that	O
the	O
deactivations	B-OUTCOME
observed	I-OUTCOME
in	O
the	O
present	O
studies	O
were	O
caused	O
by	O
stimulation	O
of	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
other	O
than	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
;	O
however	O
,	O
this	O
seems	O
unlikely	O
given	O
that	O
the	O
affinity	O
of	O
psychedelics	B-DRUG
for	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
correlates	O
with	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
potency	I-NEURAL MECHANISM/CORRELATE
(	O
12	O
)	O
and	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
antagonists	I-NEURAL MECHANISM/CORRELATE
block	B-OUTCOME
the	I-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
(	O
13	O
)	O
.	O
There	O
is	O
a	O
large	O
body	O
of	O
preclinical	O
evidence	O
that	O
stimulation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
increases	O
GABAergic	B-NEURAL MECHANISM/CORRELATE
transmission	I-NEURAL MECHANISM/CORRELATE
and	O
pyramidal	B-NEURAL MECHANISM/CORRELATE
cell	I-NEURAL MECHANISM/CORRELATE
inhibition	I-NEURAL MECHANISM/CORRELATE
(	O
14–21	O
)	O
,	O
which	O
may	O
explain	O
the	O
deactivations	O
observed	O
here	O
(	O
Figs	O
.	O
2	O
and	O
4	O
)	O
.	O
fMRI	O
studies	O
with	O
serotonergic	B-DRUG
compounds	I-DRUG
that	O
stimulate	O
other	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
,	O
such	O
as	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2C	I-NEURAL MECHANISM/CORRELATE
(	O
22	O
)	O
or	O
(	O
mainly	O
)	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
(	O
23	O
)	O
,	O
have	O
not	O
found	O
comparable	O
results	O
to	O
those	O
shown	O
here	O
,	O
and	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
are	O
present	O
in	O
high	O
concentrations	O
in	O
the	O
cortical	B-OUTCOME
regions	I-OUTCOME
that	I-OUTCOME
were	I-OUTCOME
significantly	I-OUTCOME
deactivated	I-OUTCOME
and	I-OUTCOME
decoupled	I-OUTCOME
after	O
psilocybin	B-DRUG
(	O
Table	O
S2	O
)	O
.	O
Stimulation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
the	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
increases	B-OUTCOME
excitation	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
host	I-OUTCOME
cell	I-OUTCOME
by	O
reducing	O
outward	O
potassium	B-NEURAL MECHANISM/CORRELATE
currents	I-NEURAL MECHANISM/CORRELATE
(	O
24	O
)	O
.	O
Thus	O
,	O
if	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
did	O
mediate	O
the	O
observed	B-OUTCOME
deactivations	I-OUTCOME
,	O
then	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
may	O
have	O
been	O
via	O
5	B-OUTCOME
-	I-OUTCOME
HT2A	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
excitation	I-OUTCOME
of	I-OUTCOME
fast	I-OUTCOME
-	I-OUTCOME
spiking	I-OUTCOME
interneurons	I-OUTCOME
terminating	I-OUTCOME
on	I-OUTCOME
pyramidal	I-OUTCOME
cells	I-OUTCOME
(	O
e.g.	O
,	O
ref	O
.	O
24	O
)	O
or	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
induced	I-NEURAL MECHANISM/CORRELATE
excitation	I-NEURAL MECHANISM/CORRELATE
of	O
pyramidal	B-NEURAL MECHANISM/CORRELATE
cells	I-NEURAL MECHANISM/CORRELATE
projecting	O
onto	O
interneurons	B-NEURAL MECHANISM/CORRELATE
(	O
25	O
)	O
.	O
Regardless	O
of	O
how	O
these	O
effects	O
were	O
initiated	O
at	O
the	O
receptor	B-NEURAL MECHANISM/CORRELATE
level	O
,	O
it	O
is	O
necessary	O
for	O
us	O
to	O
offer	O
a	O
functional	O
explanation	O
for	O
these	O
effects	O
.	O
It	O
is	O
noteworthy	O
that	O
the	O
regions	O
which	O
showed	O
the	O
most	B-OUTCOME
consistent	I-OUTCOME
deactivations	I-OUTCOME
after	O
psilocybin	B-DRUG
(	O
e.g.	O
,	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
and	O
mPFC	B-NEURAL MECHANISM/CORRELATE
)	O
are	O
also	O
those	O
that	O
show	O
disproportionately	B-OUTCOME
high	I-OUTCOME
activity	I-OUTCOME
under	I-OUTCOME
normal	I-OUTCOME
conditions	I-OUTCOME
(	O
26	O
)	O
.	O
For	O
example	O
,	O
metabolism	B-NEURAL MECHANISM/CORRELATE
in	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
is	O
∼20	O
%	O
higher	O
than	O
most	O
other	O
brain	B-NEURAL MECHANISM/CORRELATE
regions	O
(	O
27	O
)	O
,	O
yet	O
psilocybin	B-DRUG
decreased	B-OUTCOME
the	I-OUTCOME
PCC	I-OUTCOME
blood	I-OUTCOME
flow	I-OUTCOME
by	O
up	O
to	O
20	O
%	O
in	O
some	O
subjects	O
.	O
There	O
is	O
some	O
mystery	O
about	O
the	O
function	O
of	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
;	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
large	O
size	O
,	O
buffered	O
location	O
,	O
and	O
rich	O
vasculature	O
means	O
that	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
is	O
well	O
protected	O
from	O
damage	O
.	O
The	O
high	O
metabolic	O
activity	O
of	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
default	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
mode	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	O
DMN	B-NEURAL MECHANISM/CORRELATE
)	O
with	O
which	O
is	O
it	O
associated	O
(	O
26	O
)	O
has	O
led	O
some	O
to	O
speculate	O
about	O
The	O
high	O
metabolic	O
activity	O
of	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
default	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
mode	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	O
DMN	B-NEURAL MECHANISM/CORRELATE
)	O
with	O
which	O
is	O
it	O
associated	O
(	O
26	O
)	O
functional	O
importance	O
,	O
positing	O
a	O
role	B-OUTCOME
in	I-OUTCOME
consciousness	I-OUTCOME
(	O
28	O
)	O
and	O
high	B-OUTCOME
-	I-OUTCOME
level	I-OUTCOME
constructs	I-OUTCOME
,	O
such	O
as	O
the	O
self	B-SUBJECTIVE EXPERIENCE
(	O
29	O
)	O
or	O
“	O
ego	B-SUBJECTIVE EXPERIENCE
”	O
(	O
30	O
,	O
31	O
)	O
.	O
Indeed	O
,	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
is	O
known	O
to	O
be	O
activated	O
during	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
referencing	I-SUBJECTIVE EXPERIENCE
(	O
28	O
)	O
and	O
other	O
high	O
-	O
level	O
functions	O
linked	O
to	O
the	O
self	O
-	O
construct	O
(	O
27	O
)	O
.	O
Moreover	O
,	O
DMN	B-NEURAL MECHANISM/CORRELATE
regions	O
are	O
also	O
known	O
to	O
host	O
the	O
highest	O
number	O
of	O
cortico	O
-	O
cortical	O
connections	O
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
,	O
making	O
DMN	B-NEURAL MECHANISM/CORRELATE
regions	O
important	O
“	O
connector	B-OUTCOME
hubs	I-OUTCOME
”	O
(	O
32	O
)	O
.	O
“	O
connector	O
hubs	O
”	O
(	O
32	O
)	O
may	O
be	O
critical	O
for	O
efficient	B-OUTCOME
information	I-OUTCOME
transfer	I-OUTCOME
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
by	O
allowing	B-OUTCOME
communication	I-OUTCOME
between	I-OUTCOME
different	I-OUTCOME
regions	I-OUTCOME
via	O
the	O
fewest	O
number	O
of	O
connections	O
(	O
33	O
)	O
.	O
However	O
,	O
such	O
an	O
integrative	B-OUTCOME
function	I-OUTCOME
would	O
confer	O
a	O
significant	O
responsibility	O
on	O
these	O
regions	O
,	O
which	O
may	O
explain	O
why	O
such	O
an	O
integrative	B-OUTCOME
function	I-OUTCOME
deactivation	I-OUTCOME
has	O
such	O
a	O
profound	B-OUTCOME
effect	I-OUTCOME
on	I-OUTCOME
consciousness	I-OUTCOME
,	O
as	O
shown	O
here	O
.	O
These	O
results	O
may	O
have	O
implications	O
beyond	O
explaining	O
how	O
psilocybin	B-DRUG
works	O
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
by	O
implying	O
that	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
is	O
crucial	O
for	O
the	O
maintenance	B-OUTCOME
of	I-OUTCOME
cognitive	I-OUTCOME
integration	I-OUTCOME
and	I-OUTCOME
constraint	I-OUTCOME
under	I-OUTCOME
normal	I-OUTCOME
conditions	I-OUTCOME
.	O
This	O
finding	O
is	O
consistent	O
with	O
Aldous	O
Huxley	O
's	O
“	O
reducing	O
valve	O
”	O
metaphor	O
(	O
34	O
)	O
and	O
Karl	O
Friston	O
's	O
“	O
free	O
-	O
energy	O
principle	O
”	O
(	O
35	O
)	O
,	O
which	O
propose	O
that	O
the	O
mind	B-NEURAL MECHANISM/CORRELATE
/	O
brain	B-NEURAL MECHANISM/CORRELATE
works	O
to	O
constrain	B-OUTCOME
its	I-OUTCOME
experience	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
world	I-OUTCOME
.	O
The	O
pharmaco	O
-	O
physiological	O
interaction	O
results	O
were	O
particularly	O
intriguing	O
,	O
revealing	O
significant	O
decreases	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
positive	I-OUTCOME
coupling	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
PCC	I-OUTCOME
and	I-OUTCOME
mPFC	I-OUTCOME
after	O
psilocybin	B-DRUG
.	O
This	O
result	O
can	O
be	O
understood	O
in	O
terms	O
of	O
a	O
regression	O
of	O
PCC	B-NEURAL MECHANISM/CORRELATE
activity	O
on	O
mPFC	B-NEURAL MECHANISM/CORRELATE
activity	O
,	O
in	O
which	O
the	O
regression	O
slope	O
decreases	O
.	O
This	O
finding	O
can	O
either	O
be	O
interpreted	O
as	O
a	O
decrease	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
(	I-OUTCOME
backward	I-OUTCOME
or	I-OUTCOME
top	I-OUTCOME
-	I-OUTCOME
down	I-OUTCOME
)	I-OUTCOME
connectivity	I-OUTCOME
from	O
prefrontal	B-NEURAL MECHANISM/CORRELATE
to	O
parietal	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
or	O
,	O
equivalently	O
,	O
an	O
increase	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
reciprocal	I-OUTCOME
(	I-OUTCOME
forward	I-OUTCOME
or	I-OUTCOME
bottom	I-OUTCOME
-	I-OUTCOME
up	I-OUTCOME
)	I-OUTCOME
direction	I-OUTCOME
from	O
parietal	B-NEURAL MECHANISM/CORRELATE
to	O
prefrontal	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
.	O
This	O
asymmetrical	B-OUTCOME
change	I-OUTCOME
in	I-OUTCOME
coupling	I-OUTCOME
,	O
induced	O
by	O
psilocybin	B-DRUG
,	O
is	O
consistent	O
with	O
a	O
reduction	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
sensitivity	I-OUTCOME
of	I-OUTCOME
superficial	I-OUTCOME
pyramidal	I-OUTCOME
cells	I-OUTCOME
in	O
the	O
parietal	B-NEURAL MECHANISM/CORRELATE
region	I-NEURAL MECHANISM/CORRELATE
targeted	O
by	O
prefrontal	O
afferents	O
,	O
which	O
may	O
or	O
may	O
not	O
be	O
associated	O
with	O
a	O
compensatory	O
increase	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
influence	I-OUTCOME
of	I-OUTCOME
parietal	I-OUTCOME
regions	I-OUTCOME
on	I-OUTCOME
prefrontal	I-OUTCOME
activity	I-OUTCOME
.	O
Whatever	O
the	O
underlying	O
synaptic	O
mechanisms	O
,	O
these	O
results	O
provide	O
clear	O
evidence	O
for	O
a	O
perturbation	B-OUTCOME
in	I-OUTCOME
reciprocal	I-OUTCOME
coupling	I-OUTCOME
between	O
these	O
two	O
association	O
areas	O
and	O
speak	O
to	O
a	O
rebalancing	B-OUTCOME
of	I-OUTCOME
hierarchical	I-OUTCOME
activity	I-OUTCOME
in	I-OUTCOME
distributed	I-OUTCOME
high	I-OUTCOME
-	I-OUTCOME
level	I-OUTCOME
modes	I-OUTCOME
.	O
Finally	O
,	O
consistent	O
with	O
their	O
history	O
of	O
use	O
as	O
adjuncts	O
to	O
psychotherapy	O
,	O
the	O
idea	O
has	O
recently	O
re	O
-	O
emerged	O
that	O
psychedelics	B-DRUG
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
certain	O
psychiatric	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
(	O
36	O
)	O
.	O
It	O
seems	O
relevant	O
therefore	O
that	O
activity	O
in	O
(	O
37	O
)	O
and	O
connectivity	O
with	O
(	O
38	O
)	O
the	O
mPFC	B-NEURAL MECHANISM/CORRELATE
is	O
known	O
to	O
be	O
elevated	O
in	O
depression	B-HEALTH CONDITION
and	O
normalized	O
after	O
effective	O
treatment	O
(	O
39	O
)	O
.	O
The	O
mPFC	B-OUTCOME
was	I-OUTCOME
consistently	I-OUTCOME
deactivated	I-OUTCOME
by	O
psilocybin	B-DRUG
(	O
Fig	O
.	O
4	O
)	O
and	O
the	O
magnitude	O
of	O
the	O
deactivations	O
correlated	O
with	O
the	O
drug	O
's	O
subjective	B-OUTCOME
effects	I-OUTCOME
(	O
Fig	O
.	O
3	O
)	O
.	O
Depression	B-HEALTH CONDITION
has	O
been	O
characterized	O
as	O
an	O
“	B-SUBJECTIVE EXPERIENCE
overstable	I-SUBJECTIVE EXPERIENCE
”	I-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
,	O
in	O
which	O
cognition	B-OUTCOME
is	I-OUTCOME
rigidly	I-OUTCOME
pessimistic	I-OUTCOME
(	O
39	O
)	O
.	O
Trait	O
pessimism	O
has	O
been	O
linked	O
to	O
deficient	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
stimulation	I-NEURAL MECHANISM/CORRELATE
(	O
40	O
,	O
41	O
)	O
,	O
particularly	O
in	O
the	O
mPFC	B-NEURAL MECHANISM/CORRELATE
(	O
40	O
)	O
,	O
and	O
mPFC	B-NEURAL MECHANISM/CORRELATE
hyperactivity	I-NEURAL MECHANISM/CORRELATE
has	O
been	O
linked	O
to	O
pathological	O
brooding	O
(	O
42	O
)	O
.	O
Recent	O
work	O
has	O
shown	O
that	O
psilocybin	B-DRUG
can	O
increase	O
subjective	B-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
(	O
4	O
)	O
and	O
trait	B-OUTCOME
openness	I-OUTCOME
(	O
43	O
)	O
several	O
months	O
after	O
an	O
acute	O
experience	O
,	O
and	O
depression	B-HEALTH CONDITION
scores	O
in	O
terminal	B-HEALTH CONDITION
cancer	I-HEALTH CONDITION
patients	I-HEALTH CONDITION
were	O
significantly	O
decreased	O
6	O
mo	O
after	O
treatment	O
with	O
psilocybin	B-DRUG
(	O
2	O
)	O
.	O
Our	O
results	O
suggest	O
a	O
biological	O
mechanism	O
for	O
this	O
:	O
decreased	B-OUTCOME
mPFC	I-OUTCOME
activity	I-OUTCOME
via	I-OUTCOME
5	I-OUTCOME
-	I-OUTCOME
HT2A	I-OUTCOME
receptor	I-OUTCOME
stimulation	I-OUTCOME
.	O
Further	O
work	O
is	O
required	O
to	O
test	O
this	O
hypothesis	O
and	O
the	O
putative	O
utility	O
of	O
psilocybin	B-DRUG
in	O
depression	B-HEALTH CONDITION
We	O
also	O
observed	O
decreased	B-OUTCOME
CBF	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
hypothalamus	I-OUTCOME
after	O
psilocybin	B-DRUG
(	O
Fig	O
.	O
2	O
)	O
,	O
which	O
may	O
explain	O
anecdotal	O
reports	O
that	O
psychedelics	B-DRUG
reduce	O
symptoms	O
of	O
cluster	B-HEALTH CONDITION
headaches	I-HEALTH CONDITION
(	O
44	O
)	O
.	O
Increased	B-OUTCOME
hypothalamic	I-OUTCOME
CBF	I-OUTCOME
was	O
observed	O
during	O
acute	O
headache	O
in	O
cluster	B-HEALTH CONDITION
headache	I-HEALTH CONDITION
sufferers	I-HEALTH CONDITION
(	O
45	O
)	O
and	O
inhibition	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
hypothalamus	I-OUTCOME
via	I-OUTCOME
direct	I-OUTCOME
electrical	I-OUTCOME
stimulation	I-OUTCOME
can	O
provide	O
therapeutic	B-OUTCOME
relief	I-OUTCOME
for	O
this	O
condition	O
.	O
To	O
conclude	O
,	O
here	O
we	O
used	O
an	O
advanced	O
and	O
comprehensive	O
fMRI	O
protocol	O
to	O
image	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
effects	O
of	O
psilocybin	B-DRUG
.	O
These	O
studies	O
offer	O
the	O
most	O
detailed	O
account	O
to	O
date	O
on	O
how	O
the	O
psychedelic	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
is	O
produced	O
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
.	O
The	O
results	O
suggest	O
decreased	B-OUTCOME
activity	I-OUTCOME
and	I-OUTCOME
connectivity	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
brain	I-OUTCOME
's	I-OUTCOME
connector	I-OUTCOME
hubs	I-OUTCOME
,	O
permitting	O
an	O
unconstrained	B-OUTCOME
style	I-OUTCOME
of	I-OUTCOME
cognition	I-OUTCOME
.	O
-DOCSTART- -X- O O
The	O
results	O
of	O
the	O
present	O
investigation	O
demonstrate	O
that	O
AYA	B-DRUG
has	O
significant	O
and	O
quite	O
impressive	O
acute	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
.	O
Score	O
reductions	O
were	O
observed	O
in	O
both	O
the	O
HAM	O
-	O
D	O
and	O
MADRS	O
scales	O
on	O
D1	O
and	O
D7	O
,	O
and	O
these	O
effects	O
lasted	O
for	O
several	O
days	O
.	O
It	O
is	O
noteworthy	O
that	O
these	O
changes	O
showed	O
a	O
profile	O
that	O
was	O
very	O
similar	O
across	O
volunteers	O
,	O
regardless	O
of	O
the	O
prior	O
level	O
of	O
depression	B-HEALTH CONDITION
,	O
i.e.	O
,	O
the	O
severity	O
of	O
the	O
current	O
depressive	O
episode	O
.	O
The	O
antidepressant	B-OUTCOME
potential	I-OUTCOME
of	O
AYA	B-DRUG
was	O
previously	O
demonstrated	O
in	O
a	O
study	O
that	O
reported	O
a	O
decrease	O
in	O
hopelessness	B-OUTCOME
symptoms	I-OUTCOME
after	O
acute	O
AYA	B-DRUG
intake	O
The	O
average	O
time	O
necessary	O
for	O
the	O
onset	O
of	O
therapeutic	B-OUTCOME
action	I-OUTCOME
of	O
commercially	O
available	O
antidepressants	B-ANTIDEPRESSANT_DRUG
is	O
2	O
weeks.3	O
Considering	O
currently	O
available	O
medications	O
,	O
the	O
fast	B-OUTCOME
antidepressant	I-OUTCOME
action	I-OUTCOME
of	O
AYA	B-DRUG
is	O
promising	O
,	O
as	O
the	O
fast	B-OUTCOME
antidepressant	I-OUTCOME
action	I-OUTCOME
of	O
AYA	B-DRUG
may	O
provide	O
faster	B-OUTCOME
reductions	I-OUTCOME
in	I-OUTCOME
depressive	I-OUTCOME
symptoms	I-OUTCOME
.	O
Moreover	O
,	O
the	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
alkaloids	I-DRUG
may	O
inspire	O
a	O
new	O
area	O
of	O
depression	B-HEALTH CONDITION
research	O
.	O
Interestingly	O
,	O
symptoms	B-OUTCOME
increased	I-OUTCOME
on	I-OUTCOME
D14	I-OUTCOME
as	O
measured	O
by	O
the	O
HAM	O
-	O
D	O
and	O
MADRS	O
scales	O
,	O
although	O
a	O
subsequent	O
significant	B-OUTCOME
decrease	I-OUTCOME
occurred	I-OUTCOME
on	I-OUTCOME
D21	I-OUTCOME
in	I-OUTCOME
both	I-OUTCOME
scales	I-OUTCOME
.	O
Although	O
increased	O
,	O
HAM	O
-	O
D	O
scores	O
still	O
remained	O
45	O
%	O
below	O
baseline	O
values	O
,	O
but	O
this	O
difference	O
was	O
nonsignificant	O
.	O
On	O
the	O
other	O
hand	O
,	O
MADRS	O
scores	O
on	O
D14	O
were	O
significantly	O
increased	O
The	O
decreases	B-OUTCOME
and	I-OUTCOME
increases	I-OUTCOME
in	I-OUTCOME
depressive	I-OUTCOME
symptoms	I-OUTCOME
after	O
AYA	B-DRUG
administration	O
could	O
reflect	O
complex	B-OUTCOME
intracellular	I-OUTCOME
events	I-OUTCOME
that	I-OUTCOME
remain	I-OUTCOME
active	I-OUTCOME
after	I-OUTCOME
the	I-OUTCOME
acute	I-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
have	O
subsided	O
.	O
The	O
acute	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
of	O
ketamine	B-DRUG
,	O
for	O
instance	O
,	O
may	O
be	O
sustained	O
for	O
weeks	O
to	O
months	O
and	O
are	O
associated	O
with	O
increased	B-NEURAL MECHANISM/CORRELATE
synaptogenesis	I-NEURAL MECHANISM/CORRELATE
and	O
spine	B-NEURAL MECHANISM/CORRELATE
formation	I-NEURAL MECHANISM/CORRELATE
,	O
which	O
seem	O
to	O
be	O
related	O
with	O
increases	O
in	O
brain	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
derived	I-NEURAL MECHANISM/CORRELATE
neurotrophic	I-NEURAL MECHANISM/CORRELATE
factor	I-NEURAL MECHANISM/CORRELATE
(	O
BDNF	B-NEURAL MECHANISM/CORRELATE
)	O
protein	O
levels.4,5	O
Studies	O
conducted	O
in	O
rodents	O
by	O
our	O
group	O
and	O
by	O
others	O
using	O
doses	O
of	O
10	O
-	O
15	O
mg	O
/	O
kg	O
harmine	B-DRUG
have	O
demonstrated	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
for	O
this	O
compound	O
,	O
which	O
were	O
associated	O
with	O
increases	B-OUTCOME
in	I-OUTCOME
BDNF	I-OUTCOME
levels	I-OUTCOME
.	O
Furthermore	O
,	O
harmine	B-DRUG
,	O
THH	B-DRUG
,	O
and	O
harmaline	B-DRUG
are	O
potent	B-OUTCOME
natural	I-OUTCOME
,	I-OUTCOME
selective	I-OUTCOME
,	I-OUTCOME
reversible	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
competitive	I-OUTCOME
inhibitors	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
MAO	I-OUTCOME
enzyme	I-OUTCOME
,	O
especially	O
of	O
the	O
MAO	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
A	I-NEURAL MECHANISM/CORRELATE
subtype.9,36	I-NEURAL MECHANISM/CORRELATE
THH	B-DRUG
acts	O
as	O
a	O
selective	B-ANTIDEPRESSANT_DRUG
serotonin	I-ANTIDEPRESSANT_DRUG
reuptake	I-ANTIDEPRESSANT_DRUG
inhibitor	I-ANTIDEPRESSANT_DRUG
as	O
well	O
as	O
an	O
MAOI.9,37	B-NEURAL MECHANISM/CORRELATE
Inhibition	O
of	O
both	O
systems	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
MAO	I-NEURAL MECHANISM/CORRELATE
and	O
serotonin	B-NEURAL MECHANISM/CORRELATE
reuptake	I-NEURAL MECHANISM/CORRELATE
-	O
may	O
result	O
in	O
elevated	B-OUTCOME
levels	I-OUTCOME
of	I-OUTCOME
brain	I-OUTCOME
serotonin	I-OUTCOME
and	O
other	O
monoamines	B-NEURAL MECHANISM/CORRELATE
,	O
producing	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
.	O
The	O
statistically	O
significant	O
reductions	O
in	O
BPRS	O
-	O
AD	O
scores	O
from	O
D1	O
to	O
D21	O
suggest	O
that	O
AYA	B-DRUG
produced	O
antidepressive	B-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
.	O
A	O
previous	O
study	O
reported	O
decreased	O
panic	B-OUTCOME
-	I-OUTCOME
related	I-OUTCOME
signs	I-OUTCOME
after	O
acute	O
AYA	B-DRUG
intake	O
.	O
AYA	B-DRUG
administration	O
did	O
not	O
produce	O
statistically	O
significant	O
sensory	B-OUTCOME
,	I-OUTCOME
cognitive	I-OUTCOME
,	I-OUTCOME
or	I-OUTCOME
affective	I-OUTCOME
modifications	I-OUTCOME
as	O
assessed	O
by	O
the	O
BPRS	O
and	O
YMRS	O
scales	O
.	O
Although	O
nonsignificant	O
,	O
in	O
the	O
present	O
study	O
these	O
effects	O
were	O
observed	O
during	O
a	O
period	O
ranging	O
from	O
80	O
to	O
140	O
min	O
after	O
AYA	B-DRUG
administration	O
,	O
which	O
is	O
the	O
time	O
point	O
when	O
the	O
subjective	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
are	O
peaking	O
,	O
as	O
are	O
DMT	B-DRUG
plasma	O
levels	O
.	O
The	O
absence	O
of	O
statistically	O
significant	O
effects	O
on	O
BPRS	O
-	O
TD	O
scores	O
could	O
be	O
explained	O
by	O
the	O
DMT	B-DRUG
concentration	O
found	O
in	O
our	O
AYA	B-DRUG
batch	O
(	O
0.08	O
mg	O
/	O
mL	O
)	O
,	O
which	O
is	O
lower	O
than	O
DMT	B-DRUG
doses	O
used	O
in	O
previous	O
studies	O
that	O
reported	O
significant	O
psychotropic	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
(	O
0.53	O
mg	O
/	O
mL	O
DMT).9,12	O
The	O
nonsignificant	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
on	O
the	O
BPRS	O
-	O
TD	O
subscale	O
suggest	O
that	O
changes	B-OUTCOME
in	I-OUTCOME
sensory	I-OUTCOME
perception	I-OUTCOME
and	I-OUTCOME
thought	I-OUTCOME
content	I-OUTCOME
may	O
not	O
be	O
essential	B-OUTCOME
for	I-OUTCOME
therapeutic	I-OUTCOME
effects	I-OUTCOME
.	O
AYA	B-DRUG
was	O
well	O
tolerated	O
by	O
all	O
patients	O
,	O
suggesting	O
that	O
AYA	B-DRUG
can	O
be	O
safely	O
administered	O
to	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
.	O
This	O
result	O
corroborates	O
previous	O
studies	O
reporting	O
a	O
good	B-OUTCOME
tolerability	I-OUTCOME
profile	I-OUTCOME
for	O
AYA	B-DRUG
administration	O
to	O
healthy	O
volunteers.8	O
-	O
12,15,25,39	O
In	O
the	O
present	O
study	O
,	O
the	O
psychoactive	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
were	O
considered	O
by	O
participants	O
as	O
mild	B-OUTCOME
and	I-OUTCOME
short	I-OUTCOME
-	I-OUTCOME
lived	I-OUTCOME
,	O
corroborating	O
the	O
nonsignificant	O
effect	O
of	O
AYA	B-DRUG
on	O
the	O
BPRS	O
-	O
TD	O
subscale	O
.	O
The	O
nonsignificant	B-OUTCOME
increases	I-OUTCOME
in	I-OUTCOME
blood	I-OUTCOME
pressure	I-OUTCOME
replicate	O
previous	O
findings	O
in	O
human	O
studies	O
suggesting	O
that	O
AYA	B-DRUG
produces	O
moderate	B-OUTCOME
cardiovascular	I-OUTCOME
effects	I-OUTCOME
.	O
Early	O
academic	O
research	O
on	O
classical	B-DRUG
hallucinogens	I-DRUG
was	O
designed	O
considering	O
the	O
powerful	O
influences	O
of	O
set	O
(	O
psychological	O
state	O
)	O
and	O
setting	O
(	O
environment	O
)	O
on	O
the	O
effects	O
of	O
this	O
class	O
of	O
substances.40	O
Considering	O
this	O
background	O
,	O
in	O
the	O
present	O
study	O
volunteers	O
were	O
kept	O
as	O
comfortable	O
as	O
possible	O
,	O
remaining	O
seated	O
in	O
a	O
recliner	O
in	O
a	O
quiet	O
,	O
dimly	O
lit	O
room	O
throughout	O
the	O
experimental	O
session	O
.	O
Investigator	O
interference	O
was	O
minimal	O
,	O
allowing	O
patients	O
to	O
concentrate	O
on	O
the	O
effects	O
of	O
AYA	B-DRUG
.	O
This	O
safe	O
environment	O
may	O
have	O
reduced	B-OUTCOME
the	I-OUTCOME
probability	I-OUTCOME
of	I-OUTCOME
dysphoric	I-OUTCOME
reactions	I-OUTCOME
Vomiting	B-OUTCOME
was	O
the	O
only	O
adverse	B-OUTCOME
effect	I-OUTCOME
reported	O
by	O
volunteers	O
(	O
50	O
%	O
)	O
.	O
Patients	O
were	O
informed	O
before	O
the	O
experimental	O
session	O
that	O
vomiting	B-OUTCOME
was	O
a	O
possible	O
effect	O
of	O
AYA	B-DRUG
,	O
as	O
nausea	B-OUTCOME
and	O
vomiting	B-OUTCOME
are	O
the	O
most	O
frequently	O
reported	O
adverse	B-OUTCOME
effects	I-OUTCOME
in	O
clinical	O
trials	O
of	O
acute	O
AYA	B-DRUG
administration.8	O
-	O
12,15,39	O
In	O
the	O
present	O
study	O
,	O
vomiting	B-OUTCOME
apparently	O
did	O
not	O
have	O
a	O
significant	O
influence	O
on	O
the	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
.	O
Patients	O
did	O
not	O
consider	O
this	O
emetic	B-OUTCOME
effect	I-OUTCOME
to	O
be	O
a	O
severe	B-OUTCOME
discomfort	I-OUTCOME
,	O
a	O
result	O
that	O
is	O
in	O
line	O
with	O
previous	O
studies	O
of	O
acute	O
AYA	B-DRUG
administration	O
to	O
healthy	O
volunteers	O
,	O
which	O
reported	O
that	O
most	O
participants	O
regarded	O
most	O
participants	O
AYA	B-DRUG
experience	B-OUTCOME
as	I-OUTCOME
pleasant	I-OUTCOME
despite	I-OUTCOME
the	I-OUTCOME
occurrence	I-OUTCOME
of	I-OUTCOME
vomiting	I-OUTCOME
In	O
future	O
studies	O
,	O
it	O
would	O
be	O
interesting	O
to	O
try	O
to	O
reduce	O
the	O
emetic	B-OUTCOME
effect	I-OUTCOME
of	O
AYA	B-DRUG
by	O
premedicating	O
with	O
an	O
antiemetic	O
.	O
However	O
,	O
this	O
possibility	O
should	O
be	O
explored	O
with	O
caution	O
,	O
considering	O
that	O
AYA	B-DRUG
alkaloids	I-DRUG
could	O
interact	O
with	O
antiemetic	O
drugs	O
.	O
Another	O
possibility	O
could	O
be	O
to	O
administer	O
AYA	B-DRUG
in	O
different	O
formulations	O
.	O
Freeze	O
-	O
dried	O
AYA	B-DRUG
appears	O
to	O
produce	O
less	B-OUTCOME
vomiting	I-OUTCOME
than	I-OUTCOME
oral	I-OUTCOME
AYA.8,11,15,39	O
Interestingly	O
,	O
variable	O
degrees	O
of	O
nausea	B-OUTCOME
,	O
vomiting	B-OUTCOME
,	O
and	O
,	O
occasionally	O
,	O
simultaneous	B-OUTCOME
diarrhea	I-OUTCOME
are	O
common	O
in	O
AYA	B-DRUG
rituals	O
.	O
In	O
these	O
contexts	O
,	O
however	O
,	O
these	O
purgative	B-OUTCOME
effects	I-OUTCOME
are	O
considered	O
positive	O
and	O
cleansing	B-OUTCOME
.	O
Important	O
limitations	O
of	O
the	O
present	O
open	O
-	O
label	O
study	O
include	O
the	O
small	O
sample	O
size	O
,	O
the	O
absence	O
of	O
a	O
systematic	O
inquiry	O
about	O
side	B-OUTCOME
effects	I-OUTCOME
,	O
and	O
the	O
lack	O
of	O
placebo	O
and	O
control	O
groups	O
.	O
Although	O
patients	O
did	O
not	O
spontaneously	O
report	O
adverse	B-OUTCOME
effects	I-OUTCOME
other	O
than	O
vomiting	B-OUTCOME
,	O
the	O
lack	O
of	O
a	O
systematic	O
assessment	O
of	O
adverse	B-OUTCOME
effects	I-OUTCOME
may	O
have	O
reduced	O
the	O
likelihood	O
of	O
registering	O
more	O
subtle	B-OUTCOME
effects	I-OUTCOME
,	O
such	O
as	O
impacts	O
on	O
cognition	O
.	O
Future	O
studies	O
should	O
assess	O
the	O
possible	O
adverse	B-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
in	O
clinical	O
populations	O
by	O
using	O
other	O
subjective	O
measures	O
,	O
such	O
as	O
visual	O
analogue	O
scales	O
and	O
other	O
scales	O
that	O
measure	O
hallucinogenic	B-OUTCOME
effects	I-OUTCOME
,	O
and	O
by	O
exploring	O
other	O
variables	O
that	O
could	O
be	O
modified	O
by	O
AYA	B-DRUG
administration	O
as	O
reported	O
in	O
previous	O
studies	O
,	O
such	O
as	O
neuropsychological	O
,	O
neurophysiological	O
,	O
autonomic	O
,	O
neuroendocrine	O
,	O
and	O
immunological	O
parameters	O
.	O
Ideally	O
,	O
future	O
studies	O
involving	O
AYA	B-DRUG
and	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
or	O
other	O
clinical	O
populations	O
should	O
also	O
be	O
designed	O
to	O
include	O
a	O
control	O
group	O
.	O
This	O
group	O
could	O
receive	O
a	O
placebo	O
,	O
a	O
comparator	O
drug	O
with	O
an	O
established	O
therapeutic	O
indication	O
,	O
or	O
AYA	B-DRUG
preceded	O
by	O
pretreatment	O
with	O
a	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
antagonist	I-NEURAL MECHANISM/CORRELATE
to	O
investigate	O
possible	O
mechanisms	O
of	O
action	O
.	O
Regarding	O
the	O
small	O
number	O
of	O
patients	O
,	O
additional	O
studies	O
with	O
larger	O
sample	O
sizes	O
and	O
using	O
neuroimaging	O
techniques	O
(	O
single	O
photon	O
emission	O
tomography	O
,	O
SPECT	O
)	O
are	O
underway	O
in	O
our	O
laboratory	O
.	O
The	O
aforementioned	O
limitations	O
should	O
be	O
considered	O
taking	O
into	O
account	O
the	O
novelty	O
of	O
this	O
research	O
and	O
this	O
research	O
preliminary	O
nature	O
.	O
To	O
our	O
knowledge	O
,	O
the	O
use	O
of	O
AYA	B-DRUG
in	O
a	O
controlled	O
clinical	O
setting	O
in	O
patients	O
with	O
current	O
depression	B-HEALTH CONDITION
-	O
or	O
in	O
any	O
other	O
clinical	O
population	O
-	O
has	O
never	O
been	O
investigated	O
.	O
Moreover	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
,	O
although	O
preliminary	O
,	O
are	O
corroborated	O
by	O
mounting	O
research	O
showing	O
antidepressive	B-OUTCOME
potentials	I-OUTCOME
for	O
AYA	B-DRUG
alkaloids	O
in	O
nonhuman	O
animals16	O
-	O
24	O
and	O
in	O
humans	O
.	O
Finally	O
,	O
the	O
reported	O
results	O
may	O
prompt	O
novel	O
research	O
into	O
substances	O
with	O
faster	B-OUTCOME
therapeutic	I-OUTCOME
actions	I-OUTCOME
than	O
currently	B-ANTIDEPRESSANT_DRUG
available	I-ANTIDEPRESSANT_DRUG
pharmacological	I-ANTIDEPRESSANT_DRUG
resources	I-ANTIDEPRESSANT_DRUG
,	O
thus	O
making	B-OUTCOME
antidepressive	I-OUTCOME
treatment	I-OUTCOME
more	I-OUTCOME
effective	I-OUTCOME
.	O
The	O
findings	O
of	O
this	O
preliminary	O
study	O
demonstrate	O
the	O
potential	O
antidepressant	B-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
of	O
AYA	B-DRUG
,	O
effects	O
that	O
,	O
importantly	O
,	O
have	O
an	O
earlier	B-OUTCOME
onset	I-OUTCOME
of	I-OUTCOME
action	I-OUTCOME
when	O
compared	O
to	O
traditional	O
antidepressants	B-ANTIDEPRESSANT_DRUG
.	O
These	O
findings	O
suggest	O
that	O
AYA	B-DRUG
may	O
represent	O
a	O
powerful	O
new	O
substance	O
for	O
the	O
treatment	O
of	O
depressive	B-HEALTH CONDITION
and	I-HEALTH CONDITION
anxiety	I-HEALTH CONDITION
symptoms	I-HEALTH CONDITION
.	O
However	O
,	O
these	O
results	O
deserve	O
careful	O
analysis	O
,	O
given	O
the	O
inherent	O
limitations	O
of	O
an	O
uncontrolled	O
,	O
open	O
-	O
label	O
study	O
with	O
a	O
small	O
sample	O
size	O
.	O
Other	O
studies	O
are	O
needed	O
to	O
replicate	O
these	O
preliminary	O
observations	O
and	O
to	O
test	O
,	O
for	O
example	O
,	O
the	O
most	O
effective	O
dose	O
(	O
or	O
doses	O
)	O
of	O
AYA	B-DRUG
and	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
effectiveness	O
of	O
AYA	B-DRUG
administration	O
over	O
a	O
longer	O
period	O
of	O
time	O
.	O
-DOCSTART- -X- O O
Psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
is	O
a	O
promising	O
combination	O
intervention	O
for	O
the	O
treatment	O
of	O
psychological	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
,	O
psychiatric	B-HEALTH CONDITION
conditions	I-HEALTH CONDITION
,	O
and	O
“	O
the	O
betterment	O
of	O
well	O
people	O
”	O
(	O
Bob	O
Jesse	O
,	O
cited	O
in	O
Pollan	O
,	O
2015	O
)	O
.	O
Despite	O
the	O
resurgence	O
in	O
research	O
using	O
psilocybin	B-DRUG
in	O
recent	O
years	O
,	O
the	O
psychological	B-NEURAL MECHANISM/CORRELATE
mechanisms	I-NEURAL MECHANISM/CORRELATE
of	O
action	O
involved	O
in	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
are	O
not	O
yet	O
well	O
understood	O
.	O
Current	O
theory	O
regarding	O
psychotherapeutic	O
and	O
pharmacotherapeutic	O
mechanisms	O
of	O
action	O
posits	O
that	O
the	O
occasion	O
of	O
a	O
mystical	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
is	O
the	O
primary	O
mediating	O
factor	O
leading	O
to	O
positive	O
treatment	B-OUTCOME
outcomes	I-OUTCOME
.	O
While	O
the	O
construct	O
of	O
a	O
“	O
complete	B-SUBJECTIVE EXPERIENCE
mystical	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
,	O
”	O
for	O
example	O
,	O
as	O
defined	O
by	O
exceeding	O
a	O
cutoff	O
score	O
on	O
the	O
Pahnke	O
–	O
Richards	O
Mystical	B-SUBJECTIVE EXPERIENCE
Experience	I-SUBJECTIVE EXPERIENCE
Questionnaire	O
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
)	O
has	O
been	O
shown	O
to	O
be	O
one	O
mediator	B-OUTCOME
of	I-OUTCOME
positive	I-OUTCOME
outcomes	I-OUTCOME
in	O
randomized	O
controlled	O
trials	O
(	O
Bogenschutz	O
et	O
al	O
.	O
,	O
2015	O
;	O
Griffiths	O
et	O
al	O
.	O
,	O
2008	O
;	O
MacLean	O
et	O
al	O
.	O
,	O
2011	O
)	O
,	O
the	O
findings	O
of	O
this	O
study	O
suggest	O
a	O
more	O
complex	O
topography	O
.	O
It	O
is	O
conceivable	O
that	O
a	O
single	B-OUTCOME
mediating	I-OUTCOME
factor	I-OUTCOME
is	O
insufficient	O
to	O
account	O
for	O
multilevel	O
phenomena	O
that	O
carry	O
cognitive	B-OUTCOME
,	I-OUTCOME
emotional	I-OUTCOME
,	I-OUTCOME
behavioral	I-OUTCOME
,	I-OUTCOME
psychodynamic	I-OUTCOME
,	I-OUTCOME
spiritual	I-OUTCOME
,	I-OUTCOME
existential	I-OUTCOME
,	I-OUTCOME
and/or	I-OUTCOME
experiential	I-OUTCOME
components	I-OUTCOME
of	I-OUTCOME
significance	I-OUTCOME
The	O
current	O
study	O
appears	O
to	O
be	O
the	O
first	O
qualitative	O
study	O
of	O
participant	O
experiences	O
in	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
.	O
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
there	O
are	O
important	O
relational	B-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
bodily	I-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
affective	I-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
and	I-SUBJECTIVE EXPERIENCE
other	I-SUBJECTIVE EXPERIENCE
aspects	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
participant	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
that	O
may	O
play	O
critical	O
roles	O
.	O
First	O
,	O
participants	O
universally	O
described	O
deeply	B-OUTCOME
meaningful	I-OUTCOME
attachments	I-OUTCOME
to	I-OUTCOME
important	I-OUTCOME
family	I-OUTCOME
members	I-OUTCOME
and	I-OUTCOME
significant	I-OUTCOME
others	I-OUTCOME
.	O
Relationships	O
were	O
woven	O
throughout	O
participant	O
narratives	O
,	O
with	O
themes	O
of	O
forgiveness	B-OUTCOME
of	I-OUTCOME
others	I-OUTCOME
,	O
loved	B-OUTCOME
ones	I-OUTCOME
as	I-OUTCOME
spirit	I-OUTCOME
guides	I-OUTCOME
,	O
the	O
importance	O
of	O
narrating	B-OUTCOME
one	I-OUTCOME
’s	I-OUTCOME
experience	I-OUTCOME
with	I-OUTCOME
loved	I-OUTCOME
ones	I-OUTCOME
,	O
and	O
improved	B-OUTCOME
relationships	I-OUTCOME
posttreatment	I-OUTCOME
.	O
In	O
this	O
way	O
,	O
the	O
psilocybin	B-DRUG
experience	O
may	O
be	O
conceived	O
as	O
relationally	O
embedded	O
.	O
In	O
many	O
ways	O
,	O
this	O
is	O
unsurprising	O
,	O
given	O
the	O
important	O
contributions	O
of	O
attachment	O
theory	O
(	O
Ainsworth	O
,	O
Blehar	O
,	O
Waters	O
,	O
&	O
Wall	O
,	O
2014	O
;	O
Bowlby	O
,	O
1980	O
,	O
2005	O
)	O
,	O
relational	O
theory	O
(	O
Mitchell	O
,	O
1988	O
;	O
Wachtel	O
,	O
2010	O
)	O
,	O
and	O
interpersonal	O
theory	O
(	O
Sullivan	O
,	O
2013	O
)	O
to	O
human	O
development	O
,	O
which	O
have	O
yet	O
to	O
be	O
thoroughly	O
integrated	O
into	O
psychedelic	B-DRUG
research	O
paradigms	O
.	O
Nearly	O
all	O
participants	O
reported	O
having	O
an	O
experience	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
love	I-SUBJECTIVE EXPERIENCE
and	I-SUBJECTIVE EXPERIENCE
joy	I-SUBJECTIVE EXPERIENCE
,	O
though	O
these	O
exalted	O
experiences	O
arose	O
primarily	O
through	O
a	O
specific	B-OUTCOME
human	I-OUTCOME
relationship	I-OUTCOME
with	I-OUTCOME
another	I-OUTCOME
person	I-OUTCOME
,	O
whether	O
it	O
was	O
a	O
parent	O
,	O
child	O
,	O
or	O
partner	O
.	O
As	O
Anais	O
Nin	O
(	O
1971	O
)	O
once	O
wrote	O
,	O
“	O
The	O
personal	O
,	O
if	O
it	O
is	O
deep	O
enough	O
,	O
becomes	O
universal	O
,	O
mythical	O
,	O
symbolic	O
”	O
(	O
p.	O
153	O
)	O
.	O
These	O
findings	O
indicate	O
that	O
a	O
relational	O
theoretical	O
framework	O
may	O
have	O
utility	O
in	O
assessing	O
the	O
importance	O
of	O
transformed	B-OUTCOME
interpersonal	I-OUTCOME
and	I-OUTCOME
intrapsychic	I-OUTCOME
configurations	I-OUTCOME
occasioned	O
by	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
Second	O
,	O
the	O
findings	O
of	O
the	O
current	O
study	O
also	O
suggest	O
that	O
embodiment	B-SUBJECTIVE EXPERIENCE
,	O
and	O
especially	O
alterations	B-SUBJECTIVE EXPERIENCE
or	I-SUBJECTIVE EXPERIENCE
transfigurations	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
normally	I-SUBJECTIVE EXPERIENCE
felt	I-SUBJECTIVE EXPERIENCE
embodied	I-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
,	O
is	O
a	O
critical	O
feature	O
of	O
participant	B-OUTCOME
experiences	I-OUTCOME
.	O
Although	O
participants	O
did	O
describe	O
discarnate	O
phenomena	O
,	O
some	O
of	O
the	O
most	O
compelling	O
accounts	O
spoke	O
of	O
bodily	B-OUTCOME
ejections	I-OUTCOME
of	I-OUTCOME
cancer	I-OUTCOME
and	O
visions	B-OUTCOME
of	I-OUTCOME
accepting	I-OUTCOME
some	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
most	I-OUTCOME
compelling	I-OUTCOME
accounts	I-OUTCOME
bodies	I-OUTCOME
.	O
Participants	O
described	O
enhanced	B-OUTCOME
interoceptive	I-OUTCOME
awareness	I-OUTCOME
,	O
somatic	B-OUTCOME
synesthetic	I-OUTCOME
experiences	I-OUTCOME
,	O
and	O
alterations	B-OUTCOME
to	I-OUTCOME
Participants	I-OUTCOME
sense	I-OUTCOME
of	I-OUTCOME
self	I-OUTCOME
as	O
embodied	O
beings	O
.	O
Despite	O
a	O
trend	O
toward	O
embodiment	B-SUBJECTIVE EXPERIENCE
as	O
a	O
broad	O
interpretative	O
framework	O
in	O
the	O
social	O
and	O
behavioral	O
sciences	O
(	O
Csordas	O
,	O
1994	O
;	O
Gibbs	O
,	O
2005	O
;	O
Niedenthal	O
,	O
Barsalou	O
,	O
Winkielman	O
,	O
Krauth	O
-	O
Gruber	O
,	O
&	O
Ric	O
,	O
2005	O
)	O
,	O
subjectively	B-SUBJECTIVE EXPERIENCE
experienced	I-SUBJECTIVE EXPERIENCE
body	I-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
are	O
not	O
currently	O
being	O
assessed	O
in	O
clinical	O
trials	O
with	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
Third	O
,	O
slightly	O
more	O
than	O
half	O
of	O
participants	O
recounted	O
acute	O
reactions	O
of	O
fear	B-OUTCOME
,	O
confusion	B-OUTCOME
,	O
panic	B-OUTCOME
,	O
or	O
paranoia	B-OUTCOME
during	O
the	O
psilocybin	B-DRUG
dosage	O
session	O
.	O
panic	B-OUTCOME
,	O
or	O
paranoia	B-OUTCOME
were	O
transient	O
processes	O
,	O
and	O
no	O
serious	B-OUTCOME
adverse	I-OUTCOME
events	I-OUTCOME
attributable	O
to	O
the	O
study	O
treatment	O
occurred	O
during	O
the	O
course	O
of	O
this	O
trial	O
.	O
The	O
findings	O
presented	O
here	O
suggest	O
that	O
transient	B-OUTCOME
periods	I-OUTCOME
of	I-OUTCOME
distress	I-OUTCOME
,	O
even	O
intense	B-OUTCOME
experiences	I-OUTCOME
of	I-OUTCOME
fear	I-OUTCOME
and	I-OUTCOME
panic	I-OUTCOME
,	O
can	O
be	O
well	O
tolerated	O
by	O
study	O
participants	O
in	O
a	O
supportive	O
therapeutic	O
milieu	O
.	O
The	O
development	B-OUTCOME
of	I-OUTCOME
a	I-OUTCOME
trusting	I-OUTCOME
therapeutic	I-OUTCOME
alliance	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
participant	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
study	I-OUTCOME
therapists	I-OUTCOME
before	O
the	O
psilocybin	B-DRUG
administration	O
session	O
,	O
followed	O
by	O
adequate	O
integration	O
psychotherapy	O
sessions	O
afterward	O
,	O
provides	O
a	O
crucial	B-OUTCOME
supportive	I-OUTCOME
context	I-OUTCOME
.	O
While	O
a	O
straightforward	O
review	O
may	O
deem	O
experiences	O
of	O
transient	B-OUTCOME
psychological	I-OUTCOME
distress	I-OUTCOME
as	O
undesirable	B-OUTCOME
side	I-OUTCOME
effects	I-OUTCOME
,	O
both	O
participants	O
and	O
the	O
research	O
team	O
came	O
to	O
understand	O
these	O
difficult	O
experiences	O
as	O
part	O
of	O
a	O
necessary	B-OUTCOME
and	I-OUTCOME
ultimately	I-OUTCOME
beneficial	I-OUTCOME
process	I-OUTCOME
.	O
In	O
the	O
midst	O
of	O
fear	B-OUTCOME
and	O
dysphoria	B-OUTCOME
,	O
participants	O
described	O
how	O
participants	O
came	O
to	O
surrender	B-OUTCOME
or	I-OUTCOME
“	I-OUTCOME
let	I-OUTCOME
go	I-OUTCOME
,	I-OUTCOME
”	I-OUTCOME
leading	O
from	O
a	O
defensive	O
posture	O
of	O
emotional	O
or	O
psychological	O
resistance	O
to	O
an	O
accepting	O
posture	O
characterized	O
by	O
feelings	B-OUTCOME
of	I-OUTCOME
relief	I-OUTCOME
,	I-OUTCOME
wholeness	I-OUTCOME
,	I-OUTCOME
freedom	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
affirmation	I-OUTCOME
.	O
Through	O
a	O
collaborative	O
interpretative	O
process	O
,	O
our	O
research	O
team	O
generated	O
a	O
variety	O
of	O
ways	O
of	O
labeling	O
these	O
transient	B-OUTCOME
phenomena	I-OUTCOME
,	O
including	O
the	O
following	O
:	O
the	O
shadow	O
,	O
the	O
difficult	O
struggle	O
,	O
the	O
dark	O
night	O
of	O
the	O
soul	O
,	O
wrathful	O
guardians	O
of	O
the	O
gates	O
of	O
the	O
mandala	O
,	O
ego	O
death	O
,	O
heaven	O
and	O
hell	O
,	O
and	O
existential	O
collapse	O
.	O
Each	O
offered	O
certain	O
advantages	O
but	O
also	O
brought	O
with	O
Each	O
unwanted	O
baggage	O
from	O
the	O
psychological	O
,	O
theological	O
,	O
and	O
psychedelic	O
traditions	O
from	O
which	O
Each	O
were	O
borrowed	O
.	O
Such	O
periods	O
of	O
transient	B-OUTCOME
distress	I-OUTCOME
may	O
serve	O
as	O
a	O
necessary	O
“	O
turning	O
point	O
”	O
in	O
an	O
unfolding	O
process	O
,	O
as	O
feelings	B-OUTCOME
of	I-OUTCOME
fear	I-OUTCOME
,	I-OUTCOME
panic	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
anxiety	I-OUTCOME
transmute	O
into	O
feelings	B-OUTCOME
of	I-OUTCOME
love	I-OUTCOME
,	I-OUTCOME
joy	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
forgiveness	I-OUTCOME
Fourth	O
,	O
these	O
findings	O
indicate	O
that	O
psilocybin	B-DRUG
occasions	O
a	B-OUTCOME
rich	I-OUTCOME
and	I-OUTCOME
complex	I-OUTCOME
range	I-OUTCOME
of	I-OUTCOME
human	I-OUTCOME
emotions	I-OUTCOME
.	O
Participants	O
described	O
powerful	B-OUTCOME
and	I-OUTCOME
healing	I-OUTCOME
catharses	I-OUTCOME
suggesting	O
an	O
emotional	O
trajectory	O
.	O
Participant	O
affects	O
have	O
either	O
not	O
been	O
assessed	O
formally	O
in	O
clinical	O
trials	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
,	O
or	O
the	O
range	O
of	O
assessment	O
is	O
limited	O
,	O
as	O
with	O
the	O
use	O
of	O
visual	O
analogue	O
scales	O
assessing	O
feelings	B-OUTCOME
of	I-OUTCOME
fear	I-OUTCOME
,	I-OUTCOME
paranoia	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
joy	I-OUTCOME
(	O
Turton	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
participants	O
may	O
emerge	O
from	O
this	O
treatment	O
having	O
experienced	B-OUTCOME
profound	I-OUTCOME
emotional	I-OUTCOME
depths	I-OUTCOME
and	O
expanded	B-OUTCOME
affective	I-OUTCOME
boundaries	I-OUTCOME
.	O
Future	O
research	O
may	O
evaluate	O
cathartic	B-OUTCOME
release	I-OUTCOME
and	O
the	O
depth	B-OUTCOME
and	I-OUTCOME
breadth	I-OUTCOME
of	I-OUTCOME
affect	I-OUTCOME
states	I-OUTCOME
occasioned	O
during	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
Fifth	O
,	O
participant	O
accounts	O
reveal	O
a	O
colorful	B-OUTCOME
,	I-OUTCOME
even	I-OUTCOME
fantastical	I-OUTCOME
range	I-OUTCOME
of	I-OUTCOME
complex	I-OUTCOME
closed	I-OUTCOME
-	I-OUTCOME
eye	I-OUTCOME
visual	I-OUTCOME
phenomena	I-OUTCOME
.	O
These	O
visions	O
are	O
ideographically	O
instantiated	O
within	O
subjective	O
processes	O
.	O
These	O
complex	B-OUTCOME
visualizations	I-OUTCOME
are	O
not	O
merely	O
interesting	O
scenes	O
painted	O
on	O
the	O
proscenium	O
curtain	O
of	O
the	O
theater	O
of	O
the	O
mind	O
.	O
Rather	O
,	O
among	O
study	O
participants	O
,	O
these	O
visions	O
served	O
as	O
principle	B-OUTCOME
organizing	I-OUTCOME
motifs	I-OUTCOME
of	I-OUTCOME
subjective	I-OUTCOME
experience	I-OUTCOME
with	I-OUTCOME
multifold	I-OUTCOME
vectors	I-OUTCOME
(	O
e.g.	O
,	O
audiovisual	O
,	O
relational	O
,	O
autobiographical	O
,	O
spiritual	O
,	O
epistemological	O
,	O
ontological	O
)	O
.	O
Such	O
visions	B-OUTCOME
were	O
often	O
deeply	B-OUTCOME
coded	I-OUTCOME
with	I-OUTCOME
layers	I-OUTCOME
of	I-OUTCOME
meaning	I-OUTCOME
by	O
participants	O
Sixth	O
,	O
study	O
participants	O
described	O
lasting	B-OUTCOME
impacts	I-OUTCOME
to	I-OUTCOME
study	I-OUTCOME
participants	I-OUTCOME
quality	I-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
,	O
life	B-OUTCOME
priorities	I-OUTCOME
,	O
and	O
study	O
participants	O
sense	B-OUTCOME
of	I-OUTCOME
identity	I-OUTCOME
.	O
During	O
study	O
participants	O
psilocybin	B-DRUG
experiences	O
,	O
many	O
participants	O
“	O
remembered	B-OUTCOME
”	I-OUTCOME
aspects	I-OUTCOME
of	I-OUTCOME
many	I-OUTCOME
participants	I-OUTCOME
that	I-OUTCOME
had	I-OUTCOME
been	I-OUTCOME
forgotten	I-OUTCOME
.	O
many	O
participants	O
recovered	B-OUTCOME
a	I-OUTCOME
sense	I-OUTCOME
of	I-OUTCOME
what	I-OUTCOME
is	I-OUTCOME
most	I-OUTCOME
important	I-OUTCOME
and	I-OUTCOME
vital	I-OUTCOME
in	O
many	O
participants	O
lives	O
,	O
such	O
as	O
being	B-OUTCOME
present	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
moment	I-OUTCOME
or	O
being	O
kind	B-OUTCOME
to	I-OUTCOME
other	I-OUTCOME
people	I-OUTCOME
.	O
Participants	O
described	O
feeling	B-OUTCOME
“	I-OUTCOME
reborn	I-OUTCOME
,	O
”	O
more	B-OUTCOME
expansive	I-OUTCOME
,	O
more	B-OUTCOME
confident	I-OUTCOME
,	O
more	B-OUTCOME
connected	I-OUTCOME
,	O
and	O
more	B-OUTCOME
alive	I-OUTCOME
.	O
Participants	O
described	O
a	O
feeling	B-OUTCOME
of	I-OUTCOME
empowerment	I-OUTCOME
and	O
being	O
“	O
unstuck	O
,	O
”	O
with	O
resulting	O
healthier	B-OUTCOME
behaviors	I-OUTCOME
.	O
As	O
two	O
participants	O
reported	O
significant	O
weight	O
loss	O
,	O
future	O
research	O
regarding	O
the	O
efficacy	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
as	O
an	O
intervention	O
for	O
obesity	B-OUTCOME
and	O
eating	B-OUTCOME
disorders	I-OUTCOME
may	O
be	O
warranted	O
A	O
number	O
of	O
limitations	O
to	O
this	O
study	O
should	O
be	O
noted	O
.	O
The	O
interview	O
guide	O
focused	O
primarily	O
on	O
the	O
participant	O
experiences	O
during	O
the	O
psilocybin	B-DRUG
dosage	O
session	O
rather	O
than	O
the	O
preparatory	O
and	O
integration	O
psychotherapy	O
sessions	O
,	O
which	O
we	O
see	O
as	O
essential	O
components	O
.	O
The	O
timing	O
of	O
the	O
interview	O
poses	O
certain	O
concerns	O
,	O
as	O
approximately	O
half	O
the	O
sample	O
were	O
interviewed	O
within	O
1	O
week	O
following	O
certain	O
concerns	O
second	O
psilocybin	B-DRUG
dosage	O
session	O
,	O
which	O
allowed	O
little	O
time	O
to	O
review	O
lasting	B-OUTCOME
impacts	I-OUTCOME
of	O
certain	O
concerns	O
experiences	O
but	O
afforded	O
at	O
least	O
one	O
integration	O
psychotherapy	O
session	O
to	O
help	O
consolidate	O
memory	O
and	O
meaning	O
.	O
Conversely	O
,	O
as	O
eight	O
participants	O
were	O
interviewed	O
at	O
approximately	O
1	O
-	O
year	O
follow	O
-	O
up	O
,	O
the	O
clarity	O
of	O
eight	O
participants	O
recall	O
regarding	O
specific	O
phenomenal	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
a	O
year	O
earlier	O
may	O
have	O
been	O
subject	O
to	O
distortion	O
or	O
clouding	O
.	O
Additionally	O
,	O
the	O
current	O
analysis	O
does	O
not	O
formally	O
address	O
participant	O
–	O
therapist	O
interactions	O
or	O
the	O
nature	O
of	O
therapeutic	O
action	O
as	O
experienced	O
by	O
the	O
patients	O
nor	O
does	O
the	O
current	O
analysis	O
address	O
the	O
variety	O
of	O
experiences	O
related	O
to	O
cancer	B-HEALTH CONDITION
,	O
death	B-HEALTH CONDITION
,	O
and	O
spirituality	B-SUBJECTIVE EXPERIENCE
reported	O
by	O
this	O
cohort	O
of	O
cancer	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
,	O
which	O
is	O
documented	O
in	O
a	O
subsequent	O
article	O
(	O
Swift	O
et	O
al	O
.	O
,	O
2017	O
)	O
This	O
is	O
perhaps	O
the	O
first	O
qualitative	O
study	O
to	O
explore	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
inner	I-SUBJECTIVE EXPERIENCE
texture	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
participant	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
.	O
The	O
findings	O
of	O
the	O
study	O
support	O
the	O
conclusion	O
that	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
is	O
well	O
accepted	O
by	O
participants	O
and	O
constitutes	O
a	O
promising	O
intervention	O
for	O
the	O
treatment	O
of	O
existential	B-OUTCOME
and	I-OUTCOME
psychological	I-OUTCOME
distress	I-OUTCOME
provoked	O
by	O
a	O
cancer	B-HEALTH CONDITION
diagnosis	I-HEALTH CONDITION
.	O
An	O
IPA	O
revealed	O
a	O
complex	O
,	O
multilevel	O
set	O
of	O
processes	O
.	O
Participants	O
experience	O
this	O
treatment	O
as	O
relationally	B-OUTCOME
embedded	I-OUTCOME
,	O
physically	B-OUTCOME
embodied	I-OUTCOME
,	O
affect	B-OUTCOME
laden	I-OUTCOME
,	O
deeply	B-OUTCOME
meaningful	I-OUTCOME
,	O
and	O
biographically	B-OUTCOME
instantiated	I-OUTCOME
,	O
with	O
lasting	B-OUTCOME
impacts	I-OUTCOME
to	I-OUTCOME
Participants	I-OUTCOME
experience	I-OUTCOME
of	I-OUTCOME
Participants	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
world	I-OUTCOME
.	O
Future	O
research	O
is	O
warranted	O
to	O
attend	O
to	O
these	O
and	O
other	O
possible	O
mediating	O
factors	O
in	O
the	O
design	O
of	O
clinical	O
trials	O
to	O
better	O
articulate	O
psychological	O
mechanisms	O
of	O
action	O
and	O
maximize	B-OUTCOME
therapeutic	I-OUTCOME
benefit	I-OUTCOME
.	O
-DOCSTART- -X- O O
All	O
8	O
factors	O
and	O
other	O
lines	O
of	O
evidence	O
taken	O
together	O
indicate	O
the	O
profile	O
of	O
a	O
substance	B-DRUG
that	O
is	O
characterized	O
by	O
some	O
level	O
of	O
abuse	B-OUTCOME
potential	I-OUTCOME
and	O
potential	B-OUTCOME
risks	I-OUTCOME
.	O
However	O
,	O
the	O
findings	O
do	O
not	O
support	O
placement	O
more	O
restrictively	O
than	O
Schedule	O
IV	O
.	O
The	O
current	O
placement	O
in	O
Schedule	O
I	O
is	O
presently	O
necessitated	O
by	O
the	O
absence	O
of	O
FDA	O
approval	O
for	O
a	O
psilocybin	B-DRUG
containing	O
medicine	O
and	O
Schedule	O
I	O
is	O
the	O
only	O
Schedule	O
into	O
which	O
substances	O
of	O
abuse	O
can	O
be	O
placed	O
that	O
do	O
not	O
have	O
an	O
approved	O
medical	O
indication	O
.	O
However	O
,	O
it	O
is	O
the	O
opinion	O
of	O
the	O
authors	O
of	O
this	O
review	O
that	O
the	O
original	O
placement	O
of	O
psilocybin	B-DRUG
was	O
the	O
result	O
of	O
a	O
substantial	O
overestimation	O
of	O
the	O
risk	B-OUTCOME
of	I-OUTCOME
harm	I-OUTCOME
and	O
abuse	B-OUTCOME
potential	I-OUTCOME
.	O
The	O
CSA	O
stipulates	O
that	O
Schedule	O
I	O
is	O
for	O
substances	O
with	O
a	O
high	O
potential	B-OUTCOME
for	I-OUTCOME
abuse	I-OUTCOME
,	O
lack	O
of	O
therapeutic	O
approval	O
,	O
and	O
that	O
can	O
not	O
be	O
used	O
safely	O
in	O
medicine	O
.	O
History	O
of	O
use	O
and	O
available	O
scientific	O
data	O
show	O
that	O
the	O
first	O
criterion	O
is	O
questionable	O
,	O
and	O
the	O
third	O
criterion	O
is	O
likely	O
not	O
true	O
.	O
The	O
second	O
of	O
these	O
criteria	O
can	O
only	O
be	O
negated	O
by	O
FDA	O
approval	O
of	O
a	O
psilocybin	B-DRUG
-	O
containing	O
products	O
,	O
but	O
at	O
this	O
point	O
the	O
data	O
suggest	O
that	O
the	O
potential	B-OUTCOME
therapeutic	I-OUTCOME
benefits	I-OUTCOME
of	O
psilocybin	B-DRUG
-	O
assisted	O
therapy	O
are	O
real	O
,	O
and	O
of	O
potential	O
medical	B-OUTCOME
and	I-OUTCOME
public	I-OUTCOME
health	I-OUTCOME
significance	I-OUTCOME
Schedule	O
placement	O
is	O
guided	O
by	O
an	O
analysis	O
of	O
the	O
8	O
factors	O
of	O
the	O
CSA	O
that	O
will	O
be	O
drafted	O
by	O
the	O
FDA	O
with	O
input	O
from	O
NIDA	O
.	O
The	O
8	O
-	O
factor	O
analysis	O
contained	O
in	O
this	O
review	O
should	O
be	O
considered	O
an	O
abbreviated	O
assessment	O
of	O
abuse	B-OUTCOME
potential	I-OUTCOME
as	O
compared	O
to	O
what	O
would	O
be	O
required	O
by	O
the	O
FDA	O
to	O
accompany	O
the	O
submission	O
of	O
an	O
NDA	O
for	O
approval	B-OUTCOME
of	I-OUTCOME
a	I-OUTCOME
psilocybin	I-OUTCOME
containing	I-OUTCOME
drug	I-OUTCOME
product	I-OUTCOME
.	O
Furthermore	O
,	O
considerable	O
additional	O
study	O
will	O
yet	O
be	O
required	O
to	O
support	O
the	O
submission	O
of	O
a	O
complete	O
and	O
reviewable	O
NDA	O
and	O
an	O
NDA	O
abuse	O
potential	O
assessment	O
.	O
This	O
will	O
include	O
at	O
least	O
one	O
major	O
phase	O
3	O
clinical	O
efficacy	O
and	O
safety	O
trial	O
that	O
includes	O
assessments	O
relevant	O
to	O
abuse	B-OUTCOME
potential	I-OUTCOME
,	O
additional	O
Phase	O
1	O
and/or	O
2	O
clinical	O
studies	O
,	O
and	O
possibly	O
some	O
animal	O
testing	O
(	O
Calderon	O
et	O
al	O
.	O
,	O
2017	O
;	O
Sellers	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Thus	O
data	O
yet	O
to	O
be	O
collected	O
will	O
influence	O
the	O
final	O
scheduling	O
proposal	O
that	O
will	O
be	O
made	O
by	O
the	O
sponsor	O
and	O
,	O
in	O
turn	O
by	O
the	O
FDA	O
,	O
NIDA	O
,	O
and	O
DEA	O
.	O
Nonetheless	O
,	O
considerable	O
data	O
from	O
animal	O
self	O
-	O
administration	O
and	O
discrimination	O
studies	O
,	O
and	O
human	O
abuse	O
potential	O
studies	O
since	O
the	O
1960s	O
provide	O
a	O
substantial	O
basis	O
for	O
the	O
present	O
preliminary	O
evaluation	O
.	O
In	O
contrast	O
to	O
Schedule	O
III	O
drugs	O
and	O
even	O
to	O
many	O
drugs	O
placed	O
in	O
Schedule	O
IV	O
,	O
the	O
reinforcing	B-OUTCOME
effects	I-OUTCOME
in	O
preclinical	O
studies	O
are	O
marginal	O
.	O
There	O
is	O
no	B-OUTCOME
clear	I-OUTCOME
evidence	I-OUTCOME
of	I-OUTCOME
physical	I-OUTCOME
dependence	I-OUTCOME
and	I-OUTCOME
withdrawal	I-OUTCOME
in	O
preclinical	O
or	O
clinical	O
studies	O
,	O
or	O
among	O
those	O
who	O
chronically	O
used	O
illicit	O
products	O
.	O
Euphoriant	B-OUTCOME
effects	I-OUTCOME
can	O
occur	O
under	O
limited	O
circumstances	O
but	O
appear	O
attenuated	O
by	O
dysphoric	B-OUTCOME
effects	I-OUTCOME
.	O
The	O
doses	O
that	O
pose	O
a	O
risk	O
of	O
acute	O
poisoning	B-OUTCOME
death	I-OUTCOME
(	O
“	O
overdose	O
”	O
)	O
appear	O
to	O
be	O
approximately	O
1000	O
times	O
the	O
likely	O
highest	O
clinical	O
dose	O
to	O
be	O
marketed	O
,	O
psychological	B-OUTCOME
dependence	I-OUTCOME
resulting	O
in	O
daily	O
use	O
appears	O
rare	O
,	O
and	O
all	O
major	O
drug	O
surveillance	O
systems	O
reviewed	O
in	O
Factors	O
4	O
,	O
5	O
,	O
and	O
6	O
of	O
this	O
analysis	O
indicate	O
rates	B-OUTCOME
of	I-OUTCOME
abuse	I-OUTCOME
,	O
emergency	B-OUTCOME
department	I-OUTCOME
reports	I-OUTCOME
,	O
and	O
treatment	B-OUTCOME
seeking	I-OUTCOME
in	I-OUTCOME
youth	I-OUTCOME
and	I-OUTCOME
adults	I-OUTCOME
that	O
are	O
substantially	O
lower	O
than	O
are	O
evident	O
for	O
many	O
Schedule	O
IV	O
drugs	O
.	O
It	O
is	O
possible	O
,	O
of	O
course	O
that	O
subsequent	O
study	O
with	O
larger	O
populations	O
and	O
different	O
designs	O
in	O
animals	O
and	O
humans	O
,	O
would	O
yield	O
different	O
outcomes	O
,	O
but	O
this	O
review	O
suggests	O
that	O
psilocybin	B-DRUG
would	O
be	O
appropriately	O
placed	O
in	O
Schedule	O
IV	O
of	O
the	O
CSA	O
if	O
the	O
FDA	O
approves	O
a	O
psilocybin	B-DRUG
NDA	O
The	O
authors	O
of	O
this	O
review	O
recognize	O
that	O
opinions	O
in	O
the	O
general	O
population	O
may	O
differ	O
substantially	O
as	O
it	O
is	O
clear	O
that	O
there	O
remains	O
a	O
legacy	B-OUTCOME
of	I-OUTCOME
fear	I-OUTCOME
regarding	O
psychedelics	B-DRUG
since	O
the	O
1960s	O
.	O
The	O
role	O
of	O
the	O
8	O
-	O
factor	O
analysis	O
of	O
the	O
CSA	O
is	O
to	O
bring	O
science	O
to	O
bear	O
to	O
support	O
the	O
foundation	O
for	O
scheduling	O
,	O
implications	O
for	O
other	O
aspects	O
of	O
scheduling	O
which	O
are	O
based	O
on	O
much	O
of	O
the	O
same	O
data	O
.	O
In	O
particular	O
,	O
this	O
means	O
the	O
labeling	O
that	O
will	O
be	O
specific	O
to	O
the	O
label	O
section	O
,	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
section	O
9	O
of	O
the	O
drug	O
labeling	O
)	O
,	O
and	O
warnings	O
including	O
the	O
possible	O
requirement	O
of	O
a	O
Boxed	O
Warning	O
(	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
,	O
2017d	O
)	O
.	O
As	O
with	O
all	O
approved	O
drug	O
products	O
,	O
determination	O
of	O
safe	O
and	O
effective	O
by	O
the	O
FDA	O
does	B-OUTCOME
not	I-OUTCOME
mean	I-OUTCOME
without	I-OUTCOME
risk	I-OUTCOME
,	O
and	O
the	O
conclusion	O
that	O
the	O
science	B-OUTCOME
does	I-OUTCOME
not	I-OUTCOME
support	I-OUTCOME
scheduling	I-OUTCOME
more	I-OUTCOME
restrictive	I-OUTCOME
than	I-OUTCOME
IV	I-OUTCOME
does	O
not	B-OUTCOME
mean	I-OUTCOME
no	I-OUTCOME
abuse	I-OUTCOME
or	I-OUTCOME
dependence	I-OUTCOME
risk	I-OUTCOME
This	O
analysis	O
has	O
implications	O
for	O
future	O
research	O
with	O
psilocybin	B-DRUG
and	O
for	O
the	O
possible	O
development	O
of	O
related	O
drugs	O
.	O
Perhaps	O
most	O
challenging	O
and	O
important	O
is	O
research	O
to	O
better	O
understand	O
the	O
mechanisms	O
of	O
action	O
of	O
psilocybin	B-DRUG
and	O
related	O
drugs	O
that	O
can	O
produce	O
profound	B-OUTCOME
and	I-OUTCOME
very	I-OUTCOME
long	I-OUTCOME
lasting	I-OUTCOME
positive	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
in	O
people	O
who	O
were	O
resistant	O
to	O
standard	O
care	O
and	O
approved	O
medicines	O
.	O
Given	O
the	O
extent	O
to	O
which	O
undertreated	O
and	O
treatment	B-HEALTH CONDITION
resistant	I-HEALTH CONDITION
mental	I-HEALTH CONDITION
and	I-HEALTH CONDITION
behavioral	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
including	O
mood	O
,	O
anxiety	B-HEALTH CONDITION
,	O
and	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
remain	O
serious	O
problems	O
at	O
the	O
personal	O
and	O
societal	O
levels	O
in	O
the	O
US	O
and	O
globally	O
(	O
Belouin	O
and	O
Henningfield	O
,	O
2018	O
)	O
,	O
it	O
could	O
be	O
concluded	O
that	O
the	B-OUTCOME
need	I-OUTCOME
for	I-OUTCOME
such	I-OUTCOME
research	I-OUTCOME
is	I-OUTCOME
urgent	I-OUTCOME
The	O
dearth	O
of	O
therapeutic	O
and	O
mechanistic	O
studies	O
of	O
psilocybin	B-DRUG
and	O
other	O
classic	O
psychedelics	B-DRUG
over	O
the	O
past	O
half	O
-	O
century	O
does	O
not	O
stem	O
from	O
a	O
lack	O
of	O
interest	O
among	O
psychologists	O
,	O
psychiatrists	O
,	O
pharmacologists	O
and	O
neuroscientists	O
.	O
Research	O
has	O
been	O
and	O
continues	O
to	O
be	O
limited	O
by	O
the	O
provisions	O
of	O
the	O
CSA	O
and	O
the	O
lack	O
of	O
prioritization	O
of	O
such	O
research	O
by	O
potential	O
federal	O
funding	O
agencies	O
.	O
As	O
discussed	O
elsewhere	O
,	O
the	O
barriers	O
to	O
research	O
imposed	O
by	O
Schedule	O
I	O
regulation	O
are	O
formidable	O
and	O
although	O
they	O
do	O
not	O
outright	O
ban	O
such	O
research	O
,	O
the	O
consequence	O
has	O
been	O
that	O
this	B-OUTCOME
area	I-OUTCOME
of	I-OUTCOME
science	I-OUTCOME
and	I-OUTCOME
potential	I-OUTCOME
clinical	I-OUTCOME
application	I-OUTCOME
has	I-OUTCOME
been	I-OUTCOME
greatly	I-OUTCOME
under	I-OUTCOME
-	I-OUTCOME
researched	I-OUTCOME
(	O
Belouin	O
and	O
Henningfield	O
,	O
2018	O
;	O
Nutt	O
,	O
2015	O
;	O
Nutt	O
et	O
al	O
.	O
,	O
2013	O
;	O
Scientific	O
American	O
Editors	O
,	O
2014	O
;	O
Sinha	O
,	O
2001	O
;	O
Spillane	O
,	O
2004	O
;	O
Woodworth	O
,	O
2011	O
)	O
.	O
Several	O
of	O
the	O
key	O
clinical	O
studies	O
have	O
been	O
primarily	O
supported	O
by	O
private	O
foundations	O
rather	O
than	O
federal	O
institutions	O
such	O
as	O
NIH	O
(	O
Bogenschutz	O
et	O
al	O
.	O
,	O
2015	O
;	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
;	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
)	O
The	O
science	O
of	O
drug	B-OUTCOME
abuse	I-OUTCOME
potential	I-OUTCOME
assessment	O
has	O
evolved	O
considerably	O
in	O
recent	O
decades	O
and	O
this	O
is	O
evident	O
in	O
the	O
FDA	O
's	O
2017	O
guidance	O
document	O
,	O
“	O
Assessment	O
of	O
Abuse	O
Potential	O
of	O
Drugs	O
,	O
”	O
that	O
summarizes	O
research	O
strategies	O
,	O
and	O
methods	O
and	O
discusses	O
how	O
these	O
can	O
be	O
brought	O
to	O
bear	O
to	O
provide	O
the	O
regulatory	O
science	O
foundation	O
for	O
drug	O
scheduling	O
decisions	O
.	O
The	O
application	O
of	O
this	O
scientific	O
approach	O
to	O
further	O
evaluate	O
the	O
abuse	B-OUTCOME
potential	I-OUTCOME
of	O
psilocybin	B-DRUG
provides	O
an	O
example	O
of	O
how	O
this	O
area	O
of	O
regulatory	O
science	O
has	O
the	O
potential	O
to	O
facilitate	B-OUTCOME
innovative	I-OUTCOME
therapeutic	I-OUTCOME
breakthroughs	I-OUTCOME
by	O
replacing	O
fear	O
and	O
misinformation	O
with	O
scientifically	O
based	O
conclusions	O
and	O
facts	O
-DOCSTART- -X- O O
In	O
summary	O
,	O
we	O
hypothesize	O
that	O
the	O
induction	O
of	O
synapse	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
related	I-NEURAL MECHANISM/CORRELATE
gene	I-NEURAL MECHANISM/CORRELATE
expression	I-NEURAL MECHANISM/CORRELATE
in	O
key	O
neuronal	B-NEURAL MECHANISM/CORRELATE
populations	I-NEURAL MECHANISM/CORRELATE
identified	O
by	O
molecular	O
studies	O
and	O
the	O
robust	B-OUTCOME
alterations	I-OUTCOME
observed	I-OUTCOME
in	I-OUTCOME
neural	I-OUTCOME
circuits	I-OUTCOME
by	O
imaging	O
studies	O
are	O
highly	B-OUTCOME
interrelated	I-OUTCOME
processes	I-OUTCOME
(	O
Figure	O
2	O
)	O
.	O
The	O
ability	O
of	O
psychedelic	B-DRUG
drugs	I-DRUG
,	O
such	O
as	O
LSD	B-DRUG
and	O
psilocybin	B-DRUG
,	O
to	O
cause	O
disruption	B-OUTCOME
of	I-OUTCOME
established	I-OUTCOME
neural	I-OUTCOME
connectivity	I-OUTCOME
and	O
the	O
emergence	B-OUTCOME
of	I-OUTCOME
novel	I-OUTCOME
functional	I-OUTCOME
associations	I-OUTCOME
may	O
underlie	O
the	O
therapeutic	B-OUTCOME
efficacy	I-OUTCOME
of	O
psychedelics	B-DRUG
in	O
a	O
wide	O
variety	O
of	O
psychiatric	B-HEALTH CONDITION
illnesses	I-HEALTH CONDITION
[	O
41	O
]	O
.	O
The	O
results	O
of	O
psychedelic	B-DRUG
research	O
using	O
animal	O
models	O
,	O
such	O
as	O
the	O
induction	O
of	O
specific	O
synapse	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
associated	I-NEURAL MECHANISM/CORRELATE
genes	I-NEURAL MECHANISM/CORRELATE
,	O
puts	O
the	O
human	O
neuroimaging	O
findings	O
of	O
markedly	O
altered	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
into	O
a	O
new	O
context	O
.	O
Therefore	O
,	O
biomedical	O
research	O
into	O
psychedelics	B-DRUG
should	O
take	O
on	O
a	O
more	O
translational	B-OUTCOME
nature	I-OUTCOME
(	O
Figure	O
3	O
)	O
,	O
in	O
which	O
reverse	O
translation	O
(	O
or	O
bedside	O
to	O
bench	O
)	O
plays	O
a	O
prominent	O
role	O
.	O
Questions	O
remain	O
as	O
to	O
the	O
exact	B-NEURAL MECHANISM/CORRELATE
cellular	I-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
molecular	I-NEURAL MECHANISM/CORRELATE
mechanisms	I-NEURAL MECHANISM/CORRELATE
underlying	O
the	O
response	B-OUTCOME
to	I-OUTCOME
psychedelic	I-OUTCOME
drugs	I-OUTCOME
.	O
For	O
example	O
,	O
why	O
do	O
different	O
brain	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
have	O
different	B-OUTCOME
transcriptional	I-OUTCOME
responses	I-OUTCOME
in	O
what	O
appear	O
to	O
be	O
the	O
same	B-NEURAL MECHANISM/CORRELATE
cell	I-NEURAL MECHANISM/CORRELATE
type	I-NEURAL MECHANISM/CORRELATE
?	O
What	O
roles	O
do	O
interneurons	B-NEURAL MECHANISM/CORRELATE
and	O
glia	B-NEURAL MECHANISM/CORRELATE
play	O
in	O
hallucinogenic	B-OUTCOME
behaviors	I-OUTCOME
?	O
Investigators	O
can	O
therefore	O
prioritize	O
brain	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
that	O
are	O
altered	O
by	O
psychedelic	B-DRUG
exposure	O
in	O
fMRI	O
studies	O
,	O
such	O
as	O
the	O
visual	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
amygdala	B-NEURAL MECHANISM/CORRELATE
,	O
to	O
further	O
elucidate	O
what	O
molecular	O
and	O
cellular	O
mechanisms	O
may	O
underlie	O
the	O
broad	B-OUTCOME
network	I-OUTCOME
changes	I-OUTCOME
seen	O
in	O
those	O
regions	O
Clearly	O
,	O
many	O
questions	O
remain	O
regarding	O
the	O
biology	B-NEURAL MECHANISM/CORRELATE
of	O
these	O
compounds	B-DRUG
and	O
these	O
compounds	B-DRUG
use	O
in	O
the	O
clinic	O
(	O
see	O
Outstanding	O
Questions	O
)	O
.	O
Drug	O
development	O
in	O
psychiatry	O
has	O
lagged	O
dramatically	O
behind	O
other	O
biomedical	O
disciplines	O
72	O
,	O
73	O
,	O
and	O
many	O
of	O
the	O
most	O
commonly	B-ANTIDEPRESSANT_DRUG
used	I-ANTIDEPRESSANT_DRUG
psychiatric	I-ANTIDEPRESSANT_DRUG
medications	I-ANTIDEPRESSANT_DRUG
were	O
discovered	O
serendipitously	O
and	O
often	O
also	O
possess	O
complex	B-OUTCOME
adverse	I-OUTCOME
effects	I-OUTCOME
.	O
Therefore	O
,	O
given	O
the	O
promising	O
results	O
seen	O
in	O
early	O
phase	O
clinical	O
trials	O
with	O
psychedelic	B-DRUG
drugs	I-DRUG
for	O
the	O
treatment	O
of	O
addiction	B-HEALTH CONDITION
,	O
anxiety	B-HEALTH CONDITION
,	O
and	O
depression	B-HEALTH CONDITION
,	O
the	O
research	O
community	O
must	O
validate	O
the	O
efficacy	B-OUTCOME
of	O
these	O
drugs	O
in	O
more	O
rigorous	O
trials	O
to	O
achieve	O
a	O
better	O
understanding	O
of	O
these	O
drugs	O
mechanisms	O
in	O
the	O
body	O
-DOCSTART- -X- O O
Here	O
we	O
showed	O
that	O
adult	O
neural	B-NEURAL MECHANISM/CORRELATE
stem	I-NEURAL MECHANISM/CORRELATE
cell	I-NEURAL MECHANISM/CORRELATE
activity	I-NEURAL MECHANISM/CORRELATE
is	O
regulated	O
by	O
harmine	B-DRUG
,	O
THH	B-DRUG
,	O
and	O
harmaline	B-DRUG
,	O
the	O
most	O
abundant	O
alkaloids	O
in	O
B.	O
caapi	O
and	O
ayahuasca	B-DRUG
,	O
and	O
by	O
harmol	B-DRUG
,	O
the	O
main	O
metabolite	O
of	O
harmine	B-DRUG
in	O
humans31	O
.	O
Using	O
an	O
in	O
vitro	O
model	O
of	O
adult	O
neurogenesis	B-OUTCOME
,	O
we	O
found	O
that	O
all	O
four	B-DRUG
β	I-DRUG
-	I-DRUG
carbolines	I-DRUG
stimulated	B-OUTCOME
the	I-OUTCOME
proliferation	I-OUTCOME
and	I-OUTCOME
migration	I-OUTCOME
of	I-OUTCOME
progenitor	I-OUTCOME
cells	I-OUTCOME
and	O
promoted	B-OUTCOME
progenitor	I-OUTCOME
cells	I-OUTCOME
differentiation	I-OUTCOME
predominantly	O
into	O
neurons	B-NEURAL MECHANISM/CORRELATE
The	O
four	O
compounds	B-DRUG
tested	O
effectively	O
promoted	B-OUTCOME
proliferation	I-OUTCOME
,	I-OUTCOME
migration	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
differentiation	I-OUTCOME
of	I-OUTCOME
progenitor	I-OUTCOME
cells	I-OUTCOME
obtained	O
from	O
the	O
SVZ	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
SGZ	B-NEURAL MECHANISM/CORRELATE
,	O
the	O
two	O
main	O
niches	O
of	O
adult	O
neurogenesis	B-OUTCOME
in	O
rodents	O
.	O
The	O
β	B-DRUG
-	I-DRUG
carbolines	I-DRUG
increased	B-OUTCOME
the	I-OUTCOME
number	I-OUTCOME
and	I-OUTCOME
size	I-OUTCOME
of	I-OUTCOME
primary	I-OUTCOME
neurospheres	I-OUTCOME
,	O
induced	B-OUTCOME
the	I-OUTCOME
loss	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
neurospheres	I-OUTCOME
’	I-OUTCOME
undifferentiated	I-OUTCOME
state	I-OUTCOME
,	O
and	O
promoted	B-OUTCOME
subsequent	I-OUTCOME
cell	I-OUTCOME
migration	I-OUTCOME
and	O
differentiation	O
mainly	O
into	O
a	O
neuronal	B-NEURAL MECHANISM/CORRELATE
phenotype	I-NEURAL MECHANISM/CORRELATE
,	O
as	O
indicated	O
by	O
the	O
positive	O
expression	O
of	O
β	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
III	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
tubulin	I-NEURAL MECHANISM/CORRELATE
and	O
MAP2	B-NEURAL MECHANISM/CORRELATE
,	O
but	O
also	O
into	O
astroglial	B-NEURAL MECHANISM/CORRELATE
cells	I-NEURAL MECHANISM/CORRELATE
.	O
Taken	O
together	O
,	O
these	O
three	O
effects	O
indicate	O
that	O
B.	B-DRUG
caapi	I-DRUG
alkaloids	I-DRUG
have	O
the	O
capacity	O
to	O
regulate	B-OUTCOME
the	I-OUTCOME
expansion	I-OUTCOME
and	I-OUTCOME
fate	I-OUTCOME
of	I-OUTCOME
stem	I-OUTCOME
cell	I-OUTCOME
populations	I-OUTCOME
Analysis	O
of	O
the	O
proliferation	O
stage	O
showed	O
that	O
all	O
four	O
β	B-DRUG
-	I-DRUG
carbolines	I-DRUG
increased	O
the	O
number	O
and	O
size	O
of	O
neurospheres	B-NEURAL MECHANISM/CORRELATE
,	O
the	O
number	O
of	O
Ki-67	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
stained	I-NEURAL MECHANISM/CORRELATE
cells	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
the	O
amounts	O
of	O
Ki-67	B-NEURAL MECHANISM/CORRELATE
and	O
PCNA	B-NEURAL MECHANISM/CORRELATE
protein	I-NEURAL MECHANISM/CORRELATE
as	O
measured	O
by	O
Western	O
blot	O
.	O
Our	O
results	O
for	O
the	O
effect	B-OUTCOME
of	O
harmine	B-DRUG
on	O
proliferation	O
are	O
in	O
line	O
with	O
a	O
previous	O
study	O
showing	O
harmine	O
-	O
induced	O
increase	O
in	O
mitosis	B-OUTCOME
in	O
cultured	O
chick	O
embryo	O
cells32	O
,	O
and	O
in	O
human	O
neural	O
progenitor	O
cells33	O
.	O
To	O
our	O
knowledge	O
,	O
the	O
effects	O
of	O
harmaline	B-DRUG
and	O
THH	B-DRUG
on	O
neurogenesis	B-OUTCOME
have	O
not	O
been	O
studied	O
before	O
.	O
While	O
harmaline	B-DRUG
is	O
only	O
present	O
in	O
small	O
amounts	O
in	O
B.	B-DRUG
caapi	I-DRUG
,	O
THH	B-DRUG
is	O
the	O
second	O
most	O
abundant	O
β	B-DRUG
-	I-DRUG
carboline	I-DRUG
in	O
the	O
plant4	O
,	O
29	O
.	O
Additionally	O
,	O
THH	B-DRUG
shows	O
more	O
consistent	O
plasma	B-NEURAL MECHANISM/CORRELATE
levels	I-NEURAL MECHANISM/CORRELATE
between	O
individuals	O
and	O
studies	O
than	O
harmine	B-DRUG
,	O
which	O
is	O
rapidly	O
degraded	O
to	O
harmol	B-DRUG
when	O
taken	O
orally29	O
,	O
34	O
.	O
The	O
latter	O
,	O
formed	O
in	O
vivo	O
by	O
O	O
-	O
demethylation	O
of	O
the	O
parent	O
compound29	B-DRUG
,	O
showed	O
proliferative	B-OUTCOME
effects	I-OUTCOME
of	O
similar	O
magnitude	O
to	O
those	O
of	O
harmine	B-DRUG
Our	O
results	O
showed	O
that	O
B.	B-DRUG
caapi	I-DRUG
β	I-DRUG
-	I-DRUG
carbolines	I-DRUG
promoted	B-OUTCOME
cellular	I-OUTCOME
migration	I-OUTCOME
and	I-OUTCOME
differentiation	I-OUTCOME
,	O
suggesting	O
that	O
these	O
alkaloids	B-DRUG
not	O
only	O
act	O
as	O
mitogens	O
for	O
neural	B-NEURAL MECHANISM/CORRELATE
stem	I-NEURAL MECHANISM/CORRELATE
cells	I-NEURAL MECHANISM/CORRELATE
,	O
but	O
also	O
modulate	B-OUTCOME
cellular	I-OUTCOME
fate	I-OUTCOME
.	O
The	O
largest	O
effects	B-OUTCOME
on	I-OUTCOME
migration	I-OUTCOME
were	O
observed	O
for	O
harmaline	B-DRUG
and	O
THH	B-DRUG
.	O
Increased	B-OUTCOME
migration	I-OUTCOME
capacity	I-OUTCOME
is	O
relevant	O
in	O
certain	O
conditions	O
such	O
as	O
brain	B-HEALTH CONDITION
injury	I-HEALTH CONDITION
,	O
where	O
stem	B-NEURAL MECHANISM/CORRELATE
cell	I-NEURAL MECHANISM/CORRELATE
niches	O
are	O
far	O
from	O
the	O
damaged	O
area35,36,37	O
.	O
All	O
tested	O
compounds	B-DRUG
also	O
promoted	O
cellular	B-OUTCOME
differentiation	I-OUTCOME
.	O
Neural	B-NEURAL MECHANISM/CORRELATE
stem	I-NEURAL MECHANISM/CORRELATE
cells	I-NEURAL MECHANISM/CORRELATE
are	O
known	O
to	O
differentiate	O
into	O
neurons	B-NEURAL MECHANISM/CORRELATE
,	O
astrocytes	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
oligodendrocytes23	O
,	O
24	O
.	O
The	O
observed	O
increases	O
in	O
Tuj-1	B-NEURAL MECHANISM/CORRELATE
and	O
MAP-2	B-NEURAL MECHANISM/CORRELATE
protein	I-NEURAL MECHANISM/CORRELATE
expression	O
indicated	O
differentiation	B-OUTCOME
predominantly	I-OUTCOME
toward	I-OUTCOME
a	I-OUTCOME
neuronal	I-OUTCOME
phenotype	I-OUTCOME
.	O
In	O
the	O
SVZ	B-NEURAL MECHANISM/CORRELATE
All	O
tested	O
compounds	O
were	O
equally	B-OUTCOME
expressed	I-OUTCOME
after	O
each	O
of	O
the	O
four	O
treatments	O
.	O
However	O
,	O
in	O
the	O
SGZ	B-NEURAL MECHANISM/CORRELATE
harmine	B-DRUG
administration	O
did	O
not	O
influence	O
Tuj-1	B-NEURAL MECHANISM/CORRELATE
levels	I-NEURAL MECHANISM/CORRELATE
,	O
a	O
marker	O
of	O
immature	O
neurons	B-NEURAL MECHANISM/CORRELATE
,	O
but	O
significantly	O
increased	O
the	O
expression	O
of	O
MAP-2	B-NEURAL MECHANISM/CORRELATE
,	O
suggesting	O
a	O
larger	B-OUTCOME
impact	I-OUTCOME
on	I-OUTCOME
neuronal	I-OUTCOME
maturation	I-OUTCOME
All	O
the	O
above	O
indicate	O
that	O
B.	B-DRUG
caapi	I-DRUG
β	I-DRUG
-	I-DRUG
carbolines	I-DRUG
facilitate	B-OUTCOME
neurogenesis	I-OUTCOME
at	O
multiple	O
levels	O
.	O
This	O
capacity	O
is	O
of	O
interest	O
,	O
since	O
in	O
pathological	O
conditions	O
the	O
replacement	O
of	O
neurons	B-NEURAL MECHANISM/CORRELATE
may	O
be	O
optimized	O
by	O
acting	O
simultaneously	O
on	O
various	O
processes38	O
,	O
39	O
.	O
The	O
effect	O
of	O
the	O
β	B-DRUG
-	I-DRUG
carbolines	I-DRUG
on	O
cellular	B-OUTCOME
proliferation	I-OUTCOME
and	I-OUTCOME
differentiation	I-OUTCOME
is	O
not	O
unique	O
to	O
these	O
compounds	B-DRUG
,	O
having	O
been	O
observed	O
for	O
endogenous	B-NEURAL MECHANISM/CORRELATE
molecules	I-NEURAL MECHANISM/CORRELATE
such	O
as	O
leukotriene	B-NEURAL MECHANISM/CORRELATE
B440	B-NEURAL MECHANISM/CORRELATE
,	O
BMPs41	B-NEURAL MECHANISM/CORRELATE
,	O
the	O
growth	O
factors	O
EGF	B-NEURAL MECHANISM/CORRELATE
/	I-NEURAL MECHANISM/CORRELATE
FGF242	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
NGF	B-NEURAL MECHANISM/CORRELATE
/	O
BDNF	B-NEURAL MECHANISM/CORRELATE
/	O
bFGF43	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
the	O
transcription	O
factors	O
Lmx1a	B-NEURAL MECHANISM/CORRELATE
and	O
Lmx1b44	B-NEURAL MECHANISM/CORRELATE
.	O
However	O
,	O
the	O
fact	O
that	O
the	O
β	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
carbolines	I-NEURAL MECHANISM/CORRELATE
also	O
stimulated	B-OUTCOME
migration	I-OUTCOME
highlights	O
the	O
versatility	O
of	O
these	O
exogenous	O
compounds	B-DRUG
,	O
as	O
these	O
exogenous	O
compounds	B-DRUG
can	O
promote	B-OUTCOME
the	I-OUTCOME
three	I-OUTCOME
processes	I-OUTCOME
involved	I-OUTCOME
in	I-OUTCOME
full	I-OUTCOME
adult	I-OUTCOME
neurogenesis	I-OUTCOME
A	O
likely	O
possible	O
explanation	O
for	O
the	O
observed	B-OUTCOME
effects	I-OUTCOME
of	O
β	B-DRUG
-	I-DRUG
carbolines	I-DRUG
in	O
neurogenesis	B-OUTCOME
is	O
the	O
increase	O
in	O
monoamine	B-NEURAL MECHANISM/CORRELATE
levels	I-NEURAL MECHANISM/CORRELATE
caused	O
by	O
MAO	B-NEURAL MECHANISM/CORRELATE
inhibition	I-NEURAL MECHANISM/CORRELATE
.	O
With	O
this	O
said	O
,	O
we	O
must	O
acknowledge	O
that	O
the	O
magnitude	O
of	O
the	O
neurogenic	B-OUTCOME
effects	I-OUTCOME
was	O
similar	O
for	O
the	O
four	O
compounds	B-DRUG
,	O
despite	O
harmol	B-DRUG
and	O
THH	B-DRUG
being	O
inhibitors	O
that	O
are	O
between	O
a	O
hundred	O
and	O
a	O
thousand	O
times	O
weaker	O
than	O
harmine	B-DRUG
or	O
harmaline5	B-DRUG
.	O
Moreover	O
,	O
the	O
role	O
of	O
monoamines	B-NEURAL MECHANISM/CORRELATE
in	O
neurogenesis	B-OUTCOME
is	O
not	O
fully	O
understood	O
.	O
Knocking	O
out	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
in	O
mice	O
impaired	B-OUTCOME
neurogenesis	I-OUTCOME
after	O
fluoxetine	B-ANTIDEPRESSANT_DRUG
but	O
not	O
after	O
imipramine	B-ANTIDEPRESSANT_DRUG
,	O
indicating	O
that	O
neurogenesis	B-OUTCOME
was	I-OUTCOME
independent	I-OUTCOME
from	I-OUTCOME
elevated	I-OUTCOME
serotonin	I-OUTCOME
levels45	O
.	O
In	O
another	O
study	O
,	O
the	O
authors	O
reported	O
the	O
unexpected	O
finding	O
that	O
serotonin	B-NEURAL MECHANISM/CORRELATE
depletion	I-NEURAL MECHANISM/CORRELATE
actually	O
promoted	O
hippocampal	B-OUTCOME
neurogenesis	I-OUTCOME
instead	O
of	O
decreasing	O
it46	O
.	O
In	O
a	O
recent	O
paper	O
,	O
harmine	B-DRUG
,	O
but	O
not	O
the	O
MAO	O
inhibitor	O
pargyline	O
,	O
stimulated	O
proliferation	O
of	O
human	B-NEURAL MECHANISM/CORRELATE
neural	I-NEURAL MECHANISM/CORRELATE
progenitor	I-NEURAL MECHANISM/CORRELATE
cells	I-NEURAL MECHANISM/CORRELATE
in	O
vitro	O
33	O
.	O
Harmine	B-OUTCOME
effects	I-OUTCOME
were	O
mediated	O
through	O
inhibition	O
of	O
the	O
DYRK1A	B-NEURAL MECHANISM/CORRELATE
kinase	I-NEURAL MECHANISM/CORRELATE
rather	O
than	O
through	O
MAO	B-NEURAL MECHANISM/CORRELATE
inhibition	I-NEURAL MECHANISM/CORRELATE
.	O
This	O
opens	O
the	O
possibility	O
that	O
the	O
β	B-DRUG
-	I-DRUG
carbolines	I-DRUG
tested	O
here	O
regulated	B-OUTCOME
stem	I-OUTCOME
cell	I-OUTCOME
fate	I-OUTCOME
via	O
DYRK1A	B-NEURAL MECHANISM/CORRELATE
or	O
other	O
alternative	O
mechanisms	O
.	O
To	O
our	O
knowledge	O
,	O
the	O
inhibitory	B-OUTCOME
effects	I-OUTCOME
of	O
harmaline	B-DRUG
,	O
tetrahydroharmine	B-DRUG
and	O
harmol	B-DRUG
on	O
DYRK1A	B-NEURAL MECHANISM/CORRELATE
has	O
not	O
been	O
examined	O
.	O
Other	O
potential	O
molecular	B-NEURAL MECHANISM/CORRELATE
targets	O
for	O
the	O
neurogenic	B-OUTCOME
effects	I-OUTCOME
of	O
small	O
molecules	B-NEURAL MECHANISM/CORRELATE
include	O
the	O
modulation	O
of	O
the	O
GSK-3β	B-NEURAL MECHANISM/CORRELATE
/	I-NEURAL MECHANISM/CORRELATE
β	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
catenin	I-NEURAL MECHANISM/CORRELATE
pathway	I-NEURAL MECHANISM/CORRELATE
47	O
,	O
upregulation	O
of	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
derived	I-NEURAL MECHANISM/CORRELATE
neurotrophic	I-NEURAL MECHANISM/CORRELATE
factor48	I-NEURAL MECHANISM/CORRELATE
,	O
increased	O
levels	O
of	O
vascular	O
endothelial	B-NEURAL MECHANISM/CORRELATE
growth	I-NEURAL MECHANISM/CORRELATE
factor49	O
;	O
and	O
glucocorticoid	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
activation50	I-NEURAL MECHANISM/CORRELATE
.	O
Future	O
studies	O
should	O
assess	O
whether	O
B.	B-DRUG
caapi	I-DRUG
β	I-DRUG
-	I-DRUG
carbolines	I-DRUG
interact	O
with	O
one	O
or	O
more	O
of	O
these	O
pathway	O
our	O
findings	O
have	O
relevant	B-OUTCOME
therapeutic	I-OUTCOME
implications	I-OUTCOME
.	O
The	O
association	O
between	O
neurogenesis	B-OUTCOME
and	O
anti	B-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
activity	I-OUTCOME
is	O
well	O
documented45	O
,	O
51	O
.	O
Enhanced	O
hippocampal	B-OUTCOME
neurogenesis	I-OUTCOME
reduces	O
depression	B-HEALTH CONDITION
-	O
like	O
behaviors	O
in	O
animals51	O
.	O
Furthermore	O
,	O
clinically	O
effective	O
antidepressants	B-ANTIDEPRESSANT_DRUG
stimulate	B-OUTCOME
neurogenesis	I-OUTCOME
,	O
independent	O
of	O
clinically	O
effective	O
antidepressants	B-ANTIDEPRESSANT_DRUG
chemical	O
structure	O
and	O
mechanism	O
of	O
action	O
.	O
To	O
cite	O
a	O
few	O
examples	O
,	O
chronic	O
treatment	O
with	O
the	O
serotonin	B-ANTIDEPRESSANT_DRUG
reuptake	I-ANTIDEPRESSANT_DRUG
inhibitor	I-ANTIDEPRESSANT_DRUG
fluoxetine	I-ANTIDEPRESSANT_DRUG
increases	B-OUTCOME
neurogenesis	I-OUTCOME
in	O
rats52	O
,	O
53	O
,	O
as	O
does	O
chronic	O
treatment	O
with	O
the	O
selective	B-ANTIDEPRESSANT_DRUG
MAO	I-ANTIDEPRESSANT_DRUG
-	I-ANTIDEPRESSANT_DRUG
A	I-ANTIDEPRESSANT_DRUG
inhibitor	I-ANTIDEPRESSANT_DRUG
pirlindole53	I-ANTIDEPRESSANT_DRUG
.	O
The	O
association	O
between	O
neurogenesis	B-OUTCOME
and	O
antidepressant	B-OUTCOME
effect	I-OUTCOME
is	O
not	O
limited	O
to	O
rodents	O
and	O
pharmacological	O
interventions	O
.	O
Electroconvulsive	O
therapy	O
in	O
primates	O
also	O
stimulates	B-OUTCOME
proliferation	I-OUTCOME
of	I-OUTCOME
neural	I-OUTCOME
precursors	I-OUTCOME
in	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
and	O
primates	O
differentiation	O
into	O
neurons54	B-NEURAL MECHANISM/CORRELATE
.	O
Hippocampal	B-OUTCOME
neurogenesis	I-OUTCOME
appears	O
to	O
be	O
necessary	O
for	O
antidepressant	B-OUTCOME
action	I-OUTCOME
.	O
Irradiation	O
of	O
the	O
SGZ	B-NEURAL MECHANISM/CORRELATE
of	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
in	O
mice	O
prevents	O
the	O
neurogenic	B-OUTCOME
and	I-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
of	O
fluoxetine	B-ANTIDEPRESSANT_DRUG
and	O
imipramine	B-ANTIDEPRESSANT_DRUG
In	O
humans	O
,	O
two	O
recent	O
clinical	O
studies	O
have	O
demonstrated	O
rapid	B-OUTCOME
and	I-OUTCOME
long	I-OUTCOME
-	I-OUTCOME
lasting	I-OUTCOME
antidepressant	I-OUTCOME
effects	I-OUTCOME
after	O
a	O
single	O
ayahuasca	B-DRUG
dose	O
in	O
patients	O
who	O
did	O
not	O
respond	O
to	O
conventional	O
treatment11	O
,	O
12	O
.	O
The	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
of	O
ayahuasca	B-DRUG
is	O
an	O
area	O
of	O
increasing	O
research	O
interest	O
beyond	O
depression55	B-HEALTH CONDITION
.	O
Alterations	B-OUTCOME
in	I-OUTCOME
adult	I-OUTCOME
neurogenic	I-OUTCOME
niches	I-OUTCOME
have	O
been	O
associated	O
with	O
a	O
number	O
of	O
pathologies	O
affecting	O
the	O
central	B-NEURAL MECHANISM/CORRELATE
nervous	I-NEURAL MECHANISM/CORRELATE
system56,57,58,59	I-NEURAL MECHANISM/CORRELATE
.	O
Stimulation	O
of	O
these	O
niches	O
is	O
currently	O
being	O
investigated	O
as	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
neuropsychiatric	B-HEALTH CONDITION
disorders60,61,62	I-HEALTH CONDITION
.	O
Regular	O
ayahuasca	B-DRUG
use	O
has	O
been	O
associated	O
decreases	B-OUTCOME
in	I-OUTCOME
problematic	I-OUTCOME
alcohol	I-OUTCOME
,	O
cocaine	B-OUTCOME
and	I-OUTCOME
opiate	I-OUTCOME
consumption	I-OUTCOME
,	O
indicating	O
anti	B-OUTCOME
-	I-OUTCOME
addiction	I-OUTCOME
properties	I-OUTCOME
for	O
B.	B-DRUG
caapi	I-DRUG
preparations63	I-DRUG
,	O
64	O
.	O
These	O
potential	B-OUTCOME
anti	I-OUTCOME
-	I-OUTCOME
addictive	I-OUTCOME
properties	I-OUTCOME
are	O
particularly	O
relevant	O
if	O
we	O
acknowledge	O
the	O
notorious	O
difficulty	O
of	O
treating	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
Drug	B-HEALTH CONDITION
-	I-HEALTH CONDITION
dependent	I-HEALTH CONDITION
patients	I-HEALTH CONDITION
not	O
only	O
show	O
functional	O
deficits	O
in	O
reward	B-OUTCOME
processing	I-OUTCOME
and	I-OUTCOME
cognitive	I-OUTCOME
control	I-OUTCOME
,	O
but	O
also	O
structural	B-OUTCOME
alterations	I-OUTCOME
in	I-OUTCOME
brain	I-OUTCOME
gray	I-OUTCOME
and	I-OUTCOME
white	I-OUTCOME
matter	I-OUTCOME
Our	O
study	O
has	O
a	O
series	O
of	O
limitations	O
that	O
need	O
to	O
be	O
acknowledged	O
.	O
Ayahuasca	B-DRUG
brews	O
contain	O
other	O
active	O
compounds	O
that	O
were	O
not	O
tested	O
here	O
.	O
A	O
popular	O
version	O
of	O
ayahuasca	B-DRUG
in	O
the	O
USA	O
and	O
Europe	O
contains	O
DMT	B-DRUG
,	O
a	O
serotonergic	B-DRUG
psychedelic9	I-DRUG
.	O
It	O
is	O
possible	O
that	O
DMT	B-DRUG
may	O
have	O
contributed	O
to	O
the	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
reported	O
in	O
clinical	O
studies	O
using	O
ayahuasca11	B-DRUG
,	O
12	O
.	O
This	O
contribution	O
could	O
be	O
due	O
to	O
both	O
brain	B-NEURAL MECHANISM/CORRELATE
plasticity	I-NEURAL MECHANISM/CORRELATE
mediated	O
by	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
activation66	O
and	O
to	O
the	O
profound	B-OUTCOME
psychological	I-OUTCOME
experiences	I-OUTCOME
induced	O
by	O
psychedelics67	O
.	O
While	O
studying	O
DMT	B-DRUG
in	O
the	O
neurogenesis	B-OUTCOME
model	I-OUTCOME
was	O
not	O
an	O
objective	O
of	O
the	O
present	O
investigation	O
,	O
studying	O
DMT	B-DRUG
in	O
the	O
neurogenesis	B-OUTCOME
model	I-OUTCOME
could	O
be	O
assessed	O
in	O
a	O
future	O
study	O
,	O
comparing	O
studying	O
DMT	B-DRUG
in	O
the	O
neurogenesis	B-OUTCOME
model	I-OUTCOME
with	O
other	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
such	O
as	O
psilocybin	B-DRUG
or	O
LSD	B-DRUG
.	O
Although	O
several	O
animal	O
studies	O
have	O
already	O
shown	O
that	O
harmine	B-DRUG
improves	B-OUTCOME
behavioral	I-OUTCOME
measures	I-OUTCOME
of	I-OUTCOME
depression17	I-OUTCOME
,	O
18	O
,	O
future	O
studies	O
could	O
ideally	O
test	O
the	O
four	O
compounds	O
assessed	O
here	O
for	O
both	O
in	O
vivo	O
neurogenesis	B-OUTCOME
and	O
behavioral	B-OUTCOME
improvement	I-OUTCOME
.	O
Finally	O
,	O
future	O
research	O
could	O
also	O
use	O
positive	O
controls	O
to	O
compare	O
the	O
potency	O
of	O
the	O
B.	B-DRUG
caapi	I-DRUG
β	I-DRUG
-	I-DRUG
carbolines	I-DRUG
with	O
that	O
of	O
other	O
antidepressants	B-ANTIDEPRESSANT_DRUG
,	O
such	O
as	O
SSRIs	B-ANTIDEPRESSANT_DRUG
and	O
MAO	B-ANTIDEPRESSANT_DRUG
inhibitors	I-ANTIDEPRESSANT_DRUG
In	O
conclusion	O
,	O
here	O
we	O
showed	O
that	O
the	O
β	B-DRUG
-	I-DRUG
carboline	I-DRUG
alkaloids	I-DRUG
present	O
in	O
B.	B-DRUG
caapi	I-DRUG
,	O
the	O
plant	O
source	O
of	O
the	O
ayahuasca	B-DRUG
tea	O
,	O
promote	B-OUTCOME
neurogenesis	I-OUTCOME
in	O
vitro	O
by	O
stimulating	B-OUTCOME
neural	I-OUTCOME
progenitor	I-OUTCOME
pool	I-OUTCOME
expansion	I-OUTCOME
,	O
and	O
by	O
inducing	B-OUTCOME
cellular	I-OUTCOME
migration	I-OUTCOME
and	I-OUTCOME
differentiation	I-OUTCOME
into	I-OUTCOME
a	I-OUTCOME
neuronal	I-OUTCOME
phenotype	I-OUTCOME
.	O
The	O
stimulation	B-OUTCOME
of	I-OUTCOME
neurogenic	I-OUTCOME
niches	I-OUTCOME
in	O
the	O
adult	O
brain	B-NEURAL MECHANISM/CORRELATE
may	O
substantially	O
contribute	O
to	O
the	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
reported	O
for	O
ayahuasca	B-DRUG
in	O
recent	O
clinical	O
studies	O
.	O
The	O
versatility	O
and	O
full	O
neurogenic	B-OUTCOME
capacity	I-OUTCOME
of	O
the	O
B.	B-DRUG
caapi	I-DRUG
β	I-DRUG
-	I-DRUG
carbolines	I-DRUG
warrant	O
further	O
investigation	O
of	O
these	O
compounds	B-DRUG
.	O
these	O
compounds	B-DRUG
ability	O
to	O
modulate	O
brain	B-NEURAL MECHANISM/CORRELATE
plasticity	I-NEURAL MECHANISM/CORRELATE
indicates	O
these	O
compounds	B-DRUG
therapeutic	B-OUTCOME
potential	I-OUTCOME
for	O
a	O
broad	O
range	O
of	O
psychiatric	O
and	O
neurologic	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
-DOCSTART- -X- O O
In	O
this	O
systematic	O
review	O
,	O
we	O
identified	O
21	O
studies	O
on	O
the	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
of	O
ayahuasca	B-DRUG
and	O
ayahuasca	B-DRUG
alkaloids	O
that	O
met	O
we	O
inclusion	O
criteria	O
.	O
Despite	O
the	O
small	O
number	O
of	O
studies	O
and	O
the	O
high	O
degree	O
of	O
heterogeneity	O
among	O
heterogeneity	O
,	O
the	O
reported	O
results	O
consistently	O
show	O
that	O
these	B-DRUG
compounds	I-DRUG
have	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
properties	I-OUTCOME
.	O
These	O
findings	O
will	O
be	O
discussed	O
in	O
detail	O
below	O
Research	O
performed	O
among	O
ayahuasca	B-DRUG
consumers	O
over	O
the	O
last	O
20	O
years	O
shows	O
that	O
users	O
of	O
this	O
substance	O
do	B-OUTCOME
not	I-OUTCOME
exhibit	I-OUTCOME
symptoms	I-OUTCOME
of	I-OUTCOME
psychiatric	I-OUTCOME
disorders	I-OUTCOME
or	I-OUTCOME
neurocognitive	I-OUTCOME
problems	I-OUTCOME
,	O
but	O
instead	O
show	O
normal	O
or	O
better	B-OUTCOME
cognitive	I-OUTCOME
function	I-OUTCOME
,	O
increased	B-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
and	I-OUTCOME
spirituality	I-OUTCOME
,	O
and	O
reduced	B-OUTCOME
psychopathology	I-OUTCOME
,	O
including	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
symptoms.10	O
-	O
12,14,15,34	O
-	O
36	O
Moreover	O
,	O
DMT	B-DRUG
administration	O
to	O
healthy	O
volunteers	O
suggest	O
that	O
this	O
tryptamine	O
may	O
have	O
anxiolytic	B-OUTCOME
properties	I-OUTCOME
Studies	O
in	O
rodents	O
have	O
reported	O
that	O
the	O
β	O
-	O
carbolines	O
harmine	B-DRUG
and	O
harmaline	B-DRUG
,	O
as	O
well	O
as	O
ayahuasca	B-DRUG
,	O
produce	O
anxiolytic	B-OUTCOME
or	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
.	O
As	O
harmaline	B-DRUG
acts	O
as	O
a	O
MAO	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
A	I-NEURAL MECHANISM/CORRELATE
inhibitor,3,5	I-NEURAL MECHANISM/CORRELATE
the	O
anxiolytic	B-OUTCOME
effects	I-OUTCOME
of	O
this	O
compound22,23	O
could	O
be	O
theoretically	O
explained	O
by	O
an	O
enhancement	B-OUTCOME
of	I-OUTCOME
serotonin	I-OUTCOME
concentrations	I-OUTCOME
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
after	O
MAO	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
A	I-NEURAL MECHANISM/CORRELATE
inhibition.37	I-NEURAL MECHANISM/CORRELATE
Nevertheless	O
,	O
the	O
mechanisms	O
of	O
action	O
responsible	O
for	O
the	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
properties	I-OUTCOME
of	O
harmine	B-DRUG
and	O
harmaline	B-DRUG
are	O
not	O
completely	O
understood	O
,	O
and	O
other	O
non	O
-	O
serotonergic	O
mechanisms	O
could	O
also	O
be	O
involved	O
Specifically	O
,	O
the	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
of	O
harmine	B-DRUG
are	O
apparently	O
independent	O
of	O
the	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
of	O
harmine	O
effects	O
as	O
a	B-NEURAL MECHANISM/CORRELATE
MAO	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
A	I-NEURAL MECHANISM/CORRELATE
inhibitor,3,5	I-NEURAL MECHANISM/CORRELATE
and	O
seem	O
to	O
be	O
mediated	O
by	O
regulation	O
of	O
cell	O
energy	O
homeostasis	O
,	O
mitochondrial	O
functions	O
and	O
oxidative	O
stress,28	O
-	O
30	O
and	O
modulation	O
of	O
BDNF	O
,	O
an	O
endogenous	O
protein	O
involved	O
in	O
neuroplasticity	O
and	O
depressive	O
symptoms.25	O
-	O
27	O
Harmine	B-DRUG
and	O
harmaline	B-DRUG
also	O
bind	O
to	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors.38	I-NEURAL MECHANISM/CORRELATE
-	O
40	O
Since	O
hallucinogens	B-DRUG
increase	B-OUTCOME
cortical	I-OUTCOME
glutamate	I-OUTCOME
levels	I-OUTCOME
following	O
activation	O
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
,	O
increasing	O
the	O
expression	O
of	O
BDNF	O
in	O
prefrontal	O
areas,41	O
42	O
-	O
43	O
the	O
agonist	O
action	O
of	O
harmine	B-DRUG
and	O
harmaline	B-DRUG
in	O
this	O
serotonergic	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
could	O
also	O
lead	O
to	O
increased	O
BDNF	O
levels	O
A	O
study	O
suggested	O
that	O
the	O
GABAA	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
could	O
be	O
involved	O
in	O
the	O
antidepressive	B-OUTCOME
effects	I-OUTCOME
of	O
harmine.24	B-DRUG
Nevertheless	O
,	O
some	O
studies	O
suggest	O
that	O
harmine	B-DRUG
,	O
harmaline	B-DRUG
,	O
and	O
THH	B-DRUG
display	O
little	O
affinity	O
for	O
benzodiazepine	O
receptors	O
Regarding	O
DMT	B-DRUG
,	O
there	O
is	O
evidence	O
that	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A/2A/2C	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
modulate	O
emotional	B-OUTCOME
processing	I-OUTCOME
,	O
reduce	O
anxiety	B-HEALTH CONDITION
and	O
depressive	B-OUTCOME
symptoms	I-OUTCOME
,	O
and	O
increase	O
positive	O
mood	B-OUTCOME
.	O
Interestingly	O
,	O
cortical	O
expression	O
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A/2A/2C	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
is	O
altered	O
in	O
post	O
-	O
mortem	O
samples	O
of	O
depressed	B-HEALTH CONDITION
patients.43	I-HEALTH CONDITION
Therapeutic	O
drugs	O
that	O
are	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
produce	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
in	O
animals	O
and	O
humans,37,43,44	O
and	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A/2C	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
produce	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
in	O
animals.45	O
46	O
-	O
47	O
Moreover	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
anxiety	B-HEALTH CONDITION
and	O
depressive	B-HEALTH CONDITION
symptoms	I-HEALTH CONDITION
are	O
associated	O
with	O
inflammatory	O
processes	O
,	O
and	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A/2A/2C	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
have	O
anti	O
-	O
inflammatory	O
properties	O
Other	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A/2A/2C	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
,	O
such	O
as	O
psilocybin	B-DRUG
and	O
lysergic	O
acid	O
diethylamide	O
(	O
LSD	B-DRUG
)	O
,	O
also	O
produce	O
reductions	O
in	O
anxiety	B-HEALTH CONDITION
and	O
depressive	B-HEALTH CONDITION
symptoms	I-HEALTH CONDITION
and	O
increases	O
in	O
positive	O
mood	B-OUTCOME
.	O
In	O
the	O
mid-1950s	O
and	O
1960s	O
,	O
several	O
studies	O
investigated	O
the	O
potential	O
therapeutic	O
use	O
of	O
psilocybin	B-DRUG
and	O
LSD	B-DRUG
in	O
the	O
treatment	O
of	O
disorders	O
such	O
as	O
neurosis	B-HEALTH CONDITION
and	O
OCDs	B-HEALTH CONDITION
,	O
and	O
as	O
an	O
adjunctive	O
therapy	O
in	O
the	O
terminally	O
ill.42,51	O
52	O
53	O
54	O
55	O
-	O
56	O
However	O
,	O
a	O
definite	O
conclusion	O
regarding	O
the	O
potential	O
beneficial	B-OUTCOME
effects	I-OUTCOME
of	O
these	O
compounds	O
can	O
not	O
be	O
drawn	O
from	O
previous	O
investigations	O
,	O
since	O
many	O
of	O
these	O
studies	O
had	O
important	O
methodological	O
limitations	O
,	O
such	O
as	O
lack	O
of	O
a	O
control	O
group	O
or	O
randomization	O
,	O
absence	O
of	O
double	O
-	O
blind	O
/	O
placebo	O
-	O
controlled	O
designs	O
,	O
and	O
limited	O
follow	O
-	O
up	O
data	O
Recent	O
studies	O
reported	O
that	O
psilocybin	B-DRUG
produces	O
anxiolytic	B-OUTCOME
effects	I-OUTCOME
in	O
mice	O
in	O
the	O
marble	O
burying	O
test	O
,	O
an	O
animal	O
model	O
of	O
OCD,57	B-HEALTH CONDITION
and	O
that	O
LSD	B-DRUG
produced	O
antidepressive	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effects	I-OUTCOME
and	O
normalized	B-OUTCOME
learning	I-OUTCOME
behavior	I-OUTCOME
and	O
hippocampal	B-NEURAL MECHANISM/CORRELATE
serotonin	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2	I-NEURAL MECHANISM/CORRELATE
signaling	I-NEURAL MECHANISM/CORRELATE
in	O
a	O
rat	O
model	O
of	O
depression	B-HEALTH CONDITION
(	O
olfactory	O
bulbectomy	O
)	O
As	O
previously	O
reported	O
,	O
smoked	O
DMT	B-DRUG
increased	O
positive	O
mood	B-OUTCOME
in	O
healthy	O
voluntters,6	O
and	O
both	O
psilocybin59	O
60	O
61	O
62	O
-	O
63	O
and	O
LSD64	O
also	O
increased	O
positive	O
mood	B-OUTCOME
in	O
experimental	O
studies	O
in	O
humans	O
.	O
Case	O
reports56,65	O
66	O
67	O
-	O
68	O
and	O
clinical	O
trials69	O
suggest	O
that	O
psilocybin	B-DRUG
and	O
LSD	B-DRUG
may	O
be	O
beneficial	O
for	O
patients	O
with	O
OCD	B-HEALTH CONDITION
.	O
Moreover	O
,	O
psilocybin-	B-DRUG
and	O
LSD	B-DRUG
-	O
assisted	O
psychotherapy	O
has	O
been	O
shown	O
to	O
reduce	O
anxiety	B-HEALTH CONDITION
and	O
depressive	O
-	O
like	O
symptoms	O
in	O
patients	O
with	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
associated	O
with	O
life	O
-	O
threatening	O
diseases	O
such	O
as	O
advanced	O
-	O
stage	O
cancer	B-HEALTH CONDITION
The	O
antidepressive	B-OUTCOME
properties	I-OUTCOME
of	O
ayahuasca	B-DRUG
could	O
also	O
be	O
related	O
to	O
alterations	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
cortical	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
the	I-NEURAL MECHANISM/CORRELATE
default	I-NEURAL MECHANISM/CORRELATE
mode	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
DMN	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
,	O
a	O
group	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
areas	O
involved	O
in	O
introspection	O
,	O
meditative	O
states	O
,	O
daydreaming	O
,	O
imagination	O
,	O
and	O
mind	O
-	O
wandering	O
.	O
Depressive	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
are	O
associated	O
with	O
increased	O
rumination	B-OUTCOME
,	O
a	O
self	O
-	O
referential	O
process	O
that	O
may	O
become	O
difficult	O
to	O
disengage	O
and	O
is	O
associated	O
with	O
increased	B-NEURAL MECHANISM/CORRELATE
activity	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
the	I-NEURAL MECHANISM/CORRELATE
DMN	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
acute	O
ayahuasca	B-DRUG
administration	O
(	O
2.2	O
mL	O
/	O
kg	O
of	O
body	O
weight	O
)	O
significantly	B-OUTCOME
reduced	I-OUTCOME
DMN	I-OUTCOME
activation.73	I-OUTCOME
A	O
recent	O
study	O
evaluated	O
cortical	O
thickness	O
in	O
22	O
regular	O
users	O
of	O
ayahuasca	B-DRUG
(	O
average	O
5.3	O
years	O
of	O
continuous	O
use	O
;	O
range	O
:	O
2	O
-	O
13	O
years	O
)	O
using	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
reported	O
significant	O
cortical	B-OUTCOME
thinning	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
posterior	I-OUTCOME
cingulate	I-OUTCOME
cortex	I-OUTCOME
(	B-NEURAL MECHANISM/CORRELATE
PCC	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
,	I-NEURAL MECHANISM/CORRELATE
a	I-NEURAL MECHANISM/CORRELATE
key	I-NEURAL MECHANISM/CORRELATE
node	O
of	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
Regarding	O
other	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
,	O
a	O
recent	O
functional	O
MRI	O
(	O
fMRI	O
)	O
study	O
involving	O
intravenous	O
administration	O
of	O
psilocybin	B-DRUG
(	O
2	O
mg	O
)	O
to	O
15	O
healthy	O
volunteers	O
reported	O
significant	O
decreased	O
cerebral	O
blood	O
flow	O
in	O
several	O
brain	B-NEURAL MECHANISM/CORRELATE
areas	O
including	O
the	O
PCC	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
medial	B-NEURAL MECHANISM/CORRELATE
prefrontal	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
mPFC	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
,	O
another	O
important	O
component	O
of	O
the	O
DMN.75	B-NEURAL MECHANISM/CORRELATE
A	O
subsequent	O
study	O
reported	O
increased	B-NEURAL MECHANISM/CORRELATE
functional	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
the	I-NEURAL MECHANISM/CORRELATE
DMN	I-NEURAL MECHANISM/CORRELATE
and	O
the	O
task	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
positive	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
TPN	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
,	O
involved	O
in	O
goal	O
-	O
directed	O
attentional	O
tasks.76	O
Since	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
and	O
TPN	B-NEURAL MECHANISM/CORRELATE
have	O
opposite	O
functions	O
,	O
the	O
authors	O
suggested	O
that	O
the	O
subjective	B-OUTCOME
effects	I-OUTCOME
of	O
hallucinogens	B-DRUG
,	O
as	O
well	O
as	O
psychotic	B-HEALTH CONDITION
and	O
meditative	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
,	O
could	O
be	O
caused	O
by	O
disruption	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
DMN	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
TPN	I-NEURAL MECHANISM/CORRELATE
functional	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
.	O
This	O
disruption	O
would	O
obfuscate	O
the	O
separateness	O
of	O
internally	O
and	O
externally	O
focused	O
states	O
,	O
profoundly	O
altering	B-SUBJECTIVE EXPERIENCE
cognition	I-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
perceptions	I-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
emotions	I-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
and	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
.	O
However	O
,	O
no	O
significant	O
change	B-OUTCOME
was	I-OUTCOME
observed	I-OUTCOME
in	I-OUTCOME
DMN	I-OUTCOME
-	I-OUTCOME
TPN	I-OUTCOME
connectivity	I-OUTCOME
after	O
acute	O
ayahuasca	B-DRUG
administration	O
.	O
Thus	O
,	O
further	O
studies	O
are	O
needed	O
to	O
better	O
explore	O
the	O
subjective	B-OUTCOME
and	I-OUTCOME
therapeutic	I-OUTCOME
effects	I-OUTCOME
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
Animal	O
and	O
human	O
studies	O
suggest	O
that	O
ayahuasca	B-DRUG
and	O
further	O
studies	O
alkaloids	O
can	O
produce	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
,	O
which	O
are	O
probably	O
mediated	O
by	O
agonist	B-NEURAL MECHANISM/CORRELATE
action	I-NEURAL MECHANISM/CORRELATE
on	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A/2A/2C	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
.	O
These	O
receptors	O
are	O
involved	O
in	O
emotional	O
processing	O
,	O
regulation	O
of	O
BDNF	O
brain	B-NEURAL MECHANISM/CORRELATE
levels	O
,	O
anti	O
-	O
inflammatory	O
actions	O
,	O
and	O
altered	O
DMN	B-NEURAL MECHANISM/CORRELATE
functional	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
.	O
However	O
,	O
the	O
mechanisms	O
of	O
action	O
involved	O
in	O
these	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
are	O
not	O
completely	O
understood	O
,	O
and	O
,	O
at	O
least	O
in	O
the	O
case	O
of	O
harmine	B-DRUG
,	O
may	O
include	O
non	O
-	O
serotonergic	O
mechanisms	O
that	O
regulate	O
cell	O
energy	O
homeostasis	O
,	O
mitochondrial	O
functions	O
,	O
and	O
oxidative	O
stress	O
Considering	O
that	O
the	O
average	O
time	O
necessary	O
for	O
the	O
onset	O
of	O
therapeutic	O
action	O
of	O
commercially	O
available	O
antidepressants	B-ANTIDEPRESSANT_DRUG
is	O
2	O
weeks,77	O
the	O
fast	B-OUTCOME
antidepressant	I-OUTCOME
action	I-OUTCOME
of	O
ayahuasca	B-DRUG
reported	O
in	O
our	O
preliminary	O
clinical	O
trial	O
is	O
promising	O
.	O
Recently	O
,	O
our	O
group	O
increased	O
the	O
number	O
of	O
depressive	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
receiving	O
ayahuasca	B-DRUG
treatment	O
and	O
used	O
single	O
photon	O
emission	O
computed	O
tomography	O
(	O
SPECT	O
)	O
to	O
assess	O
regional	O
cerebral	O
blood	O
flow	O
after	O
drug	O
administration	O
.	O
Our	O
results	O
suggest	O
similar	O
positive	B-OUTCOME
effects	I-OUTCOME
as	O
described	O
in	O
our	O
pilot	O
study	O
In	O
summary	O
,	O
the	O
results	O
of	O
this	O
systematic	O
review	O
suggest	O
that	O
ayahuasca	B-DRUG
and	O
its	O
alkaloids	O
have	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
properties	I-OUTCOME
.	O
These	O
results	O
are	O
supported	O
by	O
studies	O
using	O
rodent	O
models	O
of	O
anxiety	B-HEALTH CONDITION
and	O
depressive	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
experimental	O
studies	O
in	O
healthy	O
volunteers	O
,	O
observational	O
studies	O
in	O
ayahuasca	B-DRUG
consumers	O
,	O
and	O
preliminary	O
data	O
from	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
Investigation	O
of	O
these	O
compounds	O
could	O
provide	O
new	O
pharmacological	O
treatments	O
with	O
fast	O
-	O
acting	O
beneficial	B-OUTCOME
effects	I-OUTCOME
for	O
patients	O
with	O
anxiety	B-HEALTH CONDITION
and	O
depressive	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
.	O
Further	O
studies	O
are	O
needed	O
to	O
replicate	O
these	O
findings	O
Limitations	O
of	O
the	O
present	O
review	O
include	O
the	O
small	O
number	O
of	O
studies	O
,	O
especially	O
clinical	O
trials	O
,	O
and	O
the	O
heterogeneity	O
among	O
reviewed	O
reports	O
.	O
Furthermore	O
,	O
most	O
evidence	O
showing	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
of	O
ayahuasca	B-DRUG
or	O
its	O
alkaloids	O
comes	O
from	O
rodent	O
studies	O
.	O
Thus	O
,	O
it	O
is	O
premature	O
to	O
extrapolate	O
these	O
results	O
to	O
humans	O
until	O
more	O
research	O
is	O
conducted	O
With	O
the	O
exception	O
of	O
a	O
single	O
pilot	O
study	O
,	O
the	O
human	O
studies	O
included	O
in	O
this	O
review	O
were	O
mostly	O
experimental	O
and	O
observational	O
in	O
nature	O
.	O
The	O
experimental	O
studies	O
described	O
had	O
small	O
sample	O
sizes	O
and	O
were	O
not	O
designed	O
to	O
assess	O
anxiolytic	B-OUTCOME
or	I-OUTCOME
antidepressive	I-OUTCOME
effect	I-OUTCOME
.	O
An	O
important	O
limitation	O
of	O
observational	O
studies	O
with	O
long	O
-	O
term	O
ayahuasca	B-DRUG
consumers	O
is	O
that	O
it	O
is	O
generally	O
very	O
hard	O
to	O
differentiate	O
whether	O
the	O
improvements	O
described	O
are	O
a	O
consequence	O
of	O
the	O
ingestion	O
of	O
ayahuasca	B-DRUG
or	O
of	O
joining	O
a	O
religious	O
group	O
,	O
which	O
can	O
improve	O
quality	O
of	O
life	O
and	O
well	O
-	O
being.79	O
Experimental	O
and	O
observational	O
studies	O
provide	O
weak	O
evidence	O
of	O
causality	O
,	O
and	O
until	O
more	O
clinical	O
trials	O
are	O
developed	O
,	O
the	O
available	O
evidence	O
in	O
humans	O
must	O
be	O
considered	O
preliminary	O
Despite	O
these	O
limitations	O
,	O
the	O
results	O
showing	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressive	I-OUTCOME
effects	I-OUTCOME
of	O
ayahuasca	B-DRUG
and	O
ayahuasca	B-DRUG
alkaloids	O
are	O
relatively	O
constant	O
,	O
and	O
have	O
been	O
reported	O
in	O
rodents	O
,	O
healthy	O
volunteers	O
,	O
and	O
depressed	B-HEALTH CONDITION
patients	I-HEALTH CONDITION
-DOCSTART- -X- O O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
further	O
investigate	O
the	O
psychological	O
mechanisms	O
underlying	O
the	O
ayahuasca	B-DRUG
experience	O
,	O
and	O
specifically	O
whether	O
ayahuasca	B-DRUG
acutely	O
affects	O
creative	B-OUTCOME
thinking	I-OUTCOME
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
shown	O
that	O
during	O
the	O
acute	O
inebriation	B-SUBJECTIVE EXPERIENCE
,	O
ayahuasca	B-DRUG
caused	O
a	O
decrease	B-OUTCOME
in	I-OUTCOME
conventional	I-OUTCOME
convergent	I-OUTCOME
thinking	I-OUTCOME
and	O
enhanced	B-OUTCOME
creative	I-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
,	O
as	O
measured	O
by	O
the	O
PCT	O
.	O
All	O
dependent	O
variables	O
associated	O
with	O
the	O
PLMT	O
remained	O
unaffected	O
The	O
ayahuasca	B-DRUG
-	O
induced	O
enhancement	B-OUTCOME
of	I-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
could	O
potentially	O
be	O
linked	O
to	O
the	O
effects	O
ayahuasca	B-DRUG
exerts	O
on	O
brain	B-NEURAL MECHANISM/CORRELATE
regions	O
involved	O
in	O
creativity	B-OUTCOME
.	O
Three	O
core	O
networks	O
,	O
i.e.	O
,	O
the	O
default	B-NEURAL MECHANISM/CORRELATE
mode	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	O
DMN	O
)	O
,	O
including	O
the	O
ventromedial	B-NEURAL MECHANISM/CORRELATE
prefrontal	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
and	O
posterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortices	I-NEURAL MECHANISM/CORRELATE
,	O
the	O
central	B-NEURAL MECHANISM/CORRELATE
executive	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	O
CEN	O
)	O
,	O
including	O
dorsolateral	B-NEURAL MECHANISM/CORRELATE
prefrontal	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
and	O
posterior	B-NEURAL MECHANISM/CORRELATE
parietal	I-NEURAL MECHANISM/CORRELATE
cortices	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
the	O
salience	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
(	O
SN	O
)	O
,	O
including	O
dorsal	B-NEURAL MECHANISM/CORRELATE
anterior	I-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
and	O
anterior	O
insula	B-NEURAL MECHANISM/CORRELATE
,	O
interact	O
during	O
divergent	B-OUTCOME
thinking	I-OUTCOME
via	O
corticostriatal	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
thalamocortical	I-NEURAL MECHANISM/CORRELATE
loops	I-NEURAL MECHANISM/CORRELATE
(	O
Chávez	O
-	O
Eakle	O
et	O
al	O
.	O
2007	O
;	O
de	O
Manzano	O
et	O
al	O
.	O
2010	O
;	O
Fink	O
et	O
al	O
.	O
2009	O
;	O
Geyer	O
and	O
Vollenweider	O
2008	O
;	O
Jung	O
et	O
al	O
.	O
2013	O
;	O
Pinho	O
et	O
al	O
.	O
2015	O
)	O
.	O
The	O
thalamus	B-NEURAL MECHANISM/CORRELATE
feeds	O
information	O
into	O
the	O
SN	B-NEURAL MECHANISM/CORRELATE
which	O
in	O
turn	O
coordinates	O
the	O
other	O
mentioned	O
networks	O
(	O
Beaty	O
et	O
al	O
.	O
2016	O
;	O
Uddin	O
2015	O
)	O
.	O
The	O
SN	B-NEURAL MECHANISM/CORRELATE
monitors	O
events	O
occurring	O
outside	O
of	O
the	O
body	O
as	O
well	O
as	O
internal	O
consciousness	B-SUBJECTIVE EXPERIENCE
and	O
is	O
able	O
to	O
direct	B-OUTCOME
attention	I-OUTCOME
to	O
whatever	O
is	O
more	O
important	O
at	O
a	O
certain	O
moment	O
in	O
time	O
.	O
It	O
is	O
suggested	O
that	O
especially	O
these	O
shifts	B-OUTCOME
between	I-OUTCOME
these	I-OUTCOME
externally	I-OUTCOME
(	I-OUTCOME
CEN	I-OUTCOME
)	I-OUTCOME
and	I-OUTCOME
internally	I-OUTCOME
(	I-OUTCOME
DMN	I-OUTCOME
)	I-OUTCOME
oriented	I-OUTCOME
cognitive	I-OUTCOME
networks	I-OUTCOME
are	O
very	O
important	O
in	O
creative	B-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
(	O
Jung	O
et	O
al	O
.	O
2013	O
;	O
Perlovsky	O
and	O
Levine	O
2012	O
)	O
.	O
Interestingly	O
,	O
previous	O
research	O
has	O
shown	O
that	O
ayahuasca	B-DRUG
reduced	B-OUTCOME
thalamic	I-OUTCOME
gating	I-OUTCOME
of	I-OUTCOME
sensory	I-OUTCOME
and	I-OUTCOME
cognitive	I-OUTCOME
information	I-OUTCOME
(	O
Riba	O
et	O
al	O
.	O
2002	O
)	O
.	O
Taking	O
into	O
account	O
the	O
neuronal	O
pathways	O
previously	O
described	O
,	O
this	O
could	O
lead	O
to	O
an	O
increase	B-OUTCOME
in	I-OUTCOME
information	I-OUTCOME
fed	I-OUTCOME
into	I-OUTCOME
the	I-OUTCOME
salience	I-OUTCOME
network	I-OUTCOME
.	O
Consistent	O
with	O
this	O
line	O
of	O
thinking	O
is	O
the	O
fact	O
that	O
Riba	O
and	O
colleagues	O
(	O
2006	O
)	O
showed	O
an	O
increase	B-OUTCOME
in	I-OUTCOME
blood	I-OUTCOME
perfusion	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
SN	I-OUTCOME
after	O
ayahuasca	B-DRUG
ingestion	O
.	O
Previously	O
,	O
other	O
imaging	O
studies	O
with	O
psychedelics	B-DRUG
also	O
showed	O
increased	B-OUTCOME
blood	I-OUTCOME
perfusion	I-OUTCOME
or	O
a	O
higher	B-OUTCOME
metabolic	I-OUTCOME
rate	I-OUTCOME
of	I-OUTCOME
glucose	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
frontal	I-OUTCOME
and	I-OUTCOME
paralimbic	I-OUTCOME
areas	I-OUTCOME
during	O
(	O
e.g.	O
,	O
anterior	O
insula	B-NEURAL MECHANISM/CORRELATE
,	O
anterior	O
cingulate	O
)	O
psilocybin	B-DRUG
and	O
mescaline	B-DRUG
(	O
Gouzoulis	O
-	O
Mayfrank	O
et	O
al	O
.	O
1999a	O
,	O
b	O
;	O
Hermle	O
et	O
al	O
.	O
1992	O
;	O
Riba	O
et	O
al	O
.	O
2006	O
;	O
Vollenweider	O
et	O
al	O
.	O
1997	O
)	O
.	O
In	O
addition	O
,	O
Alonso	O
et	O
al	O
.	O
(	O
2015	O
)	O
found	O
broad	B-OUTCOME
-	I-OUTCOME
band	I-OUTCOME
power	I-OUTCOME
decrements	I-OUTCOME
in	O
the	O
EEG	O
signal	O
after	O
ayahuasca	B-DRUG
compared	O
to	O
placebo	O
.	O
Based	O
on	O
the	O
knowledge	O
about	O
negative	O
correlations	O
between	O
EEG	O
and	O
BOLD	O
(	O
Moosmann	O
et	O
al	O
.	O
2003	O
)	O
,	O
this	O
was	O
interpreted	O
as	O
reflecting	O
increased	B-OUTCOME
activation	I-OUTCOME
of	I-OUTCOME
areas	I-OUTCOME
involved	I-OUTCOME
in	I-OUTCOME
visual	I-OUTCOME
processing	I-OUTCOME
and	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
cognitive	I-OUTCOME
-	I-OUTCOME
emotional	I-OUTCOME
processing	I-OUTCOME
anterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
ACC	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
,	O
an	O
area	O
that	O
is	O
central	O
to	O
the	O
SN	B-NEURAL MECHANISM/CORRELATE
Alonso	O
et	O
al	O
.	O
(	O
2015	O
)	O
also	O
showed	O
a	O
temporary	O
induced	O
disruption	B-OUTCOME
of	I-OUTCOME
neural	I-OUTCOME
hierarchies	I-OUTCOME
by	O
ayahuasca	B-DRUG
,	O
i.e.	O
,	O
by	O
reducing	B-OUTCOME
top	I-OUTCOME
-	I-OUTCOME
down	I-OUTCOME
control	I-OUTCOME
and	I-OUTCOME
increasing	I-OUTCOME
bottom	I-OUTCOME
-	I-OUTCOME
up	I-OUTCOME
information	I-OUTCOME
transfer	I-OUTCOME
in	O
the	O
human	O
brain	B-NEURAL MECHANISM/CORRELATE
(	O
Alonso	O
et	O
al	O
.	O
2015	O
)	O
.	O
It	O
was	O
suggested	O
that	O
the	O
higher	O
excitability	O
of	O
posterior	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
in	O
combination	O
with	O
the	O
loosening	O
of	O
the	O
cognitive	O
grip	O
exerted	O
by	O
frontal	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
responsible	O
for	O
executive	B-NEURAL MECHANISM/CORRELATE
control	I-NEURAL MECHANISM/CORRELATE
may	O
underlie	O
the	O
associations	B-OUTCOME
and	I-OUTCOME
insights	I-OUTCOME
that	O
emerge	O
during	O
the	O
experience	O
(	O
Alonso	O
et	O
al	O
.	O
2015	O
)	O
.	O
Palhano	O
-	O
Fontes	O
and	O
colleagues	O
(	O
2015	O
)	O
also	O
found	O
other	O
parts	O
of	O
these	O
networks	O
to	O
be	O
influenced	O
by	O
ayahuasca	B-DRUG
,	O
i.e.	O
,	O
Palhano	O
-	O
Fontes	O
and	O
colleagues	O
(	O
2015	O
)	O
showed	O
a	O
decrement	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
functional	I-OUTCOME
connectivity	I-OUTCOME
in	I-OUTCOME
parts	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
DMN	I-OUTCOME
after	O
ayahuasca	B-DRUG
ingestion	O
(	O
Palhano	O
-	O
Fontes	O
et	O
al	O
.	O
2015	O
)	O
.	O
It	O
was	O
suggested	O
that	O
this	O
could	O
result	O
in	O
more	O
cognitive	B-OUTCOME
flexibility	I-OUTCOME
and	O
consequently	O
potentially	O
enhanced	B-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
2014	O
)	O
.	O
However	O
,	O
Petri	O
et	O
al	O
.	O
(	O
2014	O
)	O
suggest	O
that	O
the	O
picture	O
is	O
more	O
complex	O
as	O
However	O
,	O
Petri	O
et	O
al	O
showed	O
that	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
does	O
not	O
become	O
a	O
random	O
system	O
after	O
psilocybin	B-DRUG
administration	O
but	O
still	O
has	O
stable	O
connections	O
which	O
are	O
different	O
from	O
the	O
placebo	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
and	O
only	O
present	O
in	O
the	O
psychedelic	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
(	O
Petri	O
et	O
al	O
.	O
2014	O
)	O
.	O
Likewise	O
,	O
Roseman	O
et	O
al	O
.	O
(	O
2014	O
)	O
showed	O
an	O
increase	B-OUTCOME
in	I-OUTCOME
between	I-OUTCOME
-	I-OUTCOME
network	I-OUTCOME
resting	I-OUTCOME
state	I-OUTCOME
functional	I-OUTCOME
connectivity	I-OUTCOME
under	O
psilocybin	B-DRUG
across	O
normally	O
distinct	O
brain	B-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
(	O
Roseman	O
et	O
al	O
.	O
2014	O
)	O
.	O
This	O
increased	B-OUTCOME
integration	I-OUTCOME
between	O
cortical	B-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
could	O
give	O
rise	O
to	O
more	O
associations	O
(	O
Petri	O
et	O
al	O
.	O
2014	O
)	O
and	O
an	O
increased	B-OUTCOME
influence	I-OUTCOME
of	I-OUTCOME
imagination	I-OUTCOME
on	I-OUTCOME
visual	I-OUTCOME
perception	I-OUTCOME
(	O
Roseman	O
et	O
al	O
.	O
2014	O
)	O
.	O
Still	O
,	O
the	O
precise	O
neurobiological	B-NEURAL MECHANISM/CORRELATE
underpinning	I-NEURAL MECHANISM/CORRELATE
of	O
how	O
psychedelics	B-DRUG
may	O
enhance	B-OUTCOME
divergent	I-OUTCOME
creative	I-OUTCOME
thinking	I-OUTCOME
remains	O
largely	O
unknown	O
,	O
and	O
further	O
research	O
is	O
warranted	O
Convergent	O
thinking	O
can	O
be	O
seen	O
as	O
the	O
second	O
phase	O
in	O
the	O
creative	O
thinking	O
process	O
,	O
i.e.	O
,	O
focused	O
on	O
narrowing	O
possibilities	O
to	O
a	O
workable	O
solution	O
after	O
the	O
ideas	O
have	O
been	O
generated	O
through	O
divergent	O
thinking	O
(	O
Hennessey	O
and	O
Amabile	O
2009	O
)	O
.	O
Studies	O
have	O
shown	O
this	O
phase	O
to	O
be	O
associated	O
with	O
an	O
increase	O
in	O
CEN	B-NEURAL MECHANISM/CORRELATE
activity	O
(	O
Sowden	O
et	O
al	O
.	O
2015	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
ayahuasca	B-DRUG
caused	O
deterioration	O
in	O
convergent	B-OUTCOME
thinking	I-OUTCOME
.	O
Palhano	O
-	O
Fontes	O
and	O
colleagues	O
(	O
2015	O
)	O
found	O
that	O
ayahuasca	B-DRUG
only	B-OUTCOME
influenced	I-OUTCOME
activity	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
DMN	I-OUTCOME
without	I-OUTCOME
changing	I-OUTCOME
the	I-OUTCOME
connection	I-OUTCOME
between	I-OUTCOME
DMN	I-OUTCOME
and	I-OUTCOME
CEN	I-OUTCOME
(	O
Palhano	O
-	O
Fontes	O
et	O
al	O
.	O
2015	O
)	O
.	O
The	O
absence	O
of	O
ayahuasca	B-DRUG
enhancing	O
effects	O
on	O
the	O
CEN	O
,	O
together	O
with	O
the	O
decrease	B-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
thalamic	I-NEURAL MECHANISM/CORRELATE
gating	I-NEURAL MECHANISM/CORRELATE
and	O
loosened	B-NEURAL MECHANISM/CORRELATE
cognitive	I-NEURAL MECHANISM/CORRELATE
control	I-NEURAL MECHANISM/CORRELATE
described	O
by	O
Alonso	O
and	O
colleagues	O
(	O
2015	O
)	O
,	O
could	O
explain	O
the	O
negative	B-OUTCOME
effect	I-OUTCOME
of	I-OUTCOME
ayahuasca	I-OUTCOME
on	I-OUTCOME
convergent	I-OUTCOME
thinking	I-OUTCOME
(	O
Alonso	O
et	O
al	O
.	O
2015	O
)	O
.	O
However	O
,	O
research	O
with	O
other	O
psychedelics	B-DRUG
,	O
e.g.	O
,	O
psilocybin	B-DRUG
,	O
showed	O
an	O
increase	B-OUTCOME
in	I-OUTCOME
functional	I-OUTCOME
connectivity	I-OUTCOME
between	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
task	O
-	O
positive	O
network	O
or	O
CEN	B-NEURAL MECHANISM/CORRELATE
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
2013	O
;	O
Roseman	O
et	O
al	O
.	O
2014	O
)	O
Ayahuasca	B-DRUG
selectively	O
affected	O
performance	O
in	O
the	O
PCT	B-NEURAL MECHANISM/CORRELATE
and	O
not	O
in	O
the	O
PLMT	B-NEURAL MECHANISM/CORRELATE
.	O
Anecdotal	O
reports	O
from	O
participants	O
suggest	O
that	O
the	O
stimuli	O
of	O
the	O
PCT	B-NEURAL MECHANISM/CORRELATE
elicited	O
more	B-OUTCOME
novel	I-OUTCOME
thoughts	I-OUTCOME
due	O
to	O
their	O
more	O
complex	O
and	O
colorful	O
nature	O
.	O
In	O
contrast	O
,	O
the	O
stimuli	O
in	O
the	O
PLMT	O
contrast	O
were	O
very	O
simple	O
black	O
-	O
and	O
-	O
white	O
line	O
drawings	O
.	O
The	O
latter	O
probably	O
gave	O
less	O
input	O
into	O
the	O
system	O
involved	O
in	O
the	O
generation	O
of	O
new	O
ideas	O
.	O
Another	O
point	O
to	O
be	O
mentioned	O
is	O
the	O
quasi	O
-	O
experimental	O
design	O
of	O
this	O
study	O
which	O
potentially	O
limits	O
the	O
conclusions	O
that	O
can	O
be	O
drawn	O
from	O
this	O
study	O
.	O
this	O
study	O
could	O
be	O
argued	O
that	O
because	O
ayahuasca	B-DRUG
sessions	O
always	O
followed	O
the	O
baseline	O
session	O
,	O
and	O
as	O
this	O
study	O
is	O
known	O
that	O
ideas	O
can	O
get	O
more	O
creative	O
over	O
time	O
(	O
Beaty	O
and	O
Silvia	O
2012	O
)	O
,	O
a	O
potential	O
order	B-OUTCOME
effect	I-OUTCOME
could	I-OUTCOME
have	I-OUTCOME
influenced	I-OUTCOME
the	I-OUTCOME
results	I-OUTCOME
.	O
However	O
,	O
besides	O
the	O
fact	O
that	O
parallel	O
versions	O
of	O
tasks	O
were	O
used	O
in	O
a	O
randomized	O
order	O
to	O
counter	O
potential	O
order	B-OUTCOME
effects	I-OUTCOME
,	O
the	O
double	O
dissociation	O
,	O
i.e.	O
,	O
improvement	B-OUTCOME
of	I-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
and	I-OUTCOME
impairment	I-OUTCOME
of	I-OUTCOME
convergent	I-OUTCOME
thinking	I-OUTCOME
,	O
suggests	O
that	O
results	O
were	O
not	O
subjected	O
to	O
the	O
serial	O
order	B-OUTCOME
effect	I-OUTCOME
Previously	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
connection	O
between	O
divergent	O
thinking	O
and	O
mood	B-SUBJECTIVE EXPERIENCE
is	O
particularly	O
strong	O
and	O
positive	O
(	O
Baas	O
et	O
al	O
.	O
2008	O
;	O
Davis	O
2009	O
)	O
,	O
i.e.	O
,	O
more	O
positive	O
mood	B-SUBJECTIVE EXPERIENCE
improves	O
divergent	O
thinking	O
.	O
In	O
contrast	O
,	O
convergent	O
thinking	O
and	O
mood	B-SUBJECTIVE EXPERIENCE
are	O
related	O
in	O
a	O
negative	O
way	O
:	O
more	O
positive	O
mood	B-SUBJECTIVE EXPERIENCE
lowers	O
convergent	O
thinking	O
.	O
Mood	O
of	O
participants	O
in	O
the	O
present	O
study	O
was	O
generally	O
very	O
positive	O
,	O
which	O
may	O
have	O
contributed	O
to	O
participants	O
in	O
the	O
present	O
study	O
openness	B-OUTCOME
to	I-OUTCOME
creative	I-OUTCOME
ideas	I-OUTCOME
.	O
Mood	B-SUBJECTIVE EXPERIENCE
ratings	O
were	O
only	O
taken	O
after	O
drinking	O
ayahuasca	B-DRUG
and	O
could	O
not	O
be	O
compared	O
to	O
mood	B-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
before	O
drinking	O
;	O
nonetheless	O
,	O
participants	O
in	O
the	O
present	O
study	O
differed	O
statistically	O
from	O
0	O
.	O
In	O
the	O
future	O
,	O
placebo	O
-	O
controlled	O
studies	O
including	O
measures	O
of	O
mood	O
could	O
test	O
whether	O
mood	B-OUTCOME
changes	I-OUTCOME
are	O
a	O
moderator	O
in	O
the	O
effects	O
of	O
ayahuasca	B-DRUG
.	O
Another	O
point	O
which	O
could	O
be	O
addressed	O
in	O
future	O
research	O
is	O
the	O
usefulness	O
of	O
ideas	O
generated	O
in	O
the	O
divergent	O
thinking	O
task	O
as	O
this	O
is	O
part	O
of	O
the	O
definition	O
of	O
divergent	O
creative	O
thinking	O
.	O
By	O
including	O
for	O
example	O
a	O
task	O
in	O
which	O
this	O
quality	O
can	O
be	O
assessed	O
,	O
e.g.	O
,	O
the	O
“	O
alternate	O
uses	O
task	O
,	O
”	O
this	O
quality	O
can	O
be	O
tested	O
whether	O
ayahuasca	B-DRUG
also	O
improves	O
this	O
aspect	O
of	O
divergent	O
thinking	O
It	O
would	O
be	O
interesting	O
and	O
important	O
in	O
the	O
light	O
of	O
potential	O
clinical	O
applications	O
of	O
ayahuasca	B-DRUG
to	O
investigate	O
whether	O
the	O
effects	O
are	O
stable	O
or	O
also	O
vary	O
in	O
time	O
.	O
It	O
is	O
known	O
that	O
ayahuasca	B-DRUG
induces	B-OUTCOME
an	I-OUTCOME
intense	I-OUTCOME
modified	I-OUTCOME
state	I-OUTCOME
of	I-OUTCOME
consciousness	I-OUTCOME
,	O
starting	O
between	O
35	O
and	O
40	O
min	O
after	O
administration	O
and	O
lasting	O
approximately	O
4	O
h	O
(	O
Frecska	O
et	O
al	O
.	O
2016	O
)	O
.	O
We	O
showed	O
that	O
during	O
this	O
period	O
,	O
divergent	B-OUTCOME
thinking	I-OUTCOME
was	I-OUTCOME
enhanced	I-OUTCOME
and	I-OUTCOME
convergent	I-OUTCOME
thinking	I-OUTCOME
distorted	I-OUTCOME
.	O
Soler	O
et	O
al	O
.	O
(	O
2015	O
)	O
demonstrated	O
that	O
24	O
h	O
after	O
ayahuasca	B-DRUG
intake	O
,	O
mindfulness	B-OUTCOME
-	I-OUTCOME
related	I-OUTCOME
capacities	I-OUTCOME
were	I-OUTCOME
enhanced	I-OUTCOME
(	O
Soler	O
et	O
al	O
.	O
2015	O
)	O
.	O
Mindfulness	O
,	O
a	O
state	O
of	O
nonjudgmental	O
,	O
sustained	O
,	O
and	O
alert	O
awareness	O
which	O
improves	O
people	O
’s	O
cognitive	O
,	O
emotional	O
,	O
and	O
interpersonal	O
functioning	O
,	O
has	O
been	O
shown	O
to	O
be	O
linked	O
with	O
convergent	O
thinking	O
and	O
less	O
with	O
divergent	O
thinking	O
(	O
Lebuda	O
et	O
al	O
.	O
2016	O
)	O
.	O
Based	O
on	O
these	O
findings	O
,	O
it	O
could	O
be	O
interesting	O
to	O
see	O
whether	O
convergent	O
thinking	O
is	O
recovered	O
24	O
h	O
after	O
ayahuasca	B-DRUG
administration	O
.	O
It	O
is	O
suggested	O
,	O
based	O
on	O
a	O
study	O
of	O
Bouso	O
et	O
al	O
.	O
(	O
2008	O
)	O
on	O
MDMA	B-DRUG
-	O
assisted	O
psychotherapy	O
in	O
post	B-HEALTH CONDITION
-	I-HEALTH CONDITION
traumatic	I-HEALTH CONDITION
stress	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
,	O
that	O
the	O
potential	O
effect	B-OUTCOME
pattern	I-OUTCOME
of	O
ayahuasca	B-DRUG
would	O
make	O
it	O
suited	O
for	O
psychedelic	O
-	O
assisted	O
psychotherapy	O
.	O
The	O
increase	B-OUTCOME
in	I-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
during	O
the	O
acute	O
phase	O
could	O
help	B-OUTCOME
patients	I-OUTCOME
relive	I-OUTCOME
events	I-OUTCOME
,	I-OUTCOME
recalling	I-OUTCOME
various	I-OUTCOME
associations	I-OUTCOME
without	I-OUTCOME
feeling	I-OUTCOME
inhibited	I-OUTCOME
(	O
Bouso	O
et	O
al	O
.	O
2008	O
;	O
Frecska	O
et	O
al	O
.	O
2012	O
,	O
2016	O
)	O
.	O
The	O
sub	O
-	O
acute	O
effects	O
could	O
then	O
be	O
suited	O
in	O
a	O
second	O
,	O
“	O
integration	O
”	O
session	O
in	O
which	O
patients	O
discuss	O
the	O
experiences	O
patients	O
had	O
on	O
ayahuasca	B-DRUG
and	O
find	B-OUTCOME
strategies	I-OUTCOME
that	I-OUTCOME
help	I-OUTCOME
patients	I-OUTCOME
cope	I-OUTCOME
with	I-OUTCOME
intensive	I-OUTCOME
emotions	I-OUTCOME
.	O
Future	O
studies	O
should	O
therefore	O
not	O
only	O
focus	O
on	O
either	O
the	O
acute	O
or	O
sub	O
-	O
acute	O
phase	O
but	O
also	O
take	O
both	O
stages	O
into	O
account	O
In	O
the	O
past	O
decade	O
,	O
a	O
renewed	O
interest	O
in	O
the	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
of	O
psychedelics	B-DRUG
has	O
emerged	O
(	O
Anderson	O
2012	O
;	O
McKenna	O
2004	O
;	O
Sessa	O
and	O
Johnson	O
2015	O
)	O
.	O
The	O
present	O
study	O
has	O
shown	O
that	O
ayahuasca	B-DRUG
promotes	B-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
,	O
an	O
ability	O
which	O
has	O
been	O
shown	O
to	O
be	O
an	O
important	O
aspect	O
in	O
cognitive	O
therapy	O
(	O
Forgeard	O
and	O
Elstein	O
2014	O
)	O
.	O
the	O
present	O
study	O
can	O
therefore	O
be	O
suggested	O
that	O
ayahuasca	B-DRUG
possesses	O
qualities	O
that	O
can	O
promote	O
a	O
therapeutic	B-OUTCOME
process	I-OUTCOME
.	O
However	O
,	O
since	O
convergent	B-OUTCOME
thinking	I-OUTCOME
is	O
also	O
a	O
critical	O
aspect	O
in	O
therapy	O
,	O
and	O
the	O
current	O
findings	O
show	O
that	O
ayahuasca	B-DRUG
impairs	O
this	O
facet	O
during	O
the	O
acute	O
phase	O
,	O
future	O
studies	O
have	O
to	O
investigate	O
whether	O
this	O
effect	O
profile	O
changes	O
over	O
time	O
.	O
Additional	O
research	O
utilizing	O
a	O
placebo	O
-	O
controlled	O
experimental	O
design	O
,	O
including	O
additional	O
creativity	O
measures	O
,	O
is	O
warranted	O
,	O
before	O
results	O
can	O
be	O
generalized	O
.	O


-DOCSTART- -X- O O
As	O
described	O
above	O
,	O
acute	O
ayahuasca	B-DRUG
intake	O
leads	O
to	O
a	O
transient	B-OUTCOME
modified	I-OUTCOME
state	I-OUTCOME
of	I-OUTCOME
awareness	I-OUTCOME
characterized	O
by	O
introspection	B-OUTCOME
,	O
visions	B-OUTCOME
,	O
and	O
autobiographic	B-OUTCOME
and	I-OUTCOME
emotional	I-OUTCOME
memories	I-OUTCOME
(	O
Riba	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O
Both	O
naïve	O
and	O
regular	O
ayahuasca	B-DRUG
users	O
have	O
described	O
the	O
experience	O
as	O
positive	B-OUTCOME
and	I-OUTCOME
valuable	I-OUTCOME
,	O
and	O
some	O
individuals	O
have	O
reported	O
health	B-OUTCOME
improvements	I-OUTCOME
associated	O
with	O
ayahuasca	B-DRUG
intake	O
(	O
Loizaga	O
-	O
Velder	O
,	O
2013	O
,	O
Barbosa	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Reports	O
of	O
decreased	B-OUTCOME
consumption	I-OUTCOME
of	I-OUTCOME
alcohol	I-OUTCOME
,	I-OUTCOME
cocaine	I-OUTCOME
and	I-OUTCOME
other	I-OUTCOME
addictive	I-OUTCOME
drugs	I-OUTCOME
are	O
common	O
in	O
regular	O
ayahuasca	B-DRUG
users	O
(	O
Fabregas	O
et	O
al	O
.	O
,	O
2010	O
,	O
Thomas	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Anecdotal	O
data	O
also	O
suggest	O
an	O
antidepressant	B-OUTCOME
effect	I-OUTCOME
for	O
ayahuasca	B-DRUG
(	O
Palhano	O
-	O
Fontes	O
et	O
al	O
.	O
,	O
2014	O
,	O
Schmid	O
,	O
2014	O
)	O
.	O
These	O
testimonies	O
have	O
stimulated	O
research	O
into	O
the	O
potential	O
benefits	O
of	O
ayahuasca	B-DRUG
in	O
the	O
treatment	O
of	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
and	O
other	O
psychiatric	B-HEALTH CONDITION
conditions	I-HEALTH CONDITION
The	O
available	O
literature	O
examining	O
the	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
of	O
ayahuasca	B-DRUG
can	O
be	O
classified	O
into	O
three	O
main	O
groups	O
.	O
In	O
a	O
first	O
group	O
we	O
find	O
studies	O
on	O
the	O
molecular	O
mechanisms	O
of	O
ayahuasca	B-DRUG
alkaloids	O
:	O
receptor	B-NEURAL MECHANISM/CORRELATE
binding	O
studies	O
and	O
in	O
vitro	O
assays	O
,	O
as	O
well	O
as	O
pharmacological	O
studies	O
in	O
animal	O
models	O
.	O
This	O
group	O
of	O
investigations	O
has	O
examined	O
the	O
mechanisms	O
of	O
action	O
that	O
could	O
explain	O
the	O
psychotropic	B-OUTCOME
effects	I-OUTCOME
of	O
ayahuasca	B-DRUG
and	O
the	O
beneficial	B-OUTCOME
effects	I-OUTCOME
described	O
by	O
users	O
.	O
The	O
second	O
group	O
of	O
studies	O
includes	O
case	O
reports	O
describing	O
beneficial	B-OUTCOME
effects	I-OUTCOME
in	O
psychiatric	B-HEALTH CONDITION
symptomatology	I-HEALTH CONDITION
.	O
Disorders	O
include	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
,	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
.	O
However	O
,	O
most	O
of	O
these	O
papers	O
provide	O
information	O
from	O
few	O
subjects	O
usually	O
taking	O
ayahuasca	B-DRUG
in	O
the	O
context	O
of	O
a	O
religious	O
group	O
.	O
This	O
confounding	O
factor	O
has	O
raised	O
doubts	O
as	O
to	O
whether	O
beneficial	B-OUTCOME
effects	I-OUTCOME
can	O
be	O
attributed	O
exclusively	B-OUTCOME
to	I-OUTCOME
ayahuasca	I-OUTCOME
.	O
The	O
third	O
and	O
more	O
recent	O
group	O
of	O
reports	O
includes	O
case	O
-	O
control	O
studies	O
and	O
open	O
label	O
trials	O
with	O
psychiatric	B-HEALTH CONDITION
inpatients	I-HEALTH CONDITION
.	O
a	O
first	O
group	O
constitute	O
a	O
step	O
forward	O
in	O
terms	O
of	O
methodological	O
rigor	O
,	O
but	O
designs	O
are	O
still	O
not	O
ideal	O
,	O
as	O
will	O
be	O
discussed	O
below	O
As	O
mentioned	O
in	O
previous	O
sections	O
,	O
ayahuasca	B-DRUG
is	O
a	O
complex	O
mixture	O
of	O
alkaloids	O
.	O
Thus	O
,	O
the	O
molecular	O
mechanisms	O
potentially	O
involved	O
in	O
alkaloids	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
are	O
numerous	O
Agonism	O
of	O
DMT	B-DRUG
at	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
sites	O
may	O
already	O
have	O
antidepressant	B-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
.	O
This	O
has	O
been	O
shown	O
in	O
animals	O
using	O
the	O
selective	O
agonist	B-NEURAL MECHANISM/CORRELATE
DOI	I-NEURAL MECHANISM/CORRELATE
(	O
Masuda	O
and	O
Sugiyama	O
,	O
2000	O
,	O
Nic	O
Dhonnchadha	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O
This	O
possibility	O
is	O
supported	O
by	O
the	O
success	O
of	O
recent	O
therapeutic	O
trials	O
that	O
have	O
used	O
various	O
psychedelics	B-DRUG
which	O
have	O
the	O
common	O
feature	O
of	O
stimulating	O
this	O
receptor	B-NEURAL MECHANISM/CORRELATE
(	O
Grob	O
et	O
al	O
.	O
,	O
2011	O
,	O
Gasser	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
In	O
addition	O
to	O
increased	O
glutamatergic	B-NEURAL MECHANISM/CORRELATE
transmission	I-NEURAL MECHANISM/CORRELATE
and	O
rapid	O
electrophysiological	O
changes	O
,	O
agonism	B-NEURAL MECHANISM/CORRELATE
at	O
this	O
level	O
has	O
been	O
shown	O
to	O
stimulate	O
BDNF	B-OUTCOME
release	I-OUTCOME
and	O
neurogenesis	B-OUTCOME
(	O
Baumeister	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
These	O
slower	O
secondary	O
events	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
beneficial	B-OUTCOME
effects	I-OUTCOME
of	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
The	O
recently	O
uncovered	O
modulatory	O
role	O
of	O
DMT	B-DRUG
at	O
the	O
orphan	O
receptor	O
sigma-1	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
(	I-NEURAL MECHANISM/CORRELATE
S1R	I-NEURAL MECHANISM/CORRELATE
)	I-NEURAL MECHANISM/CORRELATE
(	O
Fontanilla	O
et	O
al	O
.	O
,	O
2009	O
)	O
could	O
also	O
be	O
involved	O
in	O
the	O
effects	O
of	O
ayahuasca	B-DRUG
.	O
As	O
discussed	O
above	O
,	O
the	O
SR1	B-NEURAL MECHANISM/CORRELATE
is	O
a	O
chaperone	O
receptor	B-NEURAL MECHANISM/CORRELATE
promoting	O
neural	B-OUTCOME
plasticity	I-OUTCOME
.	O
Long	O
-	O
term	O
exposure	O
to	O
ayahuasca	B-DRUG
could	O
potentially	O
lead	O
to	O
neural	B-OUTCOME
changes	I-OUTCOME
mediated	O
through	O
this	O
mechanism	O
The	O
pharmacology	O
of	O
the	O
beta	O
-	O
carbolines	O
can	O
be	O
directly	O
associated	O
with	O
therapeutic	O
effects	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
.	O
MAO	O
inhibition	O
is	O
a	O
known	O
therapeutic	O
approach	O
to	O
treat	O
these	O
disorders	O
.	O
All	O
three	O
major	O
beta	O
-	O
carbolines	O
,	O
harmol	O
,	O
harmalol	O
and	O
tetrahydroharmol	O
have	O
MAO	O
-	O
inhibiting	O
properties	O
(	O
Buckholtz	O
and	O
Boggan	O
,	O
1977a	O
)	O
.	O
Additionally	O
,	O
THH	O
is	O
a	O
serotonin	B-ANTIDEPRESSANT_DRUG
reuptake	I-ANTIDEPRESSANT_DRUG
inhibitor	I-ANTIDEPRESSANT_DRUG
(	O
Buckholtz	O
and	O
Boggan	O
,	O
1977b	O
)	O
.	O
Inhibition	O
of	O
the	O
serotonin	O
transporter	O
is	O
the	O
main	O
pharmacological	O
mechanism	O
of	O
many	O
of	O
the	O
antidepressants	B-ANTIDEPRESSANT_DRUG
currently	O
used	O
in	O
clinical	O
practice	O
.	O
Increased	O
monoamine	O
concentrations	O
in	O
the	O
synapse	O
following	O
ayahuasca	B-DRUG
intake	O
could	O
contribute	O
to	O
the	O
antidepressant	B-OUTCOME
and	I-OUTCOME
antianxiety	I-OUTCOME
properties	I-OUTCOME
of	O
B.	O
caapi	O
preparations	O
.	O
Harmine	O
is	O
also	O
known	O
to	O
inhibit	O
DYRK1A	O
(	O
dual	O
specificity	O
tyrosine-(Y)-phosphorylation	O
regulated	O
kinase	O
1A	O
)	O
in	O
a	O
potent	O
and	O
specific	O
manner	O
(	O
Adayev	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
This	O
kinase	O
that	O
affects	O
neurite	O
formation	O
and	O
maturation	O
is	O
up	O
-	O
regulated	O
in	O
Down	O
Syndrome	O
as	O
a	O
result	O
of	O
the	O
trisomy	O
(	O
Mazur	O
-	O
Kolecka	O
et	O
al	O
.	O
,	O
2012	O
)	O
Halpern	O
et	O
al	O
.	O
(	O
2008	O
)	O
reported	O
a	O
remission	B-OUTCOME
of	I-OUTCOME
drug	I-OUTCOME
or	I-OUTCOME
alcohol	I-OUTCOME
abuse	I-OUTCOME
/	O
dependence	O
in	O
an	O
ayahuasca	B-DRUG
community	O
sample	O
(	O
6.5	O
years	O
average	O
of	O
membership	O
)	O
.	O
In	O
another	O
case	O
series	O
study	O
(	O
Thomas	O
et	O
al	O
.	O
,	O
2013	O
)	O
,	O
the	O
authors	O
found	O
statistically	O
significant	O
reductions	O
in	O
cocaine	B-HEALTH CONDITION
use	I-HEALTH CONDITION
after	O
an	O
ayahuasca	B-DRUG
-	O
assisted	O
therapy	O
in	O
a	O
sample	O
of	O
members	O
of	O
a	O
First	O
Nations	O
community	O
in	O
Canada	O
with	O
no	O
prior	O
experience	O
with	O
ayahuasca	B-DRUG
.	O
the	O
authors	O
also	O
reported	O
improvements	B-OUTCOME
in	I-OUTCOME
mindfulness	I-OUTCOME
,	O
empowerment	B-OUTCOME
,	O
hopefulness	B-OUTCOME
,	O
quality	B-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
-	I-OUTCOME
outlook	I-OUTCOME
and	O
quality	B-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
-	I-OUTCOME
meaning	I-OUTCOME
.	O
Similar	O
effects	O
on	O
substance	O
use	O
were	O
found	O
in	O
two	O
case	O
-	O
control	O
studies	O
(	O
Fabregas	O
et	O
al	O
.	O
,	O
2010	O
,	O
Grob	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O
Grob	O
et	O
al	O
.	O
(	O
1996	O
)	O
reported	O
remission	B-OUTCOME
of	I-OUTCOME
alcohol	I-OUTCOME
,	I-OUTCOME
depressive	I-OUTCOME
,	I-OUTCOME
or	I-OUTCOME
anxiety	I-OUTCOME
disorders	I-OUTCOME
and	O
changes	B-OUTCOME
in	I-OUTCOME
behavior	I-OUTCOME
,	I-OUTCOME
attitude	I-OUTCOME
toward	I-OUTCOME
others	I-OUTCOME
and	I-OUTCOME
outlook	I-OUTCOME
on	I-OUTCOME
life	I-OUTCOME
in	O
a	O
15	O
long	O
-	O
term	O
sample	O
of	O
ayahuasca	B-DRUG
users	O
,	O
compared	O
to	O
15	O
matched	O
controls	O
with	O
no	O
prior	O
history	O
of	O
ayahuasca	B-DRUG
ingestion	O
.	O
Fabregas	O
et	O
al	O
.	O
(	O
2010	O
)	O
reported	O
an	O
improvement	B-OUTCOME
in	I-OUTCOME
alcohol	I-OUTCOME
use	I-OUTCOME
and	O
cessation	B-OUTCOME
of	I-OUTCOME
drug	I-OUTCOME
use	I-OUTCOME
(	O
except	O
cannabis	O
)	O
in	O
two	O
groups	O
of	O
jungle	O
and	O
urban	O
-	O
based	O
ayahuasca	B-DRUG
users	O
compared	O
to	O
non	O
ayahuasca	B-DRUG
users	O
.	O
These	O
findings	O
were	O
maintained	O
at	O
one	O
-	O
year	O
follow	O
-	O
up	O
.	O
Other	O
descriptive	O
studies	O
,	O
such	O
as	O
observational	O
pilot	O
studies	O
,	O
reports	O
and	O
informal	O
interviews	O
(	O
i.	O
e.	O
Bouso	O
and	O
Riba	O
,	O
2014	O
;	O
Doering	O
-	O
Silveira	O
et	O
al	O
.	O
,	O
2005	O
;	O
Labate	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
have	O
presented	O
preliminary	O
evidence	O
,	O
suggesting	O
a	O
potential	B-OUTCOME
beneficial	I-OUTCOME
role	I-OUTCOME
for	O
ayahuasca	B-DRUG
in	O
the	O
treatment	O
of	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
As	O
regards	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
,	O
Barbosa	O
et	O
al	O
.	O
(	O
2005	O
)	O
reported	O
reductions	B-OUTCOME
in	I-OUTCOME
associated	I-OUTCOME
symptomatology	I-OUTCOME
after	O
a	O
first	O
consumption	O
of	O
ayahuasca	B-DRUG
in	O
a	O
sample	O
of	O
Santo	O
Daime	O
members	O
.	O
Santo	O
Daime	O
members	O
also	O
reported	O
behavioral	B-OUTCOME
changes	I-OUTCOME
,	O
such	O
as	O
increased	B-OUTCOME
assertivity	I-OUTCOME
,	I-OUTCOME
vivacity	I-OUTCOME
and	I-OUTCOME
joy	I-OUTCOME
in	O
members	O
of	O
two	O
groups	O
of	O
ayahuasca	B-DRUG
users	O
:	O
the	O
União	O
do	O
Vegetal	O
and	O
the	O
Santo	O
Daime	O
.	O
A	O
case	O
-	O
control	O
study	O
(	O
dos	O
Santos	O
et	O
al	O
.	O
,	O
2007	O
)	O
used	O
psychometric	O
measures	O
of	O
anxiety	B-HEALTH CONDITION
,	O
panic	O
-	O
like	O
and	O
hopelessness	O
in	O
regular	O
(	O
10	O
years	O
)	O
ayahuasca	B-DRUG
users	O
,	O
members	O
of	O
the	O
Santo	O
Daime	O
.	O
While	O
under	O
the	O
acute	O
effects	O
of	O
ayahuasca	B-DRUG
,	O
participants	O
scored	O
lower	O
on	O
the	O
scales	O
for	O
panic-	B-OUTCOME
and	I-OUTCOME
hopelessness	I-OUTCOME
-	I-OUTCOME
related	I-OUTCOME
states	I-OUTCOME
,	O
but	O
no	O
modification	B-OUTCOME
of	I-OUTCOME
state-	I-OUTCOME
or	I-OUTCOME
trait	I-OUTCOME
-	I-OUTCOME
anxiety	I-OUTCOME
was	O
reported	O
following	O
ayahuasca	B-DRUG
ingestion	O
More	O
recently	O
,	O
two	O
open	O
-	O
label	O
trials	O
(	O
Osorio	O
et	O
al	O
.	O
,	O
2015	O
,	O
Sanches	O
et	O
al	O
.	O
,	O
2016	O
)	O
evaluated	O
the	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ayahuasca	B-DRUG
in	O
psychiatric	B-HEALTH CONDITION
depressive	I-HEALTH CONDITION
inpatients	I-HEALTH CONDITION
.	O
Osorio	O
et	O
al	O
.	O
(	O
2015	O
)	O
observed	O
statistically	O
significant	O
reductions	B-OUTCOME
of	I-OUTCOME
up	I-OUTCOME
to	I-OUTCOME
82	I-OUTCOME
%	I-OUTCOME
in	I-OUTCOME
depressive	I-OUTCOME
scores	I-OUTCOME
(	O
HAM	O
-	O
D	O
,	O
MADRS	O
,	O
and	O
the	O
Anxious	O
-	O
Depression	B-HEALTH CONDITION
subscale	O
of	O
the	O
BPRS	O
)	O
between	O
baseline	O
and	O
1	O
,	O
7	O
,	O
and	O
21	O
days	O
after	O
the	O
administration	O
.	O
Furthermore	O
,	O
ayahuasca	B-DRUG
administration	O
did	O
not	O
trigger	O
episodes	O
of	O
mania	B-OUTCOME
or	O
hypomania	B-OUTCOME
as	O
measured	O
by	O
the	O
Young	O
Mania	O
Rating	O
Scale	O
(	O
YMRS	O
)	O
.	O
Neither	O
did	O
it	O
lead	O
to	O
increases	O
in	O
the	O
Thinking	B-OUTCOME
disorder	I-OUTCOME
subscale	O
of	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
(	O
BPRS	O
)	O
.	O
In	O
a	O
subsequent	O
study	O
by	O
the	O
same	O
group	O
(	O
Sanches	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
the	O
authors	O
reported	O
significant	O
decreases	O
in	O
scores	O
on	O
the	O
same	O
depression	B-HEALTH CONDITION
scales	O
(	O
HAM	O
-	O
D	O
,	O
MADRS	O
,	O
BPRS-	O
Anxious	O
-	O
Depression	B-HEALTH CONDITION
)	O
,	O
from	O
80	O
min	O
after	O
administration	O
to	O
day	O
21	O
.	O
No	O
effects	O
were	O
observed	O
on	O
the	O
YMRS	O
and	O
Activation	O
BPRS	O
subscale	O
.	O
Nevertheless	O
,	O
the	O
authors	O
reported	O
increases	B-OUTCOME
in	I-OUTCOME
dissociative	I-OUTCOME
symptoms	I-OUTCOME
as	O
measured	O
by	O
the	O
Clinician	O
Administered	O
Dissociative	O
States	O
Scale	O
(	O
CADSS	O
)	O
.	O
The	O
study	O
included	O
a	O
SPECT	O
assessment	O
that	O
found	O
increased	B-OUTCOME
blood	I-OUTCOME
perfusion	I-OUTCOME
in	O
the	O
left	B-NEURAL MECHANISM/CORRELATE
nucleus	I-NEURAL MECHANISM/CORRELATE
accumbens	I-NEURAL MECHANISM/CORRELATE
,	O
right	O
insula	B-NEURAL MECHANISM/CORRELATE
and	O
left	B-NEURAL MECHANISM/CORRELATE
subgenual	I-NEURAL MECHANISM/CORRELATE
area	I-NEURAL MECHANISM/CORRELATE
,	O
a	O
series	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
regions	O
related	O
to	O
the	O
regulation	O
of	O
mood	O
and	O
emotional	O
states	O
.	O
-DOCSTART- -X- O O
In	O
this	O
open	O
-	O
label	O
,	O
single	O
-	O
arm	O
pilot	O
study	O
,	O
we	O
sought	O
to	O
examine	O
the	O
feasibility	O
of	O
administering	O
psilocybin	B-DRUG
to	O
patients	O
with	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
as	O
a	O
prelude	O
to	O
a	O
larger	O
randomised	O
controlled	O
trial	O
.	O
Our	O
results	O
support	O
the	O
view	O
that	O
,	O
done	O
with	O
appropriate	O
safeguards	O
(	O
eg	O
,	O
careful	O
screening	O
and	O
adequate	O
therapeutic	O
support	O
)	O
,	O
psilocybin	B-DRUG
can	O
be	O
safely	O
administered	O
to	O
this	O
patient	O
group	O
.	O
Because	O
this	O
was	O
a	O
small	O
-	O
scale	O
feasibility	O
study	O
with	O
an	O
open	O
-	O
label	O
design	O
,	O
strong	O
inferences	O
can	O
not	O
be	O
made	O
about	O
the	O
treatment	O
's	O
therapeutic	B-OUTCOME
efficacy	I-OUTCOME
.	O
However	O
,	O
the	O
data	O
do	O
suggest	O
that	O
further	O
research	O
is	O
warranted	O
.	O
The	O
response	O
rate	O
to	O
psilocybin	B-DRUG
was	O
67	O
%	O
(	O
n=8	O
)	O
at	O
1	O
week	O
after	O
treatment	O
(	O
HAM	O
-	O
D	O
and	O
BDI	O
)	O
,	O
and	O
seven	O
of	O
these	O
eight	O
patients	O
also	O
met	O
criteria	O
for	O
remission	B-OUTCOME
.	O
Moreover	O
,	O
58	O
%	O
(	O
n=7	O
)	O
of	O
the	O
patients	O
maintained	O
58	O
%	O
(	O
n=7	O
)	O
of	O
the	O
patients	O
response	O
for	O
3	O
months	O
,	O
and	O
42	O
%	O
(	O
n=5	O
)	O
remained	B-OUTCOME
in	I-OUTCOME
remission	I-OUTCOME
.	O
It	O
is	O
also	O
worth	O
noting	O
that	O
psilocybin	B-DRUG
has	O
a	O
favourable	B-OUTCOME
toxicity	I-OUTCOME
profile	I-OUTCOME
and	O
is	O
not	B-OUTCOME
associated	I-OUTCOME
with	I-OUTCOME
compulsive	I-OUTCOME
drug	I-OUTCOME
-	I-OUTCOME
seeking	I-OUTCOME
behaviours	I-OUTCOME
in	O
animals	O
or	O
human	O
beings	O
.	O
The	O
side	O
-	O
effects	O
that	O
we	O
noted	O
were	O
minor	O
,	O
and	O
expected	O
in	O
light	O
of	O
previous	O
studies	O
of	O
psilocybin	B-DRUG
.	O
Spontaneous	O
recovery	O
in	O
refractory	O
depression	B-HEALTH CONDITION
is	O
rare	O
,	O
and	O
many	O
of	O
the	O
patients	O
in	O
the	O
present	O
study	O
reported	O
having	O
depression	B-HEALTH CONDITION
for	O
much	O
of	O
the	O
patients	O
in	O
the	O
present	O
study	O
adult	O
lives	O
(	O
mean	O
estimated	O
illness	O
duration	O
17·8	O
years	O
[	O
SD	O
8	O
]	O
)	O
.	O
Key	O
questions	O
for	O
future	O
research	O
therefore	O
should	O
address	O
why	O
the	O
therapeutic	B-OUTCOME
effect	I-OUTCOME
observed	O
in	O
the	O
present	O
study	O
is	O
so	O
large	O
,	O
and	O
if	O
the	O
therapeutic	B-OUTCOME
effect	I-OUTCOME
observed	O
in	O
the	O
present	O
study	O
can	O
be	O
replicated	O
when	O
tighter	O
experimental	O
controls	O
are	O
introduced	O
.	O
Because	O
the	O
treatment	O
in	O
our	O
study	O
consisted	O
of	O
not	O
just	O
two	O
psilocybin	B-DRUG
administrations	O
but	O
also	O
psychological	O
support	O
before	O
,	O
during	O
,	O
and	O
after	O
these	O
sessions	O
,	O
as	O
well	O
as	O
a	O
positive	O
therapeutic	O
environment	O
for	O
the	O
sessions	O
,	O
the	O
relative	B-OUTCOME
effects	I-OUTCOME
of	O
these	O
factors	O
need	O
to	O
be	O
determined	O
,	O
which	O
can	O
only	O
be	O
done	O
by	O
conducting	O
further	O
trials	O
with	O
appropriate	O
control	O
conditions	O
.	O
A	O
logical	O
next	O
step	O
would	O
be	O
to	O
carry	O
out	O
a	O
placebo	O
-	O
controlled	O
randomised	O
trial	O
in	O
which	O
the	O
level	O
of	O
therapist	O
contact	O
is	O
consistent	O
between	O
conditions	O
.	O
This	O
would	O
enable	O
any	O
between	O
-	O
group	O
differences	O
in	O
clinical	O
outcomes	O
to	O
be	O
attributed	O
to	O
psilocybin	B-DRUG
rather	O
than	O
the	O
psychological	O
support	O
provided	O
.	O
However	O
,	O
a	O
positive	O
interaction	O
between	O
these	O
variables	O
seems	O
likely	O
,	O
and	O
inert	O
placebo	O
-	O
based	O
blinds	O
are	O
known	O
to	O
be	O
ineffective	O
in	O
studies	O
involving	O
conspicuous	O
experimental	O
interventions	O
,	O
because	O
patients	O
can	O
easily	O
discern	O
whether	O
patients	O
are	O
in	O
the	O
active	O
condition	O
or	O
not	O
.	O
Use	O
of	O
an	O
active	O
placebo	O
for	O
the	O
control	O
condition	O
might	O
therefore	O
be	O
worth	O
considering	O
.	O
Additionally	O
,	O
randomised	O
comparative	O
efficacy	O
trials	O
(	O
eg	O
,	O
with	O
an	O
optional	O
crossover	O
component	O
)	O
incorporating	O
another	O
treatment	O
for	O
refractory	O
depression	B-HEALTH CONDITION
(	O
eg	O
,	O
ketamine	B-DRUG
infusion	O
)	O
could	O
also	O
be	O
explored	O
.	O
The	O
magnitude	O
and	O
persistence	O
of	O
the	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
observed	O
here	O
are	O
not	O
incongruent	O
with	O
what	O
has	O
been	O
observed	O
previously	O
with	O
psilocybin	B-DRUG
in	O
chronic	O
psychiatric	B-HEALTH CONDITION
conditions	I-HEALTH CONDITION
.	O
For	O
example	O
,	O
80	O
%	O
of	O
long	O
-	O
term	O
heavy	O
tobacco	O
smokers	B-HEALTH CONDITION
demonstrated	O
abstinence	B-OUTCOME
from	I-OUTCOME
smoking	I-OUTCOME
6	O
months	O
after	O
two	O
treatment	O
sessions	O
with	O
psilocybin	B-DRUG
.	O
18	O
Alcohol	B-HEALTH CONDITION
-	I-HEALTH CONDITION
dependent	I-HEALTH CONDITION
patients	I-HEALTH CONDITION
demonstrated	O
significantly	O
reduced	B-OUTCOME
drinking	I-OUTCOME
behaviours	I-OUTCOME
over	O
8	O
months	O
after	O
one	O
or	O
two	O
psilocybin	B-DRUG
sessions	O
.	O
19	O
Significantly	O
decreased	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
scores	O
were	O
observed	O
3	O
and	O
6	O
months	O
after	O
a	O
single	O
dose	O
of	O
psilocybin	B-DRUG
in	O
patients	O
with	O
anxiety	B-HEALTH CONDITION
related	O
to	O
end	O
-	O
stage	O
cancer	B-HEALTH CONDITION
,	O
15	O
and	O
improvements	B-OUTCOME
in	I-OUTCOME
wellbeing	I-OUTCOME
lasting	O
for	O
more	O
than	O
1	O
year	O
were	O
observed	O
in	O
healthy	O
individuals	O
given	O
a	O
single	O
dose	O
of	O
psilocybin	B-DRUG
.	O
8	O
Rapid	B-OUTCOME
and	I-OUTCOME
enduring	I-OUTCOME
decreases	I-OUTCOME
in	I-OUTCOME
depressive	I-OUTCOME
symptoms	I-OUTCOME
were	O
also	O
recently	O
found	O
in	O
a	O
small	O
-	O
scale	O
feasibility	O
trial	O
involving	O
the	O
psychedelic	O
brew	O
,	O
ayahuasca	B-DRUG
.	O
It	O
is	O
important	O
to	O
consider	O
the	O
limitations	O
of	O
this	O
pilot	O
study	O
;	O
for	O
example	O
,	O
although	O
all	O
patients	O
showed	O
some	O
clinical	B-OUTCOME
improvements	I-OUTCOME
for	O
at	O
least	O
3	O
weeks	O
after	O
treatment	O
,	O
and	O
no	B-OUTCOME
serious	I-OUTCOME
or	I-OUTCOME
unexpected	I-OUTCOME
adverse	I-OUTCOME
reactions	I-OUTCOME
were	O
observed	O
,	O
enduring	B-OUTCOME
improvements	I-OUTCOME
beyond	O
3	O
weeks	O
were	O
not	O
observed	O
universally	O
,	O
and	O
five	O
of	O
the	O
12	O
patients	O
showed	O
a	O
degree	O
of	O
relapse	B-OUTCOME
at	I-OUTCOME
3	I-OUTCOME
months	I-OUTCOME
.	O
One	O
should	O
be	O
cautious	O
of	O
the	O
potential	O
for	O
inflated	O
effect	O
sizes	O
in	O
early	O
trials	O
,	O
particularly	O
when	O
the	O
sample	O
size	O
is	O
small	O
.	O
That	O
all	O
patients	O
showed	O
some	B-OUTCOME
improvement	I-OUTCOME
in	I-OUTCOME
all	I-OUTCOME
patients	I-OUTCOME
depressive	I-OUTCOME
symptoms	I-OUTCOME
for	O
up	O
to	O
3	O
weeks	O
after	O
treatment	O
could	O
be	O
suggestive	O
of	O
an	O
expectancy	B-OUTCOME
bias	I-OUTCOME
.	O
It	O
may	O
also	O
be	O
relevant	O
that	O
most	O
patients	O
in	O
this	O
trial	O
were	O
self	O
-	O
referring	O
and	O
,	O
thus	O
,	O
actively	O
sought	O
this	O
treatment	O
.	O
Psychedelics	B-DRUG
are	O
known	O
to	O
promote	B-OUTCOME
suggestibility	I-OUTCOME
,	O
28	O
which	O
might	O
have	O
further	O
enhanced	B-OUTCOME
positive	I-OUTCOME
outcomes	I-OUTCOME
.	O
Future	O
double	O
-	O
blind	O
randomised	O
controlled	O
trials	O
could	O
address	O
the	O
role	O
of	O
expectancy	O
and	O
suggestibility	O
by	O
measuring	O
and	O
controlling	O
these	O
variables	O
.	O
For	O
example	O
,	O
patients	O
could	O
be	O
asked	O
about	O
patients	O
pre	O
-	O
treatment	O
expectations	O
,	O
suggestions	O
could	O
be	O
controlled	O
between	O
conditions	O
,	O
and	O
outcomes	O
from	O
self	O
-	O
referred	O
patients	O
could	O
be	O
compared	O
with	O
those	O
from	O
patients	O
referred	O
via	O
clinicians	O
.	O
From	O
a	O
more	O
pragmatic	O
perspective	O
,	O
if	O
expectancy	B-OUTCOME
or	O
suggestibility	B-OUTCOME
are	O
found	O
to	O
be	O
influential	O
in	O
the	O
context	O
of	O
psychedelic	B-DRUG
therapy	O
,	O
expectancy	B-OUTCOME
or	O
suggestibility	B-OUTCOME
could	O
be	O
treated	O
as	O
exploitable	O
components	O
of	O
the	O
treatment	O
model	O
rather	O
than	O
confounding	O
variables	O
.	O
Serotonergic	B-ANTIDEPRESSANT_DRUG
antidepressants	I-ANTIDEPRESSANT_DRUG
have	O
been	O
found	O
to	O
down	B-OUTCOME
-	I-OUTCOME
regulate	I-OUTCOME
the	I-OUTCOME
primary	I-OUTCOME
receptor	I-OUTCOME
target	I-OUTCOME
of	O
psilocybin	B-DRUG
(	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT	I-NEURAL MECHANISM/CORRELATE
2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
)	O
and	O
attenuated	B-OUTCOME
subjective	I-OUTCOME
responses	I-OUTCOME
to	O
psychedelics	B-DRUG
have	O
previously	O
been	O
reported	O
in	O
individuals	O
chronically	O
medicated	O
with	O
serotonergic	B-ANTIDEPRESSANT_DRUG
antidepressants	I-ANTIDEPRESSANT_DRUG
.	O
29	O
Thus	O
,	O
patients	O
may	O
be	O
required	O
to	O
withdraw	O
from	O
concurrent	O
antidepressant	B-ANTIDEPRESSANT_DRUG
medication	O
before	O
receiving	O
psilocybin	B-DRUG
and	O
this	O
should	O
only	O
ever	O
be	O
done	O
with	O
care	O
.	O
In	O
conclusion	O
,	O
we	O
sought	O
to	O
assess	O
the	O
safety	O
and	O
tolerability	O
of	O
psilocybin	B-DRUG
plus	O
psychological	O
support	O
in	O
patients	O
with	O
unipolar	B-HEALTH CONDITION
treatment	I-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
.	O
we	O
findings	O
support	O
the	O
feasibility	O
of	O
this	O
approach	O
and	O
the	O
magnitude	O
and	O
duration	O
of	O
the	O
post	O
-	O
treatment	O
reductions	B-OUTCOME
in	I-OUTCOME
symptom	I-OUTCOME
severity	I-OUTCOME
motivate	O
further	O
controlled	O
research	O
.	O
Psilocybin	B-DRUG
has	O
a	O
novel	B-OUTCOME
pharmacological	I-OUTCOME
action	I-OUTCOME
in	O
comparison	O
with	O
currently	O
available	O
treatments	O
for	O
depression	B-HEALTH CONDITION
(	O
ie	O
,	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT	I-NEURAL MECHANISM/CORRELATE
2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonism	I-NEURAL MECHANISM/CORRELATE
)	O
and	O
thus	O
could	O
constitute	O
a	O
useful	O
addition	O
to	O
available	O
therapies	O
for	O
the	O
treatment	O
of	O
depression	B-HEALTH CONDITION
.	O
-DOCSTART- -X- O O
This	O
is	O
the	O
first	O
preregistered	O
report	O
on	O
microdosing	B-DRUG
psychedelics	I-DRUG
and	O
is	O
intended	O
to	O
inform	O
future	O
lab	O
-	O
based	O
clinical	O
intervention	O
studies	O
.	O
We	O
investigated	O
psychedelic	B-DRUG
microdosing	I-DRUG
in	O
online	O
communities	O
and	O
tested	O
pre	O
-	O
registered	O
hypotheses	O
(	O
https://osf.io/ke49d/	O
)	O
concerning	O
the	O
relationship	O
between	O
experience	O
with	O
microdosing	B-DRUG
and	O
various	O
mental	B-HEALTH CONDITION
health	I-HEALTH CONDITION
and	O
personality	O
variables	O
.	O
Our	O
results	O
suggest	O
a	O
beneficial	B-OUTCOME
relationship	I-OUTCOME
wherein	O
experience	O
with	O
microdosing	B-DRUG
is	O
associated	O
with	O
lower	B-OUTCOME
dysfunctional	I-OUTCOME
attitudes	I-OUTCOME
and	I-OUTCOME
negative	I-OUTCOME
emotionality	I-OUTCOME
and	O
higher	B-OUTCOME
wisdom	I-OUTCOME
,	I-OUTCOME
open	I-OUTCOME
-	I-OUTCOME
mindedness	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
creativity	I-OUTCOME
.	O
The	O
most	O
popular	O
substances	O
used	O
to	O
microdose	O
were	O
LSD	B-DRUG
and	O
psilocybin	B-DRUG
,	O
and	O
no	O
significant	O
differences	O
were	O
found	O
based	O
on	O
substance	O
choice	O
.	O
Hypotheses	O
predicting	O
perceived	O
importance	O
of	O
microdosing	B-DRUG
from	O
dose	O
-	O
related	O
practices	O
were	O
unsupported	O
and	O
optimal	B-OUTCOME
dose	I-OUTCOME
scheduling	I-OUTCOME
remains	O
an	O
open	O
question	O
.	O
Exploratory	O
analyses	O
revealed	O
that	O
microdosers	B-DRUG
,	O
especially	O
current	O
microdosers	O
,	O
had	O
more	O
positive	B-OUTCOME
emotional	I-OUTCOME
valence	I-OUTCOME
than	O
nonmicrodosers	O
,	O
whereas	O
emotional	B-OUTCOME
intensity	I-OUTCOME
was	I-OUTCOME
not	I-OUTCOME
significantly	I-OUTCOME
different	I-OUTCOME
.	O
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
randomized	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trials	O
(	O
RCTs	O
)	O
of	O
microdosing	B-DRUG
are	O
warranted	O
to	O
investigate	O
the	O
causal	B-OUTCOME
efficacy	I-OUTCOME
of	O
microdosing	B-DRUG
.	O
Consistent	O
with	O
our	O
hypotheses	O
,	O
microdosing	B-DRUG
experience	O
was	O
associated	O
with	O
meaningfully	B-OUTCOME
lower	I-OUTCOME
levels	I-OUTCOME
of	I-OUTCOME
dysfunctional	I-OUTCOME
attitudes	I-OUTCOME
.	O
Individuals	O
with	O
higher	O
dysfunctional	O
attitudes	O
maintain	O
a	O
set	O
of	O
disadvantageous	O
beliefs	O
that	O
increase	O
vulnerability	B-OUTCOME
to	I-OUTCOME
stressors	I-OUTCOME
(	O
Jarrett	O
et	O
al	O
.	O
,	O
2012	O
)	O
and	O
high	O
scores	O
are	O
associated	O
with	O
depression	B-HEALTH CONDITION
(	O
Adler	O
et	O
al	O
.	O
,	O
2015	O
;	O
de	O
Graaf	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
Also	O
consistent	O
with	O
our	O
hypotheses	O
was	O
the	O
lower	B-OUTCOME
negative	I-OUTCOME
emotionality	I-OUTCOME
seen	I-OUTCOME
in	I-OUTCOME
microdosers	I-OUTCOME
,	O
though	O
the	O
estimated	O
effect	O
was	O
less	O
precise	O
.	O
Tendencies	O
to	O
experience	O
negative	B-OUTCOME
emotionality	I-OUTCOME
(	O
e.g.	O
anxiety	B-HEALTH CONDITION
,	O
depression	B-HEALTH CONDITION
,	O
emotional	B-OUTCOME
volatility	I-OUTCOME
)	O
are	O
a	O
robust	O
predictor	O
of	O
mental	B-HEALTH CONDITION
and	I-HEALTH CONDITION
physical	I-HEALTH CONDITION
health	I-HEALTH CONDITION
problems	I-HEALTH CONDITION
(	O
Lahey	O
,	O
2009	O
)	O
thus	O
reduced	B-OUTCOME
vulnerability	I-OUTCOME
is	O
reflected	O
in	O
the	O
lower	O
scores	O
seen	O
in	O
microdosers	B-DRUG
.	O
Exploratory	O
analysis	O
revealed	O
that	O
microdosers	B-DRUG
had	O
more	O
positive	B-OUTCOME
emotional	I-OUTCOME
valence	I-OUTCOME
than	O
non	O
-	O
microdosers	O
,	O
linking	O
microdosing	B-DRUG
to	O
better	B-OUTCOME
mood	I-OUTCOME
states	I-OUTCOME
.	O
While	O
causation	O
can	O
not	O
be	O
inferred	O
from	O
these	O
results	O
,	O
significant	O
differences	O
were	O
preserved	O
even	O
after	O
controlling	O
for	O
potent	O
covariates	O
,	O
such	O
as	O
gender	O
and	O
history	O
of	O
mental	B-HEALTH CONDITION
illness	I-HEALTH CONDITION
,	O
indicating	O
a	O
potentially	O
distinct	O
contribution	O
of	O
microdosing	B-DRUG
on	O
mental	B-HEALTH CONDITION
health	I-HEALTH CONDITION
vulnerability	O
that	O
warrants	O
further	O
study	O
.	O
Microdosers	B-DRUG
also	O
had	O
higher	B-OUTCOME
wisdom	I-OUTCOME
,	O
which	O
is	O
a	O
complex	O
trait	O
(	O
BWSS	O
,	O
Glück	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
As	O
measured	O
by	O
the	O
BWSS	O
,	O
wisdom	O
is	O
understood	O
to	O
reflect	O
learning	O
from	O
one	O
's	O
mistakes	O
,	O
considering	O
multiple	O
perspectives	O
when	O
facing	O
a	O
situation	O
,	O
being	O
in	O
tune	O
with	O
one	O
's	O
own	O
emotions	O
and	O
the	O
emotions	O
of	O
others	O
,	O
and	O
feeling	O
a	O
sense	O
of	O
connection	O
and	O
unity	O
.	O
Higher	O
scores	O
,	O
as	O
seen	O
in	O
this	O
sample	O
of	O
microdosers	B-DRUG
,	O
may	O
be	O
associated	O
with	O
cognitive	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
emotional	I-NEURAL MECHANISM/CORRELATE
processing	I-NEURAL MECHANISM/CORRELATE
differences	I-NEURAL MECHANISM/CORRELATE
including	O
enhanced	B-OUTCOME
capacity	I-OUTCOME
for	I-OUTCOME
perspective	I-OUTCOME
taking	I-OUTCOME
,	O
resilience	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
face	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
vicissitudes	I-OUTCOME
of	I-OUTCOME
life	I-OUTCOME
,	O
and	O
increased	B-OUTCOME
feelings	I-OUTCOME
of	I-OUTCOME
engagement	I-OUTCOME
and	I-OUTCOME
connection	I-OUTCOME
.	O
RCT	O
research	O
addressing	O
the	O
relationship	B-OUTCOME
between	I-OUTCOME
wisdom	I-OUTCOME
and	O
microdosing	B-DRUG
are	O
warranted	O
.	O
Greater	O
open	B-OUTCOME
-	I-OUTCOME
mindedness	I-OUTCOME
was	O
expected	O
in	O
microdosers	B-DRUG
compared	O
to	O
controls	O
due	O
to	O
previous	O
studies	O
noting	O
increases	B-OUTCOME
in	I-OUTCOME
openness	I-OUTCOME
following	O
a	O
full	O
-	O
dose	O
of	O
psilocybin	B-DRUG
(	O
MacLean	O
,	O
Johnson	O
,	O
&	O
Griffiths	O
,	O
2011	O
)	O
.	O
These	O
differences	O
were	O
supported	O
,	O
though	O
this	O
effect	O
was	O
relatively	O
weaker	O
than	O
the	O
others	O
.	O
Still	O
,	O
given	O
the	O
findings	O
from	O
full	O
-	O
dose	O
psychedelic	O
studies	O
,	O
future	O
clinical	O
intervention	O
research	O
should	O
continue	O
investigating	O
any	O
causal	O
relationship	B-OUTCOME
between	I-OUTCOME
openmindedness	I-OUTCOME
and	O
microdosing	B-DRUG
.	O
Microdosers	B-DRUG
were	O
more	B-OUTCOME
creative	I-OUTCOME
when	O
finding	O
unusual	O
uses	O
for	O
household	O
items	O
.	O
This	O
is	O
consistent	O
with	O
Fredrickson	O
's	O
(	O
2004	O
)	O
Broaden	O
and	O
Build	O
theory	O
,	O
which	O
suggests	O
a	O
positive	B-OUTCOME
relationship	I-OUTCOME
between	I-OUTCOME
creativity	I-OUTCOME
and	I-OUTCOME
positive	I-OUTCOME
affect	I-OUTCOME
,	O
which	O
was	O
also	O
seen	O
in	O
microdosers	B-DRUG
.	O
Happier	O
,	O
more	O
creative	O
people	O
may	O
be	O
more	O
likely	O
to	O
apply	O
novel	O
modes	O
of	O
thinking	O
in	O
more	O
creative	O
people	O
personal	O
and	O
interpersonal	O
challenges	O
(	O
Fredrickson	O
,	O
2004	O
)	O
.	O
Our	O
findings	O
are	O
also	O
consistent	O
with	O
the	O
anecdotal	O
reports	O
that	O
a	O
relationship	O
between	O
microdosing	B-DRUG
,	O
creativity	B-DRUG
,	O
and	O
mood	B-DRUG
exists	O
,	O
but	O
RCTs	O
,	O
ideally	O
with	O
multiple	O
creativity	O
measures	O
,	O
are	O
required	O
.	O
None	O
of	O
Our	O
hypotheses	O
concerning	O
the	O
importance	B-OUTCOME
of	I-OUTCOME
microdosing	I-OUTCOME
benefits	I-OUTCOME
and	O
microdosing	B-OUTCOME
practices	I-OUTCOME
were	O
supported	O
.	O
It	O
is	O
likely	O
that	O
this	O
measure	O
was	O
not	O
sensitive	O
and	O
specific	O
enough	O
;	O
planned	O
analyses	O
of	O
qualitative	O
benefits	O
and	O
drawbacks	O
of	O
microdosing	B-DRUG
will	O
be	O
explored	O
in	O
a	O
separate	O
report	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
It	O
may	O
be	O
that	O
microdosing	B-DRUG
frequency	O
is	O
truly	O
unrelated	O
to	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
valuation	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
microdosing	I-SUBJECTIVE EXPERIENCE
,	O
but	O
this	O
seems	O
improbable	O
.	O
We	O
suggest	O
that	O
this	O
research	O
question	O
is	O
best	O
addressed	O
in	O
RCT	O
studies	O
focused	O
on	O
specific	O
benefits	O
with	O
experimental	O
manipulation	O
of	O
dose	O
and	O
schedule	O
to	O
determine	O
optimal	B-OUTCOME
benefit	I-OUTCOME
-	I-OUTCOME
specific	I-OUTCOME
protocols	I-OUTCOME
.	O
Similarly	O
,	O
there	O
is	O
no	O
evidence	O
that	O
outcomes	O
are	O
predicated	O
on	O
prior	O
experience	O
with	O
substances	O
,	O
whether	O
full	O
-	O
dose	O
psychedelics	B-DRUG
or	O
with	O
a	O
variety	O
of	O
substances	O
.	O
More	O
microdosers	B-DRUG
had	O
experience	O
with	O
full	O
-	O
doses	O
(	O
69	O
%	O
,	O
n=412	O
)	O
then	O
did	O
not	O
(	O
31	O
%	O
,	O
n=182	O
)	O
and	O
many	O
microdosers	B-DRUG
(	O
and	O
nonmicrodosers	O
)	O
had	O
experience	O
with	O
full	O
-	O
dose	O
psychedelics	B-DRUG
within	O
the	O
month	O
prior	O
to	O
completing	O
the	O
survey	O
.	O
As	O
full	O
-	O
dose	O
psychedelics	B-DRUG
can	O
have	O
benefits	B-OUTCOME
lasting	I-OUTCOME
at	I-OUTCOME
least	I-OUTCOME
a	I-OUTCOME
month	I-OUTCOME
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2017	O
)	O
this	O
covariate	O
should	O
be	O
formally	O
modelled	O
in	O
future	O
microdosing	B-DRUG
research	O
designs	O
,	O
which	O
should	O
aim	O
to	O
include	O
both	O
psychedelic	O
-	O
naïve	O
and	O
psychedelic	O
-	O
experienced	O
participants	O
.	O
-DOCSTART- -X- O O
This	O
is	O
the	O
first	O
report	O
of	O
long	O
-	O
term	O
effects	O
of	O
psilocybin	B-DRUG
treatment	O
in	O
patients	O
with	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychiatric	I-HEALTH CONDITION
and	I-HEALTH CONDITION
existential	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
at	O
two	O
long	O
-	O
term	O
follow	O
-	O
ups	O
.	O
The	O
data	O
suggest	O
that	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
was	O
associated	O
with	O
large	O
and	O
significant	O
reductions	O
in	O
anxiety	B-HEALTH CONDITION
,	O
depression	B-HEALTH CONDITION
,	O
hopelessness	B-OUTCOME
,	O
demoralization	B-OUTCOME
,	O
and	O
death	B-OUTCOME
anxiety	I-OUTCOME
,	O
as	O
well	O
as	O
improvements	O
in	O
spiritual	B-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
at	O
an	O
average	O
of	O
3.2	O
and	O
4.5	O
years	O
following	O
psilocybin	B-DRUG
administration	O
,	O
after	O
a	O
crossover	O
.	O
The	O
magnitudes	O
of	O
reductions	O
relative	O
to	O
baseline	O
in	O
primary	O
measures	O
of	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
were	O
large	O
,	O
with	O
the	O
largest	O
effect	O
sizes	O
seen	O
for	O
global	B-OUTCOME
distress	I-OUTCOME
of	O
combined	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
.	O
Approximately	O
60–80	O
%	O
of	O
participants	O
continued	O
to	O
meet	O
criteria	O
for	O
clinical	O
antidepressant	B-OUTCOME
or	I-OUTCOME
anxiolytic	I-OUTCOME
response	I-OUTCOME
and	O
remission	O
at	O
the	O
second	O
LTFU	O
.	O
At	O
the	O
second	O
LTFU	O
,	O
participants	O
overwhelmingly	O
(	O
71–100	O
%	O
)	O
attributed	O
subjective	B-OUTCOME
experiences	I-OUTCOME
of	I-OUTCOME
positive	I-OUTCOME
changes	I-OUTCOME
to	O
the	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
experience	O
,	O
reporting	O
improved	B-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
or	O
life	B-OUTCOME
satisfaction	I-OUTCOME
,	O
and	O
rating	O
it	O
among	O
the	O
most	O
personally	B-OUTCOME
meaningful	I-OUTCOME
and	I-OUTCOME
spiritually	I-OUTCOME
significant	I-OUTCOME
experiences	I-OUTCOME
of	O
participants	O
overwhelmingly	O
(	O
71–100	O
%	O
)	O
lives	O
Due	O
to	O
the	O
limitations	O
of	O
the	O
crossover	O
design	O
of	O
the	O
parent	O
study	O
,	O
it	O
is	O
not	O
possible	O
to	O
attribute	O
long	O
-	O
term	O
improvements	O
in	O
psychiatric	O
and	O
existential	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
directly	O
to	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
.	O
The	O
majority	O
of	O
participants	O
met	O
criteria	O
for	O
an	O
adjustment	O
disorder	O
(	O
on	O
the	O
DSM	O
-	O
IV	O
-	O
TR	O
)	O
relative	O
to	O
cancer	O
-	O
related	O
stressors	O
at	O
enrollment	O
,	O
and	O
71	O
%	O
reported	O
entering	O
partial	O
or	O
complete	O
cancer	O
remission	O
at	O
the	O
second	O
LTFU	O
.	O
Participants	O
may	O
have	O
thus	O
experienced	O
naturalistic	B-OUTCOME
or	I-OUTCOME
spontaneous	I-OUTCOME
diminishment	I-OUTCOME
of	I-OUTCOME
distress	I-OUTCOME
and	O
resolution	O
of	O
Participants	O
adjustment	O
disorders	O
as	O
Participants	O
entered	O
remission	O
and	O
approached	O
the	O
five	O
-	O
year	O
cancer	O
survival	O
threshold	O
.	O
It	O
is	O
also	O
possible	O
that	O
other	O
psychiatric	O
interventions	O
received	O
after	O
the	O
end	O
of	O
the	O
parent	O
trial	O
accounted	O
for	O
improvements	O
in	O
depressive	B-HEALTH CONDITION
or	I-HEALTH CONDITION
anxious	I-HEALTH CONDITION
symptoms	I-HEALTH CONDITION
.	O
However	O
,	O
this	O
possibility	O
is	O
less	O
likely	O
given	O
that	O
in	O
the	O
follow	O
-	O
up	O
assessment	O
period	O
only	O
8	O
%	O
of	O
participants	O
reported	O
receiving	O
any	O
psychotherapy	O
or	O
pharmacotherapy	O
specifically	O
targeting	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychiatric	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
These	O
findings	O
have	O
meaningful	O
implications	O
for	O
the	O
clinical	O
management	O
of	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
existential	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
.	O
It	O
is	O
hopeful	O
to	O
consider	O
the	O
possibility	O
that	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
could	O
represent	O
the	O
first	O
empirically	O
-	O
driven	O
pharmacotherapy	O
intervention	O
to	O
treat	B-OUTCOME
this	I-OUTCOME
indication	I-OUTCOME
.	O
Existential	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
is	O
under	O
-	O
recognized	O
and	O
under	O
-	O
treated	O
in	O
cancer	B-HEALTH CONDITION
patients	O
within	O
Western	O
medicine	O
(	O
Cepoiu	O
et	O
al	O
.	O
,	O
2008	O
;	O
Gouveia	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
Among	O
medical	O
illnesses	O
,	O
depression	B-HEALTH CONDITION
and	O
hopelessness	B-HEALTH CONDITION
associated	O
with	O
a	O
diagnosis	O
of	O
cancer	B-HEALTH CONDITION
can	O
serve	O
as	O
severe	O
stressors	O
and	O
are	O
well	O
-	O
known	O
risk	O
factors	O
for	O
suicidal	B-OUTCOME
ideation	I-OUTCOME
and	O
completed	B-OUTCOME
suicides	I-OUTCOME
(	O
Rosenfeld	O
et	O
al	O
.	O
,	O
2011	O
;	O
Breitbart	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O
The	O
potential	O
rapidity	O
and	O
long	O
-	O
term	O
durability	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
’s	O
effects	O
represents	O
a	O
promising	B-OUTCOME
protective	I-OUTCOME
strategy	I-OUTCOME
against	I-OUTCOME
suicides	I-OUTCOME
.	O
Future	O
trials	O
should	O
carefully	O
explore	O
this	O
application	O
with	O
cancer	B-HEALTH CONDITION
populations	O
with	O
chronic	O
,	O
passive	B-HEALTH CONDITION
suicidality	I-HEALTH CONDITION
,	O
as	O
there	O
is	O
preliminary	O
evidence	O
that	O
psychedelic	B-DRUG
use	O
may	O
prevent	B-OUTCOME
suicidal	I-OUTCOME
ideation	I-OUTCOME
and	O
behaviors	O
(	O
Hendricks	O
et	O
al	O
.	O
,	O
2015	O
;	O
Johansen	O
and	O
Krebs	O
,	O
2015	O
)	O
An	O
intriguing	O
finding	O
from	O
our	O
analyses	O
was	O
that	O
the	O
greater	O
amount	O
of	O
time	O
that	O
had	O
passed	O
between	O
participants	O
’	O
psilocybin	B-DRUG
session	O
and	O
the	O
second	O
LTFU	O
predicted	O
stronger	B-OUTCOME
reductions	I-OUTCOME
in	I-OUTCOME
subjective	I-OUTCOME
reports	I-OUTCOME
of	I-OUTCOME
depression	I-OUTCOME
and	O
hopelessness	B-OUTCOME
during	O
this	O
period	O
.	O
The	O
significance	O
of	O
this	O
finding	O
is	O
unclear	O
.	O
However	O
,	O
it	O
is	O
interesting	O
to	O
consider	O
that	O
certain	O
domains	O
of	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
,	O
particularly	O
certain	O
key	O
domains	O
of	O
existential	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
,	O
could	O
continue	O
to	O
improve	O
rather	O
than	O
diminish	O
over	O
time	O
in	O
relation	O
to	O
a	O
single	O
psilocybin	B-DRUG
session	O
.	O
The	O
extended	O
follow	O
-	O
up	O
is	O
an	O
important	O
strength	O
of	O
this	O
study	O
as	O
the	O
vast	O
majority	O
of	O
psycho	O
-	O
oncology	O
RCTs	O
to	O
treat	O
psychological	B-HEALTH CONDITION
distress	I-HEALTH CONDITION
report	O
a	O
follow	O
-	O
up	O
period	O
of	O
typically	O
no	O
more	O
than	O
one	O
year	O
following	O
treatment	O
(	O
Faller	O
et	O
al	O
.	O
,	O
2013	O
;	O
Gasser	O
et	O
al	O
.	O
,	O
2015	O
;	O
Stagl	O
et	O
al	O
.	O
,	O
2015	O
)	O
If	O
it	O
were	O
established	O
that	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
effectively	O
treats	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychiatric	I-HEALTH CONDITION
and	I-HEALTH CONDITION
existential	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
,	O
it	O
would	O
be	O
important	O
to	O
understand	O
the	O
neurobiological	O
and	O
psychological	O
mechanisms	O
of	O
action	O
.	O
In	O
our	O
previous	O
report	O
,	O
the	O
psilocybin	B-DRUG
-	O
facilitated	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
was	O
found	O
to	O
partially	O
mediate	O
the	O
effect	O
of	O
dose	O
sequence	O
on	O
anxiolytic	B-OUTCOME
and	I-OUTCOME
antidepressant	I-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
prior	O
to	O
the	O
crossover	O
,	O
suggesting	O
that	O
acute	O
aspects	O
of	O
participants	O
’	O
subjective	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
may	O
explain	O
changes	B-OUTCOME
in	I-OUTCOME
psychiatric	I-OUTCOME
outcomes	I-OUTCOME
up	O
to	O
seven	O
weeks	O
(	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
a	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
was	O
not	O
associated	O
with	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
changes	I-OUTCOME
at	O
the	O
LTFU	O
points	O
.	O
A	O
reduction	O
in	O
power	O
might	O
have	O
weakened	O
our	O
ability	O
to	O
detect	O
an	O
effect	O
as	O
the	O
sample	O
size	O
in	O
this	O
LTFU	O
study	O
was	O
reduced	O
by	O
50	O
%	O
.	O
It	O
is	O
also	O
possible	O
that	O
the	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
does	O
not	O
represent	O
a	O
significant	O
psychological	O
change	O
mechanism	O
accounting	O
for	O
psilocybin	B-DRUG
’s	O
therapeutic	O
effects	O
,	O
or	O
that	O
other	O
aspects	O
of	O
participants	O
’	O
experiences	O
are	O
more	O
influential	O
in	O
determining	O
longer	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
response	I-OUTCOME
.	O
However	O
,	O
given	O
the	O
growing	O
body	O
of	O
evidence	O
linking	O
the	O
intensity	O
of	O
the	O
psilocybin	B-DRUG
-	O
facilitated	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
to	O
therapeutic	B-OUTCOME
improvements	I-OUTCOME
across	O
a	O
range	O
of	O
psychiatric	O
and	O
addictive	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
(	O
Bogenschutz	O
et	O
al	O
.	O
,	O
2015	O
;	O
Garcia	O
-	O
Romeu	O
et	O
al	O
.	O
,	O
2014	O
;	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
;	O
Pahnke	O
et	O
al	O
.	O
,	O
1969	O
;	O
Roseman	O
et	O
al	O
.	O
,	O
2019	O
;	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
it	O
is	O
important	O
to	O
further	O
explore	O
this	O
potential	O
psychological	O
mechanism	O
of	O
action	O
in	O
additional	O
adequately	O
-	O
powered	O
RCTs	O
.	O
it	O
would	O
also	O
be	O
important	O
to	O
explore	O
other	O
potential	O
psychological	B-OUTCOME
change	I-OUTCOME
mechanisms	I-OUTCOME
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
in	O
this	O
patient	O
population	O
One	O
such	O
mechanism	O
may	O
relate	O
to	O
rapid	B-OUTCOME
and	I-OUTCOME
enduring	I-OUTCOME
shifts	I-OUTCOME
in	I-OUTCOME
cognition	I-OUTCOME
.	O
Classic	O
psychedelics	B-DRUG
offer	O
a	O
rapid	O
means	O
of	O
dismantling	B-OUTCOME
habitual	I-OUTCOME
mental	I-OUTCOME
templates	I-OUTCOME
that	O
,	O
over	O
time	O
,	O
may	O
rigidify	O
one	O
’s	O
attention	O
and	O
behavior	O
—	O
patterns	O
that	O
are	O
associated	O
with	O
various	O
psychiatric	O
pathologies	O
(	O
Carhart	O
-	O
Harris	O
,	O
2018	O
;	O
Carhart	O
-	O
Harris	O
and	O
Friston	O
,	O
2019	O
)	O
.	O
Psychedelic	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
induced	I-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
are	O
,	O
instead	O
,	O
associated	O
with	O
increases	B-OUTCOME
in	I-OUTCOME
trait	I-OUTCOME
openness	I-OUTCOME
and	O
cognitive	B-OUTCOME
flexibility	I-OUTCOME
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012	O
;	O
Kuypers	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
In	O
an	O
open	O
-	O
label	O
trial	O
of	O
psilocybin	B-DRUG
in	O
patients	O
with	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
participants	O
reported	O
increased	B-OUTCOME
trait	I-OUTCOME
openness	I-OUTCOME
,	O
with	O
significant	O
increases	O
in	O
the	O
following	O
sub	O
-	O
traits	O
:	O
“	O
openness	O
to	O
values	O
”	O
(	O
i.e.	O
valuing	O
open	O
-	O
mindedness	O
and	O
psychological	O
flexibility	O
)	O
and	O
“	O
openness	O
to	O
actions	O
”	O
(	O
i.e.	O
readiness	O
to	O
try	O
and	O
engage	O
in	O
new	O
activities	O
;	O
Erritzoe	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
Being	O
open	O
to	O
novel	O
and	O
more	O
constructive	O
ways	O
of	O
thinking	O
,	O
feeling	O
and	O
behaving	O
is	O
one	O
of	O
the	O
central	O
goals	O
of	O
contemporary	O
evidence	O
-	O
based	O
psychotherapies	O
(	O
e.g.	O
cognitive	O
behavioral	O
therapy	O
and	O
Acceptance	O
Commitment	O
Therapy	O
(	O
Hayes	O
et	O
al	O
.	O
,	O
2012	O
)	O
)	O
,	O
and	O
enhanced	B-OUTCOME
cognitive	I-OUTCOME
and	I-OUTCOME
psychological	I-OUTCOME
flexibility	I-OUTCOME
may	O
constitute	O
a	O
psychological	O
mechanism	O
mediating	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
’s	O
antidepressant	B-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
(	O
Watts	O
and	O
Luoma	O
,	O
2020	O
)	O
.	O
Further	O
,	O
given	O
the	O
link	O
between	O
enhanced	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
states	I-SUBJECTIVE EXPERIENCE
and	O
enduring	B-OUTCOME
increases	I-OUTCOME
in	I-OUTCOME
trait	I-OUTCOME
openness	I-OUTCOME
(	O
MacLean	O
et	O
al	O
.	O
,	O
2011	O
)	O
,	O
it	O
is	O
possible	O
that	O
certain	O
features	O
of	O
the	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
(	O
e.g.	O
dissolution	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
boundaries	I-SUBJECTIVE EXPERIENCE
and	O
feelings	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
unity	I-SUBJECTIVE EXPERIENCE
)	O
lead	O
one	O
to	O
develop	O
enduring	B-OUTCOME
increases	I-OUTCOME
in	I-OUTCOME
psychological	I-OUTCOME
flexibility	I-OUTCOME
when	O
coupled	O
with	O
supportive	O
psychotherapy	O
.	O
The	O
psilocybin	B-DRUG
experience	O
may	O
have	O
enabled	O
participants	O
to	O
establish	O
a	B-OUTCOME
new	I-OUTCOME
inner	I-OUTCOME
framework	I-OUTCOME
from	O
which	O
participants	O
could	O
flexibly	O
avail	O
participants	O
of	O
resources	O
internally	O
and	O
in	O
participants	O
environment	O
to	O
cope	B-OUTCOME
with	I-OUTCOME
life	I-OUTCOME
stressors	I-OUTCOME
,	O
particularly	O
stressors	O
associated	O
with	O
participants	O
cancer	B-HEALTH CONDITION
diagnoses	O
It	O
is	O
also	O
possible	O
that	O
other	O
aspects	O
of	O
the	O
acute	O
psilocybin	B-DRUG
experience	O
,	O
such	O
as	O
challenging	O
(	O
Barrett	O
et	O
al	O
.	O
,	O
2016	O
)	O
or	O
emotional	B-SUBJECTIVE EXPERIENCE
breakthrough	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
(	O
Roseman	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
are	O
more	O
influential	O
in	O
explaining	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
changes	I-OUTCOME
of	O
psilocybin	B-DRUG
-	O
assisted	O
psychotherapy	O
.	O
The	O
resolution	B-OUTCOME
and	I-OUTCOME
integration	I-OUTCOME
of	I-OUTCOME
difficult	I-OUTCOME
emotions	I-OUTCOME
may	O
be	O
particularly	O
relevant	O
for	O
clinical	O
populations	O
such	O
as	O
cancer	B-HEALTH CONDITION
patients	O
,	O
and	O
such	O
emotional	B-OUTCOME
processing	I-OUTCOME
may	O
support	O
the	O
development	O
of	O
greater	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
and	O
emotional	B-OUTCOME
regulation	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
long	I-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
(	O
Lane	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
It	O
would	O
be	O
important	O
to	O
assess	O
these	O
potential	O
psychological	B-OUTCOME
change	I-OUTCOME
mechanisms	I-OUTCOME
in	O
future	O
trials	O
that	O
are	O
adequately	O
designed	O
and	O
powered	O
.	O
These	O
theories	O
are	O
supported	O
by	O
a	O
growing	O
consensus	O
that	O
serotonin	B-NEURAL MECHANISM/CORRELATE
2A	I-NEURAL MECHANISM/CORRELATE
signaling	I-NEURAL MECHANISM/CORRELATE
mediates	O
functional	B-OUTCOME
shifts	I-OUTCOME
in	I-OUTCOME
connectivity	I-OUTCOME
in	O
cortico	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
striato	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
thalmo	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
cortical	I-NEURAL MECHANISM/CORRELATE
pathways	I-NEURAL MECHANISM/CORRELATE
(	O
Preller	O
et	O
al	O
.	O
,	O
2019	O
)	O
,	O
increased	B-OUTCOME
entropy	I-OUTCOME
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
(	O
Carhart	O
-	O
Harris	O
,	O
2018	O
)	O
,	O
and	O
disruption	B-OUTCOME
of	I-OUTCOME
activity	I-OUTCOME
within	I-OUTCOME
the	I-OUTCOME
default	I-OUTCOME
mode	I-OUTCOME
network	I-OUTCOME
,	O
a	O
brain	B-NEURAL MECHANISM/CORRELATE
system	O
that	O
is	O
associated	O
with	O
self	O
-	O
referential	O
information	O
processing	O
and	O
mind	O
-	O
wandering	O
(	O
Carhart	O
-	O
Harris	O
and	O
Nutt	O
,	O
2017	O
;	O
Carhart	O
-	O
Harris	O
and	O
Goodwin	O
,	O
2017	O
;	O
Ly	O
et	O
al	O
.	O
,	O
2018	O
)	O
.	O
These	O
theories	O
are	O
also	O
consistent	O
with	O
the	O
quantitative	O
(	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
qualitative	O
(	O
Belser	O
et	O
al	O
.	O
,	O
2017	O
;	O
Swift	O
et	O
al	O
.	O
,	O
2017	O
)	O
findings	O
from	O
the	O
parent	O
trial	O
and	O
the	O
present	O
study	O
of	O
highly	B-OUTCOME
memorable	I-OUTCOME
,	I-OUTCOME
meaningful	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
spiritually	I-OUTCOME
significant	I-OUTCOME
effects	I-OUTCOME
attributed	O
to	O
the	O
psilocybin	B-DRUG
experience	O
.	O
We	O
strongly	O
believe	O
,	O
however	O
,	O
that	O
an	O
isolated	O
experience	O
with	O
psilocybin	B-DRUG
does	O
not	O
inherently	B-OUTCOME
confer	I-OUTCOME
therapeutic	I-OUTCOME
benefits	I-OUTCOME
.	O
Rather	O
,	O
the	O
development	O
of	O
an	O
enduring	B-OUTCOME
therapeutic	I-OUTCOME
experience	I-OUTCOME
is	O
contingent	O
on	O
contextual	B-OUTCOME
factors	I-OUTCOME
,	O
such	O
as	O
the	O
presence	O
of	O
skilled	O
therapists	O
or	O
guides	O
,	O
which	O
facilitate	O
a	O
larger	O
psychotherapeutic	O
process	O
.	O
It	O
is	O
,	O
therefore	O
,	O
important	O
to	O
recognize	O
that	O
purely	O
neurobiological	B-NEURAL MECHANISM/CORRELATE
interpretations	O
regarding	O
brain	B-NEURAL MECHANISM/CORRELATE
activity	O
during	O
acute	O
phases	O
of	O
a	O
psilocybin	B-DRUG
experience	O
will	O
not	O
adequately	O
capture	O
the	O
dynamics	O
of	O
a	O
psychotherapeutic	O
process	O
that	O
may	O
unfold	O
in	O
the	O
weeks	O
or	O
months	O
thereafter	O
,	O
fostering	B-OUTCOME
enhanced	I-OUTCOME
meaning	I-OUTCOME
and	I-OUTCOME
greater	I-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
-DOCSTART- -X- O O
In	O
this	O
study	O
we	O
investigated	O
the	O
acute	O
effects	O
of	O
very	O
low	O
‘	O
microdoses	B-DRUG
’	O
of	O
LSD	B-DRUG
on	O
mood	B-SUBJECTIVE EXPERIENCE
,	O
cognition	B-SUBJECTIVE EXPERIENCE
,	O
and	O
behavior	B-SUBJECTIVE EXPERIENCE
in	O
healthy	O
young	O
adult	O
volunteers	O
,	O
and	O
identified	O
the	O
threshold	O
doses	O
at	O
which	O
LSD	B-DRUG
produces	O
detectable	B-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
.	O
We	O
report	O
that	O
at	O
doses	O
one	O
tenth	O
to	O
one	O
twentieth	O
those	O
used	O
recreationally	O
(	O
and	O
more	O
recently	O
in	O
therapeutic	O
settings	O
)	O
,	O
LSD	B-DRUG
produces	O
measurable	O
modest	O
increases	B-OUTCOME
in	I-OUTCOME
ratings	I-OUTCOME
of	I-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
scales	I-OUTCOME
.	O
At	O
these	O
doses	O
,	O
LSD	B-DRUG
also	O
had	O
subtle	B-OUTCOME
effects	I-OUTCOME
on	I-OUTCOME
behavioral	I-OUTCOME
tasks	I-OUTCOME
:	O
tending	O
to	O
increase	B-OUTCOME
the	I-OUTCOME
number	I-OUTCOME
of	I-OUTCOME
attempted	I-OUTCOME
trials	I-OUTCOME
on	I-OUTCOME
a	I-OUTCOME
creativity	I-OUTCOME
task	I-OUTCOME
(	O
the	O
Remote	O
Associates	O
Test	O
)	O
.	O
This	O
is	O
the	O
first	O
controlled	O
study	O
to	O
investigate	O
the	O
acute	O
subjective	B-OUTCOME
and	I-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
of	O
microdoses	B-DRUG
of	O
LSD	B-DRUG
using	O
a	O
placebo	O
-	O
controlled	O
within	O
subjects	O
design	O
in	O
healthy	O
young	O
adult	O
volunteers	O
Doses	O
of	O
13	O
and	O
26μg	O
LSD	B-DRUG
produced	O
measurable	O
subjective	B-OUTCOME
and	I-OUTCOME
physiological	I-OUTCOME
effects	I-OUTCOME
.	O
The	O
effects	O
were	O
linearly	O
dose	O
-	O
related	O
across	O
all	O
three	O
doses	O
,	O
and	O
26μg	O
LSD	B-DRUG
significantly	O
increased	O
ratings	O
of	O
“	O
feel	B-OUTCOME
drug	I-OUTCOME
,	O
”	O
“	O
like	O
drug	B-OUTCOME
,	O
”	O
“	O
feel	B-OUTCOME
high	I-OUTCOME
,	O
”	O
and	O
“	O
dislike	B-OUTCOME
drug	I-OUTCOME
,	O
”	O
and	O
scores	O
on	O
the	O
ARCI	O
-	O
LSD	B-DRUG
scale	O
and	O
the	O
Vigor	O
scale	O
on	O
the	O
POMS	O
.	O
Interestingly	O
,	O
the	O
drug	B-DRUG
also	O
produced	O
dose	O
-	O
dependent	O
alterations	B-OUTCOME
of	I-OUTCOME
consciousness	I-OUTCOME
as	O
measured	O
by	O
the	O
5D	O
-	O
ASC	O
,	O
which	O
had	O
previously	O
only	O
been	O
shown	O
at	O
100	O
-	O
200	O
μg	O
doses	O
(	O
42	O
)	O
.	O
Physiologically	O
,	O
the	O
26μg	O
dose	O
increased	B-OUTCOME
blood	I-OUTCOME
pressure	I-OUTCOME
,	O
but	O
did	O
not	B-OUTCOME
significantly	I-OUTCOME
affect	I-OUTCOME
temperature	I-OUTCOME
or	I-OUTCOME
heart	I-OUTCOME
rate	I-OUTCOME
.	O
Previous	O
studies	O
have	O
shown	O
that	O
200ug	O
LSD	B-DRUG
increase	B-OUTCOME
heart	I-OUTCOME
rate	I-OUTCOME
,	O
blood	B-OUTCOME
pressure	I-OUTCOME
,	O
and	O
body	B-OUTCOME
temperature	I-OUTCOME
(	O
23	O
)	O
,	O
but	O
the	O
present	O
findings	O
reveal	O
the	O
threshold	O
dose	O
at	O
which	O
LSD	B-DRUG
produces	O
these	O
effects	O
.	O
This	O
profile	O
of	O
responses	O
to	O
very	O
low	O
doses	O
of	O
LSD	B-DRUG
extend	O
our	O
understanding	O
of	O
the	O
basic	O
pharmacology	O
of	O
the	O
drug	O
,	O
and	O
set	O
the	O
stage	O
for	O
future	O
studies	O
on	O
the	O
behavioral	B-OUTCOME
and	I-OUTCOME
physiological	I-OUTCOME
effects	I-OUTCOME
of	O
repeated	O
doses	O
of	O
LSD	B-DRUG
There	O
is	O
some	O
evidence	O
that	O
higher	O
doses	O
of	O
LSD	B-DRUG
combined	O
with	O
psychotherapy	O
can	O
have	O
beneficial	O
effects	B-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
.	O
Case	O
reports	O
and	O
studies	O
from	O
the	O
1950s	O
and	O
1960s	O
suggest	O
that	O
LSD	B-DRUG
may	O
be	O
effective	O
in	O
a	O
clinical	O
context	O
(	O
reviewed	O
in	O
43	O
)	O
,	O
and	O
recent	O
studies	O
are	O
investigating	O
100	O
-	O
200	O
μg	O
LSD	B-DRUG
in	O
combination	O
with	O
psychotherapy	O
for	O
anxiety	B-HEALTH CONDITION
associated	O
with	O
life	O
threatening	O
illnesses	O
(	O
18	O
)	O
.	O
Our	O
participants	O
were	O
healthy	O
and	O
without	O
mood	B-HEALTH CONDITION
disturbances	I-HEALTH CONDITION
.	O
It	O
is	O
possible	O
that	O
Our	O
participants	O
increased	B-OUTCOME
ratings	I-OUTCOME
of	I-OUTCOME
“	I-OUTCOME
Vigor	I-OUTCOME
”	O
after	O
26	O
ug	O
could	O
contribute	O
to	O
beneficial	B-OUTCOME
effects	I-OUTCOME
for	O
patients	O
in	O
a	O
psychotherapy	O
setting	O
,	O
but	O
this	O
remains	O
to	O
be	O
established	O
in	O
patient	O
samples	O
.	O
The	O
items	O
on	O
the	O
Vigor	O
subscale	O
of	O
the	O
POMS	O
include	O
such	O
adjectives	O
as	O
“	O
lively	O
,	O
”	O
“	O
active	O
,	O
”	O
“	O
energetic	O
,	O
”	O
“	O
cheerful	O
,	O
”	O
“	O
alert	O
,	O
”	O
“	O
full	O
of	O
pep	O
,	O
”	O
“	O
carefree	O
,	O
”	O
and	O
“	O
vigorous	O
.	O
”	O
Although	O
some	O
of	O
these	O
effects	O
may	O
fit	O
with	O
the	O
reported	B-OUTCOME
mood	I-OUTCOME
effects	I-OUTCOME
of	O
“	O
microdosers	O
”	O
in	O
the	O
community	O
setting	O
,	O
the	O
effects	O
of	O
repeated	O
microdoses	O
of	O
LSD	B-DRUG
in	O
clinical	O
populations	O
of	O
symptomatic	O
volunteers	O
remain	O
to	O
be	O
determined	O
While	O
single	O
larger	O
doses	O
of	O
LSD	B-DRUG
have	O
been	O
shown	O
to	O
have	O
beneficial	O
effects	B-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
,	O
few	O
studies	O
have	O
examined	O
smaller	O
doses	O
administered	O
at	O
regular	O
intervals	O
.	O
In	O
rodents	O
,	O
repeated	O
low	O
doses	O
of	O
psilocin	B-DRUG
and	O
ketamine	B-DRUG
reduce	O
anxiety	B-HEALTH CONDITION
-	O
like	O
behavior	O
(	O
44	O
,	O
45	O
)	O
and	O
enhance	B-OUTCOME
learning	I-OUTCOME
in	O
animal	O
models	O
of	O
depression	B-HEALTH CONDITION
(	O
17	O
)	O
.	O
Anecdotal	O
reports	O
in	O
humans	O
suggest	O
that	O
repeated	O
(	O
every	O
3	O
days	O
)	O
ingestion	O
of	O
microdoses	O
of	O
LSD	B-DRUG
enhance	B-OUTCOME
mood	I-OUTCOME
and	O
reduce	B-OUTCOME
ratings	I-OUTCOME
of	I-OUTCOME
depression	I-OUTCOME
(	O
1	O
)	O
.	O
A	O
recent	O
survey	O
of	O
98	O
regular	O
microdosers	O
suggested	O
that	O
the	O
drug	B-DRUG
improved	O
psychological	B-OUTCOME
functioning	I-OUTCOME
including	O
reductions	O
in	O
depression	B-HEALTH CONDITION
and	O
stress	B-OUTCOME
and	O
lower	B-OUTCOME
distractibility	I-OUTCOME
(	O
6	O
)	O
.	O
Although	O
we	O
did	O
not	O
detect	O
effects	O
of	O
single	O
doses	O
on	O
mood	B-SUBJECTIVE EXPERIENCE
or	O
depression	B-HEALTH CONDITION
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
anti	B-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
effects	I-OUTCOME
would	O
be	O
detected	O
in	O
individuals	O
who	O
report	O
significant	B-HEALTH CONDITION
levels	I-HEALTH CONDITION
of	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
Although	O
some	O
previous	O
studies	O
have	O
suggested	O
improvements	O
in	O
cognition	O
,	O
these	O
were	O
not	O
detected	O
here	O
on	O
the	O
DSST	O
or	O
N	O
-	O
back	O
tasks	O
.	O
Few	O
studies	O
have	O
assessed	O
acute	O
effects	O
of	O
LSD	B-DRUG
on	O
cognition	B-OUTCOME
.	O
In	O
one	O
recent	O
study	O
LSD	B-DRUG
(	O
100	O
μg	O
)	O
significantly	O
increased	O
“	O
cognitive	B-OUTCOME
bizarreness	I-OUTCOME
”	O
(	O
46	O
)	O
,	O
and	O
in	O
another	O
study	O
LSD	B-DRUG
(	O
10	O
μg	O
)	O
altered	B-OUTCOME
time	I-OUTCOME
perception	I-OUTCOME
,	O
resulting	O
in	O
the	O
over	O
-	O
reproduction	O
of	O
temporal	O
intervals	O
greater	O
than	O
2	O
seconds	O
(	O
30	O
)	O
.	O
One	O
recent	O
naturalistic	O
,	O
open	O
-	O
label	O
(	O
pre	O
-	O
post	O
)	O
study	O
,	O
microdosing	B-DRUG
psilocybin	I-DRUG
-	O
containing	O
truffles	O
improved	B-OUTCOME
convergent	I-OUTCOME
and	I-OUTCOME
divergent	I-OUTCOME
thinking	I-OUTCOME
without	O
affecting	O
analytic	B-OUTCOME
cognition	I-OUTCOME
on	I-OUTCOME
two	I-OUTCOME
creativity	I-OUTCOME
tasks	I-OUTCOME
(	O
31	O
)	O
.	O
Although	O
we	O
found	O
that	O
LSD	B-DRUG
marginally	O
increased	B-OUTCOME
the	I-OUTCOME
number	I-OUTCOME
of	I-OUTCOME
attempted	I-OUTCOME
trials	I-OUTCOME
on	I-OUTCOME
a	I-OUTCOME
measure	I-OUTCOME
of	I-OUTCOME
creativity	I-OUTCOME
,	O
overall	O
we	O
detected	O
minimal	O
effects	B-OUTCOME
on	I-OUTCOME
cognitive	I-OUTCOME
function	I-OUTCOME
Several	O
previous	O
studies	O
using	O
higher	O
doses	O
of	O
LSD	B-DRUG
have	O
shown	O
acute	O
effects	O
on	O
emotion	B-OUTCOME
processing	I-OUTCOME
.	O
One	O
study	O
showed	O
that	O
LSD	B-DRUG
(	O
100	O
-	O
200μg	O
)	O
impaired	B-OUTCOME
recognition	I-OUTCOME
of	I-OUTCOME
fearful	I-OUTCOME
facial	I-OUTCOME
expressions	I-OUTCOME
(	O
25	O
)	O
,	O
and	O
in	O
an	O
fMRI	O
study	O
LSD	B-DRUG
(	O
100	O
μg	O
)	O
dampened	B-OUTCOME
amygdala	I-OUTCOME
and	I-OUTCOME
medial	I-OUTCOME
prefrontal	I-OUTCOME
cortex	I-OUTCOME
reactivity	I-OUTCOME
to	I-OUTCOME
fearful	I-OUTCOME
faces	I-OUTCOME
(	O
47	O
)	O
.	O
Interestingly	O
,	O
greater	O
reduction	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
response	O
was	O
related	O
to	O
greater	B-OUTCOME
subjective	I-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
.	O
In	O
another	O
recent	O
study	O
the	O
5HT1A/2A	B-NEURAL MECHANISM/CORRELATE
agonist	I-NEURAL MECHANISM/CORRELATE
,	O
psilocybin	B-DRUG
,	O
at	O
a	O
relatively	O
higher	O
dose	O
(	O
0.215mg	O
/	O
kg	O
)	O
reduced	B-OUTCOME
feelings	I-OUTCOME
of	I-OUTCOME
social	I-OUTCOME
rejection	I-OUTCOME
during	O
Cyberball	O
(	O
48	O
)	O
.	O
We	O
did	O
not	O
observe	O
similar	O
results	O
in	O
We	O
sample	O
,	O
perhaps	O
because	O
of	O
drug	O
or	O
dose	O
differences	O
.	O
Finally	O
,	O
We	O
showed	O
that	O
microdoses	B-DRUG
of	O
LSD	B-DRUG
decrease	B-OUTCOME
positivity	I-OUTCOME
ratings	I-OUTCOME
of	I-OUTCOME
positive	I-OUTCOME
images	I-OUTCOME
.	O
This	O
finding	O
was	O
surprising	O
,	O
and	O
went	O
against	O
We	O
hypothesis	O
that	O
the	O
drug	O
,	O
in	O
light	O
of	O
reports	O
of	O
antidepressant	O
effects	O
,	O
may	O
positively	O
bias	O
responses	O
to	O
affective	O
stimuli	O
.	O
One	O
possible	O
explanation	O
for	O
our	O
results	O
is	O
that	O
LSD	B-DRUG
reportedly	O
enhances	B-OUTCOME
global	I-OUTCOME
connectivity	I-OUTCOME
in	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
,	O
giving	O
rise	O
to	O
the	O
phenomenon	O
of	O
“	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
,	O
”	O
or	O
a	O
weakening	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
boundary	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
self	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
universe	I-OUTCOME
(	O
49	O
)	O
.	O
This	O
increased	B-OUTCOME
connectivity	I-OUTCOME
between	O
normally	O
distinct	O
networks	O
(	O
defaul	O
-	O
mode	O
,	O
salience	O
,	O
and	O
frontoparietal	O
attention	O
networks	O
)	O
may	O
affect	O
perception	B-OUTCOME
of	I-OUTCOME
valenced	I-OUTCOME
stimuli	I-OUTCOME
,	O
leading	O
subjects	O
to	O
rate	O
“	O
positive	O
”	O
images	O
as	O
less	O
positive	O
Our	O
study	O
had	O
a	O
number	O
of	O
strengths	O
.	O
Most	O
notably	O
,	O
Our	O
tested	O
three	O
doses	O
of	O
the	O
drug	O
,	O
compared	O
to	O
placebo	O
,	O
under	O
double	O
-	O
blind	O
conditions	O
in	O
a	O
controlled	O
laboratory	O
setting	O
.	O
The	O
participants	O
included	O
men	O
and	O
women	O
,	O
who	O
were	O
free	O
of	O
other	O
drugs	O
or	O
alcohol	O
at	O
the	O
time	O
of	O
testing	O
.	O
Our	O
allowed	O
7	O
days	O
for	O
drug	O
clearance	O
between	O
the	O
sessions	O
.	O
Our	O
used	O
standardized	O
self	O
-	O
report	O
questionnaires	O
,	O
emotion	O
and	O
cognitive	O
tests	O
and	O
obtained	O
physiological	O
measures	O
at	O
regular	O
intervals	O
.	O
Until	O
now	O
,	O
the	O
effects	O
of	O
these	O
very	O
low	O
doses	O
of	O
LSD	B-DRUG
have	O
been	O
investigated	O
mainly	O
in	O
naturalistic	O
open	O
-	O
label	O
studies	O
and	O
through	O
surveys	O
(	O
6	O
,	O
31	O
,	O
50	O
)	O
.	O
Here	O
we	O
present	O
a	O
profile	O
of	O
the	O
full	O
range	O
of	O
responses	O
to	O
the	O
acute	O
doses	O
of	O
the	O
drug	O
,	O
including	O
subjective	O
,	O
behavioral	O
,	O
affective	O
and	O
cognitive	O
,	O
in	O
healthy	O
young	O
adults	O
.	O
In	O
line	O
with	O
the	O
conclusions	O
of	O
(	O
6	O
)	O
,	O
we	O
conclude	O
that	O
the	O
13	O
μg	O
dose	O
would	O
be	O
optimal	O
for	O
a	O
repeated	O
dosing	O
study	O
,	O
as	O
a	O
repeated	O
dosing	O
study	O
produced	O
minimal	B-OUTCOME
subjective	I-OUTCOME
,	I-OUTCOME
behavioral	I-OUTCOME
or	I-OUTCOME
physiological	I-OUTCOME
effects	I-OUTCOME
that	O
might	O
interfere	O
with	O
normal	O
function	O
.	O
The	O
findings	O
form	O
a	O
basis	O
for	O
future	O
studies	O
investigating	O
repeated	O
doses	O
and	O
doses	O
in	O
clinical	O
populations	O
,	O
to	O
determine	O
the	O
empirical	O
basis	O
of	O
the	O
purported	O
therapeutic	B-OUTCOME
affects	I-OUTCOME
reported	O
by	O
regular	O
users	O
of	O
these	O
drugs	B-DRUG
The	O
effects	O
of	O
low	O
doses	O
of	O
LSD	B-DRUG
should	O
be	O
investigated	O
when	O
the	B-DRUG
drug	I-DRUG
is	O
administered	O
repeatedly	O
,	O
and	O
in	O
individuals	O
who	O
report	O
negative	B-OUTCOME
affect	I-OUTCOME
.	O
Individuals	O
who	O
report	O
microdosing	B-DRUG
in	O
their	O
everyday	O
lives	O
take	O
the	O
drug	O
every	O
3	O
-	O
5	O
days	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
beneficial	B-OUTCOME
effects	I-OUTCOME
emerge	O
only	O
after	O
repeated	O
administration	O
.	O
This	O
could	O
be	O
because	O
of	O
subtle	O
pharmacokinetic	O
accumulation	O
of	O
the	O
drug	O
,	O
or	O
This	O
could	O
be	O
because	O
of	O
pharmacodynamic	O
neural	O
adaptations	O
that	O
occur	O
over	O
days	O
.	O
An	O
important	O
aim	O
for	O
future	O
research	O
will	O
be	O
to	O
collect	O
pharmacokinetic	O
data	O
,	O
extending	O
existing	O
data	O
with	O
higher	O
doses	O
(	O
32	O
)	O
.	O
Regular	O
users	O
claim	O
that	O
the	O
drug	B-DRUG
improves	B-OUTCOME
mood	I-OUTCOME
and	I-OUTCOME
cognition	I-OUTCOME
,	O
which	O
raises	O
the	O
possibility	O
that	O
Regular	O
users	O
normal	O
mood	O
and	O
cognitive	O
function	O
were	O
less	O
than	O
optimal	O
before	O
using	O
the	O
drug	O
.	O
Therefore	O
,	O
it	O
is	O
important	O
to	O
examine	O
the	O
effect	O
of	O
LSD	B-DRUG
,	O
either	O
in	O
single	O
doses	O
or	O
in	O
repeated	O
dosing	O
regimens	O
,	O
in	O
populations	O
reporting	O
clinical	O
mood	O
symptoms	O
,	O
such	O
as	O
anxiety	B-HEALTH CONDITION
or	O
depression	B-HEALTH CONDITION
.	O
Studies	O
such	O
as	O
this	O
,	O
investigating	O
the	O
mood	B-OUTCOME
and	I-OUTCOME
cognitive	I-OUTCOME
effects	I-OUTCOME
of	O
low	O
doses	O
of	O
psychedelic	B-DRUG
drugs	I-DRUG
under	O
controlled	O
conditions	O
will	O
advance	O
our	O
understanding	B-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
neural	I-OUTCOME
and	I-OUTCOME
behavioral	I-OUTCOME
processes	I-OUTCOME
underlying	O
depressed	B-HEALTH CONDITION
mood	I-HEALTH CONDITION
,	O
and	O
could	O
lead	O
to	O
new	O
treatments	O
-DOCSTART- -X- O O
We	O
have	O
conducted	O
a	O
systematic	O
review	O
to	O
examine	O
the	O
acute	O
and	O
long	O
-	O
term	O
effects	O
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
in	O
humans	O
using	O
neuroimaging	O
methods	O
.	O
Neurochemical	O
imaging	O
studies	O
[	O
PET	O
and	O
SPECT	O
]	O
involving	O
acute	O
oral	O
administration	O
of	O
mescaline	B-DRUG
,	O
psilocybin	B-DRUG
,	O
and	O
ayahuasca	B-DRUG
suggest	O
that	O
these	O
drugs	O
induce	O
excitatory	O
effects	O
in	O
frontolateral	B-NEURAL MECHANISM/CORRELATE
/	I-NEURAL MECHANISM/CORRELATE
frontomedial	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
medial	B-NEURAL MECHANISM/CORRELATE
temporal	I-NEURAL MECHANISM/CORRELATE
lobe	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
amygdala	B-NEURAL MECHANISM/CORRELATE
–	O
regions	O
involved	O
in	O
self	O
-	O
awareness	O
,	O
cognitive	O
functioning	O
,	O
memory	O
and	O
emotion	O
processing	O
.	O
These	O
results	O
were	O
consistent	O
across	O
studies	O
.	O
Furthermore	O
,	O
these	O
studies	O
were	O
performed	O
in	O
separated	O
laboratories	O
and	O
used	O
different	O
drugs	O
and	O
neuroimaging	O
technics	O
.	O
Studies	O
using	O
fMRI	O
and	O
involving	O
acute	O
oral	O
[	O
ayahuasca	B-DRUG
]	O
or	O
intravenous	O
[	O
DMT	B-DRUG
,	O
psilocybin	B-DRUG
,	O
LSD	B-DRUG
]	O
administration	O
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
showed	O
less	O
consistent	O
results	O
.	O
Most	O
resting	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
fMRI	O
studies	O
showed	O
significant	O
reductions	B-OUTCOME
in	I-OUTCOME
brain	I-OUTCOME
activation	I-OUTCOME
in	O
the	O
same	O
regions	O
where	O
neurochemical	O
imaging	O
studies	O
showed	O
increased	O
activation	O
,	O
as	O
well	O
as	O
in	O
other	O
regions	O
such	O
as	O
the	O
thalamus	B-NEURAL MECHANISM/CORRELATE
,	O
hypothalamus	B-NEURAL MECHANISM/CORRELATE
,	O
retrosplenial	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
precuneus	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
visual	B-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
(	O
Daumann	O
et	O
al	O
.	O
,	O
2010	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012a	O
,	O
Palhano	O
-	O
Fontes	O
et	O
al	O
.	O
,	O
2015	O
)	O
According	O
to	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
(	O
2012a	O
)	O
,	O
the	O
inconsistence	O
between	O
PET	O
/	O
SPECT	O
and	O
fMRI	O
results	O
could	O
be	O
related	O
to	O
the	O
time	O
-	O
scales	O
considered	O
in	O
the	O
different	O
techniques	O
.	O
Thus	O
,	O
the	O
radiotracers	O
used	O
to	O
measure	O
blood	O
perfusion	O
/	O
glucose	B-NEURAL MECHANISM/CORRELATE
metabolism	I-NEURAL MECHANISM/CORRELATE
have	O
long	O
half	O
-	O
lives	O
[	O
e.g.	O
,	O
the	O
radiotracer	O
18F	O
FDG	O
,	O
used	O
to	O
measure	O
glucose	O
metabolism	O
,	O
has	O
a	O
half	O
-	O
life	O
of	O
110	O
min	O
]	O
,	O
using	O
much	O
greater	O
time	O
-	O
scales	O
than	O
fMRI	O
measures	O
.	O
Therefore	O
,	O
phasic	O
or	O
short	O
-	O
term	O
effects	O
of	O
psilocybin	B-DRUG
could	O
show	O
some	O
compensating	O
/	O
rebound	O
effect	O
that	O
is	O
detected	O
by	O
PET	O
or	O
SPECT	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012a	O
)	O
However	O
,	O
nonsignificant	O
(	O
Daumann	O
et	O
al	O
.	O
,	O
2008	O
,	O
Speth	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
mixed	O
(	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
and	O
opposite	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
)	O
results	O
were	O
also	O
reported	O
in	O
fMRI	O
studies	O
.	O
Moreover	O
,	O
an	O
active	O
-	O
task	O
fMRI	O
study	O
reported	O
significant	O
increases	B-OUTCOME
in	I-OUTCOME
memory	I-OUTCOME
-	I-OUTCOME
related	I-OUTCOME
activations	I-OUTCOME
in	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
,	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
,	O
putamen	B-NEURAL MECHANISM/CORRELATE
,	O
nucleus	B-NEURAL MECHANISM/CORRELATE
accumbens	I-NEURAL MECHANISM/CORRELATE
,	O
mid	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
pre	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
sensorimotor	I-NEURAL MECHANISM/CORRELATE
area	I-NEURAL MECHANISM/CORRELATE
,	O
precuneus	B-NEURAL MECHANISM/CORRELATE
,	O
subgenual	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
temporal	B-NEURAL MECHANISM/CORRELATE
pole	I-NEURAL MECHANISM/CORRELATE
,	O
medial	B-NEURAL MECHANISM/CORRELATE
prefrontal	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
frontal	B-NEURAL MECHANISM/CORRELATE
pole	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
visual	B-NEURAL MECHANISM/CORRELATE
and	O
other	O
sensory	B-NEURAL MECHANISM/CORRELATE
cortical	I-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
after	O
intravenous	O
psilocybin	B-DRUG
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012b	O
)	O
,	O
and	O
another	O
fMRI	O
study	O
using	O
an	O
imagery	O
task	O
showed	O
that	O
oral	O
ayahuasca	B-DRUG
induced	O
a	O
significant	O
activation	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
primary	I-OUTCOME
visual	I-OUTCOME
area	I-OUTCOME
comparable	O
to	O
the	O
activation	O
levels	O
of	O
a	O
natural	O
image	O
with	O
the	O
eyes	O
open	O
,	O
and	O
ayahuasca	B-DRUG
also	O
activated	O
the	O
cuneus	B-NEURAL MECHANISM/CORRELATE
and	O
lingual	B-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
and	O
parahippocampal	B-NEURAL MECHANISM/CORRELATE
,	O
retrosplenial	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
frontopolar	B-NEURAL MECHANISM/CORRELATE
cortices	I-NEURAL MECHANISM/CORRELATE
(	O
de	O
Araujo	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
Also	O
,	O
an	O
fMRI	O
study	O
reported	O
that	O
oral	O
psilocybin	B-DRUG
significantly	O
attenuated	B-OUTCOME
right	I-OUTCOME
amygdala	I-OUTCOME
activation	I-OUTCOME
to	O
both	O
negative	O
and	O
neutral	O
pictures	O
and	O
that	O
this	O
effect	O
was	O
significantly	O
correlated	O
with	O
increases	O
in	O
positive	O
mood	O
(	O
Kraehenmann	O
et	O
al	O
.	O
,	O
2015a	O
)	O
Interpretation	O
of	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
results	O
is	O
even	O
more	O
difficult	O
.	O
Functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
alterations	O
in	O
key	O
hubs	O
of	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
were	O
observed	O
in	O
several	O
studies	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012a	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2013	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2014	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
,	O
Lebedev	O
et	O
al	O
.	O
,	O
2015	O
,	O
Palhano	O
-	O
Fontes	O
et	O
al	O
.	O
,	O
2015	O
,	O
Kaelen	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
which	O
partially	O
corroborates	O
the	O
neuroanatomical	O
substrates	O
where	O
PET	O
/	O
SPECT	O
studies	O
found	O
alterations	O
in	O
blood	O
perfusion	O
/	O
glucose	B-NEURAL MECHANISM/CORRELATE
metabolism	I-NEURAL MECHANISM/CORRELATE
.	O
Moreover	O
,	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
studies	O
reported	O
increased	B-OUTCOME
coupling	I-OUTCOME
between	I-OUTCOME
cortical	I-OUTCOME
networks	I-OUTCOME
,	O
suggesting	O
an	O
increased	B-OUTCOME
integration	I-OUTCOME
between	I-OUTCOME
cortical	I-OUTCOME
regions	I-OUTCOME
(	O
de	O
Araujo	O
et	O
al	O
.	O
,	O
2012	O
,	O
Petri	O
et	O
al	O
.	O
,	O
2014	O
,	O
Roseman	O
et	O
al	O
.	O
,	O
2014	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
,	O
Kaelen	O
et	O
al	O
.	O
,	O
2016	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Furthermore	O
,	O
psilocybin	B-DRUG
decreased	B-OUTCOME
the	I-OUTCOME
threat	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
modulation	I-OUTCOME
of	I-OUTCOME
top	I-OUTCOME
-	I-OUTCOME
down	I-OUTCOME
connectivity	I-OUTCOME
from	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
to	O
primary	B-NEURAL MECHANISM/CORRELATE
visual	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
(	O
Kraehenmann	O
et	O
al	O
.	O
,	O
2015b	O
)	O
,	O
and	O
the	O
interaction	O
between	O
music	O
and	O
LSD	B-DRUG
increased	O
parahippocampal	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
/	O
visual	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
and	O
parahippocampal	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
to	O
visual	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
information	I-NEURAL MECHANISM/CORRELATE
flow	I-NEURAL MECHANISM/CORRELATE
(	O
Kaelen	O
et	O
al	O
.	O
,	O
2016	O
)	O
Regarding	O
structural	O
MRI	O
studies	O
,	O
one	O
study	O
with	O
regular	O
ayahuasca	B-DRUG
users	O
reported	O
significant	O
cortical	B-OUTCOME
thinning	I-OUTCOME
in	O
mesotemporal	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
inferior	I-NEURAL MECHANISM/CORRELATE
frontal	I-NEURAL MECHANISM/CORRELATE
gyri	I-NEURAL MECHANISM/CORRELATE
,	O
precuneus	B-NEURAL MECHANISM/CORRELATE
,	O
superior	B-NEURAL MECHANISM/CORRELATE
frontal	I-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
,	O
posterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
and	O
superior	B-NEURAL MECHANISM/CORRELATE
occipital	I-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
;	O
and	O
increased	B-OUTCOME
thickening	I-OUTCOME
in	O
precentral	B-NEURAL MECHANISM/CORRELATE
gyrus	I-NEURAL MECHANISM/CORRELATE
and	O
anterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
(	O
Bouso	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
Importantly	O
,	O
there	O
was	O
no	O
evidence	O
of	O
increased	B-OUTCOME
psychopathology	I-OUTCOME
in	O
the	O
ayahuasca	B-DRUG
group	O
,	O
suggesting	O
that	O
the	O
structural	O
alterations	O
were	O
not	O
associated	O
with	O
psychopathologies	O
.	O
Moreover	O
,	O
inverse	O
correlations	O
were	O
found	O
between	O
changes	O
in	O
cortical	O
thickness	O
in	O
the	O
posterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
and	O
age	O
of	O
onset	O
of	O
ayahuasca	B-DRUG
use	O
,	O
intensity	O
of	O
prior	O
ayahuasca	B-DRUG
use	O
,	O
and	O
“	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
transcendence”/spirituality	I-SUBJECTIVE EXPERIENCE
Another	O
structural	O
MRI	O
study	O
investigated	O
SERT	O
and	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
binding	O
in	O
polydrug	O
,	O
hallucinogen	O
-	O
preferring	O
users	O
and	O
found	O
no	O
effects	O
regarding	O
SERT	O
values	O
and	O
a	O
slight	O
reduction	O
on	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
densities	O
(	O
Erritzoe	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O
However	O
,	O
significant	O
effects	O
on	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
densities	O
were	O
observed	O
only	O
when	O
both	O
group	O
of	O
MDMA	B-DRUG
/	O
hallucinogens	B-DRUG
users	O
were	O
analyzed	O
together	O
,	O
suggesting	O
that	O
part	O
of	O
this	O
effect	O
might	O
be	O
more	O
related	O
to	O
MDMA	B-DRUG
than	O
to	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
(	O
Mueller	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Moreover	O
,	O
regional	O
decreases	O
in	O
neocortical	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
binding	O
were	O
of	O
only	O
9	O
%	O
in	O
the	O
neocortex	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
when	O
two	O
controls	O
with	O
very	O
high	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
binding	O
values	O
were	O
excluded	O
from	O
the	O
sample	O
the	O
difference	O
between	O
groups	O
was	O
no	O
longer	O
significant	O
The	O
reviewed	O
human	O
data	O
is	O
corroborated	O
by	O
several	O
preclinical	O
studies	O
showing	O
that	O
administration	O
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
induce	B-OUTCOME
genetic	I-OUTCOME
,	I-OUTCOME
neurochemical	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
behavioral	I-OUTCOME
alterations	I-OUTCOME
in	I-OUTCOME
/	I-OUTCOME
associated	I-OUTCOME
with	I-OUTCOME
brain	I-OUTCOME
regions	I-OUTCOME
such	O
as	O
the	O
medial	B-NEURAL MECHANISM/CORRELATE
prefrontal	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
anterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
amygdala	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
[	O
see	O
for	O
review	O
Hanks	O
and	O
González	O
-	O
Maeso	O
,	O
2013	O
,	O
Nichols	O
,	O
2016	O
]	O
.	O
A	O
recent	O
study	O
in	O
rats	O
reported	O
that	O
acute	O
ayahuasca	B-DRUG
administration	O
was	O
associated	O
with	O
decreased	O
concentrations	O
of	O
glycine	O
and	O
γ	O
-	O
aminobutyric	O
acid	O
[	O
GABA	B-NEURAL MECHANISM/CORRELATE
]	O
in	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
,	O
increased	O
GABA	B-NEURAL MECHANISM/CORRELATE
levels	O
in	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
an	O
increased	O
utilization	O
rate	O
of	O
noradrenaline	B-NEURAL MECHANISM/CORRELATE
,	O
dopamine	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
serotonin	B-NEURAL MECHANISM/CORRELATE
in	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
(	O
de	O
Castro	O
-	O
Neto	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
In	O
another	O
recent	O
study	O
,	O
prolonged	O
[	O
30	O
days	O
]	O
ayahuasca	B-DRUG
administration	O
to	O
rats	O
interfered	O
with	O
emotional	B-SUBJECTIVE EXPERIENCE
memory	I-SUBJECTIVE EXPERIENCE
,	O
a	O
process	O
involving	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
and	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
(	O
Favaro	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
and	O
Pic	O
-	O
Taylor	O
et	O
al	O
.	O
(	O
2015	O
)	O
administered	O
ayahuasca	B-DRUG
to	O
rats	O
to	O
investigate	O
patterns	O
of	O
neuronal	O
activation	O
using	O
c	O
-	O
fos	O
marked	O
neurons	O
and	O
found	O
higher	O
neuronal	O
activation	O
in	O
the	O
dorsal	B-NEURAL MECHANISM/CORRELATE
raphe	I-NEURAL MECHANISM/CORRELATE
nuclei	I-NEURAL MECHANISM/CORRELATE
,	O
amygdaloid	B-NEURAL MECHANISM/CORRELATE
nucleus	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
hippocampal	B-NEURAL MECHANISM/CORRELATE
formation	I-NEURAL MECHANISM/CORRELATE
after	O
ayahuasca	B-DRUG
administration	O
.	O
A	O
recent	O
study	O
showed	O
that	O
acute	O
administration	O
of	O
psilocin	B-DRUG
[	O
the	O
active	O
metabolite	O
of	O
psilocybin	B-DRUG
]	O
significantly	O
increased	O
MRI	O
signal	O
in	O
the	O
rat	O
hypothalamus	B-NEURAL MECHANISM/CORRELATE
,	O
olfactory	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
,	O
amygdala	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
other	O
limbic	B-NEURAL MECHANISM/CORRELATE
regions	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
also	O
increased	O
cerebral	O
blood	O
flow	O
in	O
the	O
somatosensory	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
after	O
sensorial	O
stimuli	O
.	O
However	O
,	O
MRI	O
signal	O
decreases	O
were	O
observed	O
in	O
the	O
cingulate	B-NEURAL MECHANISM/CORRELATE
,	O
motor	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
somatosensory	B-NEURAL MECHANISM/CORRELATE
cortices	I-NEURAL MECHANISM/CORRELATE
[	O
among	O
other	O
regions	O
]	O
,	O
and	O
the	O
amplitude	O
of	O
neuronal	O
responses	O
[	O
local	O
field	O
potentials	O
]	O
to	O
sensory	O
stimuli	O
in	O
the	O
somatosensory	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
was	O
also	O
decreased	O
,	O
suggesting	O
an	O
altered	O
relationship	O
between	O
evoked	O
neuronal	O
and	O
haemodynamic	O
response	O
magnitudes	O
(	O
Spain	O
et	O
al	O
.	O
,	O
2015	O
)	O
The	O
results	O
by	O
Spain	O
et	O
al	O
.	O
(	O
2015	O
)	O
are	O
corroborated	O
by	O
a	O
recent	O
study	O
in	O
humans	O
showing	O
that	O
psilocybin	B-DRUG
induced	O
significant	O
increases	O
on	O
BOLD	O
signal	O
variance	O
and	O
total	O
spectral	O
power	O
in	O
the	O
anterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
and	O
bilateral	B-NEURAL MECHANISM/CORRELATE
hippocampi	I-NEURAL MECHANISM/CORRELATE
,	O
while	O
significant	O
decreases	O
were	O
observed	O
in	O
local	O
field	O
potentials	O
in	O
the	B-NEURAL MECHANISM/CORRELATE
DMN	I-NEURAL MECHANISM/CORRELATE
,	O
executive	B-NEURAL MECHANISM/CORRELATE
control	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
dorsal	B-NEURAL MECHANISM/CORRELATE
attention	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
(	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
executive	B-NEURAL MECHANISM/CORRELATE
control	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
dorsal	B-NEURAL MECHANISM/CORRELATE
attention	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
(	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2014	O
)	O
study	O
by	O
Spain	O
et	O
al	O
.	O
(	O
2015	O
)	O
could	O
help	O
to	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
discrepancy	O
between	O
PET	O
/	O
SPECT	O
findings	O
of	O
increased	O
blood	B-NEURAL MECHANISM/CORRELATE
perfusion	I-NEURAL MECHANISM/CORRELATE
/	O
glucose	B-NEURAL MECHANISM/CORRELATE
metabolism	I-NEURAL MECHANISM/CORRELATE
and	O
fMRI	O
results	O
showing	O
decreased	O
cerebral	O
blood	O
flow	O
.	O
Moreover	O
,	O
neurophysiological	O
studies	O
in	O
humans	O
using	O
electroencephalography	O
[	O
EEG	O
]	O
and	O
MEG	O
consistently	O
show	O
that	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
decrease	B-OUTCOME
the	I-OUTCOME
power	I-OUTCOME
of	I-OUTCOME
lower	I-OUTCOME
frequency	I-OUTCOME
oscillations	I-OUTCOME
[	O
theta	O
/	O
alpha	O
frequency	O
range	O
,	O
<	O
20	O
Hz	O
]	O
,	O
especially	O
alpha	O
oscillations	O
[	O
8–12	O
Hz	O
]	O
,	O
in	O
key	O
regions	O
of	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
such	O
as	O
the	O
anterior	B-NEURAL MECHANISM/CORRELATE
/	I-NEURAL MECHANISM/CORRELATE
posterior	I-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortices	O
and	O
the	O
parahippocampal	B-NEURAL MECHANISM/CORRELATE
region	I-NEURAL MECHANISM/CORRELATE
,	O
which	O
induces	O
an	O
excitatory	O
effect	O
(	O
Riba	O
et	O
al	O
.	O
,	O
2002	O
,	O
Riba	O
et	O
al	O
.	O
,	O
2004	O
,	O
Muthukumaraswamy	O
et	O
al	O
.	O
,	O
2013	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2013	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2015	O
,	O
Valle	O
et	O
al	O
.	O
,	O
2016	O
)	O
Although	O
the	O
neural	O
effects	O
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
may	O
involve	O
serotonergic	O
[	O
e.g.	O
,	O
5	O
-	O
HT1A/2A/2C	O
receptors	O
]	O
and	O
non	O
-	O
serotonergic	O
[	O
e.g.	O
,	O
dopaminergic	O
and	O
sigma	O
receptors	O
]	O
neurotransmission	O
,	O
the	O
agonist	O
effect	O
of	O
these	O
drugs	O
on	O
deep	O
-	O
layer	O
pyramidal	B-NEURAL MECHANISM/CORRELATE
neurons	I-NEURAL MECHANISM/CORRELATE
rich	O
in	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
seem	O
to	O
be	O
the	O
main	O
mechanism	O
of	O
action	O
of	O
these	O
compounds	O
(	O
Vollenweider	O
et	O
al	O
.	O
,	O
1998	O
;	O
Hintzen	O
and	O
Passie	O
,	O
2010	O
,	O
Vollenweider	O
and	O
Kometer	O
,	O
2010	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2012	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2013	O
,	O
Hanks	O
and	O
González	O
-	O
Maeso	O
,	O
2013	O
,	O
Baumeister	O
et	O
al	O
.	O
,	O
2014	O
,	O
Tylš	O
et	O
al	O
.	O
,	O
2014	O
,	O
Halberstadt	O
,	O
2015	O
,	O
Nichols	O
,	O
2016	O
,	O
Valle	O
et	O
al	O
.	O
,	O
2016	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Agonism	O
at	O
these	O
receptors	O
expressed	O
in	O
frontal	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
medial	I-NEURAL MECHANISM/CORRELATE
cortical	I-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
produce	O
altered	B-OUTCOME
synchronization	I-OUTCOME
of	I-OUTCOME
cortical	I-OUTCOME
activity	I-OUTCOME
(	O
Riba	O
et	O
al	O
.	O
,	O
2002	O
,	O
Riba	O
et	O
al	O
.	O
,	O
2004	O
,	O
Muthukumaraswamy	O
et	O
al	O
.	O
,	O
2013	O
,	O
Petri	O
et	O
al	O
.	O
,	O
2014	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2015	O
,	O
McKenna	O
and	O
Riba	O
,	O
2015	O
,	O
Domínguez	O
-	O
Clavé	O
et	O
al	O
.	O
,	O
2016	O
,	O
Valle	O
et	O
al	O
.	O
,	O
2016	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
“	O
disintegration	B-OUTCOME
”	I-OUTCOME
of	I-OUTCOME
network	I-OUTCOME
connectivity	I-OUTCOME
(	O
Muthukumaraswamy	O
et	O
al	O
.	O
,	O
2013	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2014	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
,	O
Lebedev	O
et	O
al	O
.	O
,	O
2015	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
increased	B-OUTCOME
excitability	I-OUTCOME
of	I-OUTCOME
multimodal	I-OUTCOME
association	I-OUTCOME
hubs	I-OUTCOME
(	O
Riba	O
et	O
al	O
.	O
,	O
2004	O
,	O
Riba	O
et	O
al	O
.	O
,	O
2006	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2014	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2015	O
,	O
McKenna	O
and	O
Riba	O
,	O
2015	O
,	O
Domínguez	O
-	O
Clavé	O
et	O
al	O
.	O
,	O
2016	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
altered	B-OUTCOME
information	I-OUTCOME
flow	I-OUTCOME
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2014	O
,	O
Alonso	O
et	O
al	O
.	O
,	O
2015	O
,	O
McKenna	O
and	O
Riba	O
,	O
2015	O
,	O
Domínguez	O
-	O
Clavé	O
et	O
al	O
.	O
,	O
2016	O
,	O
Kaelen	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
These	O
effects	O
create	O
a	O
state	O
of	O
“	O
expanded	B-SUBJECTIVE EXPERIENCE
awareness	I-SUBJECTIVE EXPERIENCE
”	O
,	O
“	O
ego	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
”	O
,	O
and	O
“	O
unconstrained	B-SUBJECTIVE EXPERIENCE
cognition	I-SUBJECTIVE EXPERIENCE
”	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012a	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012b	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2014	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2013	O
,	O
Muthukumaraswamy	O
et	O
al	O
.	O
,	O
2013	O
,	O
Petri	O
et	O
al	O
.	O
,	O
2014	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2014	O
,	O
Tagliazucchi	O
et	O
al	O
.	O
,	O
2016	O
,	O
Gallimore	O
,	O
2015	O
,	O
McKenna	O
and	O
Riba	O
,	O
2015	O
,	O
Lebedev	O
et	O
al	O
.	O
,	O
2015	O
,	O
Domínguez	O
-	O
Clavé	O
et	O
al	O
.	O
,	O
2016	O
)	O
Agonism	O
at	O
frontocortical	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
also	O
modulates	B-OUTCOME
glutamatergic	I-OUTCOME
neurotransmission	I-OUTCOME
and	O
may	O
increase	O
the	O
expression	O
of	O
neurotrophic	O
factors	O
such	O
as	O
brain	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
derived	I-NEURAL MECHANISM/CORRELATE
neurotrophic	I-NEURAL MECHANISM/CORRELATE
factor	I-NEURAL MECHANISM/CORRELATE
[	I-NEURAL MECHANISM/CORRELATE
BDNF	I-NEURAL MECHANISM/CORRELATE
]	I-NEURAL MECHANISM/CORRELATE
and	O
glial	B-NEURAL MECHANISM/CORRELATE
cell	I-NEURAL MECHANISM/CORRELATE
line	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
derived	I-NEURAL MECHANISM/CORRELATE
neurotrophic	I-NEURAL MECHANISM/CORRELATE
factor	I-NEURAL MECHANISM/CORRELATE
[	I-NEURAL MECHANISM/CORRELATE
GDNF	I-NEURAL MECHANISM/CORRELATE
]	I-NEURAL MECHANISM/CORRELATE
,	O
thus	O
enhancing	B-OUTCOME
neuroplasticity	I-OUTCOME
and	O
neurogenesis	B-OUTCOME
by	O
increasing	O
the	O
size	O
of	O
dendritic	B-NEURAL MECHANISM/CORRELATE
spines	I-NEURAL MECHANISM/CORRELATE
on	O
cortical	B-NEURAL MECHANISM/CORRELATE
neurons	I-NEURAL MECHANISM/CORRELATE
(	O
González	O
-	O
Maeso	O
et	O
al	O
.	O
,	O
2008	O
,	O
Vollenweider	O
and	O
Kometer	O
,	O
2010	O
,	O
Moreno	O
et	O
al	O
.	O
,	O
2011	O
,	O
Moreno	O
et	O
al	O
.	O
,	O
2013	O
,	O
Hanks	O
and	O
González	O
-	O
Maeso	O
,	O
2013	O
,	O
Baumeister	O
et	O
al	O
.	O
,	O
2014	O
,	O
Carbonaro	O
et	O
al	O
.	O
,	O
2015	O
,	O
Halberstadt	O
,	O
2015	O
,	O
Nichols	O
,	O
2016	O
)	O
Interestingly	O
,	O
these	O
effects	O
seem	O
to	O
be	O
the	O
neural	B-OUTCOME
basis	I-OUTCOME
involved	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
therapeutic	I-OUTCOME
potentials	I-OUTCOME
of	I-OUTCOME
these	I-OUTCOME
compounds	I-OUTCOME
.	O
Preclinical	O
and	O
human	O
research	O
suggest	O
that	O
ayahuasca	B-DRUG
,	O
psilocybin	B-DRUG
,	O
and	O
LSD	B-DRUG
have	O
antidepressive	B-OUTCOME
,	O
anxiolytic	B-OUTCOME
,	O
and	O
antiaddictive	B-OUTCOME
properties	I-OUTCOME
(	O
dos	O
Santos	O
et	O
al	O
.	O
,	O
2016a	O
,	O
dos	O
Santos	O
et	O
al	O
.	O
,	O
2016b	O
,	O
Nunes	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Indeed	O
,	O
acute	O
administration	O
of	O
DMT	B-DRUG
(	O
Gillin	O
,	O
1976	O
,	O
Strassman	O
et	O
al	O
.	O
,	O
1994	O
,	O
Riba	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
psilocybin	B-DRUG
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2008	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2011	O
,	O
Studerus	O
et	O
al	O
.	O
,	O
2011	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2012	O
,	O
Kraehenmann	O
et	O
al	O
.	O
,	O
2015a	O
)	O
,	O
LSD	B-DRUG
(	O
Schmid	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
and	O
ayahuasca	B-DRUG
(	O
Osório	O
et	O
al	O
.	O
,	O
2015	O
,	O
Sanches	O
et	O
al	O
.	O
,	O
2016	O
)	O
is	O
associated	O
with	O
increases	B-OUTCOME
in	I-OUTCOME
positive	I-OUTCOME
mood	I-OUTCOME
.	O
Furthermore	O
,	O
the	O
studies	O
reviewed	O
show	O
that	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
decrease	O
DMN	B-NEURAL MECHANISM/CORRELATE
activity	O
,	O
which	O
is	O
increased	O
during	O
rumination	B-SUBJECTIVE EXPERIENCE
,	O
an	O
important	O
depressive	B-HEALTH CONDITION
symptom	I-HEALTH CONDITION
.	O
Together	O
with	O
decreases	B-OUTCOME
in	I-OUTCOME
amygdala	I-OUTCOME
activity	I-OUTCOME
(	O
Kraehenmann	O
et	O
al	O
.	O
,	O
2015a	O
,	O
Kraehenmann	O
et	O
al	O
.	O
,	O
2015b	O
)	O
,	O
reduced	B-OUTCOME
DMN	I-OUTCOME
activity	I-OUTCOME
may	O
be	O
another	O
possible	O
mechanism	O
involved	O
in	O
the	O
antidepressive	B-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
of	O
these	O
drugs	O
.	O
Moreover	O
,	O
observational	O
studies	O
also	O
suggest	O
that	O
psilocybin	B-DRUG
,	O
LSD	B-DRUG
,	O
and	O
ayahuasca	B-DRUG
may	O
have	O
therapeutic	B-OUTCOME
potentials	I-OUTCOME
(	O
Krebs	O
and	O
Johansen	O
,	O
2013	O
,	O
Hendricks	O
et	O
al	O
.	O
,	O
2014	O
,	O
Hendricks	O
et	O
al	O
.	O
,	O
2015	O
,	O
Johansen	O
and	O
Krebs	O
,	O
2015	O
,	O
dos	O
Santos	O
et	O
al	O
.	O
,	O
2016a	O
,	O
dos	O
Santos	O
et	O
al	O
.	O
,	O
2016b	O
,	O
Nunes	O
et	O
al	O
.	O
,	O
2016	O
)	O
Psychological	O
mechanisms	O
also	O
play	O
a	O
role	O
in	O
the	O
therapeutic	B-OUTCOME
properties	I-OUTCOME
of	O
these	O
drugs	B-DRUG
,	O
and	O
appear	O
to	O
be	O
related	O
to	O
neuroimaging	O
findings	O
.	O
For	O
instance	O
,	O
in	O
the	O
retrospective	O
MRI	O
study	O
of	O
long	O
-	O
term	O
ayahuasca	B-DRUG
users	O
,	O
the	O
ayahuasca	B-DRUG
group	O
not	O
only	O
scored	O
higher	O
than	O
controls	O
in	O
“	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
transcendence	I-SUBJECTIVE EXPERIENCE
”	O
,	O
but	O
scores	O
were	O
negatively	B-OUTCOME
correlated	I-OUTCOME
with	I-OUTCOME
cortical	I-OUTCOME
thickness	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
posterior	I-OUTCOME
cingulate	I-OUTCOME
cortex	I-OUTCOME
(	O
Bouso	O
et	O
al	O
.	O
,	O
2015	O
)	O
“	O
Self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
transcendence	I-SUBJECTIVE EXPERIENCE
”	O
is	O
a	O
character	O
dimension	O
related	O
to	O
religiousness	O
and	O
spirituality	O
,	O
and	O
the	O
beneficial	B-OUTCOME
effects	I-OUTCOME
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
appear	O
to	O
be	O
related	O
to	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
ability	O
to	O
elicit	B-SUBJECTIVE EXPERIENCE
religious	I-SUBJECTIVE EXPERIENCE
/	I-SUBJECTIVE EXPERIENCE
mystical	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
(	O
Kurland	O
et	O
al	O
.	O
,	O
1971	O
,	O
McGlothlin	O
and	O
Arnold	O
,	O
1971	O
,	O
Grispoon	O
and	O
Bakalar	O
,	O
1981	O
,	O
Grof	O
,	O
2001	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2008	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2011	O
,	O
Hintzen	O
and	O
Passie	O
,	O
2010	O
,	O
Vollenweider	O
and	O
Kometer	O
,	O
2010	O
,	O
MacLean	O
et	O
al	O
.	O
,	O
2011	O
,	O
Krebs	O
and	O
Johansen	O
,	O
2012	O
,	O
Baumeister	O
et	O
al	O
.	O
,	O
2014	O
,	O
Kometer	O
et	O
al	O
.	O
,	O
2015	O
,	O
Majić	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
Indeed	O
,	O
psilocybin	B-DRUG
induced	O
religious	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
like	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
in	O
healthy	O
volunteers	O
,	O
with	O
sustained	B-OUTCOME
improvements	I-OUTCOME
in	I-OUTCOME
attitudes	I-OUTCOME
,	I-OUTCOME
mood	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
personality	I-OUTCOME
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2008	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2011	O
,	O
MacLean	O
et	O
al	O
.	O
,	O
2011	O
)	O
,	O
and	O
psilocybin	B-DRUG
-	O
occasioned	O
mystical	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
,	O
together	O
with	O
the	O
overall	O
intensity	O
of	O
the	O
experience	O
,	O
were	O
correlated	O
with	O
improvements	B-OUTCOME
in	I-OUTCOME
tobacco	I-OUTCOME
(	I-OUTCOME
Garcia	I-OUTCOME
-	I-OUTCOME
Romeu	I-OUTCOME
et	I-OUTCOME
al	I-OUTCOME
.	I-OUTCOME
,	I-OUTCOME
2014	I-OUTCOME
,	I-OUTCOME
Johnson	I-OUTCOME
et	I-OUTCOME
al	I-OUTCOME
.	I-OUTCOME
,	I-OUTCOME
2014	I-OUTCOME
)	I-OUTCOME
and	I-OUTCOME
alcohol	I-OUTCOME
(	I-OUTCOME
Bogenschutz	I-OUTCOME
et	I-OUTCOME
al	I-OUTCOME
.	I-OUTCOME
,	I-OUTCOME
2015	I-OUTCOME
)	I-OUTCOME
dependence	I-OUTCOME
.	O
Moreover	O
,	O
the	O
religious	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
like	I-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
LSD	B-DRUG
were	O
associated	O
with	O
sustained	O
improvements	O
in	O
patients	O
with	O
anxiety	B-HEALTH CONDITION
associated	O
with	O
life	O
-	O
threatening	O
diseases	O
(	O
Gasser	O
et	O
al	O
.	O
,	O
2014	O
,	O
Gasser	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
Interestingly	O
,	O
decreased	B-OUTCOME
DMN	I-OUTCOME
activity	I-OUTCOME
and	O
decreased	B-OUTCOME
DMN	I-OUTCOME
-	I-OUTCOME
TPN	I-OUTCOME
inverse	I-OUTCOME
coupling	I-OUTCOME
were	O
observed	O
not	O
only	O
after	O
administration	O
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
,	O
but	O
also	O
in	O
meditation	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012a	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2012b	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2014	O
,	O
de	O
Araujo	O
et	O
al	O
.	O
,	O
2012	O
)	O
Taken	O
together	O
,	O
the	O
neuroimaging	O
data	O
reviewed	O
suggests	O
that	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
produce	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
effects	O
by	O
modulating	B-OUTCOME
brain	I-OUTCOME
areas	I-OUTCOME
associated	I-OUTCOME
with	I-OUTCOME
perception	I-OUTCOME
and	I-OUTCOME
emotion	I-OUTCOME
processing	I-OUTCOME
,	I-OUTCOME
executive	I-OUTCOME
functions	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
other	I-OUTCOME
complex	I-OUTCOME
cognitive	I-OUTCOME
functions	I-OUTCOME
.	O
Specifically	O
,	O
these	O
group	O
of	O
compounds	B-DRUG
may	O
induce	O
acute	O
increases	O
in	O
blood	O
perfusion	O
/	O
glucose	O
metabolism	O
in	O
prefrontal	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
limbic	I-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
involved	O
in	O
the	O
regulation	B-OUTCOME
of	I-OUTCOME
mood	I-OUTCOME
,	I-OUTCOME
interoception	I-OUTCOME
,	I-OUTCOME
cognition	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
consciousness	I-OUTCOME
;	O
decreases	O
in	O
reactivity	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
structures	O
related	O
to	O
anxiety	B-HEALTH CONDITION
/	O
fear	B-OUTCOME
processing	I-OUTCOME
such	O
as	O
the	O
amygdala	B-NEURAL MECHANISM/CORRELATE
;	O
and	O
reduced	O
brain	B-NEURAL MECHANISM/CORRELATE
activity	O
in	O
key	O
regions	O
of	O
the	O
DMN	O
,	O
involved	O
in	O
mind	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
wandering	I-SUBJECTIVE EXPERIENCE
and	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
awareness	I-SUBJECTIVE EXPERIENCE
.	O
Somehow	O
,	O
the	O
altered	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
produced	O
by	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
appears	O
to	O
create	O
a	O
disruption	B-OUTCOME
of	I-OUTCOME
repetitive	I-OUTCOME
,	I-OUTCOME
rigid	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
pathological	I-OUTCOME
patterns	I-OUTCOME
of	I-OUTCOME
negative	I-OUTCOME
thoughts	I-OUTCOME
and	I-OUTCOME
emotions	I-OUTCOME
,	O
commonly	O
observed	O
in	O
anxiety	B-HEALTH CONDITION
and	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
and	O
in	O
drug	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
,	O
and	O
this	O
effect	O
may	O
be	O
therapeutically	B-OUTCOME
relevant	I-OUTCOME
.	O
Finally	O
,	O
long	O
-	O
term	O
use	O
of	O
these	O
drugs	B-DRUG
was	O
also	O
associated	O
with	O
cortical	B-OUTCOME
thickness	I-OUTCOME
alterations	I-OUTCOME
in	I-OUTCOME
important	I-OUTCOME
areas	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
DMN	I-OUTCOME
,	O
such	O
as	O
the	O
posterior	B-NEURAL MECHANISM/CORRELATE
and	I-NEURAL MECHANISM/CORRELATE
anterior	I-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortices	I-NEURAL MECHANISM/CORRELATE
A	O
main	O
limitation	O
of	O
the	O
present	O
systematic	O
review	O
is	O
the	O
inclusion	O
of	O
studies	O
with	O
small	O
sample	O
sizes	O
,	O
high	O
degree	O
of	O
heterogeneity	O
,	O
and	O
without	O
placebo	O
or	O
control	O
groups	O
.	O
Other	O
important	O
limitations	O
include	O
the	O
variety	O
of	O
doses	O
of	O
the	O
same	O
compound	O
used	O
in	O
different	O
studies	O
and	O
the	O
difficulty	O
in	O
accurately	O
measuring	O
drug	O
dose	O
/	O
composition	O
in	O
retrospective	O
studies	O
However	O
,	O
despite	O
these	O
important	O
limitations	O
,	O
the	O
reviewed	O
results	O
suggest	O
that	O
the	O
neural	O
basis	O
of	O
the	O
effects	O
of	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
involve	O
an	O
agonist	O
action	O
of	O
these	O
drugs	O
on	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
expressed	O
in	O
deep	O
-	O
layer	O
pyramidal	B-NEURAL MECHANISM/CORRELATE
neurons	I-NEURAL MECHANISM/CORRELATE
in	O
the	O
fronto	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
parieto	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
occipito	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
temporal	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
,	O
involved	O
in	O
perception	O
,	O
memory	O
,	O
and	O
emotion	O
processing	O
,	O
cognitive	O
functions	O
,	O
regulation	O
of	O
neurotrophic	O
factors	O
,	O
and	O
consciousness	O
.	O
Moreover	O
,	O
although	O
the	O
mechanisms	O
of	O
action	O
responsible	O
for	O
the	O
effects	O
produced	O
by	O
serotonergic	B-DRUG
hallucinogens	I-DRUG
are	O
not	O
completely	O
understood	O
,	O
the	O
available	O
evidence	O
suggest	O
that	O
these	O
drugs	B-DRUG
may	O
not	O
only	O
improve	B-OUTCOME
our	I-OUTCOME
understanding	I-OUTCOME
of	I-OUTCOME
the	I-OUTCOME
neurobiology	I-OUTCOME
of	I-OUTCOME
psychiatric	I-OUTCOME
disorders	I-OUTCOME
,	I-OUTCOME
consciousness	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
other	I-OUTCOME
complex	I-OUTCOME
topics	I-OUTCOME
,	O
but	O
may	O
also	O
have	O
therapeutic	O
uses	O
in	O
treatment	B-OUTCOME
-	I-OUTCOME
resistant	I-OUTCOME
patients	I-OUTCOME
with	I-OUTCOME
anxiety	I-OUTCOME
and	O
mood	B-HEALTH CONDITION
disorders	I-HEALTH CONDITION
or	O
drug	B-HEALTH CONDITION
dependence	I-HEALTH CONDITION
.	O
Further	O
development	O
of	O
neuroimaging	O
techniques	O
,	O
better	O
sample	O
and	O
drug	O
delivery	O
standardizations	O
and	O
the	O
integration	O
of	O
data	O
across	O
neuroimaging	O
modalities	O
may	O
extend	O
progress	O
in	O
this	O
important	O
field	O
-DOCSTART- -X- O O
Major	O
hurdles	O
facing	O
research	O
with	O
psychedelics	B-DRUG
include	O
the	O
burden	O
that	O
Major	O
hurdles	O
facing	O
research	O
with	O
psychedelics	B-DRUG
Schedule	O
1	O
status	O
incurs	O
and	O
a	O
lack	O
of	O
mainstream	O
funding	O
,	O
and	O
we	O
suspect	O
these	O
things	O
are	O
related	O
.	O
The	O
Schedule	O
1	O
status	O
of	O
psychedelics	B-DRUG
led	O
to	O
vastly	O
increased	O
regulations	O
on	O
research	O
,	O
associated	O
costs	O
,	O
and	O
damaging	O
stigma	O
that	O
likely	O
deterred	O
governmental	O
agencies	O
,	O
other	O
reputable	O
funding	O
bodies	O
,	O
and	O
companies	O
from	O
backing	O
the	O
relevant	O
research	O
.	O
Before	O
LSD	B-DRUG
was	O
banned	O
,	O
the	O
US	O
NIH	O
funded	O
over	O
130	O
studies	O
exploring	O
the	O
US	O
NIH	O
clinical	O
utility	O
;	O
however	O
,	O
since	O
the	O
ban	O
,	O
the	O
US	O
NIH	O
has	O
funded	O
none	O
and	O
until	O
a	O
few	O
years	O
ago	O
,	O
no	O
company	O
was	O
committed	O
to	O
manufacturing	O
medical	O
grade	O
psychedelics	B-DRUG
and	O
thus	O
procurement	O
of	O
the	O
required	O
drugs	O
for	O
clinical	O
trials	O
was	O
almost	O
impossible	O
(	O
Nutt	O
,	O
2015	O
)	O
Nowadays	O
,	O
both	O
COMPASS	O
Pathways	O
and	O
Usona	O
are	O
making	O
psilocybin	B-DRUG
at	O
scale	O
with	O
others	O
starting	O
.	O
Natural	O
plant	O
-	O
based	O
products	O
such	O
as	O
ayahuasca	B-DRUG
,	O
peyote	B-DRUG
,	O
and	O
magic	B-DRUG
mushrooms	I-DRUG
are	O
now	O
legal	O
in	O
some	O
South	O
American	O
countries	O
and	O
are	O
becoming	O
decriminalized	O
in	O
a	O
few	O
US	O
cities	O
.	O
Moreover	O
,	O
magic	B-DRUG
mushrooms	I-DRUG
could	O
be	O
legalized	O
in	O
the	O
US	O
state	O
of	O
Oregon	O
later	O
this	O
year	O
.	O
Magic	B-DRUG
truffles	I-DRUG
,	O
which	O
contain	O
the	O
same	O
active	O
compound	O
,	O
are	O
legal	O
in	O
the	O
Netherlands	O
,	O
and	O
this	O
loophole	O
,	O
combined	O
with	O
a	O
growing	O
interest	O
in	O
the	O
therapeutic	O
potential	O
of	O
psilocybin	B-DRUG
,	O
has	O
led	O
to	O
fast	O
-	O
growing	O
industry	O
in	O
Dutch	O
truffle	O
retreats	O
.	O
Some	O
finance	O
journalists	O
have	O
begun	O
predicting	O
a	O
“	O
shroom	O
boom	O
”	O
to	O
rival	O
the	O
“	O
green	O
rush	O
”	O
seen	O
with	O
medicinal	O
cannabis	O
(	O
Raphael	O
,	O
2018	O
)	O
.	O
This	O
escalating	O
recreational	O
use	O
presents	O
an	O
opportunity	O
to	O
collect	O
“	O
Big	O
Data	O
”	O
for	O
educational	O
and	O
harm	O
-	O
reduction	O
purposes	O
,	O
and	O
we	O
have	O
set	O
-	O
up	O
an	O
online	O
platform	O
for	O
doing	O
this	O
,	O
called	O
psychedelicsurvey.com	O
It	O
is	O
possible	O
to	O
make	O
new	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonist	O
ligands	O
that	O
would	O
,	O
at	O
the	O
time	O
of	O
synthesis	O
,	O
be	O
outside	O
national	O
or	O
UN	O
Conventions	O
.	O
However	O
,	O
based	O
on	O
recent	O
examples	O
,	O
the	O
risk	O
of	O
them	O
becoming	O
restricted	O
would	O
be	O
very	O
high	O
.	O
In	O
the	O
UK	O
,	O
the	O
ultra	O
-	O
restrictive	O
2016	O
Psychoactive	O
Substances	O
Act	O
makes	O
all	O
novel	O
psychoactive	B-DRUG
compounds	I-DRUG
illegal	O
,	O
and	O
some	O
of	O
the	O
newer	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonists	I-NEURAL MECHANISM/CORRELATE
(	O
e.g.	O
,	O
the	O
NBOMeS	O
)	O
have	O
been	O
found	O
to	O
be	O
more	O
toxic	O
than	O
the	O
older	O
ones	O
,	O
a	O
situation	O
similar	O
to	O
that	O
seen	O
with	O
the	O
growth	O
of	O
legal	O
but	O
more	O
harmful	O
synthetic	O
cannabinoids	O
Overall	O
,	O
it	O
seems	O
the	O
best	O
way	O
forward	O
to	O
fostering	O
research	O
and	O
therapeutic	O
application	O
is	O
to	O
press	O
for	O
a	O
rescheduling	O
of	O
psychedelics	B-DRUG
with	O
proven	O
therapeutic	B-OUTCOME
utility	I-OUTCOME
,	O
especially	O
psilocybin	B-DRUG
.	O
That	O
psilocybin	B-DRUG
was	O
made	O
Schedule	O
1	O
(	O
i.e.	O
,	O
having	O
no	O
medical	O
value	O
)	O
on	O
the	O
shirt	O
-	O
tails	O
of	O
politically	O
motivated	O
banning	O
of	O
LSD	B-DRUG
has	O
had	O
an	O
immense	O
negative	O
effect	O
on	O
treatment	O
and	O
research	O
(	O
Nutt	O
,	O
2015	O
)	O
.	O
A	O
campaign	O
to	O
re	O
-	O
schedule	O
psilocybin	B-DRUG
is	O
now	O
underway	O
in	O
the	O
UK	O
,	O
led	O
by	O
the	O
charity	O
DrugScience.org.uk	O
and	O
has	O
international	O
,	O
scientific	O
support	O
-DOCSTART- -X- O O
The	O
present	O
retrospective	O
cross	O
-	O
sectional	O
survey	O
study	O
examined	O
whether	O
psychedelic	B-DRUG
occasioned	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
or	O
psychological	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
predicted	O
decreases	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
following	O
a	O
psychedelic	B-DRUG
experience	O
(	O
H1	O
)	O
,	O
acute	O
psychedelic	B-DRUG
effects	O
predicted	O
increases	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
(	O
H2	O
)	O
,	O
increases	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
predicted	O
decreases	O
in	O
depression	B-HEALTH CONDITION
/	O
anxiety	B-HEALTH CONDITION
,	O
(	O
H3	O
)	O
and	O
whether	O
increases	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
mediated	O
the	O
relationships	O
between	O
acute	O
psychedelic	B-DRUG
effects	O
and	O
decreases	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
symptoms	O
(	O
H4	O
)	O
.	O
Findings	O
from	O
our	O
regression	O
and	O
path	O
analysis	O
models	O
supported	O
each	O
of	O
these	O
hypotheses	O
.	O
Consistent	O
with	O
prior	O
studies	O
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
;	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
;	O
Davis	O
et	O
al	O
,	O
2019	O
)	O
,	O
in	O
the	O
present	O
study	O
mystical	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
were	O
associated	O
with	O
decreases	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
.	O
Importantly	O
,	O
these	O
observations	O
were	O
extended	O
by	O
showing	O
that	O
experiences	O
of	O
psychological	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
during	O
a	O
psychedelic	B-DRUG
experience	O
are	O
also	O
associated	O
with	O
decreases	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
.	O
Further	O
,	O
when	O
mystical	B-SUBJECTIVE EXPERIENCE
and	I-SUBJECTIVE EXPERIENCE
psychological	I-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
were	O
included	O
simultaneously	O
as	O
predictors	O
of	O
changes	O
in	O
our	O
models	O
,	O
results	O
showed	O
that	O
psychological	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
stands	O
out	O
as	O
a	O
more	O
robust	O
predictor	B-OUTCOME
of	I-OUTCOME
change	I-OUTCOME
,	O
as	O
evidenced	O
by	O
the	O
larger	O
direct	O
(	O
Insight	O
:	O
β=.46	O
versus	O
Mystical	O
:	O
β=.09	O
)	O
and	O
indirect	O
(	O
Insight	O
:	O
β=.29	O
versus	O
Mystical	O
:	O
β=.06	O
)	O
coefficients	O
in	O
the	O
path	O
analysis	O
.	O
That	O
psychological	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
is	O
strongly	O
related	O
to	O
decreases	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
is	O
perhaps	O
not	O
surprising	O
given	O
the	O
history	O
of	O
insight	O
-	O
oriented	O
therapies	O
(	O
Connolly	O
Gibbons	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
but	O
it	O
has	O
also	O
been	O
questioned	O
whether	O
gaining	O
insight	B-SUBJECTIVE EXPERIENCE
is	O
sufficient	O
in	O
and	O
of	O
it	O
to	O
produce	O
lasting	B-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
behavior	I-OUTCOME
or	I-OUTCOME
mental	I-OUTCOME
health	I-OUTCOME
functioning	I-OUTCOME
(	O
Kuncewicz	O
,	O
Lachowicz	O
-	O
Tabaczek	O
,	O
and	O
Zaluski	O
,	O
2014	O
;	O
Leichsenring	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
To	O
this	O
point	O
,	O
our	O
models	O
also	O
showed	O
that	O
psychological	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
was	O
predictive	O
of	O
change	B-OUTCOME
when	O
accounting	O
for	O
the	O
correlation	O
between	O
insight	B-SUBJECTIVE EXPERIENCE
and	O
mystical	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
.	O
Insightful	B-SUBJECTIVE EXPERIENCE
as	I-SUBJECTIVE EXPERIENCE
well	I-SUBJECTIVE EXPERIENCE
as	I-SUBJECTIVE EXPERIENCE
mystical	I-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
have	O
been	O
identified	O
as	O
subtypes	O
of	O
the	O
phenomenon	O
of	O
quantum	B-OUTCOME
change	I-OUTCOME
,	O
which	O
refers	O
to	O
a	O
sudden	O
,	O
distinctive	O
,	O
benevolent	O
,	O
and	O
enduring	O
experience	O
resulting	O
in	O
personal	B-OUTCOME
transformations	I-OUTCOME
that	O
affect	O
a	O
broad	O
range	O
of	O
personal	O
emotions	O
,	O
cognitions	O
and	O
behaviors	O
(	O
Miller	O
and	O
C’de	O
Baca	O
,	O
2001	O
)	O
.	O
Such	O
experiences	O
after	O
taking	O
a	O
psychedelic	B-DRUG
have	O
also	O
been	O
implicated	O
in	O
decreases	B-OUTCOME
in	I-OUTCOME
alcohol	I-OUTCOME
use	I-OUTCOME
among	O
individuals	O
with	O
alcohol	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
(	O
GarciaRomeu	O
et	O
al	O
.	O
,	O
2019	O
)	O
.	O
Furthermore	O
,	O
findings	O
from	O
the	O
present	O
study	O
underscore	O
a	O
potential	O
explanation	O
for	O
how	O
acute	O
psychedelic	B-DRUG
experiences	O
,	O
including	O
gaining	O
psychological	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
and	O
mystical	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
,	O
may	O
exert	O
such	O
changes	B-OUTCOME
.	O
Specifically	O
,	O
we	O
demonstrated	O
the	O
importance	O
of	O
increases	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
as	O
a	O
mediator	O
of	O
the	O
positive	B-OUTCOME
therapeutic	I-OUTCOME
effects	I-OUTCOME
.	O
Although	O
several	O
other	O
mechanisms	O
have	O
been	O
proposed	O
at	O
various	O
levels	O
of	O
functioning	O
,	O
from	O
changes	O
in	O
the	O
entropy	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2014	O
)	O
to	O
the	O
importance	O
of	O
awe	B-SUBJECTIVE EXPERIENCE
/	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
(	O
Hendricks	O
,	O
2018	O
;	O
Preller	O
&	O
Vollenweider	O
,	O
2018	O
)	O
,	O
findings	O
from	O
this	O
study	O
are	O
consistent	O
with	O
evidence	O
demonstrating	O
that	O
psychedelic	B-OUTCOME
effects	I-OUTCOME
are	O
associated	O
with	O
changes	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
among	O
a	O
small	O
sample	O
of	O
subjects	O
who	O
use	O
the	O
psychedelic	O
ayahuasca	B-DRUG
(	O
Kuypers	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
and	O
research	O
showing	O
that	O
increases	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
is	O
associated	O
with	O
positive	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
outcomes	O
(	O
Twohig	O
&	O
Levin	O
,	O
2017	O
)	O
.	O
Although	O
the	O
exploration	O
of	O
potential	O
mediators	O
of	O
psychedelic	B-OUTCOME
effects	I-OUTCOME
on	O
therapeutic	B-OUTCOME
outcomes	I-OUTCOME
is	O
in	O
therapeutic	O
outcomes	O
early	O
stages	O
,	O
if	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
emerges	O
as	O
a	O
consistent	O
and	O
robust	O
mediator	O
of	O
effects	O
in	O
prospective	O
clinical	O
trials	O
,	O
then	O
the	O
field	O
of	O
psychedelic	O
-	O
assisted	O
psychotherapy	O
should	O
consider	O
integrating	O
psychedelic	B-DRUG
administration	I-DRUG
with	O
contextual	O
behavioral	O
therapies	O
(	O
e.g.	O
,	O
ACT	O
;	O
Hayes	O
et	O
al	O
.	O
,	O
2006	O
)	O
or	O
other	O
therapies	O
designed	O
to	O
target	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
.	O
Such	O
therapies	O
are	O
designed	O
to	O
enhance	O
processes	B-OUTCOME
of	I-OUTCOME
change	I-OUTCOME
by	O
supporting	O
increases	O
in	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
which	O
could	O
be	O
enhanced	O
through	O
the	O
administration	O
of	O
a	O
psychedelic	B-DRUG
.	O
Moreover	O
,	O
it	O
is	O
possible	O
that	O
some	O
acute	O
psychedelic	B-OUTCOME
effects	I-OUTCOME
overlap	O
with	O
the	O
core	O
processes	O
of	O
the	O
ACT	O
model	O
of	O
psychopathology	O
(	O
Hayes	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
For	O
example	O
,	O
consistent	O
with	O
the	O
core	O
processes	O
of	O
ACT	O
,	O
qualitative	O
analysis	O
of	O
first	O
-	O
hand	O
accounts	O
of	O
tobacco	O
smokers	O
in	O
a	O
clinical	O
trial	O
examining	O
the	O
effect	O
of	O
psilocybin	B-DRUG
-	O
assisted	O
therapy	O
(	O
Noorani	O
et	O
al	O
.	O
,	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
suggested	O
that	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
psychedelic	O
experiences	O
helped	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
see	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
in	O
the	O
context	O
of	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	B-HEALTH CONDITION
addiction	I-HEALTH CONDITION
(	O
i.e.	O
,	O
self	O
as	O
context	O
)	O
,	O
realize	O
that	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
are	O
not	O
the	O
labels	O
(	O
e.g.	O
,	O
smoker	O
)	O
which	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
previously	O
identified	O
as	O
(	O
i.e.	O
,	O
defusion	O
)	O
,	O
understood	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
values	O
more	O
clearly	O
than	O
before	O
(	O
i.e.	O
,	O
values	O
)	O
,	O
and	O
connected	O
with	O
the	O
fullness	O
of	O
the	O
present	O
moment	O
and	O
2018	O
;	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
experience	O
of	O
it	O
(	O
i.e.	O
,	O
contact	O
with	O
the	O
present	O
moment	O
)	O
.	O
Although	O
not	O
highlighted	O
in	O
the	O
qualitative	O
reports	O
per	O
se	O
,	O
another	O
component	O
of	O
the	O
ACT	O
model	O
,	O
committed	O
action	O
,	O
was	O
demonstrated	O
in	O
the	O
clinical	O
trial	O
by	O
the	O
high	O
rates	O
(	O
80	O
%	O
)	O
of	O
biologically	B-OUTCOME
verified	I-OUTCOME
abstinence	I-OUTCOME
at	I-OUTCOME
6	I-OUTCOME
months	I-OUTCOME
post	I-OUTCOME
-	I-OUTCOME
treatment	I-OUTCOME
(	O
Johnson	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
These	O
data	O
suggest	O
that	O
psychedelics	B-DRUG
appear	O
to	O
occasion	O
both	O
mindfulness/	B-SUBJECTIVE EXPERIENCE
acceptance	B-SUBJECTIVE EXPERIENCE
processes	O
as	O
well	O
as	O
commitment	B-OUTCOME
and	I-OUTCOME
behavior	I-OUTCOME
change	I-OUTCOME
processes	I-OUTCOME
.	O
However	O
,	O
more	O
research	O
is	O
needed	O
to	O
systematically	O
investigate	O
these	O
processes	O
in	O
rigorous	O
longitudinal	O
trials	O
among	O
individuals	O
with	O
depression	B-HEALTH CONDITION
or	O
anxiety	B-HEALTH CONDITION
in	O
order	O
to	O
replicate	O
these	O
findings	O
in	O
this	O
population	O
.	O
This	O
study	O
has	O
several	O
limitations	O
.	O
Internet	O
-	O
based	O
recruitment	O
and	O
data	O
collection	O
procedures	O
were	O
anonymous	O
.	O
Although	O
this	O
likely	O
increased	O
participation	O
from	O
individuals	O
from	O
a	O
variety	O
of	O
geographical	O
locations	O
,	O
This	O
study	O
would	O
have	O
excluded	O
people	O
who	O
prefer	O
not	O
to	O
participate	O
in	O
research	O
conducted	O
on	O
the	O
internet	O
.	O
Further	O
,	O
a	O
limitation	O
of	O
survey	O
methods	O
is	O
that	O
all	O
reports	O
are	O
retrospective	O
,	O
increasing	O
the	O
likelihood	O
that	O
current	O
affect	O
and	O
personality	O
bias	O
could	O
influence	O
recollection	O
of	O
subjective	O
psychedelic	O
experiences	O
as	O
well	O
as	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
symptoms	O
that	O
were	O
experienced	O
many	O
years	O
ago	O
.	O
However	O
,	O
this	O
potential	O
confound	O
is	O
not	O
expected	O
to	O
be	O
more	O
or	O
less	O
than	O
similar	O
confounds	O
in	O
other	O
retrospective	O
survey	O
research	O
(	O
Davis	O
et	O
al	O
.	O
,	O
2018	O
;	O
Davis	O
et	O
al	O
,	O
2019	O
)	O
.	O
Additionally	O
,	O
the	O
parent	O
study	O
from	O
which	O
the	O
data	O
were	O
drawn	O
,	O
was	O
designed	O
to	O
investigate	O
the	O
acute	O
effect	O
of	O
gaining	B-SUBJECTIVE EXPERIENCE
insight	I-SUBJECTIVE EXPERIENCE
during	O
a	O
psychedelic	B-DRUG
experience	O
.	O
Although	O
the	O
mean	O
score	O
of	O
the	O
intensity	O
of	O
mystical	B-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
in	O
this	O
sample	O
was	O
similar	O
to	O
prior	O
studies	O
(	O
Davis	O
et	O
al	O
.	O
,	O
2018	O
)	O
,	O
suggesting	O
comparably	O
strong	O
mystical	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
in	O
addition	O
to	O
insight	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
,	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
recruiting	O
people	O
who	O
specifically	O
reported	O
gaining	O
insight	B-SUBJECTIVE EXPERIENCE
as	O
part	O
of	O
a	O
psychedelic	B-DRUG
experience	O
accounts	O
for	O
some	O
of	O
the	O
differential	O
strength	O
in	O
the	O
association	O
between	O
acute	O
insight	B-SUBJECTIVE EXPERIENCE
and	O
other	O
study	O
variables	O
.	O
Another	O
limitation	O
to	O
this	O
study	O
is	O
that	O
,	O
despite	O
our	O
efforts	O
to	O
recruit	O
individuals	O
with	O
diverse	O
backgrounds	O
by	O
placement	O
of	O
notices	O
on	O
a	O
variety	O
of	O
internet	O
forums	O
,	O
respondents	O
were	O
primarily	O
young	O
,	O
white	O
,	O
and	O
male	O
.	O
Although	O
our	O
sample	O
is	O
consistent	O
with	O
prior	O
studies	O
of	O
psychedelic	O
users	O
using	O
similar	O
recruitment	O
procedures	O
(	O
Davis	O
et	O
al	O
.	O
,	O
2018	O
;	O
Barret	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
similar	O
to	O
Michaels	O
et	O
al	O
.	O
(	O
2018	O
)	O
our	O
strongly	O
encourage	O
future	O
researchers	O
to	O
continue	O
efforts	O
in	O
recruiting	O
a	O
diverse	O
sample	O
.	O
There	O
are	O
several	O
possible	O
explanations	O
for	O
the	O
lack	O
of	O
diverse	O
representation	O
in	O
psychedelic	O
survey	O
studies	O
.	O
For	O
example	O
,	O
it	O
could	O
be	O
that	O
the	O
topic	O
of	O
these	O
studies	O
are	O
not	O
interesting	O
to	O
some	O
potential	O
respondents	O
,	O
that	O
there	O
is	O
a	O
perceived	O
risk	O
involved	O
with	O
reporting	O
an	O
illegal	O
behavior	O
,	O
or	O
that	O
the	O
internet	O
computer	O
format	O
excluded	O
individuals	O
from	O
differing	O
socio	O
-	O
economic	O
backgrounds	O
.	O
Efforts	O
to	O
overcome	O
these	O
factors	O
could	O
include	O
a	O
community	O
-	O
based	O
participatory	O
research	O
methodology	O
(	O
Israel	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
wherein	O
the	O
study	O
is	O
designed	O
through	O
engagement	O
with	O
leaders	O
from	O
a	O
variety	O
of	O
diverse	O
backgrounds	O
,	O
with	O
the	O
intention	O
of	O
better	O
understanding	O
the	O
ways	O
in	O
which	O
the	O
study	O
can	O
be	O
designed	O
to	O
connect	O
with	O
individuals	O
from	O
these	O
communities	O
-DOCSTART- -X- O O
Ayahuasca	B-DRUG
,	O
psilocybin	B-DRUG
and	O
LSD	B-DRUG
are	O
classical	O
psychedelics	B-DRUG
being	O
studied	O
as	O
potentially	O
therapeutic	O
agents	O
to	O
reduce	O
symptoms	O
of	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
associated	O
with	O
life	O
-	O
threatening	O
disease	O
.	O
Therefore	O
,	O
the	O
present	O
systematic	O
review	O
aimed	O
to	O
determine	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
associated	O
with	O
life	O
-	O
threatening	O
disease	O
efficacy	O
,	O
tolerability	O
and	O
mechanisms	O
of	O
action	O
.	O
The	O
main	O
findings	O
were	O
that	O
psychedelics	B-DRUG
produced	O
significant	O
anti	B-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
with	O
good	O
tolerability	B-OUTCOME
response	I-OUTCOME
.	O
These	O
results	O
,	O
in	O
addition	O
to	O
the	O
putative	O
mechanisms	O
of	O
action	O
underlying	O
These	O
results	O
beneficial	O
effects	O
,	O
will	O
be	O
further	O
discussed	O
below	O
In	O
all	O
studies	O
,	O
psychedelic	B-DRUG
administration	O
caused	O
statistically	O
significant	O
reductions	O
in	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
symptoms	O
.	O
These	O
findings	O
corroborate	O
the	O
limited	O
previous	O
research	O
conducted	O
in	O
animal	O
studies	O
and	O
healthy	O
volunteers	O
,	O
as	O
well	O
as	O
anecdotal	O
evidence	O
describing	O
improved	B-OUTCOME
mood	I-OUTCOME
and	O
reduced	B-OUTCOME
feelings	I-OUTCOME
of	I-OUTCOME
apprehension	I-OUTCOME
following	O
psychedelic	B-DRUG
administration	I-DRUG
(	O
Riba	O
et	O
al	O
.	O
,	O
2001	O
,	O
Hilber	O
and	O
Chapillon	O
,	O
2005	O
,	O
Farzin	O
and	O
Mansouri	O
,	O
2006	O
,	O
Fortunato	O
et	O
al	O
.	O
,	O
2009	O
,	O
Fortunato	O
et	O
al	O
.	O
,	O
2010aa	O
,	O
Fortunato	O
et	O
al	O
.	O
,	O
2010b	O
,	O
Santos	O
et	O
al	O
.	O
,	O
2007	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2008	O
,	O
Kast	O
,	O
1967	O
,	O
Richards	O
et	O
al	O
.	O
,	O
1977	O
)	O
.	O
These	O
improvements	O
were	O
consistently	O
observed	O
across	O
a	O
variety	O
of	O
rating	O
scales	O
,	O
and	O
this	O
is	O
suggestive	O
of	O
a	O
genuine	O
therapeutic	B-OUTCOME
effect	I-OUTCOME
rather	O
than	O
a	O
specific	O
scale	O
's	O
tendency	O
to	O
show	O
a	O
positive	O
effect	O
.	O
Moreover	O
,	O
the	O
lack	O
of	O
equivalent	O
symptom	O
reduction	O
in	O
control	O
patients	O
indicates	O
that	O
the	O
anti	B-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
can	O
be	O
attributed	O
to	O
psychedelic	B-DRUG
intervention	I-DRUG
.	O
Participants	O
also	O
described	O
the	O
experience	O
as	O
spiritually	B-SUBJECTIVE EXPERIENCE
meaningful	I-SUBJECTIVE EXPERIENCE
,	O
resulting	O
in	O
decreased	O
disease	O
-	O
related	O
demoralisation	B-SUBJECTIVE EXPERIENCE
and	O
hopelessness	B-SUBJECTIVE EXPERIENCE
as	O
well	O
as	O
improved	O
quality	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
life	I-SUBJECTIVE EXPERIENCE
(	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
,	O
Griffiths	O
et	O
(	O
Ross	O
et	O
al	O
,	O
2016	O
,	O
Grob	O
et	O
al	O
.	O
,	O
2011	O
,	O
G	O
et	O
al	O
.	O
,	O
2014	O
)	O
Psychedelics	B-DRUG
’	O
ability	O
to	O
provide	O
acute	O
symptom	B-OUTCOME
relief	I-OUTCOME
,	O
within	O
one	O
day	O
,	O
is	O
advantageous	O
when	O
compared	O
to	O
current	O
antidepressants	B-ANTIDEPRESSANT_DRUG
,	O
which	O
take	O
several	O
weeks	O
to	O
work	O
.	O
This	O
is	O
because	O
antidepressants	B-ANTIDEPRESSANT_DRUG
’	O
delayed	B-OUTCOME
therapeutic	I-OUTCOME
effects	I-OUTCOME
can	O
lead	O
to	O
non	O
-	O
compliance	O
and	O
contribute	O
to	O
increased	O
morbidity	B-OUTCOME
(	O
Machado	O
-	O
Vieira	O
et	O
al	O
.	O
,	O
2010	O
,	O
Tylee	O
and	O
Walters	O
,	O
2007	O
)	O
.	O
Moreover	O
,	O
since	O
psychedelics	B-DRUG
’	O
beneficial	B-OUTCOME
effects	I-OUTCOME
are	O
maintained	O
with	O
impressive	O
response	O
rates	O
for	O
several	O
months	O
,	O
this	O
could	O
imply	O
that	O
less	O
frequent	O
administration	O
is	O
required	O
compared	O
to	O
typical	O
pharmacotherapy	O
for	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
.	O
This	O
,	O
coupled	O
to	O
the	O
fact	O
that	O
exposure	O
to	O
treatment	O
is	O
monitored	O
,	O
could	O
help	O
to	O
overcome	O
treatment	O
-	O
resistance	O
stemming	O
from	O
non	O
-	O
compliance	O
Psychedelic	B-DRUG
treatment	O
was	O
generally	O
well	O
-	O
tolerated	O
.	O
The	O
commonest	O
adverse	O
effects	O
included	O
transient	B-OUTCOME
anxiety	I-OUTCOME
,	O
headaches	B-OUTCOME
,	O
nausea	B-OUTCOME
and	O
vomiting	B-OUTCOME
.	O
These	O
were	O
generally	O
self	O
-	O
resolving	O
except	O
for	O
three	O
patients	O
on	O
LSD	B-DRUG
requiring	O
benzodiazepines	B-DRUG
to	O
counteract	O
treatment	O
-	O
induced	O
anxiety	B-HEALTH CONDITION
and/or	O
emotional	B-OUTCOME
distress	I-OUTCOME
.	O
One	O
of	O
these	O
patients	O
had	O
received	O
the	O
placebo	O
-	O
like	O
low	O
-	O
dose	O
of	O
LSD	B-DRUG
,	O
suggesting	O
that	O
the	O
need	O
for	O
tranquilising	O
medication	O
was	O
also	O
dependent	O
on	O
individual	O
susceptibility	O
in	O
addition	O
to	O
dose	O
-	O
related	O
drug	O
factors	O
.	O
Vomiting	B-OUTCOME
was	O
considered	O
cathartic	B-SUBJECTIVE EXPERIENCE
and	O
thus	O
an	O
integral	O
component	O
of	O
the	O
therapeutic	B-OUTCOME
experience	I-OUTCOME
(	O
Osório	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
Nevertheless	O
,	O
ways	O
to	O
manage	O
(	O
Osório	O
et	O
al	O
such	O
as	O
by	O
pre	O
-	O
medicating	O
with	O
an	O
anti	O
-	O
emetic	O
can	O
be	O
explored	O
.	O
LSD	B-DRUG
-	O
induced	O
paranoia	B-OUTCOME
,	O
illusions	B-OUTCOME
and	O
feeling	B-OUTCOME
cold	I-OUTCOME
were	O
predictable	O
side	O
effects	O
and	O
may	O
be	O
explained	O
by	O
its	O
superior	O
hallucinogenic	O
strength	O
compared	O
to	O
psilocybin	B-DRUG
and	O
ayahuasca	B-DRUG
(	O
D	O
et	O
al	O
.	O
,	O
2016	O
,	O
Schmid	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
All	O
psychedelics	B-DRUG
also	O
increased	B-OUTCOME
heart	I-OUTCOME
rate	I-OUTCOME
and	I-OUTCOME
blood	I-OUTCOME
pressure	I-OUTCOME
.	O
The	O
statistically	O
significant	O
elevations	O
reported	O
by	O
Grob	O
et	O
al	O
.	O
and	O
Ross	O
et	O
al	O
.	O
with	O
psilocybin	B-DRUG
may	O
have	O
been	O
confounded	O
by	O
niacin	O
's	O
ability	O
to	O
acutely	O
lower	O
blood	O
pressure	O
through	O
vasodilation	O
in	O
the	O
controls	O
(	O
Bays	O
and	O
Rader	O
,	O
2009	O
)	O
.	O
Nevertheless	O
,	O
medical	O
intervention	O
was	O
never	O
required	O
Previous	O
research	O
has	O
shown	O
these	B-DRUG
compounds	I-DRUG
to	O
be	O
relatively	O
safe	O
when	O
used	O
in	O
medically	O
-	O
controlled	O
environments	O
(	O
Guimarães	O
dos	O
Santos	O
,	O
2013	O
,	O
J	O
et	O
al	O
.	O
,	O
2008	O
,	O
Nichols	O
,	O
2004	O
)	O
.	O
They	O
have	O
no	B-OUTCOME
reported	I-OUTCOME
risk	I-OUTCOME
of	I-OUTCOME
dependence	I-OUTCOME
as	O
daily	O
administration	O
causes	O
serotonin	O
(	O
5	O
-	O
HT2A	O
)	O
receptor	O
downregulation	O
,	O
leading	O
to	O
rapid	O
induction	O
of	O
tolerance	O
(	O
Nichols	O
,	O
2004	O
)	O
.	O
In	O
fact	O
,	O
They	O
may	O
even	O
have	O
anti	B-OUTCOME
-	I-OUTCOME
addictive	I-OUTCOME
properties	I-OUTCOME
(	O
B	O
et	O
al	O
.	O
,	O
2015	O
,	O
J	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O
Concerns	O
over	O
anti	B-OUTCOME
-	I-OUTCOME
addictive	I-OUTCOME
properties	I-OUTCOME
(	O
B	O
et	O
al	O
.	O
,	O
2015	O
,	O
J	O
et	O
al	O
impact	O
on	O
mental	O
health	O
have	O
been	O
challenged	O
by	O
large	O
-	O
scale	O
population	O
studies	O
showing	O
that	O
psychedelic	B-DRUG
users	O
have	O
lower	B-OUTCOME
rates	I-OUTCOME
of	I-OUTCOME
psychological	I-OUTCOME
distress	I-OUTCOME
and	O
suicidality	B-OUTCOME
compared	O
to	O
individuals	O
who	O
had	O
never	O
used	O
psychedelics	B-DRUG
but	O
an	O
equivalent	O
amount	O
of	O
other	O
recreational	O
drugs	O
(	O
Hendricks	O
et	O
al	O
.	O
,	O
2015	O
,	O
Krebs	O
and	O
Johansen	O
,	O
2013	O
)	O
.	O
Although	O
the	O
observational	O
nature	O
of	O
these	O
studies	O
can	O
not	O
establish	O
causality	O
,	O
these	O
studies	O
suggests	O
that	O
psychedelics	B-DRUG
are	O
not	O
counter	O
-	O
productive	O
over	O
time	O
.	O
However	O
,	O
the	O
findings	O
of	O
this	O
research	O
need	O
to	O
be	O
considered	O
in	O
light	O
of	O
certain	O
limitations	O
.	O
Only	O
seven	O
studies	O
were	O
included	O
in	O
this	O
review	O
,	O
each	O
with	O
a	O
small	O
sample	O
size	O
(	O
range	O
6–51	O
subjects	O
)	O
,	O
and	O
a	O
higher	O
proportion	O
of	O
females	O
,	O
particularly	O
Caucasian	O
,	O
among	O
the	O
cohort	O
.	O
These	O
factors	O
limit	O
the	O
generalisability	O
of	O
the	O
results	O
.	O
Additionally	O
,	O
the	O
significant	O
level	O
of	O
bias	O
present	O
across	O
the	O
studies	O
(	O
Fig	O
.	O
3a	O
/	O
b	O
)	O
affects	O
the	O
reliability	O
of	O
the	O
conclusions	O
.	O
Three	O
studies	O
were	O
open	O
-	O
label	O
proof	O
-	O
of	O
-	O
concept	O
studies	O
,	O
recruiting	O
patients	O
largely	O
by	O
self	O
-	O
referral	O
who	O
are	O
possibly	O
more	O
inclined	O
to	O
endorse	O
the	O
positive	B-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
.	O
The	O
fact	O
that	O
patients	O
are	O
aware	O
of	O
receiving	O
the	O
active	O
drug	O
could	O
introduce	O
expectancy	O
bias	O
,	O
whereby	O
patients	O
anticipate	O
a	O
beneficial	B-OUTCOME
effect	I-OUTCOME
.	O
The	O
double	O
-	O
blind	O
randomised	O
nature	O
of	O
the	O
other	O
four	O
studies	O
served	O
to	O
minimise	O
this	O
predisposition	O
.	O
However	O
,	O
even	O
in	O
these	O
instances	O
maintaining	O
blinding	O
proved	O
challenging	O
,	O
as	O
the	O
drugs	B-DRUG
’	O
psychoactive	B-OUTCOME
effects	I-OUTCOME
were	O
florid	O
,	O
with	O
patients	O
experiencing	O
a	O
heightened	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
with	O
marked	O
emotional	B-SUBJECTIVE EXPERIENCE
accompaniments	I-SUBJECTIVE EXPERIENCE
.	O
Administering	O
active	O
placebos	O
in	O
the	O
form	O
of	B-DRUG
niacin	I-DRUG
or	O
very	O
low	O
-	O
dose	O
psychedelic	B-DRUG
was	O
an	O
attempt	O
to	O
overcome	O
this	O
,	O
as	O
these	O
would	O
induce	O
mild	O
physiological	B-OUTCOME
and/or	I-OUTCOME
psychological	I-OUTCOME
effects	I-OUTCOME
but	O
would	O
be	O
incapable	O
of	O
substantially	O
facilitating	O
the	O
therapeutic	O
process	O
.	O
When	O
the	O
psychedelic	B-DRUG
was	O
administered	O
to	O
both	O
study	O
groups	O
,	O
the	O
psychedelic	B-DRUG
also	O
permitted	O
study	O
investigators	O
to	O
instruct	O
patients	O
in	O
such	O
a	O
way	O
as	O
to	O
reduce	O
expectancy	O
bias	O
i.e.	O
that	O
everyone	O
would	O
receive	O
the	O
drug	O
,	O
albeit	O
different	O
doses	O
.	O
Nevertheless	O
,	O
it	O
is	O
likely	O
that	O
patients	O
were	O
usually	O
unblinded	O
by	O
patients	O
experience	O
on	O
the	O
active	O
drug	O
.	O
Psychedelics	B-DRUG
are	O
also	O
known	O
to	O
promote	O
suggestibility	B-OUTCOME
,	O
which	O
might	O
have	O
further	O
enhanced	B-OUTCOME
positive	I-OUTCOME
outcomes	I-OUTCOME
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O
The	O
influence	O
of	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2015	O
)	O
would	O
be	O
difficult	O
to	O
avoid	O
in	O
judging	O
outcomes	O
,	O
especially	O
since	O
the	O
scales	O
used	O
to	O
measure	O
efficacy	O
are	O
largely	O
subjective	O
.	O
Therefore	O
,	O
at	O
least	O
inclusion	O
of	O
blinded	O
clinician	O
-	O
raters	O
is	O
necessary	O
in	O
future	O
studies	O
.	O
Additionally	O
,	O
more	O
objective	O
outcome	O
parameters	O
are	O
possible	O
and	O
should	O
be	O
considered	O
.	O
For	O
example	O
,	O
geolocation	O
from	O
mobile	O
phones	O
can	O
be	O
measured	O
,	O
as	O
amount	O
of	O
time	O
spent	O
at	O
home	O
correlates	O
with	O
depression	B-HEALTH CONDITION
severity	O
(	O
Palmius	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
In	O
cancer	B-HEALTH CONDITION
patients	O
,	O
treatment	B-OUTCOME
efficacy	I-OUTCOME
could	O
also	O
be	O
reflected	O
in	O
patients	O
’	O
increased	O
adherence	O
to	O
treatment	O
or	O
reduced	O
need	O
for	O
narcotic	O
pain	O
-	O
relief	O
(	O
Grof	O
et	O
al	O
.	O
,	O
1973	O
)	O
.	O
Future	O
trials	O
could	O
also	O
address	O
the	O
role	O
of	O
expectancy	B-OUTCOME
and	O
suggestibility	B-OUTCOME
by	O
measuring	O
and	O
controlling	O
for	O
these	O
variables	O
.	O
For	O
example	O
,	O
patients	O
could	O
be	O
asked	O
about	O
patients	O
pre	O
-	O
treatment	O
expectations	O
,	O
and	O
outcomes	O
from	O
self	O
-	O
referred	O
patients	O
could	O
be	O
compared	O
with	O
those	O
from	O
patients	O
referred	O
by	O
clinicians	O
.	O
If	O
expectancy	O
and	O
suggestibility	O
are	O
found	O
to	O
be	O
influential	O
,	O
expectancy	O
and	O
suggestibility	O
are	O
found	O
to	O
be	O
influential	O
could	O
be	O
treated	O
as	O
exploitable	O
components	O
of	O
the	O
treatment	O
model	O
rather	O
than	O
confounding	O
variables	O
(	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2016	O
)	O
Limitations	O
also	O
exist	O
in	O
treating	O
participants	O
with	O
grave	O
somatic	O
diseases	O
in	O
clinical	O
trials	O
.	O
This	O
is	O
because	O
improvements	O
or	O
deteriorations	O
in	O
deteriorations	O
illness	O
can	O
impact	O
psychological	O
parameters	O
independent	O
of	O
therapeutic	O
intervention	O
.	O
Additionally	O
,	O
patients	O
who	O
become	O
too	O
ill	O
to	O
continue	O
or	O
pass	O
away	O
during	O
the	O
course	O
of	O
the	O
experiment	O
contribute	O
to	O
missing	O
data	O
.	O
These	O
factors	O
can	O
introduce	O
bias	O
in	O
the	O
results	O
and	O
affect	O
the	O
overall	O
evidence	O
base	O
for	O
psychedelics	B-DRUG
’	O
therapeutic	B-OUTCOME
potential	I-OUTCOME
In	O
terms	O
of	O
methodology	O
,	O
accepting	O
only	O
English	O
citations	O
with	O
full	O
publication	O
access	O
may	O
have	O
introduced	O
a	O
minor	O
degree	O
of	O
publication	O
bias	O
(	O
Pilkington	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Moreover	O
,	O
the	O
subjective	O
nature	O
of	O
the	O
Cochrane	O
Risk	O
of	O
Bias	O
tool	O
may	O
have	O
caused	O
inaccuracies	O
in	O
the	O
bias	O
assessment	O
results	O
.	O
Considering	O
that	O
inter	O
-	O
assessor	O
agreement	O
can	O
be	O
inconsistent	O
(	O
Armijo	O
-	O
Olivo	O
et	O
al	O
.	O
,	O
2014	O
,	O
Armijo	O
-	O
Olivo	O
et	O
al	O
.	O
,	O
2012	O
,	O
Savović	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
inclusion	O
of	O
multiple	O
reviewers	O
would	O
strengthen	O
inter	O
-	O
assessor	O
agreement	O
can	O
be	O
inconsistent	O
(	O
Armijo	O
-	O
Olivo	O
et	O
al	O
validity	O
as	O
any	O
discrepancies	O
would	O
be	O
discussed	O
.	O
Before	O
widespread	O
use	O
of	O
psychedelics	B-DRUG
can	O
be	O
contemplated	O
,	O
there	O
are	O
several	O
challenges	O
that	O
future	O
research	O
needs	O
to	O
address	O
.	O
Firstly	O
,	O
the	O
aforementioned	O
promising	O
results	O
need	O
to	O
be	O
replicated	O
in	O
larger	O
-	O
scale	O
trials	O
with	O
more	O
participants	O
.	O
Ideally	O
,	O
these	O
studies	O
would	O
also	O
be	O
longer	O
in	O
duration	O
to	O
determine	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
safety	I-OUTCOME
and	I-OUTCOME
efficacy	I-OUTCOME
.	O
Although	O
observational	O
studies	O
have	O
provided	O
some	O
evidence	O
that	O
long	O
-	O
term	O
psychedelic	B-DRUG
use	O
is	O
not	O
harmful	O
(	O
Guimarães	O
dos	O
Santos	O
,	O
2013	O
,	O
Bouso	O
et	O
al	O
.	O
,	O
2012	O
,	O
Barbosa	O
et	O
al	O
.	O
,	O
2016	O
,	O
Barbosa	O
et	O
al	O
.	O
,	O
2012	O
,	O
Hendricks	O
et	O
al	O
.	O
,	O
2015	O
,	O
Krebs	O
and	O
Johansen	O
,	O
2013	O
)	O
,	O
the	O
inherent	O
limitations	O
of	O
these	O
studies	O
call	O
for	O
more	O
robust	O
long	O
-	O
term	O
clinical	O
trials	O
to	O
be	O
carried	O
out	O
.	O
It	O
must	O
be	O
recognised	O
that	O
despite	O
clinical	O
interest	O
in	O
psychedelics	B-DRUG
resuming	O
,	O
regulatory	O
obstacles	O
still	O
exist	O
,	O
therefore	O
performing	O
such	O
research	O
is	O
not	O
straightforward	O
(	O
Nutt	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Nevertheless	O
,	O
future	O
questions	O
to	O
be	O
answered	O
include	O
whether	O
repeated	O
administration	O
for	O
long	O
-	O
term	O
treatment	O
is	O
possible	O
and	O
how	O
frequently	O
long	O
-	O
term	O
treatment	O
should	O
be	O
done	O
Alongside	O
these	O
,	O
optimum	O
dosing	O
must	O
be	O
determined	O
,	O
and	O
target	O
population	O
identified	O
.	O
For	O
example	O
,	O
Griffiths	O
et	O
al	O
.	O
reduced	O
the	O
psilocybin	B-DRUG
dose	O
once	O
the	O
trial	O
had	O
commenced	O
because	O
there	O
were	O
concerns	O
over	O
the	O
high	O
dose	O
causing	O
too	O
psychologically	B-OUTCOME
challenging	I-OUTCOME
experiences	I-OUTCOME
,	O
and	O
the	O
low	O
dose	O
producing	O
psychoactive	B-OUTCOME
effects	I-OUTCOME
,	O
thus	O
not	O
serving	O
as	O
an	O
appropriate	O
placebo	O
-	O
like	O
control	O
(	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O
Protocol	O
amendments	O
like	O
this	O
are	O
less	O
than	O
ideal	O
,	O
therefore	O
defining	O
correct	O
dosing	O
is	O
key	O
.	O
Regarding	O
target	O
population	O
,	O
it	O
is	O
necessary	O
to	O
identify	O
whether	O
this	O
treatment	O
should	O
only	O
be	O
considered	O
for	O
individuals	O
with	O
depression	B-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
that	O
are	O
non	O
-	O
responsive	O
to	O
other	O
treatment	O
methods	O
,	O
or	O
whether	O
it	O
could	O
be	O
prophylactic	O
for	O
patients	O
with	O
severe	O
symptoms	O
.	O
This	O
is	O
relevant	O
as	O
long	O
-	O
term	O
antidepressant	O
use	O
can	O
obstruct	O
the	O
potential	O
therapeutic	B-OUTCOME
action	I-OUTCOME
of	O
psychedelics	B-DRUG
(	O
Bonson	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O
As	O
it	O
is	O
unclear	O
whether	O
a	O
wash	O
-	O
out	O
period	O
would	O
be	O
enough	O
to	O
negate	O
this	O
effect	O
,	O
it	O
seems	O
worthwhile	O
to	O
avoid	O
delaying	O
psychedelic	O
treatment	O
too	O
long	O
.	O
Additionally	O
,	O
treating	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychological	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
with	O
psychedelics	B-DRUG
is	O
desirable	O
,	O
however	O
in	O
reality	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
psychological	I-HEALTH CONDITION
distress	I-HEALTH CONDITION
with	O
psychedelics	B-DRUG
is	O
limited	O
by	O
a	O
variety	O
of	O
exclusion	O
criteria	O
.	O
Patients	O
may	O
also	O
be	O
reluctant	O
to	O
participate	O
in	O
such	O
an	O
intervention	O
as	O
high	B-DRUG
doses	I-DRUG
have	O
sometimes	O
been	O
associated	O
with	O
transient	B-OUTCOME
episodes	I-OUTCOME
of	I-OUTCOME
psychological	I-OUTCOME
distress	I-OUTCOME
or	O
anxiety	B-HEALTH CONDITION
(	O
G	O
et	O
al	O
.	O
,	O
2011	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2006	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
)	O
It	O
would	O
also	O
be	O
necessary	O
to	O
determine	O
an	O
early	O
proximal	O
end	O
-	O
point	O
to	O
prove	O
initial	O
impact	O
of	O
treatment	O
.	O
As	O
previously	O
mentioned	O
,	O
several	O
studies	O
have	O
shown	O
that	O
the	O
intensity	O
of	O
the	O
subjective	O
mystical	B-HEALTH CONDITION
experience	I-HEALTH CONDITION
was	O
correlated	O
with	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
clinical	I-OUTCOME
outcomes	I-OUTCOME
(	O
Ross	O
et	O
al	O
.	O
,	O
2016	O
,	O
Griffiths	O
et	O
al	O
.	O
,	O
2016	O
,	O
Carhart	O
-	O
Harris	O
et	O
al	O
.	O
,	O
2018	O
,	O
Grof	O
et	O
al	O
.	O
,	O
1973	O
,	O
Roseman	O
et	O
al	O
.	O
,	O
2017	O
,	O
Pahnke	O
,	O
1969	O
,	O
C	O
-	O
H	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
Hence	O
,	O
this	O
could	O
serve	O
as	O
a	O
useful	O
early	O
predictor	O
of	O
treatment	O
response	O
,	O
but	O
first	O
this	O
needs	O
to	O
be	O
further	O
explored	O
and	O
better	O
defined	O
Finally	O
,	O
cost	O
-	O
effectiveness	O
must	O
be	O
established	O
.	O
The	O
fact	O
that	O
psychological	O
support	O
or	O
at	O
least	O
a	O
supportive	O
environment	O
are	O
required	O
every	O
time	O
could	O
be	O
a	O
major	O
limitation	O
(	O
Johnson	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
In	O
light	O
of	O
this	O
,	O
future	O
research	O
needs	O
to	O
determine	O
the	O
relative	B-OUTCOME
therapeutic	I-OUTCOME
contribution	I-OUTCOME
of	I-OUTCOME
psychotherapy	I-OUTCOME
as	O
part	O
of	O
the	O
treatment	B-OUTCOME
model	I-OUTCOME
.	O
The	O
results	O
presented	O
herein	O
indicate	O
that	O
psychedelics	B-DRUG
caused	O
comparable	O
anti	B-OUTCOME
-	I-OUTCOME
depressant	I-OUTCOME
and	I-OUTCOME
anxiolytic	I-OUTCOME
effects	I-OUTCOME
when	O
administered	O
with	O
and	O
without	O
formal	O
psychological	O
intervention	O
.	O
Although	O
the	O
high	O
degree	O
of	O
heterogeneity	O
among	O
studies	O
limits	O
this	O
interpretation	O
,	O
The	O
results	O
suggests	O
that	O
providing	O
a	O
supportive	O
environment	O
may	O
be	O
enough	O
.	O
Understanding	O
whether	O
this	O
is	O
the	O
case	O
is	O
important	O
,	O
as	O
minimising	O
therapy	O
requirement	O
is	O
desirable	O
to	O
reduce	O
costs	O
,	O
however	O
such	O
therapy	O
minimisation	O
should	O
not	O
compromise	O
treatment	B-OUTCOME
efficacy	I-OUTCOME
or	O
jeopardise	O
patient	O
safety	O
.	O
Overall	O
,	O
the	O
direct	O
medical	O
costs	O
need	O
to	O
be	O
balanced	O
against	O
the	O
social	O
and	O
economic	O
costs	O
of	O
illness	O
(	O
C	O
-	O
H	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O
-DOCSTART- -X- O O
Our	O
results	O
reveal	O
that	O
the	O
entropy	B-OUTCOME
increases	I-OUTCOME
after	O
Ayahuasca	B-DRUG
ingestion	O
.	O
The	O
following	O
also	O
increase	O
:	O
geodesic	B-OUTCOME
distance	I-OUTCOME
,	O
clustering	B-OUTCOME
coefficient	I-OUTCOME
and	O
local	B-OUTCOME
efficiency	I-OUTCOME
.	O
However	O
,	O
the	O
global	B-OUTCOME
efficiency	I-OUTCOME
decreases	O
.	O
Overall	O
,	O
we	O
find	O
an	O
increase	B-OUTCOME
of	I-OUTCOME
local	I-OUTCOME
integration	I-OUTCOME
and	O
a	O
decrease	B-OUTCOME
of	I-OUTCOME
global	I-OUTCOME
integration	I-OUTCOME
in	O
the	O
functional	B-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
We	O
interpret	O
these	O
findings	O
in	O
the	O
context	O
of	O
some	O
well	O
understood	O
prototypical	O
classes	O
of	O
networks	O
.	O
Regular	O
lattices	O
have	O
fixed	O
coordination	O
number	O
,	O
hence	O
all	O
nodes	O
have	O
the	O
same	O
degree	O
and	O
the	O
Shannon	O
entropy	O
of	O
the	O
degree	O
distribution	O
is	O
thus	O
zero	O
.	O
In	O
contrast	O
,	O
the	B-OUTCOME
entropy	I-OUTCOME
is	O
high	O
in	O
networks	O
with	O
broad	O
distributions	O
of	O
degree	O
.	O
The	O
observed	O
increase	B-OUTCOME
in	I-OUTCOME
entropy	I-OUTCOME
after	O
Ayahuasca	B-DRUG
ingestion	O
indicates	O
that	O
the	O
degree	O
distribution	O
becomes	O
broader	O
.	O
In	O
the	O
context	O
of	O
the	O
Watts	O
-	O
Strogatz	O
model59	O
,	O
clustering	B-OUTCOME
and	I-OUTCOME
geodesic	I-OUTCOME
distance	I-OUTCOME
both	I-OUTCOME
decrease	I-OUTCOME
when	O
highly	O
regular	B-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
are	O
transformed	O
into	O
small	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
world	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
by	O
randomly	O
re	O
-	O
assigning	O
the	O
links	O
.	O
Whereas	O
clustering	B-OUTCOME
and	I-OUTCOME
geodesic	I-OUTCOME
distances	I-OUTCOME
decrease	I-OUTCOME
with	I-OUTCOME
increasing	I-OUTCOME
randomness	I-OUTCOME
in	O
such	O
models	O
,	O
we	O
find	O
the	O
opposite	O
behavior	O
for	O
Ayahuasca	B-DRUG
,	O
i.e.	O
,	O
randomness	O
as	O
measured	O
by	O
the	O
Shannon	O
entropy	O
of	O
the	O
node	O
degree	O
distribution	O
increases	O
in	O
parallel	O
with	O
clustering	O
and	O
geodesic	O
distances	O
.	O
Hence	O
,	O
our	O
findings	O
can	O
not	O
be	O
reduced	O
to	O
simple	O
explanations	O
of	O
greater	O
or	O
lesser	O
randomness	O
.	O
Locally	B-OUTCOME
,	I-OUTCOME
there	I-OUTCOME
is	I-OUTCOME
an	I-OUTCOME
increase	I-OUTCOME
in	I-OUTCOME
integration	I-OUTCOME
(	O
as	O
measured	O
by	O
network	O
efficiency	O
)	O
,	O
but	O
globally	B-OUTCOME
there	I-OUTCOME
is	I-OUTCOME
a	I-OUTCOME
decrease	I-OUTCOME
in	I-OUTCOME
integration	I-OUTCOME
.	O
Indeed	O
the	O
increase	B-OUTCOME
of	I-OUTCOME
geodesic	I-OUTCOME
distance	I-OUTCOME
and	O
decrease	B-OUTCOME
of	I-OUTCOME
global	I-OUTCOME
efficiency	I-OUTCOME
after	O
Ayahuasca	B-DRUG
intake	O
signify	O
that	O
the	O
functional	B-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
are	O
less	B-OUTCOME
globally	I-OUTCOME
integrated	I-OUTCOME
.	O
One	O
possible	O
interpretation	O
of	O
these	O
findings	O
is	O
that	O
the	O
increase	B-OUTCOME
of	I-OUTCOME
local	I-OUTCOME
robustness	I-OUTCOME
and	O
the	O
decrease	B-OUTCOME
of	I-OUTCOME
global	I-OUTCOME
integration	I-OUTCOME
reflect	O
a	O
variation	O
in	O
modular	B-NEURAL MECHANISM/CORRELATE
structure	I-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
the	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
.	O
Recent	O
studies	O
have	O
reported	O
the	O
presence	O
of	O
modularity	O
in	O
functional	B-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
on	O
several	O
scales50	O
,	O
60	O
,	O
61	O
.	O
Modular	B-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
are	O
characterized	O
by	O
the	O
existence	O
of	O
reasonably	O
well	O
-	O
defined	O
subnetworks	O
in	O
which	O
internal	O
connections	O
are	O
denser	O
than	O
connections	O
between	O
distinct	O
subnetworks50	O
.	O
However	O
,	O
traditional	O
algorithms62,63,64	O
were	O
not	O
able	O
to	O
detect	O
variation	O
on	O
modular	O
structure	O
features	O
between	O
our	O
sets	O
of	O
networks	O
Our	O
results	O
are	O
broadly	O
consistent	O
with	O
the	O
entropic	O
brain	B-NEURAL MECHANISM/CORRELATE
hypothesis	O
,	O
hence	O
Our	O
discuss	O
the	O
latter	O
in	O
the	O
context	O
of	O
Our	O
findings	O
.	O
The	O
hypothesis	O
maintains	O
that	O
the	B-SUBJECTIVE EXPERIENCE
mental	I-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
induced	O
by	O
psychedelics	B-DRUG
,	O
which	O
the	O
original	O
authors	O
term	O
“	O
primary	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
,	O
”	O
presents	O
relatively	O
elevated	B-OUTCOME
entropy	I-OUTCOME
in	O
some	O
features	O
of	O
brain	B-NEURAL MECHANISM/CORRELATE
organization	O
,	O
compared	O
to	O
the	O
ordinary	B-SUBJECTIVE EXPERIENCE
waking	I-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
(	O
termed	O
“	O
secondary”)11	O
.	O
Although	O
it	O
may	O
be	O
somewhat	O
counter	O
-	O
intuitive	O
that	O
the	O
psychedelic	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
is	O
considered	O
primary	O
while	O
ordinary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
is	O
secondary	O
,	O
ordinary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
is	O
secondary	O
hypothesis	O
is	O
inherently	O
plausible	O
considering	O
that	O
a	O
wider	O
spectrum	O
of	O
experiences	O
is	O
possible	O
with	O
psychedelics	B-DRUG
than	O
in	O
ordinary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
.	O
In	O
this	O
sense	O
,	O
ordinary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
can	O
be	O
thought	O
of	O
as	O
a	O
restriction	O
or	O
constrained	O
special	O
case	O
of	O
a	O
more	O
primary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
.	O
The	O
hypothesized	O
lower	O
entropy	O
of	O
ordinary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
relative	O
to	O
primary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
is	O
attributed	O
to	O
this	O
reduction	B-OUTCOME
of	I-OUTCOME
freedom	I-OUTCOME
.	O
In	O
fact	O
,	O
the	O
idea	O
that	O
ordinary	B-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
is	O
not	O
primary	O
was	O
previously	O
put	O
forth	O
by	O
Alan	O
Watts	O
to	O
describe	O
what	O
later	O
became	O
widely	O
known	O
as	O
mindfulness	O
65	O
.	O
(	O
We	O
emphasize	O
that	O
the	O
terms	O
“	O
primary	O
”	O
and	O
“	O
secondary	O
”	O
are	O
used	O
not	O
as	O
value	O
judgements	O
,	O
but	O
rather	O
to	O
denote	O
temporal	O
order	O
,	O
i.e.	O
the	O
order	O
of	O
appearance	O
,	O
both	O
evolutionarily	O
as	O
well	O
as	O
in	O
the	O
maturation	O
of	O
a	O
healthy	O
individual	O
)	O
More	O
specifically	O
,	O
we	O
believe	O
that	O
the	O
observed	O
increase	B-OUTCOME
in	I-OUTCOME
entropy	I-OUTCOME
may	O
be	O
related	O
to	O
the	O
temporary	O
removal	O
of	O
the	O
some	O
of	O
the	O
restrictions	O
that	O
are	O
necessary	O
for	O
sustaining	O
ordinary	B-SUBJECTIVE EXPERIENCE
(	I-SUBJECTIVE EXPERIENCE
adult	I-SUBJECTIVE EXPERIENCE
trained	I-SUBJECTIVE EXPERIENCE
)	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
.	O
With	O
these	O
restrictions	O
temporarily	O
gone	O
,	O
the	B-OUTCOME
entropy	I-OUTCOME
increases	I-OUTCOME
and	O
the	B-OUTCOME
mind	I-OUTCOME
may	I-OUTCOME
become	I-OUTCOME
effectively	I-OUTCOME
more	I-OUTCOME
“	I-OUTCOME
free	I-OUTCOME
”	O
,	O
attaining	O
a	O
more	B-OUTCOME
flexible	I-OUTCOME
state	I-OUTCOME
in	O
which	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
referential	I-SUBJECTIVE EXPERIENCE
narratives	I-SUBJECTIVE EXPERIENCE
and	O
thoughts	B-SUBJECTIVE EXPERIENCE
about	O
the	O
past	O
or	O
the	O
future	O
are	O
no	O
longer	O
mentally	O
identified	O
with	O
the	O
reality	O
that	O
they	O
represent	O
.	O
We	O
emphasize	O
,	O
however	O
,	O
that	O
“	O
correlation	O
is	O
not	O
causation	O
”	O
and	O
that	O
the	O
entropy	B-OUTCOME
increases	I-OUTCOME
may	O
occurr	O
in	O
parallel	O
with	O
the	B-SUBJECTIVE EXPERIENCE
loss	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
constraints	I-SUBJECTIVE EXPERIENCE
,	O
rather	O
than	O
bear	O
a	O
direct	O
causal	O
relation	O
to	O
rather	O
.	O
These	O
ideas	O
are	O
further	O
explored	O
in	O
the	O
Supplementary	O
Discussion	O
(	O
see	O
also	O
refs	O
.	O
[	O
80,81,82,83	O
]	O
)	O
Relatively	O
few	O
studies	O
have	O
investigated	O
entropy	B-OUTCOME
in	O
brain	B-NEURAL MECHANISM/CORRELATE
functional	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
,	O
hence	O
additional	O
comments	O
are	O
in	O
order	O
.	O
Tagliazucchi	O
et	O
al.14	O
showed	O
that	O
psilocybin	B-DRUG
(	O
psychedelic	O
present	O
in	O
some	O
species	O
of	O
mushrooms	O
)	O
may	O
be	O
responsible	O
for	O
increases	B-OUTCOME
of	I-OUTCOME
a	I-OUTCOME
different	I-OUTCOME
entropy	I-OUTCOME
measure	O
in	O
functional	B-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
of	O
the	O
4	O
regions	O
of	O
Default	B-NEURAL MECHANISM/CORRELATE
Mode	I-NEURAL MECHANISM/CORRELATE
Network	I-NEURAL MECHANISM/CORRELATE
(	O
DMN	O
)	O
,	O
a	O
relevant	O
functional	O
network	O
related	O
to	O
resting	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
.	O
Recently	O
,	O
Yao	O
et	O
al.66	O
correlated	O
entropy	B-OUTCOME
increases	I-OUTCOME
in	O
the	O
human	O
brain	B-NEURAL MECHANISM/CORRELATE
with	O
age	O
.	O
This	O
study	O
also	O
supports	O
the	O
view	O
that	O
entropy	B-OUTCOME
is	O
correlated	O
to	O
brain	B-NEURAL MECHANISM/CORRELATE
function	I-NEURAL MECHANISM/CORRELATE
(	O
and	O
perhaps	O
also	O
This	O
study	O
development	O
)	O
.	O
Moreover	O
,	O
in	O
agreement	O
with	O
our	O
results	O
,	O
a	O
study	O
by	O
Schröter	O
et	O
al.4	O
similarly	O
suggests	O
that	O
functional	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
topology	I-NEURAL MECHANISM/CORRELATE
may	O
have	O
a	O
central	O
role	O
in	O
consciousness	B-SUBJECTIVE EXPERIENCE
quality	O
.	O
functional	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
topology	I-NEURAL MECHANISM/CORRELATE
may	O
have	O
a	O
central	O
role	O
in	O
consciousness	B-SUBJECTIVE EXPERIENCE
quality	O
investigated	O
the	O
effects	O
on	O
the	O
human	O
brain	B-NEURAL MECHANISM/CORRELATE
of	O
the	O
anesthetic	O
propofol	B-DRUG
,	O
which	O
can	O
induce	O
loss	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness67	I-SUBJECTIVE EXPERIENCE
.	O
functional	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
topology	I-NEURAL MECHANISM/CORRELATE
may	O
have	O
a	O
central	O
role	O
in	O
consciousness	B-SUBJECTIVE EXPERIENCE
quality	O
reported	O
a	O
decrease	O
of	O
the	O
clustering	O
coefficient	O
,	O
which	O
is	O
strongly	O
influenced	O
by	O
degree	O
distribution	O
(	O
however	O
,	O
geodesic	O
distance	O
remained	O
unchanged	O
)	O
.	O
Very	O
recently	O
,	O
Lebedev	O
et	O
al.15	O
and	O
separately	O
Schartner	O
et	O
al.16	O
have	O
reported	O
evidence	O
of	O
increases	B-OUTCOME
in	I-OUTCOME
measures	I-OUTCOME
of	I-OUTCOME
entropy	I-OUTCOME
,	O
the	O
former	O
with	O
LSD	B-DRUG
and	O
the	O
latter	O
with	O
LSD	B-DRUG
,	O
psilocybin	B-DRUG
and	O
ketamine	B-DRUG
We	O
briefly	O
comment	O
on	O
the	O
limitations	O
of	O
We	O
method	O
:	O
(	O
i	O
)	O
the	O
reduced	O
number	O
of	O
subjects	O
and	O
the	O
fact	O
that	O
all	O
of	O
them	O
were	O
experienced	O
with	O
Ayahuasca	B-DRUG
do	O
not	O
allow	O
population	O
inferences	O
and	O
do	O
not	O
elucidate	O
whether	O
the	O
effects	O
observed	O
here	O
were	O
only	O
due	O
the	O
acute	O
administration	O
or	O
if	O
previous	O
experience	O
also	O
played	O
a	O
significant	O
role	O
;	O
(	O
ii	O
)	O
expectancy	O
and	O
suggestion	O
were	O
not	O
controlled	O
,	O
as	O
placebo	O
was	O
not	O
used	O
;	O
(	O
iii	O
)	O
networks	O
were	O
built	O
upon	O
a	O
number	O
of	O
critical	O
choices	O
,	O
such	O
as	O
the	O
atlas	O
used	O
to	O
partition	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
,	O
the	O
method	O
used	O
to	O
build	O
the	O
correlation	O
matrix	O
,	O
and	O
the	O
cutoff	O
thresholds	O
for	O
generating	O
the	O
adjacency	O
matrices	O
from	O
correlation	O
matrices68	O
,	O
69	O
,	O
which	O
may	O
affect	O
the	O
final	O
results	O
;	O
(	O
iv	O
)	O
the	O
chosen	O
range	O
of	O
correlation	O
values	O
automatically	O
limits	O
the	O
networks	O
’	O
behavior	O
to	O
a	O
small	O
-	O
world	O
network	O
.	O
Despite	O
this	O
limitation	O
,	O
it	O
is	O
important	O
to	O
highlight	O
that	O
several	O
studies	O
have	O
consistently	O
demonstrated	O
that	O
brain	B-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
exhibit	O
a	O
small	B-OUTCOME
-	I-OUTCOME
world	I-OUTCOME
behavior	I-OUTCOME
Finally	O
,	O
We	O
speculate	O
about	O
whether	O
or	O
not	O
We	O
finding	O
of	O
larger	B-OUTCOME
mean	I-OUTCOME
geodesic	I-OUTCOME
distances	I-OUTCOME
may	O
have	O
any	O
relation	O
to	O
self	O
-	O
reports	O
of	O
“	O
mind	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
expansion	I-SUBJECTIVE EXPERIENCE
”	O
by	O
users	O
of	O
psychedelics	B-DRUG
(	O
see	O
also	O
ref	O
.	O
16	O
)	O
.	O
Could	O
there	O
be	O
a	O
direct	O
relation	O
between	O
entropy	B-OUTCOME
increases	I-OUTCOME
and	O
the	O
higher	B-OUTCOME
creativity	I-OUTCOME
reported	O
by	O
users	O
of	O
psychedelics	B-DRUG
?	O
Such	O
questions	O
merit	O
further	O
investigation	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
are	O
broadly	O
consistent	O
with	O
the	O
hypothesis	O
that	O
psychedelics	B-DRUG
increase	B-OUTCOME
the	I-OUTCOME
entropy	I-OUTCOME
in	I-OUTCOME
brain	I-OUTCOME
functions	I-OUTCOME
.	O
By	O
calculating	O
the	O
Shannon	O
entropy	O
of	O
the	O
degree	O
distribution	O
of	O
complex	O
networks	O
generated	O
from	O
fMRI	O
data	O
,	O
we	O
have	O
taken	O
a	O
new	O
low	O
-	O
computational	O
-	O
cost	O
approach	O
to	O
investigating	O
brain	B-NEURAL MECHANISM/CORRELATE
function	I-NEURAL MECHANISM/CORRELATE
under	O
the	O
influence	O
of	O
psychedelics	B-DRUG
-DOCSTART- -X- O O
Dennett	O
(	O
1992	O
)	O
famously	O
argued	O
that	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
is	O
a	O
‘	O
centre	O
of	O
narrative	O
gravity	O
’	O
akin	O
to	O
the	O
centre	O
of	O
gravity	O
of	O
an	O
object	O
:	O
an	O
abstraction	O
,	O
but	O
no	O
less	O
real	O
or	O
predictively	O
useful	O
for	O
that	O
.	O
On	O
the	O
predictive	O
coding	O
construal	O
of	O
the	O
integrative	O
self	O
,	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
-	O
model	O
functions	O
as	O
a	O
centre	O
of	O
representational	O
gravity	O
—	O
not	O
just	O
in	O
narrative	O
processes	O
but	O
also	O
in	O
lower	O
-	O
level	O
affective	O
,	O
bodily	O
,	O
and	O
spatial	O
processes	O
.	O
It	O
is	O
a	O
representation	O
of	O
the	O
′point′	O
around	O
which	O
everything	O
else	O
revolves	O
.	O
But	O
crucially	O
,	O
it	O
is	O
not	O
a	O
representation	O
as	O
of	O
a	O
mere	O
point	O
,	O
but	O
as	O
of	O
a	O
particular	O
.	O
This	O
is	O
why	O
we	O
reject	O
Dennett	O
’s	O
metaphysics	O
of	O
selfhood	O
,	O
as	O
well	O
as	O
Hohwy	O
and	O
Michael	O
’s	O
claim	O
that	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
-	O
model	O
has	O
enough	O
of	O
the	O
right	O
attributes	O
to	O
qualify	O
as	O
a	O
self	O
If	O
our	O
conjectures	O
are	O
right	O
,	O
the	O
content	O
of	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
-	O
model	O
is	O
Cartesian	O
:	O
it	O
is	O
of	O
a	O
substance	O
or	O
an	O
entity	O
which	O
has	O
the	O
properties	O
and	O
experiences	O
.	O
And	O
here	O
we	O
agree	O
with	O
Metzinger	O
that	O
there	O
‘	O
is	O
just	O
no	O
entity	O
there	O
,	O
no	O
individual	O
substance	O
,	O
and	O
scientifically	O
we	O
can	O
predict	O
and	O
explain	O
everything	O
we	O
want	O
to	O
predict	O
and	O
explain	O
in	O
a	O
much	O
more	O
parsimonious	O
way	O
’	O
(	O
quoted	O
in	O
Marshall	O
2016	O
)	O
.	O
Thus	O
,	O
our	O
view	O
is	O
structurally	O
analogous	O
to	O
Mackie	O
’s	O
(	O
1977	O
)	O
error	O
theory	O
of	O
morality	O
,	O
conjoining	O
the	O
psychosemantic	O
claim	O
that	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
-	O
representation	O
is	O
as	O
of	O
a	O
Cartesian	O
substance	O
with	O
the	O
ontological	O
claim	O
that	O
no	O
such	O
substance	O
exists	O
.	O
It	O
is	O
also	O
substantially	O
similar	O
to	O
Metzinger	O
’s	O
views	O
about	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
-	O
model	O
,	O
developed	O
in	O
the	O
context	O
of	O
a	O
specific	O
case	O
and	O
a	O
mechanistic	O
proposal	O
(	O
self	O
-	O
binding	O
on	O
predictive	O
processing	O
principles	O
)	O
about	O
how	O
the	O
model	O
performs	O
the	O
model	O
adaptive	O
functions	O
for	O
the	O
organism	O
All	O
of	O
this	O
fits	O
smoothly	O
with	O
the	O
idea	O
that	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
and	O
SLN	B-NEURAL MECHANISM/CORRELATE
implement	O
narrative	O
and	O
embodied	B-SUBJECTIVE EXPERIENCE
aspects	O
of	O
self	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
representation	O
,	O
respectively	O
.	O
The	O
self	O
-	O
representation	O
as	O
we	O
conceive	O
The	O
self	O
-	O
representation	O
as	O
we	O
conceive	O
serves	O
as	O
an	O
organizing	O
principle	O
at	O
different	O
levels	O
and	O
in	O
different	O
domains	O
of	O
processing	O
.	O
Perceptual	B-SUBJECTIVE EXPERIENCE
representations	I-SUBJECTIVE EXPERIENCE
are	O
organized	O
in	O
an	O
egocentric	O
space	O
;	O
interoceptive	B-SUBJECTIVE EXPERIENCE
representations	I-SUBJECTIVE EXPERIENCE
are	O
interpreted	O
as	O
signals	O
of	O
adaptively	O
relevant	O
events	O
or	O
‘	O
core	O
relational	O
themes	O
’	O
(	O
Prinz	O
2004	O
)	O
;	O
and	O
narratives	O
are	O
structured	O
around	O
the	O
fortunes	O
and	O
prospects	O
of	O
a	O
protagonist	O
.	O
At	O
all	O
levels	O
,	O
salience	O
is	O
attributed	O
,	O
attention	O
directed	O
,	O
and	O
information	O
integrated	O
in	O
accordance	O
with	O
the	O
relevance	O
of	O
information	O
to	O
the	O
organism	O
’s	O
goals	O
.	O
As	O
James	O
Kingsland	O
(	O
2016	O
,	O
209	O
)	O
puts	O
it	O
,	O
‘	O
we	O
have	O
evolved	O
into	O
an	O
ape	O
that	O
takes	O
things	O
personally	O
-DOCSTART- -X- O O
Based	O
on	O
the	O
results	O
from	O
experimental	O
studies	O
of	O
moderate	O
to	O
high	O
dose	O
psychedelics	B-DRUG
we	O
believe	O
that	O
the	O
case	O
for	O
subjective	B-DRUG
effects	I-DRUG
playing	O
a	O
major	O
role	O
in	O
enduring	B-OUTCOME
beneficial	I-OUTCOME
effects	I-OUTCOME
is	O
compelling	O
.	O
Across	O
a	O
number	O
of	O
studies	O
,	O
when	O
the	O
intensity	O
of	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
psychedelic	I-SUBJECTIVE EXPERIENCE
effect	I-SUBJECTIVE EXPERIENCE
is	O
controlled	O
,	O
certain	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
predict	O
desirable	B-OUTCOME
outcomes	I-OUTCOME
.	O
Underlying	O
neurobiological	O
-	O
based	O
mechanisms	O
are	O
undoubtedly	O
necessary	O
but	O
likely	O
not	O
sufficient	O
to	O
confer	O
full	O
beneficial	B-OUTCOME
effects	I-OUTCOME
.	O
In	O
the	O
nonsubjective	B-SUBJECTIVE EXPERIENCE
anesthesia	I-SUBJECTIVE EXPERIENCE
test	O
that	O
we	O
describe	O
,	O
we	O
would	O
not	O
be	O
surprised	O
to	O
see	O
some	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
but	O
that	O
some	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
would	O
be	O
of	O
lower	O
magnitude	O
and/or	O
more	O
transient	O
.	O
We	O
suspect	O
that	O
the	O
proportion	O
of	O
the	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
beneficial	I-OUTCOME
outcomes	I-OUTCOME
that	O
are	O
mediated	O
through	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
is	O
substantial	O
,	O
accounting	O
for	O
the	O
majority	O
of	O
the	O
lasting	B-OUTCOME
beneficial	I-OUTCOME
effects	I-OUTCOME
of	O
psychedelics	B-DRUG
.	O
For	O
an	O
alternative	O
perspective	O
,	O
please	O
see	O
a	O
companion	O
Viewpoint	O
in	O
this	O
issue	O
-DOCSTART- -X- O O
Until	O
recently	O
,	O
it	O
was	O
unknown	O
if	O
nonhallucinogenic	B-DRUG
psychoplastogens	I-DRUG
could	O
produce	O
beneficial	B-OUTCOME
behavioral	I-OUTCOME
effects	I-OUTCOME
comparable	O
to	O
psychedelics	B-DRUG
.	O
Through	O
careful	O
chemical	O
design	O
,	O
we	O
were	O
able	O
to	O
engineer	O
tabernanthalog	B-DRUG
(	I-DRUG
TBG)—a	I-DRUG
nonhallucinogenic	O
analogue	O
of	O
5	B-DRUG
-	I-DRUG
MeO	I-DRUG
-	I-DRUG
DMT	I-DRUG
that	O
promotes	O
cortical	B-OUTCOME
neuron	I-OUTCOME
structural	I-OUTCOME
plasticity	I-OUTCOME
through	O
activation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors.33	I-NEURAL MECHANISM/CORRELATE
Like	O
psychedelic	B-DRUG
compounds	I-DRUG
,	O
TBG	B-DRUG
has	O
demonstrated	O
preclinical	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
suggesting	O
that	O
TBG	B-DRUG
might	O
be	O
effective	O
at	O
treating	B-OUTCOME
a	I-OUTCOME
range	I-OUTCOME
of	I-OUTCOME
neuropsychiatric	I-OUTCOME
diseases	I-OUTCOME
including	O
depression	B-HEALTH CONDITION
,	O
alcohol	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
,	O
and	O
heroin	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorder.33	I-HEALTH CONDITION
Future	O
work	O
needs	O
to	O
address	O
why	O
functionally	B-NEURAL MECHANISM/CORRELATE
selective	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
ligands	I-NEURAL MECHANISM/CORRELATE
such	O
as	O
TBG	B-DRUG
can	O
produce	O
plasticity	B-OUTCOME
and	I-OUTCOME
therapeutic	I-OUTCOME
behavioral	I-OUTCOME
responses	I-OUTCOME
without	O
inducing	O
behavioral	B-OUTCOME
effects	I-OUTCOME
characteristic	O
of	O
classic	O
psychedelics	B-DRUG
Ultimately	O
,	O
clinical	O
trials	O
will	O
be	O
necessary	O
to	O
determine	O
if	O
psychoplastogenic	B-DRUG
analogues	I-DRUG
of	O
psychedelics	B-DRUG
can	O
produce	O
therapeutic	B-OUTCOME
effects	I-OUTCOME
in	O
humans	O
without	O
inducing	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
like	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
.	O
Additionally	O
,	O
there	O
are	O
several	O
other	O
experiments	O
that	O
could	O
potentially	O
be	O
performed	O
to	O
elucidate	O
the	O
roles	O
of	O
both	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
and	O
enhanced	B-OUTCOME
neural	I-OUTCOME
plasticity	I-OUTCOME
in	O
the	O
therapeutic	O
properties	O
of	O
psychedelics	B-DRUG
.	O
One	O
option	O
is	O
to	O
employ	O
a	O
compound	O
producing	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
like	I-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
without	O
promoting	O
neuronal	O
growth	O
in	O
the	O
PFC	B-NEURAL MECHANISM/CORRELATE
as	O
a	O
true	O
active	O
placebo	O
.	O
However	O
,	O
no	O
such	O
compound	O
has	O
been	O
identified	O
yet	O
,	O
and	O
such	O
a	O
compound	O
might	O
not	O
even	O
exist	O
if	O
hallucinogenic	B-OUTCOME
effects	I-OUTCOME
inevitably	O
lead	O
to	O
enhanced	B-OUTCOME
neural	I-OUTCOME
plasticity	I-OUTCOME
Alternatively	O
,	O
psychedelics	B-DRUG
could	O
be	O
administered	O
to	O
patients	O
under	O
anesthesia	O
.	O
This	O
would	O
solve	O
the	O
blinding	O
issue	O
by	O
preventing	O
patients	O
from	O
experiencing	O
the	O
altered	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
consciousness	I-SUBJECTIVE EXPERIENCE
.	O
Such	O
an	O
experimental	O
design	O
could	O
be	O
a	O
powerful	O
way	O
to	O
dissociate	O
the	O
psychological	B-OUTCOME
from	I-OUTCOME
the	I-OUTCOME
neurobiological	I-OUTCOME
effects	I-OUTCOME
of	O
these	O
drugs	O
.	O
However	O
,	O
care	O
must	O
be	O
taken	O
in	O
the	O
design	O
of	O
such	O
studies	O
,	O
as	O
several	O
common	O
anesthetics	B-DRUG
are	O
known	O
to	O
promote	O
neural	B-OUTCOME
plasticity	I-OUTCOME
and	O
produce	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
care	O
To	O
the	O
best	O
of	O
my	O
knowledge	O
,	O
no	O
clinical	O
trial	O
has	O
administered	O
a	O
classic	O
serotonergic	B-DRUG
psychedelic	I-DRUG
after	O
the	O
induction	O
of	O
general	O
anesthesia	O
.	O
However	O
,	O
several	O
studies	O
have	O
demonstrated	O
that	O
intraoperative	O
ketamine	B-DRUG
can	O
improve	O
postoperative	B-OUTCOME
mood	I-OUTCOME
despite	O
the	O
fact	O
that	O
patients	O
were	O
unconscious	O
during	O
ketamine	B-DRUG
administration.34−36	O
While	O
this	O
suggests	O
that	O
ketamine	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
mystical	I-OUTCOME
experiences	I-OUTCOME
may	O
not	O
be	O
necessary	O
to	O
produce	O
therapeutic	B-OUTCOME
responses	I-OUTCOME
,	O
the	O
patients	O
in	O
these	O
studies	O
were	O
not	O
severely	O
depressed	B-HEALTH CONDITION
.	O
Thus	O
,	O
studies	O
administering	O
ketamine	B-DRUG
under	O
general	O
anesthesia	O
to	O
patients	O
with	O
major	B-HEALTH CONDITION
depressive	I-HEALTH CONDITION
disorder	I-HEALTH CONDITION
are	O
warranted	O
,	O
and	O
at	O
least	O
one	O
such	O
study	O
is	O
currently	O
ongoing	O
While	O
preliminary	O
evidence	O
suggests	O
that	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
psychedelics	B-DRUG
are	O
not	O
necessary	O
to	O
produce	O
therapeutic	B-OUTCOME
responses	I-OUTCOME
,	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
psychedelics	B-DRUG
are	O
not	O
necessary	O
to	O
produce	O
therapeutic	B-OUTCOME
responses	I-OUTCOME
may	O
be	O
critical	O
for	O
achieving	O
maximal	O
efficacy	B-OUTCOME
.	O
Though	O
the	O
strong	O
positive	O
correlation	O
between	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
and	O
the	O
strength	O
of	O
therapeutic	B-OUTCOME
responses	I-OUTCOME
does	O
not	O
imply	O
causation	O
,	O
the	O
strong	O
positive	O
correlation	O
between	O
mystical	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
type	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
and	O
the	O
strength	O
of	O
therapeutic	B-OUTCOME
responses	I-OUTCOME
does	O
not	O
imply	O
causation	O
does	O
implicate	O
either	O
psychological	B-OUTCOME
mechanisms	I-OUTCOME
or	O
perhaps	O
an	O
exceptionally	B-OUTCOME
strong	I-OUTCOME
placebo	I-OUTCOME
effect	I-OUTCOME
in	O
the	O
impressive	O
effect	O
sizes	O
observed	O
following	O
psychedelic	O
-	O
assisted	O
therapy	O
.	O
Thus	O
,	O
the	O
combination	O
of	O
a	O
pharmacologically	O
induced	O
state	O
of	O
heightened	B-OUTCOME
neural	I-OUTCOME
plasticity	I-OUTCOME
with	O
a	O
profound	B-SUBJECTIVE EXPERIENCE
subjective	I-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
could	O
prove	O
invaluable	O
for	O
treating	B-OUTCOME
those	O
who	O
are	O
especially	O
ill	O
or	O
who	O
have	O
attempted	O
other	O
treatments	O
without	O
success	O
Despite	O
the	O
promising	O
therapeutic	B-OUTCOME
responses	I-OUTCOME
produced	O
by	O
psychedelic	O
-	O
assisted	O
therapy	O
,	O
the	O
intense	B-SUBJECTIVE EXPERIENCE
subjective	I-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
these	O
drugs	B-DRUG
make	O
it	O
unlikely	O
that	O
these	O
drugs	B-DRUG
will	O
ever	O
become	O
widespread	O
treatments	O
for	O
disorders	O
such	O
as	O
depression	B-HEALTH CONDITION
.	O
In	O
contrast	O
,	O
strategies	O
for	O
rewiring	B-OUTCOME
pathological	I-OUTCOME
neural	I-OUTCOME
circuitry	I-OUTCOME
without	O
producing	O
psychedelic	O
-	O
like	O
mystical	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
hold	O
enormous	O
promise	O
as	O
potential	O
first	O
-	O
line	O
treatments	O
for	O
a	O
variety	O
of	O
neuropsychiatric	B-HEALTH CONDITION
diseases	I-HEALTH CONDITION
.	O
Regardless	O
,	O
nonhallucinogenic	B-DRUG
analogues	I-DRUG
of	O
psychedelics	B-DRUG
will	O
provide	O
a	O
wealth	O
of	O
information	O
about	O
the	O
fundamental	O
neurobiology	B-NEURAL MECHANISM/CORRELATE
underlying	O
both	O
compound	O
-	O
induced	O
neural	B-OUTCOME
plasticity	I-OUTCOME
and	O
hallucinogenic	B-OUTCOME
effects	I-OUTCOME
.	O
For	O
an	O
alternative	O
perspective	O
,	O
please	O
see	O
a	O
companion	O
Viewpoint	O
in	O
this	O
issue	O
-DOCSTART- -X- O O
The	O
current	O
meta	O
-	O
analysis	O
evaluated	O
effects	O
of	O
psilocybin	B-DRUG
coupled	O
with	O
supportive	O
behavioral	O
interventions	O
on	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
.	O
Although	O
a	O
small	O
number	O
of	O
studies	O
were	O
included	O
,	O
available	O
data	O
were	O
promising	O
.	O
Within	O
-	O
group	O
effects	O
at	O
post	O
-	O
treatment	O
and	O
six	O
-	O
month	O
follow	O
-	O
up	O
showed	O
large	O
reductions	O
in	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
symptoms	O
with	O
no	O
evidence	O
of	O
publication	O
bias	O
.	O
Qualitative	O
assessment	O
of	O
risk	O
of	O
bias	O
was	O
more	O
concerning	O
,	O
with	O
high	O
risk	O
in	O
several	O
domains	O
.	O
High	O
between	O
-	O
study	O
heterogeneity	O
suggests	O
there	O
may	O
be	O
systematic	O
variation	O
across	O
the	O
studies	O
.	O
Future	O
meta	O
-	O
analyses	O
should	O
examine	O
study	O
features	O
(	O
e.g.	O
,	O
psilocybin	B-DRUG
dose	O
)	O
as	O
moderators	O
of	O
treatment	O
effects	O
Effects	O
of	O
psilocybin	B-DRUG
on	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
were	O
also	O
evident	O
in	O
three	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
studies	O
.	O
Effect	O
sizes	O
(	O
gs	O
=	O
0.82	O
to	O
0.83	O
for	O
psilocybin	B-DRUG
vs.	O
placebo	O
)	O
are	O
similar	O
to	O
psychological	O
interventions	O
versus	O
no	O
treatment	O
(	O
d	O
=	O
0.80	O
;	O
Wampold	O
and	O
Imel	O
,	O
2015	O
)	O
and	O
cognitive	O
behavioral	O
therapy	O
versus	O
no	O
treatment	O
(	O
d	O
=	O
0.82	O
;	O
Butler	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
Given	O
both	O
psilocybin	B-DRUG
and	O
placebo	O
groups	O
received	O
equivalent	O
behavioral	O
interventions	O
,	O
the	O
additive	O
benefit	O
of	O
psilocybin	B-DRUG
may	O
be	O
substantial	O
.	O
However	O
,	O
this	O
effect	O
was	O
not	O
robust	O
to	O
publication	O
bias	O
,	O
highlighting	O
the	O
need	O
for	O
further	O
placebo	O
-	O
controlled	O
studies	O
.	O
As	O
supportive	O
behavioral	O
interventions	O
were	O
included	O
in	O
all	O
studies	O
,	O
results	O
can	O
not	O
be	O
interpreted	O
to	O
indicate	O
general	O
benefits	O
associated	O
with	O
the	O
use	O
of	O
psilocybin	B-DRUG
in	O
the	O
absence	O
of	O
support	O
Additional	O
large	O
-	O
scale	O
studies	O
examining	O
the	O
effects	O
of	O
psilocybin	B-DRUG
on	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
may	O
be	O
warranted	O
,	O
as	O
only	O
one	O
of	O
the	O
four	O
studies	O
focused	O
on	O
this	O
population	O
.	O
It	O
may	O
be	O
valuable	O
to	O
evaluate	O
various	O
behavioral	O
interventions	O
to	O
support	O
or	O
extend	O
benefits	O
of	O
psilocybin	B-DRUG
treatments	O
The	O
current	O
meta	O
-	O
analysis	O
has	O
several	O
limitations	O
.	O
Only	O
four	O
studies	O
(	O
N	O
=	O
117	O
)	O
were	O
available	O
,	O
limiting	O
the	O
reliability	O
of	O
the	O
observed	O
effects	O
.	O
Small	O
sample	O
studies	O
can	O
introduce	O
biases	O
(	O
Button	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Heterogeneity	O
in	O
effect	O
sizes	O
and	O
design	O
features	O
were	O
generally	O
high	O
.	O
High	O
risk	O
of	O
bias	O
was	O
present	O
for	O
most	O
studies	O
(	O
performance	O
bias	O
and	O
detection	O
bias	O
due	O
to	O
lack	O
of	O
blinding	O
,	O
attrition	O
bias	O
)	O
.	O
Selection	O
bias	O
also	O
limits	O
generalizability	O
of	O
the	O
available	O
evidence	O
as	O
all	O
participants	O
were	O
willing	O
to	O
receive	O
a	O
Schedule	O
I	O
substance	O
.	O
Three	O
of	O
the	O
four	O
studies	O
included	O
individuals	O
with	O
terminal	B-HEALTH CONDITION
cancer	I-HEALTH CONDITION
diagnoses	I-HEALTH CONDITION
,	O
which	O
may	O
not	O
represent	O
anxiety	B-HEALTH CONDITION
and	O
depression	B-HEALTH CONDITION
generally	O
.	O
Limited	O
racial	O
/	O
ethnic	O
diversity	O
reduces	O
generalizability	O
Nonetheless	O
,	O
the	O
current	O
meta	O
-	O
analysis	O
suggests	O
psilocybin	B-DRUG
in	O
combination	O
with	O
behavioral	O
support	O
may	O
provide	O
a	O
safe	O
and	O
effective	O
treatment	O
option	O
for	O
reducing	B-OUTCOME
symptoms	I-OUTCOME
of	I-OUTCOME
anxiety	I-OUTCOME
and	O
depression	B-HEALTH CONDITION
.	O
This	O
is	O
an	O
area	O
for	O
additional	O
careful	O
,	O
scientific	O
study	O
-DOCSTART- -X- O O
A	O
limitation	O
of	O
all	O
talking	O
therapies	O
is	O
that	O
all	O
talking	O
therapies	O
operate	O
through	O
language	O
,	O
thus	O
risking	O
getting	O
caught	O
in	O
language	O
traps	O
.	O
The	O
PFM	O
model	O
recognises	O
these	O
traps	O
and	O
tries	O
to	O
target	O
the	O
excesses	O
of	O
language	O
to	O
enhance	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
.	O
Psychedelics	B-DRUG
provide	O
another	O
route	O
to	O
disrupting	B-OUTCOME
ordinary	I-OUTCOME
language	I-OUTCOME
processes	I-OUTCOME
that	O
unhelpfully	O
narrow	O
and	O
constrain	O
behaviour	O
and	O
appear	O
to	O
enhance	B-OUTCOME
psychological	I-OUTCOME
flexibility	I-OUTCOME
,	O
potentially	O
more	O
intensely	O
and	O
without	O
verbal	O
instruction	O
.	O
Psychedelics	B-DRUG
offer	O
a	O
route	O
to	O
embodied	B-OUTCOME
awareness	I-OUTCOME
and	O
the	O
relief	O
and	O
learning	O
this	O
can	O
bring	O
.	O
Psychedelics	B-DRUG
also	O
offer	O
the	O
opportunity	O
for	O
more	O
patients	O
to	O
experience	O
profound	B-OUTCOME
psychological	I-OUTCOME
change	I-OUTCOME
than	O
through	O
talking	O
therapy	O
alone	O
Conversely	O
,	O
the	O
PFM	O
can	O
inform	O
how	O
psychedelic	O
preparation	O
and	O
integration	O
are	O
conducted	O
so	O
as	O
to	O
enhance	O
and	O
sustain	O
change	O
.	O
The	O
PFM	O
can	O
guide	O
preparation	O
to	O
potentially	O
enhance	O
the	O
effects	O
of	O
psilocybin	B-DRUG
dosing	O
sessions	O
.	O
Afterwards	O
,	O
as	O
psilocybin	B-DRUG
induced	O
psychological	B-OUTCOME
flexibility	I-OUTCOME
waxes	O
and	O
wanes	O
,	O
acceptance	O
-	O
focused	O
work	O
can	O
help	O
remind	O
patients	O
of	O
how	O
they	O
can	O
engage	O
with	O
they	O
felt	O
sense	O
,	O
continuing	O
to	O
open	O
up	O
to	O
challenging	O
events	O
.	O
Perhaps	O
most	O
importantly	O
,	O
the	O
behaviour	O
change	O
emphasis	O
of	O
the	O
PFM	O
can	O
empower	O
patients	O
to	O
continue	O
to	O
connect	B-OUTCOME
with	I-OUTCOME
new	I-OUTCOME
perspectives	I-OUTCOME
gained	O
and	O
prolong	B-OUTCOME
and	I-OUTCOME
deepen	I-OUTCOME
the	I-OUTCOME
behaviour	I-OUTCOME
change	I-OUTCOME
that	O
would	O
likely	O
have	O
faded	O
without	O
support	O
This	O
paper	O
outlined	O
how	O
the	O
PFM	O
model	O
can	O
be	O
used	O
to	O
guide	O
psilocybin	B-DRUG
assisted	O
therapy	O
for	O
depression	B-HEALTH CONDITION
and	O
reviewed	O
qualitative	O
evidence	O
suggesting	O
that	O
PFM	O
is	O
central	O
to	O
the	O
processes	O
of	O
change	O
involved	O
in	O
this	O
therapeutic	O
modality	O
.	O
We	O
also	O
reviewed	O
how	O
the	O
PFM	O
has	O
been	O
adapted	O
for	O
use	O
in	O
psilocybin	B-DRUG
preparation	O
and	O
integration	O
and	O
how	O
the	O
resulting	O
model	O
,	O
called	O
ACE	O
(	O
Accept	O
,	O
Connect	O
,	O
Embody	O
)	O
,	O
is	O
being	O
utilised	O
in	O
an	O
ongoing	O
clinical	O
trial	O
.	O
As	O
the	O
PFM	O
is	O
now	O
being	O
used	O
as	O
the	O
principal	O
therapeutic	O
modality	O
in	O
other	O
studies	O
using	O
psilocybin	B-DRUG
to	O
treat	O
depression	B-HEALTH CONDITION
(	O
i.e.	O
,	O
NYU	O
,	O
Yale	O
)	O
as	O
well	O
,	O
we	O
may	O
be	O
at	O
the	O
beginning	O
of	O
a	O
new	O
phase	O
in	O
psychedelic	O
assisted	O
therapy	O
,	O
in	O
which	O
the	O
psychotherapy	O
component	O
is	O
more	O
fully	O
nurtured	O
,	O
grown	O
,	O
and	O
studied	O
.	O
It	O
is	O
our	O
hope	O
that	O
the	O
psychedelic	O
therapy	O
models	O
of	O
the	O
future	O
will	O
be	O
comprehensive	O
enough	O
to	O
support	O
habits	B-OUTCOME
of	I-OUTCOME
acceptance	I-OUTCOME
,	I-OUTCOME
connection	I-OUTCOME
and	I-OUTCOME
embodiment	I-OUTCOME
that	O
last	O
a	O
lifetime	O
and	O
catalyse	O
transformational	B-OUTCOME
processes	I-OUTCOME
in	O
individuals	O
and	O
the	O
communities	O
in	O
which	O
they	O
live	O
-DOCSTART- -X- O O
The	O
present	O
study	O
investigated	O
acute	O
effects	O
of	O
LSD	B-DRUG
using	O
a	O
range	O
of	O
well	O
-	O
defined	O
doses	O
in	O
healthy	O
subjects	O
.	O
Previous	O
recent	O
studies	O
mostly	O
used	O
LSD	B-DRUG
products	O
that	O
were	O
not	O
developed	O
according	O
to	O
pharmaceutical	O
standards	O
,	O
as	O
discussed	O
elsewhere	O
[	O
20	O
]	O
.	O
Additionally	O
,	O
we	O
determined	O
plasma	O
LSD	B-DRUG
concentrations	O
as	O
measures	O
of	O
exposure	O
to	O
the	O
substance	O
in	O
the	O
body	O
that	O
are	O
a	O
prerequisite	O
for	O
a	O
valid	O
dose	O
-	O
finding	O
study	O
.	O
We	O
used	O
LSD	B-DRUG
doses	O
in	O
the	O
psychedelic	B-SUBJECTIVE EXPERIENCE
effect	I-SUBJECTIVE EXPERIENCE
dose	O
range	O
(	O
25–200	O
µg	O
of	O
LSD	B-DRUG
base	O
)	O
that	O
were	O
expected	O
to	O
induce	O
full	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
of	O
LSD	B-DRUG
as	O
previously	O
reported	O
by	O
comparable	O
studies	O
that	O
used	O
single	O
-	O
dose	O
levels	O
[	O
4	O
,	O
10,11,12	O
]	O
.	O
Plasma	O
LSD	B-DRUG
concentrations	O
increased	O
proportionally	O
with	O
increasing	O
doses	O
and	O
decreased	O
according	O
to	O
first	O
-	O
order	O
elimination	O
.	O
The	O
PK	O
parameters	O
were	O
consistent	O
with	O
single	O
-	O
dose	O
studies	O
[	O
20	O
,	O
31	O
]	O
.	O
A	O
preliminary	O
report	O
of	O
a	O
longer	O
terminal	O
elimination	O
half	O
-	O
life	O
of	O
LSD	B-DRUG
[	O
32	O
]	O
was	O
not	O
confirmed	O
in	O
the	O
present	O
study	O
.	O
We	O
found	O
no	O
sex	O
differences	O
in	O
LSD	B-DRUG
concentrations	O
or	O
effects	O
consistent	O
with	O
previous	O
studies	O
using	O
no	O
body	O
weight	O
adjustment	O
of	O
LSD	B-DRUG
doses	O
[	O
20	O
,	O
31	O
,	O
32	O
]	O
LSD	B-DRUG
dose	O
-	O
dependently	O
increased	B-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
that	O
were	O
largely	O
similar	O
to	O
previous	O
studies	O
that	O
used	O
single	O
-	O
dose	O
levels	O
[	O
10,11,12,13	O
,	O
26	O
]	O
.	O
Importantly	O
,	O
a	O
ceiling	O
effect	O
was	O
reached	O
at	O
higher	O
doses	O
of	O
LSD	B-DRUG
(	O
>	O
100	O
µg	O
)	O
with	O
regard	O
to	O
higher	O
doses	O
of	O
LSD	B-DRUG
(	O
>	O
100	O
µg	O
)	O
positive	B-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
,	O
with	O
no	O
difference	O
in	O
good	O
drug	O
effects	O
between	O
the	O
100	O
and	O
200	O
µg	O
doses	O
.	O
However	O
,	O
the	O
200	O
µg	O
dose	O
of	O
LSD	B-DRUG
produced	O
significantly	O
greater	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
and	O
anxious	B-SUBJECTIVE EXPERIENCE
ego	I-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
than	O
the	O
100	O
µg	O
dose	O
.	O
Additionally	O
,	O
only	O
the	O
200	O
µg	O
dose	O
and	O
not	O
the	O
100	O
µg	O
dose	O
of	O
LSD	B-DRUG
-	O
induced	O
significant	O
anxiety	B-HEALTH CONDITION
.	O
However	O
,	O
doses	O
above	O
100	O
µg	O
may	O
be	O
used	O
if	O
the	O
goal	O
is	O
to	O
induce	O
the	O
experience	O
of	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
or	O
disembodiment	B-SUBJECTIVE EXPERIENCE
.	O
These	O
experiences	O
,	O
however	O
,	O
were	O
produced	O
at	O
doses	O
that	O
also	O
produced	O
more	O
anxiety	B-HEALTH CONDITION
compared	O
with	O
lower	O
doses	O
.	O
LSD	B-DRUG
doses	O
of	O
100	O
and	O
200	O
µg	O
were	O
both	O
subjectively	O
identified	O
as	O
high	O
doses	O
but	O
could	O
not	O
be	O
subjectively	O
distinguished	O
with	O
certainty	O
from	O
each	O
other	O
.	O
Both	O
of	O
these	O
doses	O
can	O
clearly	O
be	O
considered	O
full	O
psychedelic	O
doses	O
and	O
have	O
previously	O
been	O
investigated	O
in	O
healthy	O
subjects	O
[	O
11	O
,	O
12	O
]	O
.	O
No	O
previous	O
studies	O
directly	O
compared	O
LSD	B-DRUG
doses	O
of	O
100	O
and	O
200	O
µg	O
.	O
In	O
contrast	O
to	O
the	O
present	O
findings	O
,	O
we	O
previously	O
reported	O
moderately	O
greater	O
effects	O
of	O
a	O
200	O
µg	O
dose	O
of	O
LSD	B-DRUG
in	O
one	O
study	O
[	O
12	O
]	O
compared	O
with	O
100	O
µg	O
in	O
another	O
study	O
[	O
11	O
]	O
.	O
Specifically	O
,	O
200	O
µg	O
LSD	B-DRUG
produced	O
significantly	O
greater	B-OUTCOME
total	I-OUTCOME
scores	I-OUTCOME
on	I-OUTCOME
the	I-OUTCOME
5D	I-OUTCOME
-	I-OUTCOME
ASC	I-OUTCOME
scale	I-OUTCOME
,	O
including	O
higher	O
ratings	B-OUTCOME
of	I-OUTCOME
blissful	I-OUTCOME
state	I-OUTCOME
,	O
insightfulness	B-OUTCOME
,	O
and	O
changed	B-OUTCOME
meaning	I-OUTCOME
of	I-OUTCOME
percepts	I-OUTCOME
compared	O
with	O
100	O
µg	O
[	O
26	O
]	O
.	O
In	O
a	O
previous	O
study	O
,	O
the	O
200	O
µg	O
dose	O
of	O
LSD	B-DRUG
also	O
produced	O
higher	O
ratings	O
of	O
good	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
,	O
bad	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
,	O
fear	B-OUTCOME
,	O
open	B-OUTCOME
,	O
and	O
trust	B-OUTCOME
on	O
the	O
VAS	O
compared	O
with	O
100	O
µg	O
[	O
11	O
]	O
.	O
There	O
are	O
two	O
explanations	O
for	O
the	O
absence	O
of	O
an	O
LSD	B-DRUG
dose	O
response	O
for	O
good	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
in	O
the	O
present	O
study	O
compared	O
with	O
our	O
previous	O
studies	O
.	O
First	O
,	O
the	O
true	O
doses	O
that	O
were	O
used	O
in	O
the	O
previous	O
studies	O
were	O
60–70	O
and	O
150	O
µg	O
rather	O
than	O
the	O
reported	O
100	O
and	O
200	O
µg	O
doses	O
because	O
of	O
the	O
use	O
of	O
an	O
unstable	O
formulation	O
with	O
a	O
lower	O
LSD	B-DRUG
content	O
,	O
as	O
discussed	O
elsewhere	O
[	O
20	O
]	O
.	O
Second	O
,	O
the	O
past	O
comparison	O
was	O
between	O
different	O
subjects	O
and	O
studies	O
[	O
11	O
,	O
26	O
]	O
,	O
whereas	O
the	O
present	O
study	O
used	O
valid	O
within	O
-	O
subject	O
and	O
within	O
-	O
study	O
comparisons	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
observed	O
a	O
ceiling	O
effect	O
on	O
the	O
dose	O
–	O
response	O
curve	O
.	O
Considering	O
that	O
the	O
previously	O
reported	O
200	O
µg	O
dose	O
likely	O
contained	O
only	O
150	O
µg	O
of	O
active	O
LSD	B-DRUG
,	O
additional	O
positive	B-OUTCOME
effects	I-OUTCOME
may	O
be	O
reached	O
with	O
150	O
µg	O
compared	O
with	O
100	O
µg	O
.	O
This	O
possibility	O
remains	O
to	O
be	O
tested	O
.	O
One	O
of	O
our	O
recent	O
studies	O
also	O
used	O
an	O
analytically	O
confirmed	O
LSD	B-DRUG
dose	O
of	O
100	O
µg	O
,	O
which	O
produced	O
scores	B-OUTCOME
on	I-OUTCOME
the	I-OUTCOME
VAS	I-OUTCOME
and	I-OUTCOME
5D	I-OUTCOME
-	I-OUTCOME
ASC	I-OUTCOME
scale	I-OUTCOME
that	I-OUTCOME
were	I-OUTCOME
nominally	I-OUTCOME
higher	I-OUTCOME
than	I-OUTCOME
those	I-OUTCOME
that	I-OUTCOME
were	I-OUTCOME
reported	I-OUTCOME
after	I-OUTCOME
100	I-OUTCOME
µg	I-OUTCOME
administration	I-OUTCOME
in	O
the	O
present	O
study	O
[	O
13	O
]	O
and	O
more	O
similar	O
to	O
the	O
scores	O
that	O
were	O
reported	O
herein	O
after	O
200	O
µg	O
administration	O
.	O
Altogether	O
,	O
the	O
available	O
data	O
support	O
the	O
view	O
that	O
mainly	O
high	B-OUTCOME
acute	I-OUTCOME
positive	I-OUTCOME
effects	I-OUTCOME
of	O
LSD	B-DRUG
can	O
be	O
induced	O
at	O
a	O
100	O
µg	O
dose	O
of	O
LSD	B-DRUG
base	O
.	O
Therefore	O
,	O
we	O
speculate	O
that	O
a	O
dose	O
of	O
100	O
µg	O
of	O
LSD	B-DRUG
may	O
be	O
selected	O
for	O
the	O
treatment	O
of	O
depression	B-HEALTH CONDITION
or	O
anxiety	B-HEALTH CONDITION
where	O
higher	O
Oceanic	B-SUBJECTIVE EXPERIENCE
Boundlessness	I-SUBJECTIVE EXPERIENCE
and	O
lower	O
anxiety	B-HEALTH CONDITION
ratings	O
acutely	O
induced	O
by	O
psychedelics	B-DRUG
predicted	O
better	B-OUTCOME
treatment	I-OUTCOME
efficacy	I-OUTCOME
[	O
16,17,18,19	O
]	O
.	O
The	O
50	O
µg	O
dose	O
that	O
was	O
used	O
in	O
the	O
present	O
study	O
also	O
produced	O
substantial	O
positive	B-OUTCOME
mood	I-OUTCOME
effects	I-OUTCOME
and	O
notably	O
only	O
very	O
small	O
and	O
nonsignificant	O
anxious	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
,	O
with	O
no	O
anxiety	B-HEALTH CONDITION
.	O
Thus	O
,	O
the	O
50	O
µg	O
dose	O
may	O
be	O
useful	O
for	O
inducing	O
a	O
moderately	B-OUTCOME
intense	I-OUTCOME
and	I-OUTCOME
predominantly	I-OUTCOME
positive	I-OUTCOME
psychedelic	I-OUTCOME
experience	I-OUTCOME
.	O
This	O
low	O
psychedelic	B-DRUG
dose	I-DRUG
would	O
likely	O
be	O
a	O
good	O
starting	O
dose	O
to	O
be	O
used	O
in	O
patients	O
with	O
no	O
previous	O
experience	O
with	O
psychedelics	B-DRUG
or	O
in	O
subjects	O
who	O
are	O
considered	O
to	O
be	O
more	O
sensitive	O
to	O
the	O
effects	O
of	O
psychedelics	B-DRUG
[	O
33	O
]	O
In	O
the	O
present	O
study	O
,	O
LSD	B-DRUG
produced	O
moderate	B-OUTCOME
elevations	I-OUTCOME
of	I-OUTCOME
arterial	I-OUTCOME
blood	I-OUTCOME
pressure	I-OUTCOME
and	I-OUTCOME
heart	I-OUTCOME
rate	I-OUTCOME
starting	O
at	O
the	O
50	O
µg	O
dose	O
that	O
were	O
largely	O
similar	O
to	O
the	O
effects	O
of	O
100	O
and	O
200	O
µg	O
.	O
Similarly	O
,	O
previous	O
studies	O
that	O
used	O
pharmaceutically	O
not	O
well	O
-	O
characterized	O
doses	O
of	O
100	O
and	O
200	O
µg	O
LSD	B-DRUG
found	O
no	O
difference	O
in	O
the	O
acute	B-OUTCOME
cardiostimulant	I-OUTCOME
effects	I-OUTCOME
of	O
these	O
doses	O
[	O
11	O
]	O
.	O
A	O
previous	O
study	O
in	O
patients	O
did	O
not	O
observe	O
any	O
increases	B-OUTCOME
in	I-OUTCOME
blood	I-OUTCOME
pressure	I-OUTCOME
using	O
a	O
non	O
-	O
confirmed	O
dose	O
of	O
200	O
µg	O
of	O
LSD	B-DRUG
[	O
34	O
]	O
.	O
Methylenedioxymethamphetamine	B-DRUG
clearly	O
has	O
more	O
pronounced	O
cardiostimulant	O
effects	O
and	O
a	O
less	O
favorable	O
overall	O
physical	O
safety	O
profile	O
than	O
LSD	B-DRUG
[	O
13	O
,	O
35	O
]	O
.	O
In	O
contrast	O
,	O
the	O
psychotropic	B-OUTCOME
effects	I-OUTCOME
of	O
LSD	B-DRUG
are	O
significantly	O
greater	O
compared	O
with	O
MDMA	B-DRUG
[	O
13	O
]	O
In	O
the	O
present	O
study	O
,	O
administration	O
of	O
the	O
5	B-DRUG
-	I-DRUG
HT2A	I-DRUG
receptor	I-DRUG
antagonist	I-DRUG
ketanserin	I-DRUG
1	O
h	O
before	O
LSD	B-DRUG
administration	O
markedly	O
reduced	O
the	O
subjective	O
response	O
to	O
the	O
200	O
µg	O
LSD	B-DRUG
dose	O
to	O
levels	O
that	O
were	O
similar	O
to	O
the	O
25	O
µg	O
dose	O
.	O
Retrospective	O
reports	O
showed	O
that	O
ketanserin	B-DRUG
and	O
LSD	B-DRUG
together	O
were	O
identified	O
correctly	O
by	O
the	O
participants	O
or	O
mistaken	O
as	O
a	O
low	O
dose	O
of	O
LSD	B-DRUG
but	O
never	O
mistaken	O
for	O
a	O
high	O
dose	O
of	O
LSD	B-DRUG
.	O
The	O
present	O
findings	O
are	O
consistent	O
with	O
a	O
previous	O
study	O
in	O
which	O
ketanserin	B-DRUG
administration	O
prior	O
to	O
the	O
administration	O
of	O
100	O
µg	O
LSD	B-DRUG
almost	O
completely	O
prevented	O
the	O
acute	O
effects	O
of	O
LSD	B-DRUG
[	O
4	O
]	O
.	O
These	O
findings	O
support	O
the	O
view	O
that	O
LSD	B-DRUG
primarily	O
produces	O
its	O
acute	B-OUTCOME
psychedelic	I-OUTCOME
effects	I-OUTCOME
in	O
humans	O
via	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
activation	I-NEURAL MECHANISM/CORRELATE
[	O
3,4,5	O
,	O
36	O
]	O
,	O
which	O
was	O
also	O
shown	O
for	O
a	O
high	O
and	O
fully	O
psychedelic	O
dose	O
of	O
LSD	B-DRUG
.	O
ketanserin	B-DRUG
also	O
prevented	O
acute	B-OUTCOME
adverse	I-OUTCOME
effects	I-OUTCOME
of	O
LSD	B-DRUG
and	O
the	O
LSD	B-DRUG
-	O
induced	O
heart	O
rate	O
response	O
.	O
However	O
,	O
the	O
weak	B-OUTCOME
blood	I-OUTCOME
pressure	I-OUTCOME
-	I-OUTCOME
elevating	I-OUTCOME
effects	I-OUTCOME
of	O
LSD	B-DRUG
were	O
only	O
transiently	O
prevented	O
by	O
ketanserin	B-DRUG
and	O
reappeared	O
later	O
during	O
the	O
LSD	B-DRUG
response	O
.	O
This	O
observation	O
is	O
consistent	O
with	O
the	O
relatively	O
short	O
half	O
-	O
life	O
of	O
ketanserin	B-DRUG
(	O
i.e.	O
,	O
2	O
h	O
)	O
during	O
the	O
first	O
1–9	O
h	O
following	O
administration	O
[	O
37	O
,	O
38	O
]	O
In	O
the	O
present	O
study	O
,	O
200	O
µg	O
LSD	B-DRUG
significantly	O
increased	B-OUTCOME
BDNF	I-OUTCOME
plasma	I-OUTCOME
concentration	I-OUTCOME
compared	O
with	O
placebo	O
with	O
a	O
peak	O
at	O
6	O
h.	O
Additionally	O
,	O
there	O
were	O
nonsignificant	B-OUTCOME
increases	I-OUTCOME
in	I-OUTCOME
plasma	I-OUTCOME
BDNF	I-OUTCOME
after	O
lower	O
doses	O
of	O
LSD	B-DRUG
or	O
after	O
ketanserin	B-DRUG
with	O
LSD	B-DRUG
.	O
In	O
previous	O
studies	O
,	O
100	O
µg	O
LSD	B-DRUG
had	O
no	B-OUTCOME
effect	I-OUTCOME
on	I-OUTCOME
BDNF	I-OUTCOME
plasma	I-OUTCOME
levels	O
[	O
13	O
]	O
up	O
to	O
5	O
h	O
while	O
the	O
psychedelic	O
ayahuasca	B-DRUG
increased	B-OUTCOME
BDNF	I-OUTCOME
at	I-OUTCOME
2	I-OUTCOME
days	I-OUTCOME
.	O
Further	O
,	O
higher	B-OUTCOME
BDNF	I-OUTCOME
levels	I-OUTCOME
were	O
associated	O
with	O
lower	O
depression	B-HEALTH CONDITION
ratings	O
after	O
administration	O
of	O
ayahuasca	B-DRUG
[	O
39	O
]	O
.	O
More	O
research	O
is	O
needed	O
to	O
define	O
the	O
time	O
course	O
of	O
the	O
BDNF	B-OUTCOME
response	I-OUTCOME
and	O
whether	O
there	O
is	O
a	O
link	O
between	O
psychedelics	B-DRUG
,	O
BDNF	O
,	O
and	O
the	O
antidepressant	B-OUTCOME
response	I-OUTCOME
[	O
39	O
]	O
In	O
addition	O
to	O
providing	O
dose	O
–	O
response	O
data	O
on	O
full	O
psychedelic	O
doses	O
of	O
LSD	B-DRUG
,	O
the	O
present	O
study	O
further	O
characterized	O
the	O
effects	O
of	O
small	O
doses	O
of	O
LSD	B-DRUG
[	O
9	O
,	O
40	O
]	O
.	O
The	O
lowest	O
dose	O
that	O
was	O
used	O
in	O
the	O
present	O
study	O
contained	O
25	O
µg	O
of	O
LSD	B-DRUG
base	O
.	O
This	O
dose	O
produced	O
subjective	O
“	O
any	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
”	O
that	O
were	O
significantly	O
different	O
from	O
placebo	O
and	O
retrospectively	O
identified	O
as	O
LSD	B-DRUG
by	O
the	O
majority	O
(	O
>	O
85	O
%	O
)	O
of	O
the	O
participants	O
.	O
Very	O
low	O
doses	O
of	O
LSD	B-DRUG
have	O
typically	O
been	O
referred	O
to	O
as	O
“	O
microdoses	B-DRUG
.	O
”	O
Psychedelic	B-DRUG
microdoses	I-DRUG
have	O
been	O
postulated	O
to	O
have	O
beneficial	O
prolonged	B-OUTCOME
effects	I-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
while	O
producing	O
no	O
or	O
only	O
minimal	O
acute	B-OUTCOME
adverse	I-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
[	O
40,41,42,43	O
]	O
.	O
Positive	B-OUTCOME
long	I-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
effects	I-OUTCOME
of	O
psychedelic	B-DRUG
microdoses	I-DRUG
remain	O
to	O
be	O
documented	O
[	O
42	O
]	O
,	O
and	O
remaining	O
unclear	O
are	O
the	O
LSD	B-DRUG
doses	O
that	O
actually	O
have	O
no	B-OUTCOME
acute	I-OUTCOME
subjective	I-OUTCOME
effects	I-OUTCOME
and	O
thus	O
could	O
be	O
considered	O
microdoses	B-DRUG
[	O
40	O
]	O
.	O
Very	O
low	O
to	O
low	O
doses	O
of	O
LSD	B-DRUG
were	O
recently	O
studied	O
in	O
two	O
placebo	O
-	O
controlled	O
trials	O
[	O
9	O
,	O
21	O
,	O
44	O
,	O
45	O
]	O
.	O
One	O
study	O
also	O
provided	O
preliminary	O
PK	O
data	O
[	O
45	O
]	O
.	O
In	O
older	O
healthy	O
volunteers	O
,	O
5–20	O
µg	O
of	O
LSD	B-DRUG
tartrate	O
produced	O
small	O
but	O
significant	O
linear	O
dose	O
-	O
dependent	O
increases	O
in	O
ratings	O
of	O
all	O
of	O
the	O
following	O
:	O
subjective	B-OUTCOME
drug	I-OUTCOME
effects	I-OUTCOME
,	O
vigilance	B-OUTCOME
reduction	I-OUTCOME
,	O
dizziness	B-OUTCOME
,	O
and	O
changes	B-OUTCOME
in	I-OUTCOME
body	I-OUTCOME
feeling	I-OUTCOME
[	O
21	O
,	O
45	O
]	O
.	O
The	O
frequency	O
of	O
adverse	B-OUTCOME
effects	I-OUTCOME
of	O
LSD	B-DRUG
at	O
doses	O
up	O
to	O
20	O
µg	O
was	O
not	O
different	O
from	O
placebo	O
.	O
The	O
mean	O
plasma	O
Cmax	O
values	O
of	O
LSD	B-DRUG
(	O
non	O
-	O
compartmental	O
analyses	O
)	O
were	O
0.44	O
ng	O
/	O
ml	O
(	O
n	O
=	O
8)	O
after	O
the	O
administration	O
of	O
20	O
µg	O
of	O
LSD	B-DRUG
tartrate	O
[	O
45	O
]	O
and	O
0.51	O
ng	O
/	O
ml	O
after	O
the	O
administration	O
of	O
25	O
µg	O
of	O
LSD	B-DRUG
base	O
in	O
the	O
present	O
study	O
,	O
indicating	O
comparable	O
dose	O
-	O
proportional	O
peak	O
concentrations	O
.	O
The	O
previous	O
study	O
included	O
younger	O
healthy	O
subjects	O
and	O
found	O
dose	O
-	O
dependent	O
increases	B-OUTCOME
in	I-OUTCOME
subjective	I-OUTCOME
ratings	I-OUTCOME
of	I-OUTCOME
“	I-OUTCOME
feel	I-OUTCOME
drug	I-OUTCOME
”	I-OUTCOME
and	I-OUTCOME
“	I-OUTCOME
like	I-OUTCOME
drug	I-OUTCOME
”	I-OUTCOME
on	I-OUTCOME
VASs	I-OUTCOME
and	I-OUTCOME
on	I-OUTCOME
the	I-OUTCOME
5D	I-OUTCOME
-	I-OUTCOME
ASC	I-OUTCOME
scale	I-OUTCOME
after	O
the	O
administration	O
of	O
6.5	O
,	O
13	O
,	O
and	O
26	O
µg	O
of	O
LSD	B-DRUG
tartrate	O
[	O
9	O
]	O
.	O
Notably	O
,	O
a	O
26	O
µg	O
dose	O
of	O
LSD	B-DRUG
tartrate	O
would	O
be	O
lower	O
than	O
the	O
25	O
µg	O
dose	O
of	O
LSD	B-DRUG
base	O
(	O
i.e.	O
,	O
31	O
µg	O
of	O
LSD	B-DRUG
tartrate	O
equivalent	O
)	O
that	O
was	O
used	O
in	O
the	O
present	O
study	O
.	O
Nevertheless	O
,	O
the	O
26	O
µg	O
dose	O
of	O
LSD	B-DRUG
tartrate	O
produced	O
significant	O
effects	B-OUTCOME
on	I-OUTCOME
the	I-OUTCOME
5D	I-OUTCOME
-	I-OUTCOME
ASC	I-OUTCOME
scale	I-OUTCOME
compared	O
with	O
placebo	O
and	O
nominally	O
greater	B-OUTCOME
ratings	I-OUTCOME
on	I-OUTCOME
the	I-OUTCOME
5D	I-OUTCOME
-	I-OUTCOME
ASC	I-OUTCOME
subscales	I-OUTCOME
than	O
the	O
25	O
µg	O
dose	O
that	O
was	O
used	O
in	O
the	O
present	O
study	O
.	O
Unfortunately	O
,	O
no	O
plasma	O
LSD	B-DRUG
concentration	O
data	O
have	O
been	O
published	O
for	O
the	O
26	O
µg	O
dose	O
of	O
LSD	B-DRUG
tartrate	O
[	O
9	O
]	O
.	O
Therefore	O
,	O
a	O
comparison	O
of	O
drug	O
exposures	O
between	O
this	O
previous	O
study	O
and	O
the	O
present	O
study	O
to	O
further	O
validate	O
the	O
dose	O
comparison	O
is	O
not	O
possible	O
.	O
Altogether	O
,	O
the	O
available	O
data	O
from	O
these	O
controlled	O
studies	O
,	O
including	O
the	O
present	O
study	O
that	O
used	O
very	O
small	O
and	O
small	O
doses	O
of	O
LSD	B-DRUG
,	O
indicate	O
that	O
the	O
25	O
µg	O
dose	O
of	O
LSD	B-DRUG
is	O
clearly	O
acutely	B-OUTCOME
psychoactive	I-OUTCOME
in	O
the	O
majority	O
of	O
subjects	O
.	O
Doses	O
in	O
the	O
range	O
of	O
21–30	O
µg	O
of	O
LSD	B-DRUG
base	O
may	O
thus	O
be	O
considered	O
“	O
minidoses	B-DRUG
”	O
rather	O
than	O
“	O
microdoses	B-DRUG
.	O
”	O
Doses	O
of	O
LSD	B-DRUG
base	O
in	O
the	O
1–20	O
µg	O
range	O
may	O
be	O
considered	O
“	O
microdoses	B-DRUG
”	O
but	O
need	O
further	O
study	O
.	O
However	O
,	O
Doses	O
of	O
LSD	B-DRUG
base	O
in	O
the	O
1–20	O
µg	O
range	O
may	O
already	O
elicit	O
small	O
dose	O
-	O
dependent	O
subjective	B-OUTCOME
effects	I-OUTCOME
,	O
although	O
Doses	O
of	O
LSD	B-DRUG
base	O
in	O
the	O
1–20	O
µg	O
range	O
are	O
unlikely	O
to	O
relevantly	O
impair	B-OUTCOME
cognition	I-OUTCOME
or	I-OUTCOME
produce	I-OUTCOME
adverse	I-OUTCOME
effects	I-OUTCOME
[	O
9	O
,	O
21	O
,	O
44	O
,	O
45	O
]	O
Overall	O
,	O
the	O
present	O
dose	O
–	O
response	O
study	O
characterized	O
a	O
range	O
of	O
LSD	B-DRUG
doses	O
.	O
Based	O
on	O
the	O
available	O
data	O
,	O
the	O
following	O
dosing	O
terminology	O
may	O
be	O
useful	O
for	O
future	O
LSD	B-DRUG
research	O
:	O
“	O
microdose	O
”	O
(	O
1–20	O
µg	O
)	O
,	O
“	O
minidose	O
”	O
(	O
21–30	O
µg	O
)	O
,	O
and	O
“	O
psychedelic	O
dose	O
”	O
(	O
>	O
30	O
µg	O
)	O
.	O
Within	O
the	O
psychedelic	O
LSD	B-DRUG
dose	O
range	O
,	O
good	O
effects	O
likely	O
predominate	O
at	O
doses	O
of	O
30–100	O
µg	O
(	O
good	O
-	O
effect	O
dose	O
)	O
,	O
whereas	O
ego	B-HEALTH CONDITION
dissolution	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
increase	O
at	O
doses	O
above	O
100	O
µg	O
(	O
ego	O
-	O
dissolution	O
dose	O
)	O
The	O
present	O
study	O
has	O
numerous	O
strengths	O
.	O
Four	O
different	O
doses	O
of	O
LSD	B-DRUG
were	O
used	O
within	O
subjects	O
and	O
compared	O
with	O
placebo	O
under	O
double	O
-	O
blind	O
conditions	O
in	O
a	O
controlled	O
laboratory	O
setting	O
.	O
A	O
ketanserin	O
-	O
LSD	B-DRUG
condition	O
was	O
also	O
included	O
to	O
elucidate	O
the	O
mechanism	O
of	O
action	O
of	O
LSD	B-DRUG
and	O
enhance	O
blinding	O
between	O
the	O
different	O
conditions	O
.	O
We	O
also	O
included	O
equal	O
numbers	O
of	O
male	O
and	O
female	O
participants	O
and	O
used	O
internationally	O
established	O
standardized	O
and	O
validated	O
psychometric	O
outcome	O
measures	O
.	O
The	O
doses	O
of	O
LSD	B-DRUG
were	O
pharmaceutically	O
well	O
-	O
characterized	O
,	O
and	O
plasma	O
LSD	B-DRUG
concentrations	O
and	O
PK	O
parameters	O
were	O
determined	O
up	O
to	O
24	O
h	O
for	O
all	O
doses	O
.	O
Notwithstanding	O
these	O
strengths	O
,	O
the	O
present	O
study	O
also	O
has	O
limitations	O
.	O
The	O
study	O
used	O
a	O
highly	O
controlled	O
setting	O
and	O
included	O
only	O
healthy	O
subjects	O
.	O
Additionally	O
,	O
participants	O
willing	O
to	O
participate	O
in	O
LSD	B-DRUG
research	O
are	O
likely	O
to	O
have	O
positive	O
expectations	O
and	O
some	O
participants	O
had	O
past	O
substance	O
experiences	O
.	O
Thus	O
,	O
subjects	O
in	O
different	O
environments	O
and	O
patients	O
with	O
psychiatric	O
disorders	O
may	O
respond	O
differently	O
to	O
LSD	B-DRUG
-DOCSTART- -X- O O
Evidence	O
from	O
carefully	O
designed	O
and	O
performed	O
open	O
and	O
controlled	O
trials	O
involving	O
the	O
administration	O
of	O
single	O
or	O
few	O
doses	O
of	O
serotoninergic	B-DRUG
hallucinogens	I-DRUG
suggests	O
that	O
these	O
compounds	O
have	O
antidepressive	B-OUTCOME
,	O
anxiolytic	B-OUTCOME
,	O
and	O
antiaddictive	B-OUTCOME
properties	O
that	O
should	O
be	O
further	O
investigated	O
in	O
controlled	O
trials	O
with	O
larger	O
samples	O
sizes	O
.	O
Importantly	O
,	O
the	O
incidence	O
of	O
severe	O
adverse	O
reactions	O
such	O
as	O
psychotic	B-HEALTH CONDITION
episodes	I-HEALTH CONDITION
in	O
these	O
trials	O
is	O
extremely	O
low	O
or	O
nonexistent	O
,	O
which	O
is	O
based	O
on	O
careful	O
screening	O
,	O
preparation	O
of	O
the	O
subject	O
and	O
of	O
the	O
experimental	O
context	O
,	O
and	O
monitoring	O
during	O
drug	B-OUTCOME
effects	I-OUTCOME
.	O
Furthermore	O
,	O
evidence	O
from	O
observational	O
studies	O
on	O
the	O
physical	O
and	O
mental	B-HEALTH CONDITION
health	I-HEALTH CONDITION
of	O
ritual	O
ayahuasca	B-DRUG
users	O
suggest	O
a	O
low	B-OUTCOME
toxicity	I-OUTCOME
profile	I-OUTCOME
for	O
this	O
practice	O
,	O
and	O
even	O
suggests	O
benefits	B-OUTCOME
on	I-OUTCOME
mood	I-OUTCOME
,	O
anxiety	B-HEALTH CONDITION
,	O
a	O
substance	O
use	O
disorders	O
In	O
2018	O
the	O
investigation	O
of	O
psilocybin	B-DRUG
as	O
a	O
possible	O
treatment	O
for	O
treatment	B-HEALTH CONDITION
-	I-HEALTH CONDITION
resistant	I-HEALTH CONDITION
MDD	I-HEALTH CONDITION
received	O
the	O
Breakthrough	O
Therapy	O
designation	O
by	O
the	O
FDA	O
,	O
and	O
similar	O
trials	O
are	O
planned	O
to	O
occur	O
in	O
Europe	O
(	O
Anon	O
.	O
,	O
2018	O
)	O
.	O
If	O
these	O
trials	O
show	O
positive	O
results	O
,	O
the	O
carefully	O
controlled	O
use	O
of	O
psilocybin	B-DRUG
can	O
become	O
available	O
for	O
treating	O
MDD	B-HEALTH CONDITION
in	O
the	O
US	O
and	O
Europe	O
,	O
which	O
could	O
later	O
expand	O
to	O
the	O
off	O
-	O
label	O
and	O
compassionate	O
use	O
of	O
psilocybin	B-DRUG
in	O
cancer	B-HEALTH CONDITION
-	I-HEALTH CONDITION
related	I-HEALTH CONDITION
depression	I-HEALTH CONDITION
and	O
anxiety	B-HEALTH CONDITION
and	O
maybe	O
in	O
other	O
medical	O
conditions	O
characterized	O
by	O
mood	O
and	O
anxiety	B-HEALTH CONDITION
symptoms	O
.	O
The	O
therapeutic	O
use	O
of	O
LSD	B-DRUG
should	O
follow	O
the	O
same	O
steps	O
as	O
those	O
of	O
psilocybin	B-DRUG
In	O
the	O
case	O
of	O
ayahuasca	B-DRUG
,	O
indigenous	O
and	O
mestizo	O
communities	O
of	O
the	O
Northwestern	O
Amazon	O
and	O
Brazilian	O
syncretic	O
religions	O
have	O
been	O
using	O
it	O
ritually	O
and	O
therapeutically	O
for	O
generations	O
,	O
and	O
these	O
practices	O
are	O
continuously	O
evolving	O
into	O
new	O
forms	O
and	O
expanding	O
to	O
new	O
territories	O
.	O
If	O
the	O
clinical	O
trials	O
with	O
ayahuasca	B-DRUG
continue	O
to	O
show	O
positive	O
results	B-OUTCOME
,	O
regulatory	O
agencies	O
worldwide	O
(	O
including	O
in	O
Brazil	O
)	O
may	O
be	O
faced	O
with	O
the	O
challenge	O
of	O
regulating	O
a	O
plant	B-DRUG
-	I-DRUG
based	I-DRUG
hallucinogen	I-DRUG
/	O
psychedelic	B-DRUG
It	O
should	O
also	O
be	O
considered	O
that	O
a	O
synthetic	O
equivalent	O
of	O
ayahuasca	B-DRUG
could	O
be	O
developed	O
(	O
for	O
example	O
by	O
combing	O
harmine	O
with	O
DMT	B-DRUG
)	O
,	O
which	O
could	O
bypass	O
the	O
complexities	O
of	O
a	O
plant	O
-	O
based	O
preparation	O
.	O
Chemical	O
changes	O
in	O
the	O
DMT	B-DRUG
molecule	O
could	O
allow	O
the	O
DMT	B-DRUG
molecule	O
oral	O
absorption	O
.	O
While	O
the	O
use	O
of	O
synthetic	O
equivalents	O
may	O
be	O
unacceptable	O
to	O
some	O
people	O
involved	O
in	O
the	O
religious	O
ayahuasca	B-DRUG
practices	O
,	O
it	O
may	O
be	O
a	O
more	O
practical	O
way	O
to	O
have	O
the	O
medicine	O
become	O
approved	O
for	O
use	O
in	O
patients	O
.	O
However	O
,	O
legislations	O
regarding	O
the	O
use	O
of	O
purified	O
DMT	B-DRUG
are	O
very	O
restrict	O
.	O
Thus	O
,	O
the	O
use	O
of	O
a	O
plant	O
-	O
based	O
preparation	O
that	O
is	O
already	O
allowed	O
in	O
some	O
countries	O
could	O
be	O
the	O
fastest	O
and	O
cheapest	O
way	O
to	O
make	O
the	O
medicine	O
reach	O
the	O
population	O
.	O
Moreover	O
,	O
the	O
ritual	O
users	O
of	O
ayahuasca	B-DRUG
developed	O
over	O
the	O
generations	O
techniques	O
to	O
use	O
ayahuasca	B-DRUG
in	O
a	O
safe	O
manner	O
.	O
This	O
could	O
also	O
facilitate	O
the	O
incorporation	O
of	O
ayahuasca	B-DRUG
as	O
a	O
medicine	O
,	O
at	O
least	O
in	O
countries	O
were	O
these	O
religious	O
groups	O
are	O
present	O
Mood	O
,	O
anxiety	B-HEALTH CONDITION
,	O
and	O
substance	B-HEALTH CONDITION
use	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
are	O
among	O
the	O
most	O
important	O
contributors	O
to	O
global	O
disability	O
.	O
Available	B-ANTIDEPRESSANT_DRUG
medications	I-ANTIDEPRESSANT_DRUG
are	O
ineffective	B-OUTCOME
for	I-OUTCOME
many	I-OUTCOME
patients	I-OUTCOME
,	O
induce	O
significant	O
adverse	B-OUTCOME
reactions	I-OUTCOME
,	O
and	O
need	O
weeks	O
of	O
daily	O
intake	O
before	O
therapeutic	O
effects	O
appear	O
.	O
Therefore	O
,	O
new	O
drugs	O
with	O
rapid	O
onset	O
of	O
action	O
and	O
sustained	O
effects	O
after	O
single	O
or	O
few	O
doses	O
could	O
be	O
beneficial	O
for	O
many	O
patients	O
Moreover	O
,	O
although	O
ketamine	B-DRUG
(	O
which	O
also	O
has	O
hallucinogenic	B-DRUG
/	O
psychedelic	B-DRUG
effects	O
and	O
has	O
been	O
recently	O
approved	O
by	O
the	O
FDA	O
to	O
treat	O
MDD	O
)	O
has	O
a	O
rapid	O
onset	O
of	O
action	O
and	O
enduring	B-OUTCOME
effects	I-OUTCOME
,	O
ketamine	B-DRUG
(	O
which	O
also	O
has	O
hallucinogenic	B-DRUG
/	O
psychedelic	B-DRUG
effects	O
and	O
has	O
been	O
recently	O
approved	O
by	O
the	O
FDA	O
to	O
treat	O
MDD	O
)	O
use	O
may	O
be	O
associated	O
with	O
tolerance	B-OUTCOME
,	I-OUTCOME
potential	I-OUTCOME
for	I-OUTCOME
dependence	I-OUTCOME
and	I-OUTCOME
diversion	I-OUTCOME
,	O
and	O
urinary	O
adverse	O
events	O
(	O
Radvansky	O
et	O
al	O
.	O
,	O
2016	O
;	O
CADTH	O
,	O
2019	O
)	O
.	O
None	O
of	O
these	O
problems	O
have	O
been	O
observed	O
in	O
trials	O
with	O
serotoninergic	B-DRUG
hallucinogen	I-DRUG
,	O
but	O
long	O
-	O
term	O
studies	O
are	O
lacking	O
.	O
Further	O
clinical	O
trials	O
using	O
different	O
doses	O
of	O
serotoninergic	B-DRUG
hallucinogens	I-DRUG
and	O
larger	O
samples	O
are	O
necessary	O
to	O
evaluate	O
the	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
efficacy	I-OUTCOME
and	I-OUTCOME
safety	I-OUTCOME
of	I-OUTCOME
these	I-OUTCOME
drugs	I-OUTCOME
,	O
as	O
well	O
as	O
naturalistic	O
studies	O
of	O
large	O
populations	O
of	O
ritual	O
ayahuasca	B-DRUG
regular	O
users	O
-DOCSTART- -X- O O
The	O
present	O
study	O
demonstrates	O
the	O
first	O
attempt	O
to	O
assess	O
the	O
acute	O
effects	O
of	O
psilocybin	B-DRUG
on	O
glutamate	B-NEURAL MECHANISM/CORRELATE
levels	I-NEURAL MECHANISM/CORRELATE
in	O
key	O
areas	O
of	O
the	O
human	B-NEURAL MECHANISM/CORRELATE
brain	I-NEURAL MECHANISM/CORRELATE
,	O
which	O
may	O
play	O
a	O
major	O
role	O
in	O
the	O
actions	O
of	O
serotonergic	O
psychedelics	B-DRUG
.	O
Using	O
an	O
ultra	O
-	O
high	O
field	O
multimodal	O
MRI	O
approach	O
,	O
we	O
demonstrated	O
that	O
,	O
compared	O
with	O
placebo	O
,	O
psilocybin	B-DRUG
-	O
induced	O
region	B-OUTCOME
-	I-OUTCOME
dependent	I-OUTCOME
alterations	I-OUTCOME
in	I-OUTCOME
neurometabolite	I-OUTCOME
concentrations	I-OUTCOME
.	O
Specifically	O
,	O
participants	O
who	O
received	O
psilocybin	B-DRUG
demonstrated	O
higher	B-OUTCOME
relative	I-OUTCOME
glutamate	I-OUTCOME
concentration	I-OUTCOME
levels	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
mPFC	I-OUTCOME
,	O
and	O
lower	B-OUTCOME
relative	I-OUTCOME
glutamate	I-OUTCOME
concentration	I-OUTCOME
levels	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
hippocampus	I-OUTCOME
.	O
Analyses	O
indicated	O
that	O
region	B-OUTCOME
-	I-OUTCOME
dependent	I-OUTCOME
alterations	I-OUTCOME
in	I-OUTCOME
glutamate	I-OUTCOME
were	O
also	O
correlated	O
with	O
different	O
dimensions	O
of	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
.	O
Whereas	O
changes	B-OUTCOME
in	I-OUTCOME
mPFC	I-OUTCOME
glutamate	I-OUTCOME
were	O
found	O
to	O
be	O
the	O
strongest	O
predictor	O
of	O
negatively	B-OUTCOME
experienced	I-OUTCOME
ego	I-OUTCOME
dissolution	I-OUTCOME
,	O
changes	B-OUTCOME
in	I-OUTCOME
hippocampal	I-OUTCOME
glutamate	I-OUTCOME
were	O
found	O
to	O
be	O
the	O
strongest	O
predictor	O
of	O
positively	B-SUBJECTIVE EXPERIENCE
experienced	I-SUBJECTIVE EXPERIENCE
ego	I-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
mPFC	B-NEURAL MECHANISM/CORRELATE
is	O
highly	O
enriched	O
with	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
located	O
primarily	O
on	O
layer	B-NEURAL MECHANISM/CORRELATE
V	I-NEURAL MECHANISM/CORRELATE
pyramidal	I-NEURAL MECHANISM/CORRELATE
neurons	I-NEURAL MECHANISM/CORRELATE
[	O
61	O
]	O
,	O
and	O
modulate	O
excitatory	O
transmission	O
in	O
cortical	B-NEURAL MECHANISM/CORRELATE
circuits	I-NEURAL MECHANISM/CORRELATE
[	O
43	O
,	O
62	O
,	O
63	O
]	O
.	O
Preclinical	O
studies	O
have	O
demonstrated	O
that	O
activation	O
of	O
such	O
receptors	B-NEURAL MECHANISM/CORRELATE
via	O
serotonergic	O
psychedelics	B-DRUG
results	O
in	O
a	O
predominantly	B-OUTCOME
excitatory	I-OUTCOME
response	I-OUTCOME
[	O
18	O
,	O
64	O
]	O
via	O
an	O
increase	B-OUTCOME
in	I-OUTCOME
glutamate	I-OUTCOME
release	I-OUTCOME
,	O
as	O
observed	O
in	O
humans	O
for	O
the	O
first	O
time	O
in	O
this	O
study	O
.	O
A	O
glutamatergic	B-OUTCOME
increase	I-OUTCOME
in	O
this	O
area	O
is	O
also	O
in	O
accordance	O
with	O
human	O
functional	O
imaging	O
studies	O
which	O
have	O
demonstrated	O
a	O
hyperfrontal	B-OUTCOME
regional	I-OUTCOME
cerebral	I-OUTCOME
blood	I-OUTCOME
flow	I-OUTCOME
(	I-OUTCOME
CBF	I-OUTCOME
)	I-OUTCOME
pattern	I-OUTCOME
after	O
psilocybin	B-DRUG
[	O
46	O
,	O
65	O
]	O
,	O
and	O
similar	O
5	O
-	O
HT2A	O
agonist	O
psychedelics	B-DRUG
[	O
66	O
,	O
67	O
]	O
However	O
,	O
we	O
also	O
found	O
that	O
psilocybin	B-DRUG
administration	O
was	O
associated	O
with	O
higher	B-OUTCOME
levels	I-OUTCOME
of	I-OUTCOME
GABA	I-OUTCOME
in	O
this	O
area	O
,	O
results	O
in	O
line	O
with	O
findings	O
that	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
are	O
also	O
located	O
on	O
GABAergic	B-NEURAL MECHANISM/CORRELATE
interneurons	I-NEURAL MECHANISM/CORRELATE
[	O
17	O
,	O
68	O
]	O
.	O
Taken	O
together	O
,	O
findings	O
suggest	O
that	O
activation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
the	I-NEURAL MECHANISM/CORRELATE
mPFC	I-NEURAL MECHANISM/CORRELATE
results	O
in	O
both	O
excitation	B-OUTCOME
and	I-OUTCOME
inhibition	I-OUTCOME
of	I-OUTCOME
cortical	I-OUTCOME
pyramidal	I-OUTCOME
cells	I-OUTCOME
[	O
17	O
]	O
,	O
potentially	O
resulting	O
in	O
an	O
increased	B-OUTCOME
metabolic	I-OUTCOME
rate	I-OUTCOME
in	I-OUTCOME
this	I-OUTCOME
area	I-OUTCOME
,	I-OUTCOME
but	I-OUTCOME
not	I-OUTCOME
necessarily	I-OUTCOME
increased	I-OUTCOME
neural	I-OUTCOME
input	I-OUTCOME
or	I-OUTCOME
output	I-OUTCOME
In	O
contrast	O
to	O
the	B-NEURAL MECHANISM/CORRELATE
mPFC	I-NEURAL MECHANISM/CORRELATE
,	O
the	O
present	O
study	O
demonstrated	O
that	O
participants	O
who	O
received	O
psilocybin	B-DRUG
demonstrated	O
lower	B-OUTCOME
relative	I-OUTCOME
glutamate	I-OUTCOME
concentrations	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
hippocampus	I-OUTCOME
,	O
suggesting	O
that	O
psilocybin	B-DRUG
decreases	B-OUTCOME
glutamate	I-OUTCOME
in	I-OUTCOME
this	I-OUTCOME
area	I-OUTCOME
.	O
Such	O
a	O
decrease	O
is	O
in	O
line	O
with	O
data	O
from	O
a	O
recent	O
functional	O
imaging	O
study	O
with	O
psilocybin	B-DRUG
,	O
demonstrating	B-OUTCOME
reduced	I-OUTCOME
absolute	I-OUTCOME
CBF	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
hippocampus	I-OUTCOME
compared	O
with	O
placebo	O
[	O
69	O
]	O
,	O
of	O
which	O
the	O
authors	O
proposed	O
two	O
potential	O
mechanisms	O
.	O
Namely	O
,	O
decrements	O
could	O
be	O
due	O
to	O
agonism	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
located	O
on	B-NEURAL MECHANISM/CORRELATE
GABAergic	I-NEURAL MECHANISM/CORRELATE
interneurons	I-NEURAL MECHANISM/CORRELATE
[	O
44	O
]	O
,	O
which	O
can	O
indirectly	B-OUTCOME
inhibit	I-OUTCOME
pyramidal	I-OUTCOME
neurons	I-OUTCOME
,	I-OUTCOME
decreasing	I-OUTCOME
activation	I-OUTCOME
in	I-OUTCOME
this	I-OUTCOME
area	I-OUTCOME
.	O
Conversely	O
,	O
agonism	O
of	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
located	O
on	O
GABAergic	B-NEURAL MECHANISM/CORRELATE
interneurons	I-NEURAL MECHANISM/CORRELATE
[	O
44	O
]	O
,	O
which	O
can	O
indirectly	B-OUTCOME
inhibit	I-OUTCOME
pyramidal	I-OUTCOME
neurons	I-OUTCOME
,	I-OUTCOME
decreasing	I-OUTCOME
activation	I-OUTCOME
in	I-OUTCOME
this	I-OUTCOME
area	I-OUTCOME
has	O
also	O
been	O
established	O
that	O
,	O
along	O
with	O
the	B-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
,	O
psilocin	B-DRUG
also	O
has	O
a	O
high	O
affinity	O
for	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
[	O
70	O
,	O
71	O
]	O
.	O
Referred	O
to	O
as	O
serotonin	O
’s	O
principal	O
inhibitory	O
receptor	O
[	O
72	O
]	O
,	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
highest	O
density	O
is	O
found	O
in	O
the	O
limbic	O
regions	O
of	O
the	O
brain	B-NEURAL MECHANISM/CORRELATE
such	O
as	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
[	O
73	O
]	O
where	O
the	O
5	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
highest	O
density	O
is	O
expressed	O
on	O
neurons	B-NEURAL MECHANISM/CORRELATE
that	O
are	O
postsynaptic	O
to	O
the	O
serotonergic	O
input	O
.	O
Thus	O
lower	B-OUTCOME
levels	I-OUTCOME
in	I-OUTCOME
glutamate	I-OUTCOME
as	O
seen	O
in	O
this	O
study	O
,	O
as	O
well	O
as	O
regional	O
decreases	O
reflected	O
in	O
others	O
[	O
69	O
]	O
,	O
could	O
be	O
due	O
to	O
activation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
postsynaptic	I-NEURAL MECHANISM/CORRELATE
inhibitory	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT1A	I-NEURAL MECHANISM/CORRELATE
receptors	I-NEURAL MECHANISM/CORRELATE
Nevertheless	O
,	O
due	O
to	O
methodological	O
limitations	O
,	O
this	O
study	O
is	O
not	O
able	O
to	O
delineate	O
which	O
mechanism	O
is	O
contributing	O
to	O
the	O
lower	B-OUTCOME
levels	I-OUTCOME
in	I-OUTCOME
glutamate	I-OUTCOME
.	O
Further	O
information	O
could	O
have	O
been	O
potentially	O
gained	O
from	O
quantification	O
of	O
GABA	B-NEURAL MECHANISM/CORRELATE
in	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
,	O
however	O
we	O
were	O
unable	O
to	O
reliably	O
do	O
so	O
,	O
due	O
to	O
inherent	O
quantification	O
challenges	O
when	O
assessing	O
GABA	B-NEURAL MECHANISM/CORRELATE
levels	O
,	O
arising	O
from	O
low	O
brain	B-NEURAL MECHANISM/CORRELATE
concentration	O
levels	O
,	O
metabolite	O
signal	O
overlap	O
,	O
and	O
low	O
signal	O
-	O
to	O
-	O
noise	O
in	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
[	O
74	O
,	O
75	O
]	O
.	O
Future	O
studies	O
with	O
sequences	O
developed	O
to	O
specifically	O
quantify	O
GABA	B-NEURAL MECHANISM/CORRELATE
in	I-NEURAL MECHANISM/CORRELATE
low	I-NEURAL MECHANISM/CORRELATE
signal	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
to	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
noise	I-NEURAL MECHANISM/CORRELATE
areas	I-NEURAL MECHANISM/CORRELATE
should	O
make	O
further	O
attempts	O
to	O
do	O
so	O
,	O
given	O
recent	O
research	O
implicating	O
hippocampal	B-NEURAL MECHANISM/CORRELATE
GABA	I-NEURAL MECHANISM/CORRELATE
in	O
the	O
pathology	O
of	O
disorders	O
that	O
psychedelics	B-DRUG
are	O
being	O
investigated	O
to	O
treat	O
[	O
76	O
]	O
In	O
the	O
current	O
study	O
,	O
psilocybin	B-DRUG
induced	O
previously	O
established	O
key	O
features	O
of	O
a	O
psychedelic	O
experience	O
:	O
increases	B-SUBJECTIVE EXPERIENCE
in	I-SUBJECTIVE EXPERIENCE
feelings	I-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
ego	I-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
,	O
and	O
disrupted	B-OUTCOME
RSN	I-OUTCOME
activity	I-OUTCOME
.	O
Psilocybin	B-DRUG
increased	O
scores	O
on	O
all	O
dimensions	O
of	O
the	O
5D	O
-	O
ASC	O
[	O
16	O
]	O
,	O
as	O
well	O
as	O
on	O
the	O
EDI	O
[	O
1	O
]	O
.	O
In	O
addition	O
,	O
psilocybin	B-DRUG
altered	B-OUTCOME
within	I-OUTCOME
-	I-OUTCOME
network	I-OUTCOME
FC	I-OUTCOME
similarly	O
as	O
has	O
been	O
shown	O
with	O
LSD	B-DRUG
,	O
including	O
decrements	O
in	O
coactivation	B-OUTCOME
within	I-OUTCOME
the	I-OUTCOME
DMN	I-OUTCOME
,	O
visual	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
1	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
the	O
auditory	B-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
[	O
32	O
,	O
33	O
]	O
.	O
Finally	O
,	O
we	O
demonstrated	O
higher	B-OUTCOME
between	I-OUTCOME
-	I-OUTCOME
network	I-OUTCOME
FC	I-OUTCOME
across	O
all	O
networks	O
,	O
which	O
is	O
similar	O
with	O
previous	O
studies	O
assessing	O
the	O
same	O
after	O
psilocybin	B-DRUG
[	O
35	O
,	O
42	O
]	O
and	O
LSD	B-DRUG
Finally	O
,	O
we	O
assessed	O
the	O
relationship	O
between	O
psilocybin	B-DRUG
-	O
induced	O
changes	B-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
brain	I-OUTCOME
,	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
subjective	I-OUTCOME
experience	I-OUTCOME
of	I-OUTCOME
sense	I-OUTCOME
of	I-OUTCOME
self	I-OUTCOME
.	O
Canonical	O
correlations	O
were	O
conducted	O
to	O
predict	O
increases	O
in	O
ratings	O
of	O
AED	O
,	O
the	O
dimension	O
encompassing	O
the	O
loss	O
of	O
autonomy	O
and	O
self	O
-	O
control	O
of	O
thought	O
processes	O
,	O
intentionality	O
,	O
decision	O
making	O
,	O
and	O
spontaneous	O
movements	O
[	O
46	O
]	O
.	O
Our	O
data	O
support	O
the	O
conclusion	O
that	O
increasing	B-OUTCOME
levels	I-OUTCOME
of	I-OUTCOME
mPFC	I-OUTCOME
glutamate	I-OUTCOME
were	O
the	O
strongest	O
predictor	O
in	O
regards	O
to	O
feelings	B-OUTCOME
of	I-OUTCOME
AED	I-OUTCOME
,	O
with	O
decreasing	B-OUTCOME
anterior	I-OUTCOME
DMN	I-OUTCOME
FC	I-OUTCOME
and	I-OUTCOME
hippocampal	I-OUTCOME
glutamate	I-OUTCOME
being	O
secondary	O
predictors	O
.	O
These	O
findings	O
are	O
in	O
line	O
with	O
previous	O
work	O
,	O
implicating	O
increased	B-NEURAL MECHANISM/CORRELATE
frontal	I-NEURAL MECHANISM/CORRELATE
metabolism	I-NEURAL MECHANISM/CORRELATE
in	O
feelings	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
AED	I-SUBJECTIVE EXPERIENCE
after	O
psilocybin	B-DRUG
[	O
46	O
]	O
and	O
ego	B-SUBJECTIVE EXPERIENCE
pathology	I-SUBJECTIVE EXPERIENCE
in	O
the	O
ketamine	B-DRUG
model	O
of	O
psychosis	B-HEALTH CONDITION
[	O
77	O
]	O
.	O
Interestingly	O
,	O
AED	B-OUTCOME
-	I-OUTCOME
associated	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
mood	I-OUTCOME
include	O
paranoia	B-HEALTH CONDITION
,	O
heightened	B-HEALTH CONDITION
arousal	I-HEALTH CONDITION
and	O
attention	O
to	O
the	O
surroundings	O
,	O
and	O
anxiety	B-HEALTH CONDITION
[	O
46	O
]	O
.	O
A	O
paradoxical	O
effect	O
of	O
serotonergic	O
psychedelics	B-DRUG
is	O
that	O
acutely	O
they	O
have	O
been	O
found	O
to	O
increase	O
feelings	O
of	O
anxiety	B-HEALTH CONDITION
[	O
6	O
,	O
78	O
]	O
,	O
whereas	O
clinical	O
trials	O
with	O
psychedelic	O
drugs	O
suggest	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
anxiety	I-OUTCOME
relief	I-OUTCOME
in	O
patients	O
[	O
11	O
,	O
12	O
,	O
14	O
]	O
.	O
Accordingly	O
,	O
there	O
is	O
a	O
wide	O
range	O
of	O
animal	O
and	O
human	O
pharmacological	O
evidence	O
supporting	O
the	O
role	O
of	O
the	O
glutamatergic	B-NEURAL MECHANISM/CORRELATE
system	I-NEURAL MECHANISM/CORRELATE
in	O
anxiety	B-HEALTH CONDITION
[	O
79	O
]	O
,	O
with	O
increases	B-OUTCOME
in	I-OUTCOME
glutamate	I-OUTCOME
in	I-OUTCOME
the	I-OUTCOME
frontal	I-OUTCOME
cortex	I-OUTCOME
associated	O
with	O
high	O
versus	O
low	O
state	O
-	O
trait	O
anxiety	B-HEALTH CONDITION
[	O
80	O
]	O
,	O
and	O
reductions	O
corresponding	O
to	O
anxiety	B-OUTCOME
-	I-OUTCOME
related	I-OUTCOME
symptomatic	I-OUTCOME
relief	I-OUTCOME
[	O
81	O
]	O
.	O
Taken	O
together	O
,	O
the	O
finding	O
that	O
mPFC	B-NEURAL MECHANISM/CORRELATE
glutamate	I-NEURAL MECHANISM/CORRELATE
was	O
by	O
far	O
the	O
strongest	O
predictor	O
of	O
increased	B-OUTCOME
feelings	I-OUTCOME
of	I-OUTCOME
anxiety	I-OUTCOME
,	O
one	O
could	O
propose	O
that	O
acute	B-OUTCOME
psychedelic	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
anxiety	I-OUTCOME
may	O
be	O
due	O
to	O
localized	B-OUTCOME
glutamate	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
hyperfrontality	I-OUTCOME
,	O
whereas	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
reductions	I-OUTCOME
could	O
be	O
due	O
to	O
agonist	B-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
5	I-OUTCOME
-	I-OUTCOME
HT2A	I-OUTCOME
receptor	I-OUTCOME
downregulation	I-OUTCOME
in	I-OUTCOME
this	I-OUTCOME
area	I-OUTCOME
[	O
72	O
,	O
82	O
]	O
.	O
Nonetheless	O
,	O
future	O
studies	O
should	O
assess	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
changes	I-OUTCOME
in	I-OUTCOME
5	I-OUTCOME
-	I-OUTCOME
HT2A	I-OUTCOME
receptor	I-OUTCOME
function	O
in	O
the	O
mPFC	B-NEURAL MECHANISM/CORRELATE
,	O
and	O
future	O
studies	O
relation	O
with	O
subjective	B-SUBJECTIVE EXPERIENCE
effects	I-SUBJECTIVE EXPERIENCE
We	O
also	O
assessed	O
the	O
relationship	O
between	O
psilocybin	B-DRUG
-	O
induced	O
brain	B-NEURAL MECHANISM/CORRELATE
changes	O
and	O
feelings	O
of	O
positively	O
experienced	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
,	O
including	O
ratings	O
on	O
the	O
EDI	O
,	O
and	O
scores	O
of	O
OB	O
on	O
the	O
5D	O
-	O
ASC	O
.	O
We	O
found	O
that	O
the	O
primary	O
predictor	O
of	O
positively	O
experienced	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
was	O
a	O
decrement	B-OUTCOME
in	I-OUTCOME
hippocampal	I-OUTCOME
glutamate	I-OUTCOME
,	O
with	O
secondary	O
contributions	O
of	O
mPFC	B-NEURAL MECHANISM/CORRELATE
glutamate	I-NEURAL MECHANISM/CORRELATE
and	O
posterior	B-NEURAL MECHANISM/CORRELATE
DMN	I-NEURAL MECHANISM/CORRELATE
integrity	O
.	O
Previous	O
work	O
has	O
implicated	O
both	O
the	O
MTL	B-NEURAL MECHANISM/CORRELATE
(	O
containing	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
)	O
and	O
DMN	B-NEURAL MECHANISM/CORRELATE
circuitry	I-NEURAL MECHANISM/CORRELATE
in	O
the	O
neural	O
correlates	O
of	O
the	B-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
[	O
49	O
]	O
.	O
Namely	O
,	O
abnormal	B-OUTCOME
function	I-OUTCOME
of	I-OUTCOME
MTL	I-OUTCOME
regions	O
have	O
been	O
implicated	O
in	O
psychotic	B-HEALTH CONDITION
states	I-HEALTH CONDITION
[	O
83	O
,	O
84	O
]	O
and	O
feelings	O
of	O
depersonalization	B-SUBJECTIVE EXPERIENCE
[	O
85	O
]	O
and	O
ego	B-SUBJECTIVE EXPERIENCE
-	I-SUBJECTIVE EXPERIENCE
disturbances	I-SUBJECTIVE EXPERIENCE
[	O
86	O
]	O
.	O
Similarly	O
,	O
studies	O
of	O
drug	O
-	O
induced	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
have	O
found	O
that	O
the	O
decoupling	B-OUTCOME
of	I-OUTCOME
MTL	I-OUTCOME
regions	I-OUTCOME
such	I-OUTCOME
as	I-OUTCOME
the	I-OUTCOME
parahippocampus	I-OUTCOME
and	I-OUTCOME
the	I-OUTCOME
DMN	I-OUTCOME
correlate	O
positively	O
with	O
feelings	O
of	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
[	O
49	O
,	O
87	O
]	O
,	O
with	O
this	O
decoupling	O
being	O
hypothesized	O
to	O
be	O
one	O
of	O
the	O
main	O
underlying	O
mechanisms	O
of	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
[	O
47,48,49	O
]	O
.	O
In	O
regards	O
to	O
why	O
this	O
gives	O
rise	O
to	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
,	O
this	O
has	O
been	O
suggested	O
that	O
psychedelic	B-OUTCOME
drug	I-OUTCOME
-	I-OUTCOME
induced	I-OUTCOME
decoupling	I-OUTCOME
of	I-OUTCOME
these	I-OUTCOME
regions	I-OUTCOME
results	O
in	O
a	O
temporary	B-OUTCOME
loss	I-OUTCOME
of	I-OUTCOME
access	I-OUTCOME
of	I-OUTCOME
semantic	I-OUTCOME
autobiographical	I-OUTCOME
information	I-OUTCOME
,	O
resulting	O
in	O
a	O
breakdown	B-OUTCOME
of	I-OUTCOME
one	I-OUTCOME
’s	I-OUTCOME
personal	I-OUTCOME
identity	I-OUTCOME
[	O
87	O
]	O
.	O
Our	O
data	O
add	O
to	O
this	O
hypothesis	O
,	O
suggesting	O
that	O
modulations	O
of	O
hippocampal	B-NEURAL MECHANISM/CORRELATE
glutamate	I-NEURAL MECHANISM/CORRELATE
in	O
particular	O
may	O
be	O
a	O
key	O
mediator	O
in	O
the	O
decoupling	O
underlying	O
feelings	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
(	I-SUBJECTIVE EXPERIENCE
positive	I-SUBJECTIVE EXPERIENCE
)	I-SUBJECTIVE EXPERIENCE
ego	I-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
.	O
Interestingly	O
,	O
although	O
the	O
DMN	B-NEURAL MECHANISM/CORRELATE
has	O
been	O
the	O
most	O
implicated	O
RSN	O
in	O
this	O
process	O
,	O
Lebedev	O
et	O
al	O
.	O
[	O
49	O
]	O
found	O
that	O
increases	O
in	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
correlated	O
with	O
decreased	B-OUTCOME
FC	I-OUTCOME
between	I-OUTCOME
the	I-OUTCOME
parahippocampal	I-OUTCOME
formation	I-OUTCOME
and	I-OUTCOME
other	I-OUTCOME
major	I-OUTCOME
networks	I-OUTCOME
,	O
such	O
as	O
the	O
salience	O
,	O
frontoparietal	O
,	O
and	O
sensorimotor	O
network	O
;	O
suggesting	O
a	O
key	O
role	O
in	O
this	O
area	O
in	O
particular	O
,	O
as	O
our	O
data	O
also	O
demonstrate	O
.	O
However	O
future	O
research	O
should	O
further	O
assess	O
the	O
contribution	O
of	O
other	O
areas	O
to	O
this	O
experience	O
,	O
such	O
as	O
the	O
posterior	B-NEURAL MECHANISM/CORRELATE
cingulate	I-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
Implications	O
of	O
these	O
findings	O
also	O
extend	O
far	O
beyond	O
understanding	O
the	O
neurobiology	O
of	O
the	O
acute	O
psychedelic	O
experience	O
and	O
drug	O
-	O
induced	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
.	O
There	O
is	O
growing	O
evidence	O
that	O
psychedelics	B-DRUG
can	O
provide	O
therapeutic	O
relief	O
for	O
individuals	O
suffering	O
from	O
increasingly	O
common	O
and	O
difficult	O
to	O
treat	O
disorders	O
such	O
as	O
depression	B-HEALTH CONDITION
,	O
anxiety	B-HEALTH CONDITION
,	O
addiction	B-HEALTH CONDITION
,	O
and	O
post	B-HEALTH CONDITION
-	I-HEALTH CONDITION
traumatic	I-HEALTH CONDITION
stress	I-HEALTH CONDITION
disorders	I-HEALTH CONDITION
[	O
4	O
,	O
9	O
,	O
11	O
,	O
88	O
,	O
89	O
]	O
.	O
Thus	O
understanding	O
the	O
mechanisms	O
by	O
which	O
psychedelics	B-DRUG
provide	O
symptomatic	O
relief	O
may	O
identify	O
novel	B-OUTCOME
therapeutic	I-OUTCOME
targets	I-OUTCOME
.	O
Interestingly	O
,	O
the	O
degree	O
of	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
has	O
been	O
found	O
to	O
correlate	O
with	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
clinical	I-OUTCOME
outcomes	I-OUTCOME
[	O
90	O
]	O
and	O
increases	B-OUTCOME
in	I-OUTCOME
well	I-OUTCOME
-	I-OUTCOME
being	I-OUTCOME
[	O
10	O
,	O
91	O
]	O
.	O
In	O
addition	O
,	O
a	O
hypothetical	O
(	O
neurobiological	O
)	O
model	O
has	O
been	O
proposed	O
to	O
explain	O
the	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
effects	I-OUTCOME
witnessed	O
in	O
clinical	O
trials	O
.	O
the	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
effects	I-OUTCOME
witnessed	O
in	O
clinical	O
trials	O
has	O
been	O
suggested	O
that	O
indirect	O
activation	B-NEURAL MECHANISM/CORRELATE
of	I-NEURAL MECHANISM/CORRELATE
glutamate	I-NEURAL MECHANISM/CORRELATE
networks	I-NEURAL MECHANISM/CORRELATE
via	I-NEURAL MECHANISM/CORRELATE
5	I-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
HT2A	I-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
agonism	O
increases	O
BDNF	O
,	O
and	O
ultimately	O
enhances	O
neuroplasticity	B-OUTCOME
[	O
16	O
]	O
.	O
In	O
line	O
with	O
this	O
,	O
the	O
long	B-OUTCOME
-	I-OUTCOME
term	I-OUTCOME
effects	I-OUTCOME
witnessed	O
in	O
clinical	O
trials	O
has	O
been	O
shown	O
in	O
preclinical	O
models	O
that	O
psychedelics	B-DRUG
increase	B-OUTCOME
functional	I-OUTCOME
and	I-OUTCOME
structural	I-OUTCOME
neuroplasticity	I-OUTCOME
[	O
92	O
]	O
,	O
however	O
evidence	O
in	O
humans	O
is	O
limited	O
,	O
due	O
to	O
restrictions	O
of	O
methodological	O
techniques	O
.	O
Our	O
data	O
provide	O
indirect	O
evidence	O
that	O
psychedelics	B-DRUG
might	O
have	O
the	O
potential	O
to	O
increase	B-OUTCOME
neuroplasticity	I-OUTCOME
in	O
the	O
human	B-NEURAL MECHANISM/CORRELATE
cortex	I-NEURAL MECHANISM/CORRELATE
via	O
increased	B-NEURAL MECHANISM/CORRELATE
glutamatergic	I-NEURAL MECHANISM/CORRELATE
activity	I-NEURAL MECHANISM/CORRELATE
,	O
but	O
not	O
in	O
the	O
hippocampus	B-NEURAL MECHANISM/CORRELATE
;	O
findings	O
that	O
are	O
in	O
accordance	O
with	O
previous	O
5	O
-	O
HT2A	B-NEURAL MECHANISM/CORRELATE
receptor	I-NEURAL MECHANISM/CORRELATE
activation	I-NEURAL MECHANISM/CORRELATE
studies	O
[	O
27	O
,	O
93	O
,	O
94	O
]	O
.	O
In	O
addition	O
,	O
psilocybin	B-DRUG
administration	O
was	O
associated	O
with	O
higher	B-OUTCOME
levels	I-OUTCOME
of	I-OUTCOME
mPFC	I-OUTCOME
NAA	I-OUTCOME
,	O
a	O
compound	O
regarded	O
as	O
a	O
measure	O
of	O
neuronal	B-OUTCOME
viability	I-OUTCOME
and	I-OUTCOME
function	I-OUTCOME
,	O
and	O
decreased	O
in	O
disorders	O
associated	O
with	O
regional	O
neuronal	O
loss	O
and	O
disrupted	O
neuronal	O
function	O
Of	O
note	O
,	O
compared	O
to	O
previous	O
psychedelic	O
studies	O
,	O
the	O
dose	O
administered	O
was	O
low	O
to	O
moderate	O
[	O
96	O
]	O
,	O
and	O
thus	O
not	O
high	O
enough	O
to	O
induce	O
total	O
ego	B-SUBJECTIVE EXPERIENCE
dissolution	I-SUBJECTIVE EXPERIENCE
.	O
However	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
not	O
to	O
assess	O
maximal	O
effects	O
of	O
psilocybin	B-DRUG
,	O
but	O
rather	O
an	O
effective	O
dose	O
that	O
would	O
induce	O
a	O
relevant	O
psychedelic	B-SUBJECTIVE EXPERIENCE
state	I-SUBJECTIVE EXPERIENCE
that	O
participants	O
could	O
endure	O
in	O
the	O
MRI	O
scanner	O
.	O
Our	O
data	O
demonstrate	O
that	O
the	O
dose	O
was	O
effective	O
,	O
inducing	O
significantly	O
higher	B-OUTCOME
levels	I-OUTCOME
of	I-OUTCOME
both	I-OUTCOME
positively	I-OUTCOME
and	I-OUTCOME
negatively	I-OUTCOME
experienced	I-OUTCOME
ego	I-OUTCOME
dissolution	I-OUTCOME
compared	O
with	O
placebo	O
,	O
as	O
well	O
as	O
the	O
other	O
subjective	O
effects	O
representative	O
of	O
a	O
psychedelic	O
state	O
(	O
Figs	O
.	O
1	O
,	O
S1	O
)	O
.	O
Furthermore	O
,	O
although	O
BOLD	O
sensitivity	O
is	O
increased	O
by	O
the	O
use	O
of	O
ultra	O
-	O
high	O
magnetic	O
fields	O
,	O
geometric	O
distortions	O
become	O
more	O
prominent	O
,	O
which	O
could	O
have	O
affected	O
our	O
BOLD	O
signal	O
in	O
inferior	O
brain	B-NEURAL MECHANISM/CORRELATE
regions	O
[	O
97	O
]	O
,	O
and	O
our	O
scan	O
time	O
was	O
arguably	O
short	O
from	O
a	O
test	O
–	O
retest	O
reliability	O
standpoint	O
[	O
98	O
]	O
.	O
Nevertheless	O
,	O
our	O
results	O
are	O
similar	O
to	O
aforementioned	O
studies	O
[	O
32	O
,	O
33	O
,	O
35	O
,	O
42	O
]	O
who	O
acquired	O
our	O
results	O
data	O
at	O
a	O
lower	O
field	O
strength	O
,	O
with	O
varying	O
scanning	O
lengths	O
.	O
Finally	O
,	O
an	O
inherent	O
difficulty	O
of	O
studying	O
substances	O
with	O
such	O
salient	O
subjective	O
effects	O
is	O
maintaining	O
the	O
treatment	O
blind	O
.	O
Thus	O
,	O
it	O
could	O
be	O
suggested	O
that	O
participant	O
recognition	O
of	O
the	O
treatment	O
condition	O
could	O
affect	O
neural	O
and	O
subjective	O
results	O
,	O
emphasizing	O
the	O
importance	O
of	O
active	O
placebo	O
conditions	O
or	O
cross	O
-	O
psychotropic	O
comparisons	O
in	O
future	O
trials	O
In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
that	O
the	O
serotonergic	O
psychedelic	O
,	O
psilocybin	B-DRUG
,	O
acutely	O
induces	O
region	O
dependent	O
alterations	O
in	O
glutamate	O
that	O
correlate	O
with	O
established	O
behavioral	O
changes	O
during	O
the	O
psychedelic	O
state	O
.	O
Such	O
findings	O
provide	O
further	O
insights	O
into	O
the	O
underlying	O
neurobiological	O
mechanisms	O
of	O
the	O
psychedelic	O
state	O
,	O
and	O
importantly	O
,	O
provide	O
a	O
neurochemical	O
basis	O
for	O
how	O
these	O
substances	O
alter	O
individuals	O
’	O
sense	O
of	O
self	O
,	O
and	O
may	O
be	O
giving	O
rise	O
to	O
therapeutic	O
effects	O
witnessed	O
in	O
ongoing	O
clinical	O
trials	O
-DOCSTART- -X- O O
Despite	O
having	O
a	O
rudimentary	O
default	B-NEURAL MECHANISM/CORRELATE
mode	I-NEURAL MECHANISM/CORRELATE
network	I-NEURAL MECHANISM/CORRELATE
,	O
(	O
34	O
)	O
and	O
showing	O
interest	O
in	O
mirrors	O
,	O
video	O
feed	O
,	O
and	O
still	O
images	O
of	O
other	O
rats	O
,	O
(	O
35	O
)	O
rats	O
are	O
not	O
commonly	O
believed	O
to	O
be	O
among	O
the	O
menagerie	O
of	O
self	O
-	O
aware	O
animals	O
.	O
Thus	O
,	O
as	O
far	O
as	O
modern	O
science	O
is	O
able	O
to	O
determine	O
,	O
rats	O
do	O
not	O
have	O
a	O
sense	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
self	I-SUBJECTIVE EXPERIENCE
and	O
are	O
incapable	O
of	O
having	O
existential	O
anxiety	B-HEALTH CONDITION
,	O
pondering	O
the	O
meaning	O
behind	O
rats	O
own	O
existence	O
or	O
fearing	B-SUBJECTIVE EXPERIENCE
a	I-SUBJECTIVE EXPERIENCE
reality	I-SUBJECTIVE EXPERIENCE
in	O
which	O
rats	O
,	O
as	O
individuals	O
,	O
do	O
not	O
exist	O
.	O
No	O
one	O
knows	O
what	O
the	O
subjective	B-SUBJECTIVE EXPERIENCE
experience	I-SUBJECTIVE EXPERIENCE
of	O
a	O
rat	O
is	O
after	O
being	O
given	O
a	O
psychedelic	B-DRUG
,	O
but	O
a	O
rat	O
is	O
highly	O
unlikely	O
that	O
they	O
are	O
able	O
to	O
place	O
that	O
within	O
the	O
context	O
of	O
they	O
life	O
experiences	O
and	O
utilize	O
that	O
knowledge	O
therapeutically	O
to	O
improve	B-OUTCOME
they	I-OUTCOME
affective	I-OUTCOME
state	I-OUTCOME
.	O
Therefore	O
,	O
because	O
psilocybin	B-DRUG
has	O
robust	O
effects	O
similar	O
to	O
those	O
of	O
other	O
antidepressants	B-DRUG
in	O
rats	O
that	O
is	O
very	O
long	B-OUTCOME
lasting	I-OUTCOME
,	O
which	O
is	O
similar	O
to	O
the	O
long	B-OUTCOME
lasting	I-OUTCOME
antidepressant	I-OUTCOME
effects	I-OUTCOME
of	O
psilocybin	B-DRUG
to	O
alleviate	O
the	O
symptoms	B-OUTCOME
of	I-OUTCOME
depression	I-OUTCOME
in	O
humans	O
,	O
we	O
posit	O
that	O
the	O
basis	O
for	O
the	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
in	O
humans	O
is	O
at	O
the	O
antidepressant	B-OUTCOME
effects	I-OUTCOME
in	O
humans	B-NEURAL MECHANISM/CORRELATE
core	I-NEURAL MECHANISM/CORRELATE
biological	I-NEURAL MECHANISM/CORRELATE
in	O
nature	O
,	O
and	O
that	O
while	O
correlated	O
to	O
antidepressant	B-OUTCOME
effect	I-OUTCOME
(	O
27	O
)	O
peak	O
ego	B-HEALTH CONDITION
dissolution	I-HEALTH CONDITION
subjective	O
experiences	O
following	O
psilocybin	B-DRUG
administration	O
is	O
not	O
causational	O
to	O
antidepressant	B-OUTCOME
effect	I-OUTCOME
.	O
These	O
biological	B-NEURAL MECHANISM/CORRELATE
processes	I-NEURAL MECHANISM/CORRELATE
could	O
include	O
cellular	B-NEURAL MECHANISM/CORRELATE
proliferation	I-NEURAL MECHANISM/CORRELATE
,	O
increased	B-NEURAL MECHANISM/CORRELATE
synaptic	I-NEURAL MECHANISM/CORRELATE
connectivity	I-NEURAL MECHANISM/CORRELATE
,	O
and	O
anti	B-NEURAL MECHANISM/CORRELATE
-	I-NEURAL MECHANISM/CORRELATE
inflammatory	I-NEURAL MECHANISM/CORRELATE
effects	I-NEURAL MECHANISM/CORRELATE
.	O
Drugs	O
like	O
LSD	B-DRUG
and	O
psilocybin	B-DRUG
have	O
been	O
demonstrated	O
to	O
elicit	O
these	O
types	O
of	O
changes	O
in	O
preclinical	O
models	O
,	O
and	O
these	O
types	O
of	O
physiological	B-OUTCOME
effects	I-OUTCOME
have	O
each	O
been	O
associated	O
with	O
antidepressant	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
behavioral	I-OUTCOME
outcomes	I-OUTCOME
.	O
(	O
32,36	O
)	O
Although	O
we	O
propose	O
that	O
the	O
antidepressant	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effects	I-OUTCOME
are	O
primarily	O
rooted	O
in	B-NEURAL MECHANISM/CORRELATE
biological	I-NEURAL MECHANISM/CORRELATE
processes	I-NEURAL MECHANISM/CORRELATE
,	O
our	O
data	O
suggest	O
that	O
post	O
drug	O
administration	O
environmental	O
factors	O
also	O
play	O
a	O
critical	O
role	O
in	O
overall	O
drug	O
effects	O
.	O
Our	O
results	O
suggest	O
that	O
psilocybin	B-DRUG
facilitates	O
a	O
period	O
of	O
behavioral	B-OUTCOME
flexibility	I-OUTCOME
in	O
which	O
exploration	O
of	O
a	O
non	O
-	O
home	O
-	O
cage	O
environment	O
reduces	O
their	O
anxiety	B-HEALTH CONDITION
during	O
future	O
exploration	O
of	O
a	O
novel	O
environment	O
(	O
the	O
EPM	O
,	O
Figure	O
3A	O
)	O
,	O
but	O
FST	O
evaluation	O
1	O
week	O
after	O
psilocybin	B-DRUG
blunts	O
the	B-OUTCOME
antidepressant	I-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effect	I-OUTCOME
in	O
the	O
FST	O
(	O
Figure	O
2A	O
,	O
F	O
,	O
G	O
)	O
.	O
In	O
this	O
context	O
,	O
psilocybin	B-DRUG
may	O
open	O
a	O
window	O
during	O
which	O
time	O
certain	O
experiences	O
are	O
salient	O
to	O
the	O
development	B-OUTCOME
of	I-OUTCOME
new	I-OUTCOME
coping	I-OUTCOME
strategies	I-OUTCOME
,	O
similar	O
to	O
MDMA	B-DRUG
-	O
facilitated	O
social	B-OUTCOME
learning	I-OUTCOME
reported	I-OUTCOME
in	I-OUTCOME
mice	I-OUTCOME
.	O
(	O
37	O
)	O
As	O
the	O
FST	O
measures	O
the	O
coping	B-OUTCOME
strategies	I-OUTCOME
of	O
rodents	O
challenged	O
with	O
the	O
threat	B-SUBJECTIVE EXPERIENCE
of	I-SUBJECTIVE EXPERIENCE
drowning	I-SUBJECTIVE EXPERIENCE
,	O
successfully	B-OUTCOME
surviving	I-OUTCOME
the	O
first	O
trial	O
by	O
floating	O
may	O
make	O
rats	O
given	O
psilocybin	B-DRUG
more	O
likely	O
to	O
use	O
this	O
coping	B-OUTCOME
strategy	I-OUTCOME
in	O
the	O
future	O
,	O
whereas	O
rats	O
given	O
psilocybin	B-DRUG
and	O
not	O
subjected	O
to	O
FST	O
for	O
5	O
weeks	O
choose	O
active	B-OUTCOME
coping	I-OUTCOME
strategies	I-OUTCOME
.	O
Interestingly	O
,	O
that	O
is	O
not	O
true	O
of	O
ketamine	B-DRUG
,	O
as	O
ketamine	B-DRUG
’s	O
antidepressant	B-OUTCOME
-	I-OUTCOME
like	I-OUTCOME
effect	I-OUTCOME
was	O
independent	O
of	O
repeated	O
FST	O
,	O
but	O
transient	O
(	O
Figure	O
2D	O
,	O
G	O
)	O
and	O
no	O
anxiolytic	B-OUTCOME
effect	I-OUTCOME
was	O
observed	O
(	O
Figure	O
3C	O
)	O
.	O
Therefore	O
,	O
overall	O
efficacy	B-OUTCOME
in	O
humans	O
is	O
likely	O
a	O
combination	O
of	O
both	O
the	O
acute	O
neurological	B-NEURAL MECHANISM/CORRELATE
effects	I-NEURAL MECHANISM/CORRELATE
of	O
the	O
drug	O
and	O
subjective	B-SUBJECTIVE EXPERIENCE
,	I-SUBJECTIVE EXPERIENCE
contextual	I-SUBJECTIVE EXPERIENCE
experiences	I-SUBJECTIVE EXPERIENCE
during	O
and/or	O
immediately	O
following	O
the	O
drug	O
administration	O
session	O